<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD003115.pub4" GROUP_ID="MUSKEL" ID="982601012712422491" MERGED_FROM="" MODIFIED="2014-09-13 09:13:28 -0400" MODIFIED_BY="Elizabeth Tanjong Ghogomu" REVIEW_NO="C140-R" REVMAN_SUB_VERSION="5.3.4 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="7.2">
<COVER_SHEET MODIFIED="2014-09-13 09:13:28 -0400" MODIFIED_BY="Elizabeth Tanjong Ghogomu">
<TITLE MODIFIED="2014-08-18 06:45:26 -0400" MODIFIED_BY="Anne Lawson">Oral or transdermal opioids for osteoarthritis of the knee or hip</TITLE>
<CONTACT>
<PERSON ID="63946946052527852742120320190755" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Bruno</FIRST_NAME>
<MIDDLE_INITIALS>R</MIDDLE_INITIALS>
<LAST_NAME>da Costa</LAST_NAME>
<SUFFIX/>
<POSITION>Research fellow, PhD</POSITION>
<EMAIL_1>bdacosta@ispm.unibe.ch</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE>+41 31 991 12 64</MOBILE_PHONE>
<ADDRESS>
<DEPARTMENT>Institute of Social and Preventive Medicine (ISPM)</DEPARTMENT>
<ORGANISATION>University of Bern</ORGANISATION>
<ADDRESS_1>Finkenhubelweg 11</ADDRESS_1>
<ADDRESS_2/>
<CITY>Bern</CITY>
<ZIP>3012</ZIP>
<REGION>Bern</REGION>
<COUNTRY CODE="CH">Switzerland</COUNTRY>
<PHONE_1>+41 31 631 35 08</PHONE_1>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CONTACT>
<CREATORS MODIFIED="2014-09-13 09:13:28 -0400" MODIFIED_BY="Elizabeth Tanjong Ghogomu">
<PERSON ID="63946946052527852742120320190755" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Bruno</FIRST_NAME>
<MIDDLE_INITIALS>R</MIDDLE_INITIALS>
<LAST_NAME>da Costa</LAST_NAME>
<SUFFIX/>
<POSITION>Research fellow, PhD</POSITION>
<EMAIL_1>bdacosta@ispm.unibe.ch</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE>+41 31 991 12 64</MOBILE_PHONE>
<ADDRESS>
<DEPARTMENT>Institute of Social and Preventive Medicine (ISPM)</DEPARTMENT>
<ORGANISATION>University of Bern</ORGANISATION>
<ADDRESS_1>Finkenhubelweg 11</ADDRESS_1>
<ADDRESS_2/>
<CITY>Bern</CITY>
<ZIP>3012</ZIP>
<REGION>Bern</REGION>
<COUNTRY CODE="CH">Switzerland</COUNTRY>
<PHONE_1>+41 31 631 35 08</PHONE_1>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="6701E84582E26AA201880571E7219167" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Eveline</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Nüesch</LAST_NAME>
<SUFFIX/>
<POSITION>Lecturer</POSITION>
<EMAIL_1>enueesch@ispm.unibe.ch</EMAIL_1>
<EMAIL_2>eveline.nuesch@lshtm.ac.uk</EMAIL_2>
<URL>www.ispm.unibe.ch</URL>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Faculty of Epidemiology and Population Health</DEPARTMENT>
<ORGANISATION>London School of Hygiene and Tropical Medicine</ORGANISATION>
<ADDRESS_1>Keppel Street</ADDRESS_1>
<ADDRESS_2/>
<CITY>London</CITY>
<ZIP/>
<REGION/>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="z1301241600391004735285903682456" ROLE="AUTHOR">
<PREFIX>Ms</PREFIX>
<FIRST_NAME>Rahel</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Kasteler</LAST_NAME>
<SUFFIX/>
<POSITION>MD-student</POSITION>
<EMAIL_1>rahel.kasteler@bluewin.ch</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE>+41 79 735 23 39</MOBILE_PHONE>
<ADDRESS>
<DEPARTMENT>Institute of Social and Preventive Medicine (ISPM)</DEPARTMENT>
<ORGANISATION>University of Bern</ORGANISATION>
<ADDRESS_1>Seidenweg 56</ADDRESS_1>
<ADDRESS_2/>
<CITY>Bern</CITY>
<ZIP>3012</ZIP>
<REGION>Bern</REGION>
<COUNTRY CODE="CH">Switzerland</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="14950" ROLE="AUTHOR">
<PREFIX/>
<FIRST_NAME>Elaine</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Husni</LAST_NAME>
<SUFFIX>MD</SUFFIX>
<POSITION>Director, Clinical Outcomes Research</POSITION>
<EMAIL_1>husnie@ccf.org</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Rheumatic and Immunologic Diseases</DEPARTMENT>
<ORGANISATION>Cleveland Clinic: Orthopedic and Rheumatologic Institute</ORGANISATION>
<ADDRESS_1>9500 Euclid Ave- A50</ADDRESS_1>
<ADDRESS_2/>
<CITY>Cleveland</CITY>
<ZIP>44195</ZIP>
<REGION>OH</REGION>
<COUNTRY CODE="US">USA</COUNTRY>
<PHONE_1>1-216-445-1853</PHONE_1>
<PHONE_2/>
<FAX_1>1-216-445-7569</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="13312" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Vivian</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Welch</LAST_NAME>
<SUFFIX/>
<POSITION>Associate Scientist</POSITION>
<EMAIL_1>vivian.welch@uottawa.ca</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE>1 613 219 9290</MOBILE_PHONE>
<ADDRESS>
<DEPARTMENT>Bruyere Research Institute</DEPARTMENT>
<ORGANISATION>University of Ottawa</ORGANISATION>
<ADDRESS_1>43 Bruyere Street</ADDRESS_1>
<ADDRESS_2/>
<CITY>Ottawa</CITY>
<ZIP>K1N 5C8</ZIP>
<REGION>ON</REGION>
<COUNTRY CODE="CA">Canada</COUNTRY>
<PHONE_1>+1 613 562-6262 x1352</PHONE_1>
<PHONE_2>+1 613 562-5800 ext 2921</PHONE_2>
<FAX_1>+1 613 562-5659</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="55AAB96B82E26AA2000F11BC5E70C1F3" ROLE="AUTHOR">
<PREFIX/>
<FIRST_NAME>Anne</FIRST_NAME>
<MIDDLE_INITIALS>WS</MIDDLE_INITIALS>
<LAST_NAME>Rutjes</LAST_NAME>
<SUFFIX/>
<POSITION>Senior research fellow</POSITION>
<EMAIL_1>arutjes@ispm.unibe.ch</EMAIL_1>
<EMAIL_2>rutjes@live.it</EMAIL_2>
<URL>http://www.ispm.ch</URL>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Institute of Social and Preventive Medicine (ISPM)</DEPARTMENT>
<ORGANISATION>University of Bern</ORGANISATION>
<ADDRESS_1>Finkenhubelweg 11</ADDRESS_1>
<ADDRESS_2/>
<CITY>Bern</CITY>
<ZIP>3012</ZIP>
<REGION/>
<COUNTRY CODE="CH">Switzerland</COUNTRY>
<PHONE_1>+39 0871 355 67 20</PHONE_1>
<PHONE_2>+39 389 999 36 50</PHONE_2>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="10779" ROLE="AUTHOR">
<PREFIX>Prof</PREFIX>
<FIRST_NAME>Peter</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Jüni</LAST_NAME>
<SUFFIX/>
<POSITION>Head of Division</POSITION>
<EMAIL_1>juni@ispm.unibe.ch</EMAIL_1>
<EMAIL_2/>
<URL>http://www.ispm.ch</URL>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Institute of Social and Preventive Medicine (ISPM)</DEPARTMENT>
<ORGANISATION>University of Bern</ORGANISATION>
<ADDRESS_1>Finkenhubelweg 11</ADDRESS_1>
<ADDRESS_2/>
<CITY>Bern</CITY>
<ZIP/>
<REGION/>
<COUNTRY CODE="CH">Switzerland</COUNTRY>
<PHONE_1>+41 31 631 33 78</PHONE_1>
<PHONE_2/>
<FAX_1>+41 31 631 35 20</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CREATORS>
<DATES MODIFIED="2014-09-13 09:13:28 -0400" MODIFIED_BY="Elizabeth Tanjong Ghogomu">
<UP_TO_DATE>
<DATE DAY="15" MONTH="8" YEAR="2012"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="15" MONTH="8" YEAR="2012"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="17" MONTH="12" YEAR="2015"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="2" YEAR="2001"/>
<REVIEW_PUBLISHED ISSUE="4" YEAR="2009"/>
<LAST_CITATION_ISSUE ISSUE="9" YEAR="2014"/>
</DATES>
<WHATS_NEW MODIFIED="2014-09-11 11:25:14 -0400" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2013-03-22 10:29:24 -0400" MODIFIED_BY="[Empty name]">
<DATE DAY="22" MONTH="3" YEAR="2013"/>
<DESCRIPTION>
<P>Search updated with 12 additional trials included.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2014-09-11 11:25:14 -0400" MODIFIED_BY="[Empty name]">
<DATE DAY="22" MONTH="8" YEAR="2012"/>
<DESCRIPTION>
<P>Change in authorship</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2013-03-22 10:44:38 -0400" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2013-03-22 10:44:38 -0400" MODIFIED_BY="[Empty name]">
<DATE DAY="8" MONTH="10" YEAR="2009"/>
<DESCRIPTION>
<P>NNTs for pain and function were corrected</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2013-03-22 10:44:35 -0400" MODIFIED_BY="[Empty name]">
<DATE DAY="13" MONTH="5" YEAR="2008"/>
<DESCRIPTION>
<P>Change in authorship</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2013-03-22 10:44:31 -0400" MODIFIED_BY="[Empty name]">
<DATE DAY="1" MONTH="5" YEAR="2008"/>
<DESCRIPTION>
<P>CMSG ID C141-R</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT MODIFIED="2013-02-04 05:48:27 -0500" MODIFIED_BY="[Empty name]">
<INTERNAL_SOURCES MODIFIED="2009-03-03 04:09:13 -0500" MODIFIED_BY="[Empty name]">
<SOURCE MODIFIED="2009-03-03 04:09:13 -0500" MODIFIED_BY="[Empty name]">
<NAME>Institute of Social and Preventive Medicine, University or Bern</NAME>
<COUNTRY CODE="CH">Switzerland</COUNTRY>
<DESCRIPTION>
<P>Intramural grants</P>
</DESCRIPTION>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES MODIFIED="2013-02-04 05:48:27 -0500" MODIFIED_BY="[Empty name]">
<SOURCE MODIFIED="2009-03-03 04:09:36 -0500" MODIFIED_BY="[Empty name]">
<NAME>Swiss National Science Foundation</NAME>
<COUNTRY CODE="CH">Switzerland</COUNTRY>
<DESCRIPTION>
<P>National Research Program 53 on musculoskeletal health (grant numbers 4053-40-104762/3 and 3200-066378)</P>
</DESCRIPTION>
</SOURCE>
<SOURCE MODIFIED="2013-02-04 05:48:27 -0500" MODIFIED_BY="[Empty name]">
<NAME>Marie Curie Intra-European Fellowship</NAME>
<COUNTRY CODE="NONE">Other</COUNTRY>
<DESCRIPTION>
<P>Dr Nüesch was recipient of a Marie Curie Intra-European Fellowship for Career Development (grant number FP7-PEOPLE-2010-IEF-273673)</P>
</DESCRIPTION>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2014-08-21 15:34:16 -0400" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2014-08-21 15:34:16 -0400" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2009-07-21 15:44:03 -0400" MODIFIED_BY="[Empty name]">Opioids for osteoarthritis</TITLE>
<SUMMARY_BODY MODIFIED="2014-08-21 15:34:16 -0400" MODIFIED_BY="[Empty name]">
<P>This summary of a Cochrane review of 22 studies with 8275 participants (search update: 15 August 2012) presents what we know from research about the effect of opioids on osteoarthritis (OA). We searched scientific databases for clinical trials looking at pain, function, safety, and addiction of oral or transdermal opioids compared with placebo or no intervention in people with knee or hip osteoarthritis.</P>
<P>
<B>The review shows that in people with osteoarthritis:</B>
</P>
<P>- Opioids have a small effect on pain or physical function.<BR/>- Opioids probably cause side effects. However, we do not have precise information about rare but serious side effects.<BR/>
</P>
<P>
<B>What is osteoarthritis and what are opioids?</B>
</P>
<P>OA is a disease of the joints, such as your knee or hip. When the joint loses cartilage, the bone grows to try to repair the damage. Instead of making things better, however, the bone grows abnormally and makes things worse. For example, the bone can become misshapen and make the joint painful and unstable. This can affect your physical function or ability to use your knee.<BR/>
</P>
<P>Opioids are generally conceived as powerful pain-relieving substances that are used for the pain of cancer or osteoarthritis. Some examples of opioids are codeine-containing Tylenol® (1, 2, 3, and 4), hydromorphone (Dilaudid), oxycodone (Percocet, Percodan), morphine, and others. They can be taken in a pill form, as an injection, or as a patch placed on the painful area. </P>
<P>
<B>Best estimate of what happens to people with osteoarthritis who take opioids</B>
</P>
<P>
<B>Pain</B>
</P>
<P>- People who took opioids rated improvement in their pain to be about 3 points on a scale of 0 (no pain) to 10 (extreme pain) after one month.<BR/>- People who took a placebo rated improvement in their pain to be about 2 points on a scale of 0 (no pain) to 10 (extreme pain) after one month.</P>
<P>Another way of saying this is:<BR/>- 41 people out of 100 who used opioids responded to treatment (41%).<BR/>- 31 people out of 100 who used placebo responded to treatment (31%).<BR/>- 10 more people responded to treatment with opioids than with placebo (difference of 10%). (High-quality evidence)</P>
<P>
<B>Physical function</B>
</P>
<P>- People who took opioids rated improvement in their physical function to be about 2 points on a scale of 0 (no disability) to 10 (extreme disability) after one month.<BR/>- People who took a placebo rated improvement in their physical function to be about 1 point on a scale of 0 (no disability) to 10 (extreme disability) after one month.</P>
<P>Another way of saying this is:</P>
<P>- 34 people out of 100 who used opioids responded to treatment (34%).<BR/>- 26 people out of 100 who used placebo responded to treatment (26%).<BR/>- 8 more people responded to treatment with opioids than with placebo (difference of 8%). (High-quality evidence)</P>
<P>
<B>Side effects</B>
</P>
<P>- 22 people out of 100 who used opioids experienced side effects (22%).<BR/>- 15 people out of 100 who used a placebo experienced side effects (15%).<BR/>- 7 more people experienced side effects with opioids than with placebo (difference of 7%). (Moderate-quality evidence)</P>
<P>
<B>Drop-outs because of side effects</B>
</P>
<P>- 64 people out of 1000 who used opioids dropped out because of side effects (6.4%).<BR/>- 17 people out of 1000 who used a placebo dropped out because of side effects (1.7%).<BR/>- 47 more people dropped out because of side effects with opioids than with placebo (difference of 4.7%). (High-quality evidence)</P>
<P>
<B>Side effects resulting in hospitalisation, persistent disability, or death</B>
</P>
<P>- 13 people out of 1000 who used opioids experienced side effects resulting in hospitalisation, persistent disability, or death (1.3%).<BR/>- 4 people out of 1000 who used a placebo experienced side effects resulting in hospitalisation, persistent disability, or deaths (0.4%).<BR/>- 9 more people experienced side effects resulting in hospitalisation, persistent disability, or death with opioids than with placebo (difference of 0.9%). (Low-quality evidence)</P>
<P>
<B>Withdrawal symptoms</B>
</P>
<P>- 24 people out of 1000 who used opioids experienced withdrawal symptoms (2.4%).<BR/>- 9 people out of 1000 who used a placebo experienced withdrawal symptoms (0.9%).<BR/>- 15 more people experienced withdrawal symptoms with opioids than with placebo (difference of 1.5%). (Moderate-quality evidence)</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2014-08-15 09:46:54 -0400" MODIFIED_BY="Anne Lawson">
<ABS_BACKGROUND MODIFIED="2014-08-14 06:27:27 -0400" MODIFIED_BY="Anne Lawson">
<P>Osteoarthritis is the most common form of joint disease and the leading cause of pain and physical disability in older people. Opioids may be a viable treatment option if people have severe pain or if other analgesics are contraindicated. However, the evidence about their effectiveness and safety is contradictory. This is an update of a Cochrane review first published in 2009.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2014-08-14 06:34:52 -0400" MODIFIED_BY="Anne Lawson">
<P>To determine the effects on pain, function, safety, and addiction of oral or transdermal opioids compared with placebo or no intervention in people with knee or hip osteoarthritis.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2014-08-15 09:46:54 -0400" MODIFIED_BY="Anne Lawson">
<P>We searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE and CINAHL (up to 28 July 2008, with an update performed on 15 August 2012), checked conference proceedings, reference lists, and contacted authors.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2014-08-14 06:28:45 -0400" MODIFIED_BY="Anne Lawson">
<P>We included randomised or quasi-randomised controlled trials that compared oral or transdermal opioids with placebo or no treatment in people with knee or hip osteoarthritis. We excluded studies of tramadol. We applied no language restrictions.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2014-08-14 06:29:39 -0400" MODIFIED_BY="Anne Lawson">
<P>We extracted data in duplicate. We calculated standardised mean differences (SMDs) and 95% confidence intervals (CI) for pain and function, and risk ratios for safety outcomes. We combined trials using an inverse-variance random-effects meta-analysis.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2014-08-14 06:38:20 -0400" MODIFIED_BY="Anne Lawson">
<P>We identified 12 additional trials and included 22 trials with 8275 participants in this update. Oral oxycodone was studied in 10 trials, transdermal buprenorphine and oral tapentadol in four, oral codeine in three, oral morphine and oral oxymorphone in two, and transdermal fentanyl and oral hydromorphone in one trial each. All trials were described as double-blind, but the risk of bias for other domains was unclear in several trials due to incomplete reporting. Opioids were more beneficial in pain reduction than control interventions (SMD -0.28, 95% CI -0.35 to -0.20), which corresponds to a difference in pain scores of 0.7 cm on a 10-cm visual analogue scale (VAS) between opioids and placebo. This corresponds to a difference in improvement of 12% (95% CI 9% to 15%) between opioids (41% mean improvement from baseline) and placebo (29% mean improvement from baseline), which translates into a number needed to treat (NNTB) to cause one additional treatment response on pain of 10 (95% CI 8 to 14). Improvement of function was larger in opioid-treated participants compared with control groups (SMD -0.26, 95% CI -0.35 to -0.17), which corresponds to a difference in function scores of 0.6 units between opioids and placebo on a standardised Western Ontario and McMaster Universities Arthritis Index (WOMAC) disability scale ranging from 0 to 10. This corresponds to a difference in improvement of 11% (95% CI 7% to 14%) between opioids (32% mean improvement from baseline) and placebo (21% mean improvement from baseline), which translates into an NNTB to cause one additional treatment response on function of 11 (95% CI 7 to 14). We did not find substantial differences in effects according to type of opioid, analgesic potency, route of administration, daily dose, methodological quality of trials, and type of funding. Trials with treatment durations of four weeks or less showed larger pain relief than trials with longer treatment duration (P value for interaction = 0.001) and there was evidence for funnel plot asymmetry (P value = 0.054 for pain and P value = 0.011 for function). Adverse events were more frequent in participants receiving opioids compared with control. The pooled risk ratio was 1.49 (95% CI 1.35 to 1.63) for any adverse event (9 trials; 22% of participants in opioid and 15% of participants in control treatment experienced side effects), 3.76 (95% CI 2.93 to 4.82) for drop-outs due to adverse events (19 trials; 6.4% of participants in opioid and 1.7% of participants in control treatment dropped out due to adverse events), and 3.35 (95% CI 0.83 to 13.56) for serious adverse events (2 trials; 1.3% of participants in opioid and 0.4% of participants in control treatment experienced serious adverse events). Withdrawal symptoms occurred more often in opioid compared with control treatment (odds ratio (OR) 2.76, 95% CI 2.02 to 3.77; 3 trials; 2.4% of participants in opioid and 0.9% of participants control treatment experienced withdrawal symptoms).</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2014-08-14 06:42:28 -0400" MODIFIED_BY="Anne Lawson">
<P>The small mean benefit of non-tramadol opioids are contrasted by significant increases in the risk of adverse events. For the pain outcome in particular, observed effects were of questionable clinical relevance since the 95% CI did not include the minimal clinically important difference of 0.37 SMDs, which corresponds to 0.9 cm on a 10-cm VAS.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2014-08-21 12:50:48 -0400" MODIFIED_BY="Anne Lawson">
<BACKGROUND MODIFIED="2014-08-15 09:34:09 -0400" MODIFIED_BY="Anne Lawson">
<CONDITION MODIFIED="2014-08-15 09:11:22 -0400" MODIFIED_BY="Anne Lawson">
<P>Osteoarthritis is the most common form of joint disease and the leading cause of pain, functional limitations, and loss of independence in older adults (<LINK REF="REF-Altman-1986" TYPE="REFERENCE">Altman 1986</LINK>). It is a progressive disease of synovial joints resulting from biomechanical and systemic effects, and is characterised by a breakdown of the joint cartilage accompanied by subchondral bone changes, deterioration of tendons and ligaments, and various degrees of inflammation of the synovium (<LINK REF="REF-Hochberg-2012" TYPE="REFERENCE">Hochberg 2012</LINK>).</P>
</CONDITION>
<INTERVENTION MODIFIED="2014-08-15 09:33:30 -0400" MODIFIED_BY="Anne Lawson">
<P>Pharmacological therapy for osteoarthritis, as an alternative or in addition to other therapeutic options, consists mainly of analgesics and non-steroidal anti-in&#64258;ammatory drugs (NSAIDs). However, paracetamol may be inadequate to treat more severe, long-term pain in osteoarthritis and chronic NSAID use may cause serious gastrointestinal and cardiovascular adverse events. Opioids could be a viable alternative if people have severe pain with insufficient response to conventional treatment or if other analgesics are contraindicated (<LINK REF="REF-Avouac-2007" TYPE="REFERENCE">Avouac 2007</LINK>).</P>
</INTERVENTION>
<THEORY MODIFIED="2012-12-13 08:33:18 -0500" MODIFIED_BY="[Empty name]">
<P>Opioids are potent analgesics that work by targeting mainly spinal and supraspinal opioid receptors. In addition, cellular studies suggest that there are peripheral opioid receptors in inflamed osteoarthritic synovial tissue, which may mediate analgesic effects (<LINK REF="REF-Stein-1996" TYPE="REFERENCE">Stein 1996</LINK>).</P>
</THEORY>
<IMPORTANCE MODIFIED="2014-08-15 09:34:09 -0400" MODIFIED_BY="Anne Lawson">
<P>The American College of Rheumatology guidelines on management of osteoarthritis, updated in 2012, suggest that opioids can be used in people with osteoarthritis after having failed medical therapy who were not willing or had contraindications for total joint replacement (<LINK REF="REF-Hochberg-2012" TYPE="REFERENCE">Hochberg 2012</LINK>). British guidelines propose opioids as an alternative if inadequate pain relief is achieved with topical NSAIDs or paracetamol (<LINK REF="REF-Eccles-1998" TYPE="REFERENCE">Eccles 1998</LINK>; <LINK REF="REF-NICE-2008" TYPE="REFERENCE">NICE 2008</LINK>). However, the use of strong opioids for the treatment of non-cancer pain remains controversial. Concerns have been expressed about long-term use of opioids for chronic non-cancer pain mainly due to the risks of addiction (<LINK REF="REF-Von-Korff-2004" TYPE="REFERENCE">Von Korff 2004</LINK>; <LINK REF="REF-Zhang-2008" TYPE="REFERENCE">Zhang 2008</LINK>).</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2014-08-15 09:36:22 -0400" MODIFIED_BY="Anne Lawson">
<P>To determine the effects on pain, function, safety, and addiction of oral or transdermal opioids compared with placebo or no intervention in people with knee or hip osteoarthritis.</P>
</OBJECTIVES>
<METHODS MODIFIED="2014-08-21 12:50:48 -0400" MODIFIED_BY="Anne Lawson">
<SELECTION_CRITERIA MODIFIED="2014-08-17 16:38:28 -0400" MODIFIED_BY="Anne Lawson">
<CRIT_STUDIES MODIFIED="2009-07-30 23:51:19 -0400" MODIFIED_BY="[Empty name]">
<P>Randomised or quasi-randomised controlled trials with a control group receiving placebo or no intervention.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2014-08-15 09:37:15 -0400" MODIFIED_BY="Anne Lawson">
<P>At least 75% of participants with clinically or radiologically confirmed osteoarthritis of the knee or hip. We did not consider trials exclusively including people with inflammatory arthritis, such as rheumatoid arthritis.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2009-07-30 23:53:00 -0400" MODIFIED_BY="[Empty name]">
<P>Any type of opioid except tramadol, which is covered in a separate Cochrane Review (<LINK REF="REF-Cepeda-2006" TYPE="REFERENCE">Cepeda 2006</LINK>).</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2014-08-17 16:38:28 -0400" MODIFIED_BY="Anne Lawson">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2014-08-17 16:37:29 -0400" MODIFIED_BY="Anne Lawson">
<P>The main outcomes were pain and function, as currently recommended for osteoarthritis trials (<LINK REF="REF-Altman-1996" TYPE="REFERENCE">Altman 1996</LINK>; <LINK REF="REF-Pham-2004" TYPE="REFERENCE">Pham 2004</LINK>). If data on more than one pain scale were provided for a trial, we referred to a previously described hierarchy of pain-related outcomes (<LINK REF="REF-J_x00fc_ni-2006" TYPE="REFERENCE">Jüni 2006</LINK>; <LINK REF="REF-Reichenbach-2007" TYPE="REFERENCE">Reichenbach 2007</LINK>), and extracted data on the pain scale that was highest on this list:</P>
<OL>
<LI>global pain;</LI>
<LI>pain on walking;</LI>
<LI>Western Ontario and McMaster Universities Arthritis Index (WOMAC) osteoarthritis index pain subscore;</LI>
<LI>composite pain scores other than WOMAC;</LI>
<LI>pain on activities other than walking;</LI>
<LI>rest pain or pain during the night;</LI>
<LI>WOMAC global algofunctional score;</LI>
<LI>Lequesne osteoarthritis index global score;</LI>
<LI>other algofunctional scale;</LI>
<LI>participant's global assessment;</LI>
<LI>physician's global assessment.</LI>
</OL>
<P>If data on more than one function scale were provided for a trial, we extracted data according to the hierarchy:</P>
<OL>
<LI>global disability score;</LI>
<LI>walking disability;</LI>
<LI>WOMAC disability subscore;</LI>
<LI>composite disability scores other than WOMAC;</LI>
<LI>disability other than walking;</LI>
<LI>WOMAC global scale;</LI>
<LI>Lequesne osteoarthritis index global score;</LI>
<LI>other algofunctional scale;</LI>
<LI>participant's global assessment;</LI>
<LI>physician's global assessment.</LI>
</OL>
<P>If pain or function outcomes were reported at several time points, we extracted the measure at the end of the treatment period.</P>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2014-08-17 16:38:28 -0400" MODIFIED_BY="Anne Lawson">
<P>Secondary outcomes were the number of participants who experienced any adverse event, withdrew because of adverse events, experienced any serious adverse events, and experienced symptoms of opioid dependence such as craving or physical withdrawal symptoms. We defined serious adverse events as events resulting in hospitalisation, prolongation of hospitalisation, persistent or significant disability, congenital abnormality or birth defect of offspring, life-threatening events, or death.</P>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2014-08-21 12:50:48 -0400" MODIFIED_BY="Anne Lawson">
<ELECTRONIC_SEARCHES MODIFIED="2014-08-15 09:48:18 -0400" MODIFIED_BY="Anne Lawson">
<P>We searched the electronic databases the Cochrane Central Register of Controlled Trials (CENTRAL) (<A HREF="http://mrw.interscience.wiley.com/cochrane/">mrw.interscience.wiley.com/cochrane/</A>), MEDLINE and EMBASE through the Ovid platform (<A HREF="http://www.ovid.com">www.ovid.com</A>), and CINAHL through EBSCOhost (all from implementation to July 28 2008) using truncated variations of preparation names including brand names combined with truncated variations of terms related to osteoarthritis, all as text words. We applied a validated methodological filter for controlled clinical trials (<LINK REF="REF-Dickersin-1994" TYPE="REFERENCE">Dickersin 1994</LINK>). The specific search algorithms are displayed in <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK> and <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>. We updated the search using CENTRAL, MEDLINE, and EMBASE up to 15 August 2012.</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2014-08-21 12:50:48 -0400" MODIFIED_BY="Anne Lawson">
<P>We manually searched conference proceedings, used Science Citation Index to retrieve reports citing relevant articles, contacted content experts and trialists, and screened reference lists of all obtained articles. Finally, we searched several clinical trial registries (<A HREF="http://www.clinicaltrials.gov/ct2/home">clinicaltrials.gov</A>, <A HREF="http://www.controlled-trials.com">metaRegister of Controlled Trials</A>, <A HREF="http://www.anzctr.org.au">Australian New Zealand Clinical Trials Registry</A>, <A HREF="http://www.umin.ac.jp/ctr">UMIN Clinical Trials Registry</A>) to identify ongoing trials. We performed the last update of the search on 20 September 2012. We did not search OARSI conference proceedings for the update, as we no longer had access to this database.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2014-08-17 16:57:13 -0400" MODIFIED_BY="Anne Lawson">
<P>We used a generic protocol with instructions for data extraction, quality assessment, and statistical analyses, which was approved by the editorial board of the Cochrane Musculoskeletal Group. We applied the same protocol in our previous reviews (<LINK REF="REF-Rutjes-2009a" TYPE="REFERENCE">Rutjes 2009a</LINK>; <LINK REF="REF-Rutjes-2009b" TYPE="REFERENCE">Rutjes 2009b</LINK>; <LINK REF="REF-Reichenbach-2010" TYPE="REFERENCE">Reichenbach 2010</LINK>; <LINK REF="REF-Rutjes-2010" TYPE="REFERENCE">Rutjes 2010</LINK>; <LINK REF="REF-da-Costa-2012b" TYPE="REFERENCE">da Costa 2012b</LINK>).</P>
<STUDY_SELECTION MODIFIED="2014-08-15 09:58:07 -0400" MODIFIED_BY="Anne Lawson">
<P>Two review authors independently evaluated all titles and abstracts for eligibility (originally EN and AR, BdC and RK for the update) (see <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>). We resolved disagreements by discussion. We applied no language restrictions. If multiple reports described the same trial, we considered all.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2014-08-17 16:57:13 -0400" MODIFIED_BY="Anne Lawson">
<P>Two review authors (originally EN and AR, BdC and RK for the update) extracted trial information independently using a standardised, piloted extraction form accompanied by a codebook. We resolved disagreements by discussion. We extracted both the generic and trade name of the experimental intervention, the type of control used, dosage, frequency, route of administration, duration of treatment, participant characteristics (gender, mean age and duration of symptoms, types of joints affected), types of measures used and pain- and function-related outcomes, trial design, trial size, duration of follow-up, type and source of financial support, and publication status. When necessary, we approximated means and measures of dispersion from figures in the reports. For cross-over trials, we extracted data from the first period only. Whenever possible, we used results from an intention-to-treat analysis. If effect sizes could not be calculated, we contacted the authors for additional data.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2014-08-17 16:38:43 -0400" MODIFIED_BY="Anne Lawson">
<P>Two review authors (originally EN and AR, BdC and RK for the update) independently assessed randomisation, blinding, and adequacy of analyses (<LINK REF="REF-J_x00fc_ni-2001" TYPE="REFERENCE">Jüni 2001</LINK>). We resolved disagreements by consensus. We assessed two components of randomisation: generation of allocation sequences and concealment of allocation. We considered generation of sequences to be adequate if it resulted in an unpredictable allocation schedule; mechanisms considered adequate included random-number tables, computer-generated random numbers, minimisation, coin tossing, shuffling cards, and drawing lots. We considered trials using an unpredictable allocation sequence to be randomised; we considered trials using potentially predictable allocation mechanisms, such as alternation or the allocation of participants according to date of birth, to be quasi-randomised. We considered concealment of allocation to be adequate if participants and investigators responsible for participant selection were unable to suspect before allocation which treatment was next. Methods considered adequate include central randomisation; pharmacy-controlled randomisation using identical pre-numbered containers; and sequentially numbered, sealed, opaque envelopes. We considered blinding of participants to be adequate if experimental and control preparations were explicitly described as indistinguishable or if a double-dummy technique was used. We considered analyses to be adequate if all randomised participants were included in the analysis according to the intention-to-treat principle. We further assessed the reporting of primary outcomes, sample size calculations, and funding source. Finally, we used GRADE to describe the quality of the overall body of evidence (<LINK REF="REF-Guyatt-2008" TYPE="REFERENCE">Guyatt 2008</LINK>; <LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>), defined as the extent of confidence into the estimates of treatment benefits and harms.</P>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2014-08-17 08:16:37 -0400" MODIFIED_BY="Anne Lawson">
<P>We summarised continuous outcomes using standardised mean differences (SMD) with 95% confidence intervals (CI), with the differences in mean values at the end of treatment across treatment groups divided by the pooled standard deviation (SD). If differences in mean values at the end of the treatment were unavailable, we used differences in mean changes. If some of the required data were unavailable, we used approximations, as previously described (<LINK REF="REF-Reichenbach-2007" TYPE="REFERENCE">Reichenbach 2007</LINK>). An SMD of -0.20 SD units can be considered a small difference between the experimental and control groups, an SMD of -0.50 a moderate difference, and -0.80 a large difference (<LINK REF="REF-Cohen-1988" TYPE="REFERENCE">Cohen 1988</LINK>; <LINK REF="REF-J_x00fc_ni-2006" TYPE="REFERENCE">Jüni 2006</LINK>). SMDs can also be interpreted in terms of the per cent of overlap of the experimental group's scores with scores of the control group. An SMD of -0.20 indicates an overlap in the distribution of pain or function scores in about 85% of cases, an SMD of -0.50 in about 67%, and an SMD of -0.80 in about 53% of cases (<LINK REF="REF-Cohen-1988" TYPE="REFERENCE">Cohen 1988</LINK>; <LINK REF="REF-J_x00fc_ni-2006" TYPE="REFERENCE">Jüni 2006</LINK>). On the basis of a median pooled SD of 2.5 cm, found in large-scale osteoarthritis trials that assessed pain using a 10-cm visual analogue scale (VAS) (<LINK REF="REF-N_x00fc_esch-2009" TYPE="REFERENCE">Nüesch 2009</LINK>), SMDs of -0.20 correspond to approximate differences in pain scores between experimental and control groups of 0.5 on a 10-cm VAS, -0.50 of 1.25 on a 10-cm VAS, and -0.80 of 2 on a 10-cm VAS. We back transformed SMDs for function to a standardised WOMAC disability score (<LINK REF="REF-Bellamy-1995" TYPE="REFERENCE">Bellamy 1995</LINK>), ranging from 0 to 10 on the basis of a median pooled SD of 2.1 units observed in large-scale osteoarthritis trials (<LINK REF="REF-N_x00fc_esch-2009" TYPE="REFERENCE">Nüesch 2009</LINK>). We expressed binary outcomes as risk ratios (RR) with 95% CI.</P>
</EFFECT_MEASURES>
<DATA_SYNTHESIS MODIFIED="2014-08-17 16:38:57 -0400" MODIFIED_BY="Anne Lawson">
<P>We used a standard inverse-variance random-effects meta-analysis to combine the trials (<LINK REF="REF-DerSimonian-1986" TYPE="REFERENCE">DerSimonian 1986</LINK>). We quantified heterogeneity between trials using the I<SUP>2</SUP> statistic (<LINK REF="REF-Higgins-2003" TYPE="REFERENCE">Higgins 2003</LINK>), which describes the percentage of variation across trials that is attributable to heterogeneity rather than to chance. I<SUP>2</SUP> values of 25% may be interpreted as low, 50% as moderate, and 75% as high between-trial heterogeneity, although its interpretation depends on the size and number of trials included (<LINK REF="REF-R_x00fc_cker-2008" TYPE="REFERENCE">Rücker 2008</LINK>). The association between trial size and treatment effects was investigated in funnel plots, plotting effect sizes on the vertical axis against their standard errors on the horizontal axis (<LINK REF="REF-Sterne-2011" TYPE="REFERENCE">Sterne 2011</LINK>). We assessed asymmetry by the asymmetry coefficient, the difference in effect size per unit increase in standard error (<LINK REF="REF-Sterne-2001" TYPE="REFERENCE">Sterne 2001</LINK>), which is mainly a surrogate for sample size, and used univariable, meta-regression analysis to predict treatment effects in trials as large as the largest trials included in the meta-analysis using the standard error as the explanatory variable (<LINK REF="REF-Shang-2005" TYPE="REFERENCE">Shang 2005</LINK>). We then performed analyses of the primary outcomes, pain and function, stratified by the following trial characteristics: type of opioid, analgesic potency (strong versus weak), route of administration (oral versus transdermal), type of control (placebo versus no intervention), concealment of allocation (adequate versus inadequate or unclear), blinding of participants (adequate versus inadequate or unclear), analysis in accordance with the intention-to-treat principle (yes versus no or unclear), trial size, funding (funding by pharmaceutical industry or unclear versus no funding by pharmaceutical industry), duration of treatment, and type of osteoarthritis (hip only versus knee only versus mixed). We classified buprenorphine, fentanyl, morphine, oxycodone, oxymorphone, and tapentadol as strong opioids, and codeine and dextropropoxyphene as weak opioids. We used a cut-off of 200 allocated participants to distinguish between small-scale and large-scale trials. A sample size of 2 x 100 participants will yield more than 80% power to detect a small-to-moderate SMD of -0.40 at a two-sided P value of 0.05, which corresponds to a difference of 1 cm on a 10-cm VAS between the experimental and control intervention (<LINK REF="REF-N_x00fc_esch-2010" TYPE="REFERENCE">Nüesch 2010</LINK>). We used a cut-off of one month to distinguish between short-term and long-term trials. We used univariable, random-effects meta-regression models to determine whether treatment effects were affected by these factors (<LINK REF="REF-Thompson-1999" TYPE="REFERENCE">Thompson 1999</LINK>). In addition, we included the following two continuous variables at trial level in univariable meta-regression: daily morphine equivalence dosage and treatment duration. We calculated morphine equivalence doses as previously described: oral morphine 10 mg was considered equivalent to oral codeine 65 mg, oral hydromorphone 2 mg, oral oxycodone 7.5 mg, and oral oxymorphone 10 mg and oral tapentadol 25 mg (<LINK REF="REF-Loeser-2001" TYPE="REFERENCE">Loeser 2001</LINK>; <LINK REF="REF-Schug-2006" TYPE="REFERENCE">Schug 2006</LINK>). Patches of fentanyl 25 &#956;g/hour was considered equivalent to oral morphine 90 mg per day and patches of buprenorphine 5, 10, and 20 &#956;g/hour equivalent to 10, 15, and 30 mg oral morphine per day (<LINK REF="REF-British-Pain-Society-2010" TYPE="REFERENCE">British Pain Society 2010</LINK>).</P>
<P>We converted SMDs of pain intensity and function to odds ratios (OR) (<LINK REF="REF-Chinn-2000" TYPE="REFERENCE">Chinn 2000</LINK>; <LINK REF="REF-da-Costa-2012a" TYPE="REFERENCE">da Costa 2012a</LINK>) to derive numbers needed to treat to cause one additional treatment response on pain or function as compared with placebo (NNTB), and numbers needed to treat to cause one additional adverse outcome (NNTH). We defined treatment response as a 50% improvement in scores (<LINK REF="REF-Clegg-2006" TYPE="REFERENCE">Clegg 2006</LINK>). With a median standardised pain intensity at baseline of 2.4 SD units, observed in large osteoarthritis trials (<LINK REF="REF-N_x00fc_esch-2009" TYPE="REFERENCE">Nüesch 2009</LINK>), this corresponds to a mean decrease in scores of 1.2 SD units. Based on the median standardised decrease in pain scores of 0.72 SD units (<LINK REF="REF-N_x00fc_esch-2009" TYPE="REFERENCE">Nüesch 2009</LINK>), we calculated that a median of 31% of participants in the placebo group would achieve an improvement of pain scores of 50% or more. This percentage was used as the control group response rate to calculate NNTBs for treatment response on pain. Based on the median standardised WOMAC function score at baseline of 2.7 SD units and the median standardised decrease in function scores of 0.58 SD units (<LINK REF="REF-N_x00fc_esch-2009" TYPE="REFERENCE">Nüesch 2009</LINK>), 26% of participants in the placebo group would achieve a reduction in function of 50% or more. Again, this percentage was used as the control group response rate to calculate NNTBs for treatment response on function. We used the median risks of 150 participants with adverse events per 1000 participant-years, four participants with serious adverse events per 1000 participant-years, and 17 drop-outs due to adverse events per 1000 participant-years as observed in placebo groups in large osteoarthritis trials (<LINK REF="REF-N_x00fc_esch-2009" TYPE="REFERENCE">Nüesch 2009</LINK>), to calculate NNTHs for safety outcomes. All P values were two-sided. We performed analyses using Review Manager 5 (<LINK REF="REF-RevMan-2012" TYPE="REFERENCE">RevMan 2012</LINK>), and STATA version 11.2 (StataCorp, College Station, Texas).</P>
</DATA_SYNTHESIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2014-08-17 16:59:16 -0400" MODIFIED_BY="Anne Lawson">
<STUDY_DESCRIPTION MODIFIED="2014-08-17 16:59:16 -0400" MODIFIED_BY="Anne Lawson">
<P>We identified 5099 potentially relevant references through our electronic searches (<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>); we excluded 4984 references after screening titles and abstracts and retrieved 115 potentially relevant references for full-text assessment. We included 22 randomised controlled trials in the review. Checking reference lists, trial registers, and handsearching of conference proceedings yielded five additional trials.</P>
<P>Three trials evaluated weak opioids. All three compared codeine with placebo (<LINK REF="STD-Kjaersgaard_x002d_Andersen-1990" TYPE="STUDY">Kjaersgaard-Andersen 1990</LINK>; <LINK REF="STD-Quiding-1992" TYPE="STUDY">Quiding 1992</LINK>; <LINK REF="STD-Peloso-2000" TYPE="STUDY">Peloso 2000</LINK>), one of these with paracetamol 3000 mg daily as analgesic co-intervention administered in both the experimental and control groups (<LINK REF="STD-Kjaersgaard_x002d_Andersen-1990" TYPE="STUDY">Kjaersgaard-Andersen 1990</LINK>), and another with ibuprofen 1200 mg daily administered in both groups (<LINK REF="STD-Quiding-1992" TYPE="STUDY">Quiding 1992</LINK>). Strong opioids were compared with placebo in 19 trials. Hydromorphone was used in one trial (<LINK REF="STD-NCT00980798" TYPE="STUDY">NCT00980798</LINK>), morphine in two trials (<LINK REF="STD-Caldwell-2002" TYPE="STUDY">Caldwell 2002</LINK>; <LINK REF="STD-Katz-2010" TYPE="STUDY">Katz 2010</LINK>), oxymorphone in two trials (<LINK REF="STD-Matsumoto-2005" TYPE="STUDY">Matsumoto 2005</LINK>; <LINK REF="STD-Kivitz-2006" TYPE="STUDY">Kivitz 2006</LINK>), oxycodone in 10 trials (<LINK REF="STD-Chindalore-2005" TYPE="STUDY">Chindalore 2005</LINK>; <LINK REF="STD-Markenson-2005" TYPE="STUDY">Markenson 2005</LINK>; <LINK REF="STD-Matsumoto-2005" TYPE="STUDY">Matsumoto 2005</LINK>; <LINK REF="STD-Zautra-2005" TYPE="STUDY">Zautra 2005</LINK>; <LINK REF="STD-Hartrick-2009" TYPE="STUDY">Hartrick 2009</LINK>; <LINK REF="STD-Afilalo-2010" TYPE="STUDY">Afilalo 2010</LINK>; <LINK REF="STD-Etropolski-2011" TYPE="STUDY">Etropolski 2011</LINK>; <LINK REF="STD-Fidelholtz-2011" TYPE="STUDY">Fidelholtz 2011</LINK>; <LINK REF="STD-Friedmann-2011" TYPE="STUDY">Friedmann 2011</LINK>; <LINK REF="STD-NCT00486811" TYPE="STUDY">NCT00486811</LINK>), and tapentadol in four trials (<LINK REF="STD-Hartrick-2009" TYPE="STUDY">Hartrick 2009</LINK>; <LINK REF="STD-Afilalo-2010" TYPE="STUDY">Afilalo 2010</LINK>; <LINK REF="STD-Etropolski-2011" TYPE="STUDY">Etropolski 2011</LINK>; <LINK REF="STD-NCT00486811" TYPE="STUDY">NCT00486811</LINK>). Transdermal opioids were studied in five trials: buprenorphine in four trials (<LINK REF="STD-Shannon-2005" TYPE="STUDY">Shannon 2005</LINK>; <LINK REF="STD-Breivik-2010" TYPE="STUDY">Breivik 2010</LINK>; <LINK REF="STD-Munera-2010" TYPE="STUDY">Munera 2010</LINK>; <LINK REF="STD-NCT00531427" TYPE="STUDY">NCT00531427</LINK>), and fentanyl in one trial (<LINK REF="STD-Langford-2006" TYPE="STUDY">Langford 2006</LINK>). Opioids were administered at a median daily dose of 59-mg morphine equivalents (range 13 to 160 mg).</P>
<P>The median treatment duration was four weeks (range three days to six months). Trials randomised a median of 344 participants (range 27 to 10301 participants). Twenty trials (90%) were multicentre trials, 21 were parallel group, and one was a cross-over trial (<LINK REF="STD-Quiding-1992" TYPE="STUDY">Quiding 1992</LINK>). Two trials exclusively included participants with hip osteoarthritis (<LINK REF="STD-Kjaersgaard_x002d_Andersen-1990" TYPE="STUDY">Kjaersgaard-Andersen 1990</LINK>; <LINK REF="STD-Quiding-1992" TYPE="STUDY">Quiding 1992</LINK>), four trials included only participants with knee osteoarthritis (<LINK REF="STD-Zautra-2005" TYPE="STUDY">Zautra 2005</LINK>; <LINK REF="STD-NCT00486811" TYPE="STUDY">NCT0048681</LINK>; <LINK REF="STD-Afilalo-2010" TYPE="STUDY">Afilalo 2010</LINK>
<LINK REF="STD-NCT00486811" TYPE="STUDY">1</LINK>; <LINK REF="STD-NCT00531427" TYPE="STUDY">NCT00531427</LINK>), and 16 trials included a mixed population of both knee and hip osteoarthritis (<LINK REF="STD-Peloso-2000" TYPE="STUDY">Peloso 2000</LINK>; <LINK REF="STD-Caldwell-2002" TYPE="STUDY">Caldwell 2002</LINK>; <LINK REF="STD-Chindalore-2005" TYPE="STUDY">Chindalore 2005</LINK>; <LINK REF="STD-Markenson-2005" TYPE="STUDY">Markenson 2005</LINK>; <LINK REF="STD-Matsumoto-2005" TYPE="STUDY">Matsumoto 2005</LINK>; <LINK REF="STD-Shannon-2005" TYPE="STUDY">Shannon 2005</LINK>; <LINK REF="STD-Kivitz-2006" TYPE="STUDY">Kivitz 2006</LINK>; <LINK REF="STD-Langford-2006" TYPE="STUDY">Langford 2006</LINK>; <LINK REF="STD-Hartrick-2009" TYPE="STUDY">Hartrick 2009</LINK>; <LINK REF="STD-Breivik-2010" TYPE="STUDY">Breivik 2010</LINK>; <LINK REF="STD-Katz-2010" TYPE="STUDY">Katz 2010</LINK>; <LINK REF="STD-Munera-2010" TYPE="STUDY">Munera 2010</LINK>; <LINK REF="STD-Etropolski-2011" TYPE="STUDY">Etropolski 2011</LINK>; <LINK REF="STD-Fidelholtz-2011" TYPE="STUDY">Fidelholtz 2011</LINK>; <LINK REF="STD-Friedmann-2011" TYPE="STUDY">Friedmann 2011</LINK>; <LINK REF="STD-NCT00980798" TYPE="STUDY">NCT00980798</LINK>). In 17 studies, only participants with insufficient analgesic response to paracetamol, NSAIDs, or previous opioid treatment were included (<LINK REF="STD-NCT00980798" TYPE="STUDY">NCT00980798</LINK>; <LINK REF="STD-NCT00531427" TYPE="STUDY">NCT00531427</LINK>; <LINK REF="STD-Caldwell-2002" TYPE="STUDY">Caldwell 2002</LINK>; <LINK REF="STD-Chindalore-2005" TYPE="STUDY">Chindalore 2005</LINK>; <LINK REF="STD-Markenson-2005" TYPE="STUDY">Markenson 2005</LINK>; <LINK REF="STD-Matsumoto-2005" TYPE="STUDY">Matsumoto 2005</LINK>; <LINK REF="STD-Shannon-2005" TYPE="STUDY">Shannon 2005</LINK>; <LINK REF="STD-Kivitz-2006" TYPE="STUDY">Kivitz 2006</LINK>; <LINK REF="STD-Langford-2006" TYPE="STUDY">Langford 2006</LINK>; <LINK REF="STD-Hartrick-2009" TYPE="STUDY">Hartrick 2009</LINK>; <LINK REF="STD-Afilalo-2010" TYPE="STUDY">Afilalo 2010</LINK>; <LINK REF="STD-Breivik-2010" TYPE="STUDY">Breivik 2010</LINK>; <LINK REF="STD-Katz-2010" TYPE="STUDY">Katz 2010</LINK>; <LINK REF="STD-Munera-2010" TYPE="STUDY">Munera 2010</LINK>; <LINK REF="STD-Etropolski-2011" TYPE="STUDY">Etropolski 2011</LINK>; <LINK REF="STD-Friedmann-2011" TYPE="STUDY">Friedmann 2011</LINK>; <LINK REF="STD-NCT00486811" TYPE="STUDY">NCT00486811</LINK>). None of these trials provided detailed information about the dosage of the analgesic treatments before entering the trial. The three trials assessing codeine included participants with a need for analgesic treatment but without any requirement of previous insufficient treatment response (<LINK REF="STD-Kjaersgaard_x002d_Andersen-1990" TYPE="STUDY">Kjaersgaard-Andersen 1990</LINK>; <LINK REF="STD-Quiding-1992" TYPE="STUDY">Quiding 1992</LINK>; <LINK REF="STD-Peloso-2000" TYPE="STUDY">Peloso 2000</LINK>); two trials did not provide information about eligibility criteria concerning the previous analgesic therapy (<LINK REF="STD-Zautra-2005" TYPE="STUDY">Zautra 2005</LINK>; <LINK REF="STD-Fidelholtz-2011" TYPE="STUDY">Fidelholtz 2011</LINK>).</P>
<P>The <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK> table displays the reasons why we did not consider trials in this systematic review. Typical reasons were more than 25% of participants with rheumatoid arthritis in the sample, the use of active control interventions, or the use of cross-over designs without providing sufficient information on the first phase.</P>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2014-08-17 16:39:43 -0400" MODIFIED_BY="Anne Lawson">
<P>
<LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK> summarises the methodological characteristics and sources of funding of included trials. Six trials (27%) reported both adequate sequence generation and adequate allocation concealment (<LINK REF="STD-Markenson-2005" TYPE="STUDY">Markenson 2005</LINK>; <LINK REF="STD-Kivitz-2006" TYPE="STUDY">Kivitz 2006</LINK>; <LINK REF="STD-Langford-2006" TYPE="STUDY">Langford 2006</LINK>; <LINK REF="STD-Afilalo-2010" TYPE="STUDY">Afilalo 2010</LINK>; <LINK REF="STD-Breivik-2010" TYPE="STUDY">Breivik 2010</LINK>; <LINK REF="STD-Etropolski-2011" TYPE="STUDY">Etropolski 2011</LINK>), two trials reported only adequate sequence generation (<LINK REF="STD-Matsumoto-2005" TYPE="STUDY">Matsumoto 2005</LINK>; <LINK REF="STD-Hartrick-2009" TYPE="STUDY">Hartrick 2009</LINK>), and two trials reported adequate concealment but remained unclear about the generation of allocation sequence (<LINK REF="STD-Zautra-2005" TYPE="STUDY">Zautra 2005</LINK>; <LINK REF="STD-Katz-2010" TYPE="STUDY">Katz 2010</LINK>). In the remaining 12 trials, low quality of reporting hampered any judgement regarding sequence generation and concealment of allocation. All 22 trials were described as double blind. Eleven trials reported the use of indistinguishable interventions to blind participants whereas another four trials used double-dummy techniques (<LINK REF="STD-Quiding-1992" TYPE="STUDY">Quiding 1992</LINK>; <LINK REF="STD-Caldwell-2002" TYPE="STUDY">Caldwell 2002</LINK>; <LINK REF="STD-Kivitz-2006" TYPE="STUDY">Kivitz 2006</LINK>; <LINK REF="STD-Afilalo-2010" TYPE="STUDY">Afilalo 2010</LINK>). Fourteen trials explicitly reported adequate blinding of physicians. Seventeen trials described their analysis to be according to the intention-to-treat principle, but only one trial was considered to have an intention-to-treat analysis of pain (<LINK REF="STD-NCT00531427" TYPE="STUDY">NCT00531427</LINK>), and one trial of function outcomes at end of treatment (<LINK REF="STD-Katz-2010" TYPE="STUDY">Katz 2010</LINK>), according to our criteria. Exclusion of participants from the analysis of pain outcomes ranged from 0.6% to 52% in the experimental groups and from 0% to 33% in the control groups. For eight trials, no information was available on the proportion of excluded participants (<LINK REF="STD-NCT00980798" TYPE="STUDY">NCT00980798</LINK>; <LINK REF="STD-Quiding-1992" TYPE="STUDY">Quiding 1992</LINK>; <LINK REF="STD-Caldwell-2002" TYPE="STUDY">Caldwell 2002</LINK>; <LINK REF="STD-Markenson-2005" TYPE="STUDY">Markenson 2005</LINK>; <LINK REF="STD-Langford-2006" TYPE="STUDY">Langford 2006</LINK>; <LINK REF="STD-Hartrick-2009" TYPE="STUDY">Hartrick 2009</LINK>; <LINK REF="STD-Fidelholtz-2011" TYPE="STUDY">Fidelholtz 2011</LINK>; <LINK REF="STD-NCT00486811" TYPE="STUDY">NCT00486811</LINK>). For the analysis of function outcomes, exclusion of participants ranged from 1% to 73% in the experimental groups and from 0.6% to 53% in the control groups; in four trials, no information was available on the proportion of excluded patients (<LINK REF="STD-Caldwell-2002" TYPE="STUDY">Caldwell 2002</LINK>; <LINK REF="STD-Markenson-2005" TYPE="STUDY">Markenson 2005</LINK>; <LINK REF="STD-Langford-2006" TYPE="STUDY">Langford 2006</LINK>; <LINK REF="STD-NCT00486811" TYPE="STUDY">NCT00486811</LINK>).</P>
<P>All trials (95%) except for one (<LINK REF="STD-Quiding-1992" TYPE="STUDY">Quiding 1992</LINK>) reported a primary outcome of which eight explicitly reported it to be pre-specified in the protocol (<LINK REF="STD-Peloso-2000" TYPE="STUDY">Peloso 2000</LINK>; <LINK REF="STD-Caldwell-2002" TYPE="STUDY">Caldwell 2002</LINK>; <LINK REF="STD-Markenson-2005" TYPE="STUDY">Markenson 2005</LINK>; <LINK REF="STD-Matsumoto-2005" TYPE="STUDY">Matsumoto 2005</LINK>; <LINK REF="STD-Langford-2006" TYPE="STUDY">Langford 2006</LINK>; <LINK REF="STD-Katz-2010" TYPE="STUDY">Katz 2010</LINK>; <LINK REF="STD-NCT00486811" TYPE="STUDY">NCT00486811</LINK>; <LINK REF="STD-NCT00531427" TYPE="STUDY">NCT00531427</LINK>), and 13 trials reported a sample size calculation for this primary outcome. Twenty trials received financial support from a commercial organisation, two were unclear about their source of funding (<LINK REF="STD-Kjaersgaard_x002d_Andersen-1990" TYPE="STUDY">Kjaersgaard-Andersen 1990</LINK>; <LINK REF="STD-Quiding-1992" TYPE="STUDY">Quiding 1992</LINK>), whereas no trial was explicitly supported by a non-profit organisation. For the effectiveness outcomes pain and function, the quality of the evidence (<LINK REF="REF-Guyatt-2008" TYPE="REFERENCE">Guyatt 2008</LINK>) was classified as high in view of the low risk of bias in the included trials and the low heterogeneity between trials (<LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>). For adverse event and serious adverse event outcomes, the quality of the evidence (<LINK REF="REF-Guyatt-2008" TYPE="REFERENCE">Guyatt 2008</LINK>) was classified as moderate to low because of the small number of trials reporting the outcomes and the small number of serious adverse events, which resulted in imprecise estimates (<LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>).</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2014-08-17 16:40:45 -0400" MODIFIED_BY="Anne Lawson">
<SUBSECTION>
<HEADING LEVEL="3">Primary outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Knee or hip pain</HEADING>
<P>Twenty-two trials including 5180 participants in experimental groups and 3095 participants in control groups contributed to the analyses of knee or hip pain. <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK> presents results of the analysis, overall and stratified according to type of opioid. In the overall analysis, combined oral and transdermal opioids were more effective in pain reduction than control interventions (SMD -0.28, 95% CI -0.35 to -0.20), which corresponds to a difference in pain scores of 0.7 cm on a 10-cm VAS between opioids and placebo. This corresponds to a difference in improvement of 12% (95% CI 9% to 15%) between opioids and placebo (<LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>), which translates into an NNTB to cause one additional treatment response on pain of 10 (95% CI 8 to 14) (<LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>). An I<SUP>2</SUP> statistic of 58% indicated a moderate degree of between-trial heterogeneity (P for heterogeneity &lt; 0.001). A visual inspection of the funnel plot suggested asymmetry (asymmetry coefficient -1.86, 95% CI -3.50 to -0.21) and the test for asymmetry indicated some evidence for asymmetry (P value = 0.054) (<LINK REF="FIG-04" TYPE="FIGURE">Figure 4</LINK>). Benefits were moderate for codeine (SMD -0.51, 95% CI -1.01 to -0.01; 3 trials); small to moderate for oxycodone (SMD -0.31, 95% CI -0.47 to -0.15; 10 trials), oxymorphone (SMD -0.39, 95% CI -0.58 to -0.21; 2 trials), and tapentadol (SMD -0.31, 95% CI -0.46 to -0.16, 4 trials); and small for morphine (SMD -0.25, 95% CI -0.42 to -0.09; 2 trials) and transdermal opioids such as buprenorphine (SMD -0.19, 95% CI -0.30 to -0.09, 4 trials) and fentanyl (SMD -0.22, 95% CI -0.42 to -0.03; 1 trial). No benefit was observed for hydromorphone (SMD 0.04, 95% CI -0.19 to 0.28, 1 trial). The CIs were wide and a test for interaction between benefit and type of opioid was non-significant (P value = 0.66). <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK> presents the results of stratified analyses. We found little evidence for an association of SMDs with analgesic potency, route of administration, type of control intervention, use of analgesic co-interventions, type of osteoarthritis, concealment of allocation, adequate blinding of participants, or intention-to-treat analysis. Effects were similar in studies including participants with only knee osteoarthritis (SMD -0.22, 95% CI -0.41 to -0.04, 4 trials), with only hip osteoarthritis (SMD -0.33, 95% CI -0.93 to 0.28, 2 trials), and with knee or hip osteoarthritis (SMD -0.29, 95% CI -0.38 to -0.20, 16 trials, P value for interaction = 0.77). We found larger benefits in trials with 200 or fewer randomised participants (difference in SMD -0.23, 95% CI -0.49 to 0.02, P for interaction = 0.08) and in trials with a short treatment duration of one month or less (difference in SMD -0.25, 95% CI -0.37 to -0.13, P value for interaction = 0.001). The effect of treatment duration on treatment benefits was similar, when we restricted the analyses to large trials only (P value for interaction 0.001). Thirty-three comparisons from 22 trials contributed to the analysis of a linear association between equivalence dose and treatment benefit (<LINK REF="FIG-05" TYPE="FIGURE">Figure 5</LINK>). We found little evidence for a linear association between daily equivalence doses and pain reduction (P value = 0.49).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Function</HEADING>
<P>Twelve studies including 2124 participants in experimental groups and 1429 participants in control groups contributed to the analysis of function. Improvement of function was larger in opioid-treated participants compared with control groups (SMD -0.26, 95% CI -0.35 to -0.17) (<LINK REF="FIG-06" TYPE="FIGURE">Figure 6</LINK>), which corresponds to a difference in function scores of 0.6 units between opioids and placebo on a standardised WOMAC disability scale ranging from 0 to 10. This corresponds to a difference in improvement of 11% (95% CI 7% to 14%) between opioids and placebo (<LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>), which translates into an NNTB to cause one additional treatment response on function of 11 (95% CI 7 to 14) (<LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>). An I<SUP>2</SUP> statistic of 32% indicated a low degree of between-trial heterogeneity (P value for heterogeneity = 0.12). We found a moderate benefit for codeine (SMD -0.42, 95% CI -0.74 to -0.10; 2 trials) and oxymorphone (SMD -0.38, 95% CI -0.56 to -0.19, 2 trials) and small benefits for morphine (SMD -0.20, 95% CI -0.38 to -0.02, 2 trials), oxycodone (SMD -0.30, 95% CI -0.58 to -0.01, 4 trials), tapentadol (SMD -0.15, 95% CI -0.45 to 0.16, 2 trials), and for transdermal opioids such as buprenorphine (SMD -0.23, 95% CI -0.40 to -0.05, 2 trials) and fentanyl (SMD -0.28, 95% CI -0.48 to -0.09; 1 trial). As was the case for pain, CIs of estimates were wide and a test for interaction between benefit and type of opioid was non-significant (P value = 0.87). Heterogeneity between trials was low with an I<SUP>2</SUP> statistic estimate of 32% (P value for heterogeneity = 0.12). The funnel plot (<LINK REF="FIG-07" TYPE="FIGURE">Figure 7</LINK>) appeared asymmetrical (asymmetry coefficient -3.33, 95% CI -5.76 to -0.89, P value for asymmetry = 0.011). <LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK> presents the results of the stratified analyses. We found little evidence for an association of SMDs with analgesic potency, route of administration, type of control intervention, treatment duration, use of analgesic co-interventions, type of osteoarthritis, allocation concealment, and intention-to-treat analysis. Effects were similar in studies including participants with only knee osteoarthritis (SMD -0.16, 95% CI -0.43 to 0.11, 2 trials), only hip OA (SMD -0.29, 95% CI -0.68 to 0.11, 1 trial), and knee or hip OA (SMD -0.31, 95% CI -0.41 to -0.20, 9 trials, P value for interaction 0.45). Adequately powered trials with 200 or more randomised participants tended to show smaller improvements of function (difference in SMD 0.23, 95% CI -0.06 to 0.52, P value for interaction = 0.11) and trials with adequate participant blinding larger benefits of function (difference in SMD -0.25, 95% CI -0.41 to -0.09, P value for interaction = 0.008). Eighteen comparisons from 12 trials contributed to the analysis of a linear association between equivalence dose and treatment benefit for function (<LINK REF="FIG-08" TYPE="FIGURE">Figure 8</LINK>). We found no evidence for an association between daily equivalence doses and improvement of function (P value = 0.48).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Secondary outcomes</HEADING>
<P>Ten trials reported the occurrence of any adverse event in 2490 out of 3222 participants in experimental groups and 891 of 1676 participants in control groups (<LINK REF="FIG-09" TYPE="FIGURE">Figure 9</LINK>). Participants were 49% more likely to experience adverse events in experimental groups compared with placebo (RR 1.49, 95% CI 1.35 to 1.63). The NNTH to cause one additional participant to experience an adverse event, as compared to placebo, was 14 (95% CI 11 to 19) (<LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>). We found high heterogeneity between different studies (I<SUP>2 </SUP>= 71%, P value for heterogeneity &lt; 0.001), but no evidence that RRs differed between different types of opioids (P value for interaction = 0.47) or length of treatment duration (P value = 0.09). Eighteen comparisons in nine trials contributed to the analysis of the association between equivalence dose and log relative risk (<LINK REF="FIG-10" TYPE="FIGURE">Figure 10</LINK>). We found little evidence for a relationship (P value = 0.24).</P>
<P>Twenty-one trials with 8128 participants contributed to the meta-analysis of participants withdrawn or dropped out because of adverse events (<LINK REF="FIG-11" TYPE="FIGURE">Figure 11</LINK>). Participants receiving opioid therapy were 3.8 times as likely as participants receiving placebo to be withdrawn or drop-out due to adverse events (RR 3.76, 95% CI 2.93 to 4.82), with moderate between-trial heterogeneity (I<SUP>2</SUP> = 59%, P value for heterogeneity &lt; 0.001). The NNTH to cause one additional drop-out or withdrawal due to adverse events compared with placebo was 21 (95% CI 15 to 30) (<LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>). We found the highest pooled RR for oxycodone versus placebo (RR 5.55, 95% CI 3.47 to 8.87, 9 trials) and the lowest pooled RR for morphine versus placebo (RR 2.12, 95% CI 0.87 to 5.15, 2 trials) but CIs were wide and a test for interaction between type of opioids and relative risk of being withdrawn or dropping out because of adverse events negative gave a P value for interaction of 0.41. We found no evidence for an association between treatment duration and risk of withdrawals or drop-outs due to adverse events (P value for interaction 0.78). Thirty-two comparisons in 22 trials contributed to the analysis of the association between equivalence dose and log relative risk (<LINK REF="FIG-12" TYPE="FIGURE">Figure 12</LINK>). We found little evidence for a relationship (P value = 0.94).</P>
<P>Three trials with 681 participants contributed to the analysis of participants experiencing any serious adverse event (<LINK REF="FIG-13" TYPE="FIGURE">Figure 13</LINK>). One trial reported one death in the oxycodone group, but no other serious adverse events and was not included in the analysis (<LINK REF="STD-Afilalo-2010" TYPE="STUDY">Afilalo 2010</LINK>). Of the three trials included, one trial reported that no participant experienced a serious adverse event (<LINK REF="STD-Kjaersgaard_x002d_Andersen-1990" TYPE="STUDY">Kjaersgaard-Andersen 1990</LINK>). Overall data from the remaining two trials indicated that participants receiving opioids tended be more likely to experience a serious adverse event (RR 3.35, 95% CI 0.83 to 13.56). Due to the low number of trials and events, we neither performed an analysis of the association between treatment duration or equivalence dose and log relative risk for this outcome, nor a calculation of NNTH to cause one additional participant to experience a serious adverse event compared with placebo.</P>
<P>Three trials reported symptoms of opioid dependency (<LINK REF="STD-Langford-2006" TYPE="STUDY">Langford 2006</LINK>; <LINK REF="STD-Afilalo-2010" TYPE="STUDY">Afilalo 2010</LINK>; <LINK REF="STD-Katz-2010" TYPE="STUDY">Katz 2010</LINK>). Two studies reported 25 of 397 participants with withdrawal symptoms in oral opioids and five of 255 in control groups (<LINK REF="STD-Afilalo-2010" TYPE="STUDY">Afilalo 2010</LINK>; <LINK REF="STD-Katz-2010" TYPE="STUDY">Katz 2010</LINK>). One study assessed opiate withdrawal symptoms after eight weeks of transdermal fentanyl therapy, using the Short Opiate Withdrawal Scale questionnaire (<LINK REF="REF-Gossop-1990" TYPE="REFERENCE">Gossop 1990</LINK>; <LINK REF="STD-Langford-2006" TYPE="STUDY">Langford 2006</LINK>). On average, participants in the opioids groups had a 2.8-fold increased risk of withdrawal symptoms compared with control groups with a pooled OR of 2.76 (95% CI 2.02 to 3.77) (<LINK REF="FIG-14" TYPE="FIGURE">Figure 14</LINK>). The NNTH to cause one additional participant to experience withdrawal symptoms, as compared with control, was 65 (95% CI 42 to 110).</P>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2014-08-17 16:40:51 -0400" MODIFIED_BY="Anne Lawson">
<SUMMARY_OF_RESULTS MODIFIED="2014-08-17 16:40:47 -0400" MODIFIED_BY="Anne Lawson">
<P>In this update of our systematic review and meta-analysis, we found only small benefits of oral or transdermal opioids being more effective compared with placebo in terms of pain relief and improvement of function in people with osteoarthritis. If participants received opioids for more than four weeks, benefits on pain relief were even further reduced. The occurrence of adverse events often caused participants to stop taking the opioids, which is likely to limit the usefulness of opioids in the long term. The potentially higher risk of serious adverse events and substance addiction might further limit their use. The reporting of safety outcomes was incomplete and adverse events were reported in only about half of the trials, and serious adverse events in three trials only. Trials that did report safety outcomes consistently observed a significant increase in the risk of adverse events with opioid use.</P>
</SUMMARY_OF_RESULTS>
<QUALITY_OF_EVIDENCE MODIFIED="2014-08-17 16:40:49 -0400" MODIFIED_BY="Anne Lawson">
<P>Most of the trials were funded by the pharmaceutical industry and we did not have enough data to explore whether the type of funding was associated with the estimated treatment effects. We found larger benefits on pain relief in studies with opioid use for less than four weeks compared with longer treatments, but not dependence of benefits on function or safety outcomes according to treatment duration. Thus, the effectiveness of opioids may drop during chronic use as the analgesic effects of opioids are mediated through opioids receptors, but safety concerns were not affected by this. The relatively low dose of morphine equivalents (median daily dose 67 mg) administered in the included trials might provide an explanation of the small benefits observed as compared with other studies (<LINK REF="REF-Maier-2002" TYPE="REFERENCE">Maier 2002</LINK>). Our ability to provide a reliable assessment of dose dependency might have been hampered by the generally low morphine equivalent doses used and the lack of individual participant data. The generally used distinction between weak and strong opioids can be misleading, because the analgesic potency depends also on the dosage. Thus, we calculated morphine equivalence doses to be able to compare different opioids, but found no evidence for dose-dependent effects. We found little evidence that stronger opioid agents or higher doses of these agents will result in larger treatment effects. However, it is possible that type of opioids interacts with dosage. For instance, higher doses could have larger treatment effects for stronger but not for weaker opioids. The characteristics of the trials included in our review did not allow us to explore such interaction properly.</P>
<P>Data on risks of addiction due to opioid therapy is scarce, and currently available trials are not designed to evaluate these issues. There is a clear need for additional randomised trials and observational studies using longer follow-up times to address the risks of substance dependence associated with different opioids. In this systematic review, only three out of 22 trials reported measures of withdrawal symptoms (<LINK REF="STD-Langford-2006" TYPE="STUDY">Langford 2006</LINK>; <LINK REF="STD-Afilalo-2010" TYPE="STUDY">Afilalo 2010</LINK>; <LINK REF="STD-Katz-2010" TYPE="STUDY">Katz 2010</LINK>). Similar to previous systematic reviews of randomised trials on opioids therapy for non-cancer pain (<LINK REF="REF-Kalso-2004" TYPE="REFERENCE">Kalso 2004</LINK>; <LINK REF="REF-Furlan-2006" TYPE="REFERENCE">Furlan 2006</LINK>), we found that most of the trials included in our review had a treatment duration of several days or a few weeks only. Although some of the newer trials in the update had slightly longer treatment durations (<LINK REF="STD-Afilalo-2010" TYPE="STUDY">Afilalo 2010</LINK>; <LINK REF="STD-Breivik-2010" TYPE="STUDY">Breivik 2010</LINK>; <LINK REF="STD-NCT00486811" TYPE="STUDY">NCT00486811</LINK>; <LINK REF="STD-NCT00980798" TYPE="STUDY">NCT00980798</LINK>), in none of the trials did participants receive opioids for longer than six months. This is still too short to address the impact of opioid treatment on routine clinical practice in the treatment of a chronic condition such as osteoarthritis. While no evidence of long-term effects is available from randomised trials, observational studies indicate that long-term treatment with opioids of chronic conditions such as osteoarthritis may have deleterious effects and do not seem to improve pain relief (<LINK REF="REF-Eriksen-2006" TYPE="REFERENCE">Eriksen 2006</LINK>).</P>
</QUALITY_OF_EVIDENCE>
<POTENTIAL_BIASES MODIFIED="2014-08-16 08:07:04 -0400" MODIFIED_BY="Anne Lawson">
<P>We based our review on a broad literature search. Even though we cannot exclude potential publication bias, it seems rather unlikely that we missed relevant trials (<LINK REF="REF-Egger-2003" TYPE="REFERENCE">Egger 2003</LINK>). Two review authors independently performed selection of trials and data extraction to minimise bias and transcription errors (<LINK REF="REF-Egger-2001" TYPE="REFERENCE">Egger 2001</LINK>; <LINK REF="REF-G_x00f8_tzsche-2007" TYPE="REFERENCE">Gøtzsche 2007</LINK>). The most recent systematic review on opioids for osteoarthritis (<LINK REF="REF-Avouac-2007" TYPE="REFERENCE">Avouac 2007</LINK>), updated in October 2006, considered 18 studies that compared opioids with placebo. We included data from six of these in our meta-analysis and data from four additional trials (<LINK REF="STD-Kjaersgaard_x002d_Andersen-1990" TYPE="STUDY">Kjaersgaard-Andersen 1990</LINK>; <LINK REF="STD-Quiding-1992" TYPE="STUDY">Quiding 1992</LINK>; <LINK REF="STD-Matsumoto-2005" TYPE="STUDY">Matsumoto 2005</LINK>; <LINK REF="STD-Kivitz-2006" TYPE="STUDY">Kivitz 2006</LINK>). We excluded six trials with tramadol as the experimental intervention and one trial that was likely to have included only a minority of people with osteoarthritis. In our update, we identified 12 additional trials, of which three are unpublished. In conclusion, we are likely to have included all relevant trials in our systematic review.<BR/>
</P>
</POTENTIAL_BIASES>
<AGREEMENT MODIFIED="2014-08-17 16:40:51 -0400" MODIFIED_BY="Anne Lawson">
<P>We excluded tramadol from our review to avoid overlap with another Cochrane review that focused on this specific opioid in osteoarthritis (<LINK REF="REF-Cepeda-2006" TYPE="REFERENCE">Cepeda 2006</LINK>). Extracted pain and function outcomes and follow-up time in the previous systematic review about opioids for osteoarthritis (<LINK REF="REF-Avouac-2007" TYPE="REFERENCE">Avouac 2007</LINK>) were similar to our systematic review. Comparing opioids with placebo controls, <LINK REF="REF-Avouac-2007" TYPE="REFERENCE">Avouac 2007</LINK> found a large pooled effect for pain intensity (SMD -0.79, 95% CI -0.98 to -0.59) and a moderate pooled effect for function (SMD -0.31, 95% CI -0.39 to -0.24). These effects are consistent with our results for function but are substantially larger for pain reduction. This discrepancy might be due to the exclusion of some trials in our systematic review and to inclusion of newer trials in our update in 2012. <LINK REF="REF-Avouac-2007" TYPE="REFERENCE">Avouac 2007</LINK> reported moderate-to-large effects of tramadol for pain, between -0.36 to -0.93 SD units, in several large trials and unrealistically large beneficial effects on pain intensity in an oxycodone trial that was excluded from our review due to the likely very low percentage of participants with knee or hip osteoarthritis (<LINK REF="STD-Roth-2000" TYPE="STUDY">Roth 2000</LINK>). These trials often did not report function outcomes and could not, therefore, contribute to the pooled analysis, or they reported considerably smaller effects for function than for pain (<LINK REF="REF-Avouac-2007" TYPE="REFERENCE">Avouac 2007</LINK>). In line with other studies, we found that adverse events occurring in participants treated with opioids often caused withdrawals and drop-outs (<LINK REF="REF-Kalso-2004" TYPE="REFERENCE">Kalso 2004</LINK>; <LINK REF="REF-Furlan-2006" TYPE="REFERENCE">Furlan 2006</LINK>; <LINK REF="REF-Avouac-2007" TYPE="REFERENCE">Avouac 2007</LINK>; <LINK REF="REF-Gehling-2011" TYPE="REFERENCE">Gehling 2011</LINK>). Tramadol may be similar to, or even more effective than, the opioids evaluated in our review in reducing pain and improving function, but safety concerns have to be addressed further (<LINK REF="REF-Cepeda-2006" TYPE="REFERENCE">Cepeda 2006</LINK>).<BR/>
</P>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2014-08-21 11:10:16 -0400" MODIFIED_BY="Anne Lawson">
<IMPLICATIONS_PRACTICE MODIFIED="2014-08-21 11:10:16 -0400" MODIFIED_BY="Anne Lawson">
<P>Opioids decrease pain intensity and improve function but the benefits observed are small. Dose increases do not appear to result in further pain reduction, while prolongation of treatment duration resulted in even smaller pain reduction. Observed effects for pain were of questionable clinical relevance since the 95% confidence intervals did not include the minimal clinically important difference of 0.37 standardised mean differences (SMDs), which corresponds to 0.9 cm on a 10-cm visual analogue scale (VAS) (<LINK REF="REF-Wandel-2010" TYPE="REFERENCE">Wandel 2010</LINK>; <LINK REF="REF-Rutjes-2012" TYPE="REFERENCE">Rutjes 2012</LINK>). The occurrence of adverse events caused one in 20 participants to stop taking the preparations, which is likely to limit their usefulness in the long-term treatment of osteoarthritis of the hip or knee. The higher risk of serious adverse events and the occurrence of addiction to opioid therapy might further limit their clinical use, although evidence is limited by the short duration of follow-up of the studies assessing these outcomes. Nevertheless, use of opioids might be warranted in special situations, such as for short-term treatment of later stage osteoarthritis awaiting surgery. However, clinicians should inform participants about the substantial risks and only small benefits of opioid treatment and therapeutic alternatives.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2014-08-17 16:40:59 -0400" MODIFIED_BY="Anne Lawson">
<P>The effectiveness and safety of opioid and non-opioid analgesics in participants with inadequate pain relief should be directly compared in appropriately powered randomised controlled trials accompanied by separate Cochrane reviews or reviews of reviews including network meta-analyses, which integrate direct and indirect evidence in one single analysis while maintaining randomisation (<LINK REF="REF-Caldwell-2005" TYPE="REFERENCE">Caldwell 2005</LINK>). The evidence of the effectiveness and safety of opioid therapy is mainly from a few short-term trials, despite the fact that the underlying condition is chronic and requires safe, long-term treatments (<LINK REF="REF-Kalso-2004" TYPE="REFERENCE">Kalso 2004</LINK>; <LINK REF="REF-Furlan-2006" TYPE="REFERENCE">Furlan 2006</LINK>). Further long-term observational studies would increase our understanding of their long-term effectiveness, safety, and the potential for addiction. In addition, future trials might be performed in participants with clear failures of previous analgesic therapies with non-steroidal anti-inflammatory drugs or opioids and might target special subgroups, such as separately study and report participants with knee or hip osteoarthritis to acknowledge the different mechanisms resulting in pain in these two phenotypes, or participants with and without pain sensitisation.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2009-07-31 02:35:24 -0400" MODIFIED_BY="[Empty name]">
<P>We thank the Cochrane Musculoskeletal editorial team for valuable comments and Malcolm Sturdy for database support. The authors are grateful to Hans Quiding for providing us with additional information concerning design and outcome data.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2014-08-16 08:27:51 -0400" MODIFIED_BY="Anne Lawson">
<P>None.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2014-08-16 08:27:51 -0400" MODIFIED_BY="Anne Lawson">
<P>Protocol completion: Nüesch, Rutjes, Husni, Jüni.<BR/>Acquisition of data: Nüesch, da Costa, Kasteler, Rutjes.<BR/>Analysis and interpretation of data: Nüesch, da Costa, Kasteler, Husni, Welch, Rutjes, Jüni.<BR/>Manuscript preparation: Nüesch, da Costa, Kasteler, Husni, Welch, Rutjes, Jüni.<BR/>Statistical analysis: Nüesch, da Costa, Rutjes, Jüni.</P>
<P>Drs. Nüesch and da Costa contributed equally to this review.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2014-08-17 15:49:51 -0400" MODIFIED_BY="Anne Lawson">
<P>The cut-off to distinguish between short-term and long-term trials was changed from 26 weeks to one month. Six months was considered to be rather long as the cut-off for an agent that is not considered to be a structure-modifying drug. In the absence of definitions for short-term treatment in osteoarthritis treatment guidelines, we used the median follow-up duration in the trials included in the first review (four weeks) as a cut-off to discriminate between trials of shorter and longer duration.<BR/>We did not include the electronic database CINAHL in our search update since, in our previous search, this database did not identify any additional hits. Finally, we did not include the OARSI database in our search update, as we no longer had access to this database. We added analyses stratified by type of osteoarthritis (hip only versus knee only versus mixed) upon request of peer reviewers.</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2014-08-18 14:48:01 -0400" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2014-08-18 14:48:01 -0400" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2014-08-18 14:48:01 -0400" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Afilalo-2010" MODIFIED="2014-08-17 17:23:46 -0400" MODIFIED_BY="Anne Lawson" NAME="Afilalo 2010" YEAR="2010">
<REFERENCE MODIFIED="2014-08-16 10:55:28 -0400" MODIFIED_BY="Anne Lawson" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Afilalo M, Etropolski MS, Kuperwasser B, Kelly K, Okamoto A, Van Hove I, et al</AU>
<TI>Efficacy and safety of tapentadol extended release compared with oxycodone controlled release for the management of moderate to severe chronic pain related to osteoarthritis of the knee: a randomized, double-blind, placebo- and active-controlled phase III study</TI>
<SO>Clinical Drug Investigation</SO>
<YR>2010</YR>
<VL>30</VL>
<NO>8</NO>
<PG>489-505</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2014-08-17 15:58:52 -0400" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="OTHER">
<AU>Grünenthal GmbH</AU>
<TI>A study to evaluate the efficacy and safety of cg5503 prolonged release (PR) in subjects with moderate to severe chronic pain due to osteoarthritis of the knee</TI>
<SO>clinicaltrials.gov/show/NCT00486811</SO>
<YR>(accessed 16 August 2014)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2014-08-17 17:23:35 -0400" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="OTHER">
<AU>Kelly K, Etropolski M, Kuperwasser B, Okamoto A, Steup A, vanHove I, et al</AU>
<TI>Similar analgesic effect and improved tolerability of tapentadol extended release versus oxycodone controlled release for the management of chronic osteoarthritis knee pain: results from a randomized, double-blind, phase3 trial</TI>
<SO>Proceedings of the Annual EULAR Conference; 2009 Jun 10-13; Copenhagen, Denmark</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2014-08-17 17:23:46 -0400" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="OTHER">
<AU>Kelly K, Lange B, Etropolski M, Kuperwasser B, Okamoto A, vanHove I, et al</AU>
<TI>Dose stability of tapentadol extended release (ER) for the relief of moderate-to-severe chronic osteoarthritic knee pain</TI>
<SO>Proceedings of the 26th Annual Meeting of the American Academy of Pain Medicine; 2010 Feb 3-6; San Antonio, TX</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2014-08-17 16:01:23 -0400" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lange B, Kuperwasser B, Okamoto A, Häufel T, Ashworth J</AU>
<TI>Efficacy and safety of tapentadol prolonged release (PR) based on prior experience in patients with chronic osteoarthritis knee pain</TI>
<SO>Annals of Rheumatic Diseases</SO>
<YR>2010</YR>
<VL>69</VL>
<PG>287</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2014-08-17 16:01:49 -0400" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lange R, Lange B, Greene A, Okamoto A, Etropolski M, Ashworth J</AU>
<TI>Short Form-36 (SF-36) and EUROQOL-5 Dimension (EQ-5D) results from randomized, double-blind phase 3 studies of tapentadol prolonged release (PR) in patients with moderate to severe chronic nociceptive and neuropathic pain</TI>
<SO>Osteoarthritis and Cartilage</SO>
<YR>2010</YR>
<VL>18</VL>
<PG>S147-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2013-02-04 05:27:53 -0500" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Breivik-2010" MODIFIED="2014-08-16 10:46:10 -0400" MODIFIED_BY="Anne Lawson" NAME="Breivik 2010" YEAR="2010">
<REFERENCE MODIFIED="2014-08-16 10:46:10 -0400" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Breivik H, Ljosaa TM, Stengaard-Pedersen K, Persson J, Aro H, Villumsen J, et al</AU>
<TI>A 6-months, randomised, placebo-controlled evaluation of efficacy and tolerability of a low-dose 7-day buprenorphine transdermal patch in osteoarthritis patients naive to potent opioids</TI>
<SO>Scandinavian Journal of Pain</SO>
<YR>2010</YR>
<VL>1</VL>
<PG>122-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Caldwell-2002" MODIFIED="2014-08-16 10:46:22 -0400" MODIFIED_BY="Anne Lawson" NAME="Caldwell 2002" YEAR="2002">
<REFERENCE MODIFIED="2014-08-16 10:46:22 -0400" MODIFIED_BY="Anne Lawson" NOTES="Date of Publication: 2002" NOTES_MODIFIED="2014-08-16 10:46:22 -0400" NOTES_MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Caldwell JR, Rapoport RJ, Davis JC, Offenberg HL, Marker HW, Roth SH, et al</AU>
<TI>Efficacy and safety of a once-daily morphine formulation in chronic, moderate-to-severe osteoarthritis pain: results from a randomized, placebo-controlled, double-blind trial and an open-label extension trial</TI>
<SO>Journal of Pain and Symptom Management</SO>
<YR>2002</YR>
<VL>23</VL>
<NO>4</NO>
<PG>278-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chindalore-2005" MODIFIED="2014-08-16 10:46:39 -0400" MODIFIED_BY="Anne Lawson" NAME="Chindalore 2005" YEAR="2005">
<REFERENCE MODIFIED="2014-08-16 10:46:39 -0400" MODIFIED_BY="Anne Lawson" NOTES="Date of Publication: Jun 2005" NOTES_MODIFIED="2014-08-16 10:46:39 -0400" NOTES_MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chindalore VL, Craven RA, Yu KP, Butera PG, Burns LH, Friedmann N</AU>
<TI>Adding ultra low-dose naltrexone to oxycodone enhances and prolongs analgesia: a randomized, controlled trial of oxytrex</TI>
<SO>Journal of Pain</SO>
<YR>2005</YR>
<VL>6</VL>
<NO>6</NO>
<PG>392-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Etropolski-2011" MODIFIED="2014-08-16 10:55:18 -0400" MODIFIED_BY="Anne Lawson" NAME="Etropolski 2011" YEAR="2011">
<REFERENCE MODIFIED="2014-08-16 10:55:18 -0400" MODIFIED_BY="Anne Lawson" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Etropolski M, Kelly K, Okamoto A, Rauschkolb C</AU>
<TI>Comparable efficacy and superior gastrointestinal tolerability (nausea, vomiting, constipation) of tapentadol compared with oxycodone hydrochloride</TI>
<SO>Advances in Therapy</SO>
<YR>2011</YR>
<VL>28</VL>
<NO>5</NO>
<PG>401-17</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2014-08-16 10:47:32 -0400" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="OTHER">
<AU>Johnson &amp; Johnson</AU>
<TI>A study to compare the frequency of constipation symptoms with tapentadol immediate release (IR) treatment versus oxycodone IR treatment in patients with end-stage joint disease</TI>
<SO>clinicaltrials.gov/show/NCT00784277</SO>
<YR>(accessed 16 August 2014)</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fidelholtz-2011" MODIFIED="2014-08-17 17:23:15 -0400" MODIFIED_BY="Anne Lawson" NAME="Fidelholtz 2011" YEAR="2011">
<REFERENCE MODIFIED="2014-08-17 17:23:15 -0400" MODIFIED_BY="Anne Lawson" PRIMARY="YES" TYPE="OTHER">
<AU>Fidelholtz J, Tark M, Spierings E, Wolfram G, Annis K, Smith MD, et al</AU>
<TI>A phase 3 placebo- and oxycodone-controlled study of tanezumab in adults with osteoarthritis</TI>
<SO>Proceedings of the ACR/ARHP Scientific Meeting; 2011 Nov 9-11; Chicago</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2014-08-16 10:56:25 -0400" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="OTHER">
<AU>Pfizer</AU>
<TI>Tanezumab in osteoarthritis of the hip or knee</TI>
<SO>clinicaltrials.gov/show/NCT00985621</SO>
<YR>(accessed 16 August 2014)</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Friedmann-2011" MODIFIED="2014-08-16 10:57:21 -0400" MODIFIED_BY="Anne Lawson" NAME="Friedmann 2011" YEAR="2011">
<REFERENCE MODIFIED="2014-08-16 10:57:21 -0400" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Friedmann N, Klutzaritz V, Webster L</AU>
<TI>Efficacy and safety of an extended-release oxycodone (Remoxy®) formulation in patients with moderate to severe osteoarthritic pain</TI>
<SO>Journal of Opioid Management</SO>
<YR>2011</YR>
<VL>7</VL>
<NO>3</NO>
<PG>193-202</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hartrick-2009" MODIFIED="2014-08-16 10:58:36 -0400" MODIFIED_BY="Anne Lawson" NAME="Hartrick 2009" YEAR="2009">
<REFERENCE MODIFIED="2014-08-16 10:57:40 -0400" MODIFIED_BY="Anne Lawson" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Hartrick C, Van Hove I, Stegmann JU, Oh C, Upmalis D</AU>
<TI>Efficacy and tolerability of tapentadol immediate release and oxycodone HCl immediate release in patients awaiting primary joint replacement surgery for end-stage joint disease: a 10-day, phase III, randomized, double-blind, active- and placebo-controlled study</TI>
<SO>Clinical Therapeutics</SO>
<YR>2009</YR>
<VL>31</VL>
<NO>2</NO>
<PG>260-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2014-08-16 10:58:36 -0400" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="OTHER">
<AU>Johnson &amp; Johnson</AU>
<TI>A study to evaluate the effectiveness and safety of multiple doses of tapentadol (CG5503) in patients awaiting joint replacement surgery</TI>
<SO>clinicaltrials.gov/show/NCT00361582</SO>
<YR>(accessed 16 August 2014)</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Katz-2010" MODIFIED="2014-08-17 17:25:02 -0400" MODIFIED_BY="Anne Lawson" NAME="Katz 2010" YEAR="2010">
<REFERENCE MODIFIED="2014-08-16 10:59:12 -0400" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="OTHER">
<AU>Alpharma</AU>
<TI>A study of embeda (Kadian NT, ALO-01) in subjects with pain due to osteoarthritis of the hip or knee</TI>
<SO>clinicaltrials.gov/show/NCT00420992</SO>
<YR>(accessed 16 August 2014)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2014-08-17 17:25:02 -0400" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="OTHER">
<AU>Jones JB, Wagner G, Morris D, Stauffer J</AU>
<TI>Efficacy of morphine sulfate extended-release with sequestered naltrexone hydrochloride (ALO-01) in patients with chronic, moderate to severe pain of osteoarthritis of the hip or knee</TI>
<SO>Proceedings of the American College of Rheumatology Annual Scientific Meeting; 2008 Oct 24-29; San Francisco</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2014-08-16 10:58:46 -0400" MODIFIED_BY="Anne Lawson" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Katz N, Hale M, Morris D, Stauffer J</AU>
<TI>Morphine sulfate and naltrexone hydrochloride extended release capsules in patients with chronic osteoarthritis pain</TI>
<SO>Postgraduate Medicine</SO>
<YR>2010</YR>
<VL>122</VL>
<NO>4</NO>
<PG>112-28</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2014-08-17 17:23:57 -0400" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="OTHER">
<AU>Katz N, Setnik B, Webster L</AU>
<TI>Safety profile of EMBEDA&#8482; (morphine sulfate and naltrexone hydrochloride) Extended Release Capsules in older patients</TI>
<SO>Proceedings of the 29th Annual Scientific Meeting of the American Pain Society; 2010 May 6-8; Baltimore, MD</SO>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kivitz-2006" MODIFIED="2009-07-31 02:59:37 -0400" MODIFIED_BY="[Empty name]" NAME="Kivitz 2006" YEAR="2006">
<REFERENCE MODIFIED="2009-07-31 02:59:37 -0400" MODIFIED_BY="[Empty name]" NOTES="Date of Publication: Mar 2006" NOTES_MODIFIED="2009-07-31 02:59:37 -0400" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kivitz A, Ma C, Ahdieh H, Galer BS</AU>
<TI>A 2-week, multicenter, randomized, double-blind, placebo-controlled, dose-ranging, phase III trial comparing the efficacy of oxymorphone extended release and placebo in adults with pain associated with osteoarthritis of the hip or knee</TI>
<SO>Clinical Therapeutics</SO>
<YR>2006</YR>
<VL>28</VL>
<NO>3</NO>
<PG>352-64</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kjaersgaard_x002d_Andersen-1990" MODIFIED="2009-07-31 02:59:59 -0400" MODIFIED_BY="[Empty name]" NAME="Kjaersgaard-Andersen 1990" YEAR="1990">
<REFERENCE MODIFIED="2009-07-31 02:59:59 -0400" MODIFIED_BY="[Empty name]" NOTES="Date of Publication: 1990" NOTES_MODIFIED="2009-07-31 02:59:59 -0400" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kjaersgaard-Andersen P, Nafei A, Skov O, Madsen F, Andersen HM, Kroner K, et al</AU>
<TI>Codeine plus paracetamol versus paracetamol in longer-term treatment of chronic pain due to osteoarthritis of the hip. A randomised, double-blind, multi-centre study</TI>
<SO>Pain</SO>
<YR>1990</YR>
<VL>43</VL>
<NO>3</NO>
<PG>309-18</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Langford-2006" MODIFIED="2014-08-17 07:06:14 -0400" MODIFIED_BY="Anne Lawson" NAME="Langford 2006" YEAR="2006">
<REFERENCE MODIFIED="2014-08-17 07:06:14 -0400" MODIFIED_BY="Anne Lawson" NOTES="Date of Publication: Jun 2006" NOTES_MODIFIED="2014-08-17 07:06:14 -0400" NOTES_MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Langford R, McKenna F, Ratcliffe S, Vojtassak J, Richarz U</AU>
<TI>Transdermal fentanyl for improvement of pain and functioning in osteoarthritis: a randomized, placebo-controlled trial</TI>
<SO>Arthritis and Rheumatism</SO>
<YR>2006</YR>
<VL>54</VL>
<NO>6</NO>
<PG>1829-37</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Markenson-2005" MODIFIED="2009-07-31 03:00:23 -0400" MODIFIED_BY="[Empty name]" NAME="Markenson 2005" YEAR="2005">
<REFERENCE MODIFIED="2009-07-31 03:00:23 -0400" MODIFIED_BY="[Empty name]" NOTES="Date of Publication: Nov 2005" NOTES_MODIFIED="2009-07-31 03:00:23 -0400" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Markenson JA, Croft J, Zhang PG, Richards P</AU>
<TI>Treatment of persistent pain associated with osteoarthritis with controlled-release oxycodone tablets in a randomized controlled clinical trial</TI>
<SO>Clinical Journal of Pain</SO>
<YR>2005</YR>
<VL>21</VL>
<NO>6</NO>
<PG>524-35</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Matsumoto-2005" MODIFIED="2014-08-17 07:06:42 -0400" MODIFIED_BY="Anne Lawson" NAME="Matsumoto 2005" YEAR="2005">
<REFERENCE MODIFIED="2014-08-17 07:06:42 -0400" MODIFIED_BY="Anne Lawson" NOTES="Date of Publication: Sep 2005" NOTES_MODIFIED="2014-08-17 07:06:42 -0400" NOTES_MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Matsumoto AK, Babul N, Ahdieh H</AU>
<TI>Oxymorphone extended-release tablets relieve moderate to severe pain and improve physical function in osteoarthritis: results of a randomized, double-blind, placebo- and active-controlled phase III trial</TI>
<SO>Pain Medicine</SO>
<YR>2005</YR>
<VL>6</VL>
<NO>5</NO>
<PG>357-66</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Munera-2010" MODIFIED="2014-08-17 07:09:30 -0400" MODIFIED_BY="Anne Lawson" NAME="Munera 2010" YEAR="2010">
<REFERENCE MODIFIED="2014-08-17 07:07:05 -0400" MODIFIED_BY="Anne Lawson" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Munera C, Drehobl M, Sessler NE, Landau C</AU>
<TI>A randomized, placebo-controlled, double-blinded, parallel-group, 5-week study of buprenorphine transdermal system in adults with osteoarthritis</TI>
<SO>Journal of Opioid Management</SO>
<YR>2010</YR>
<VL>6</VL>
<NO>3</NO>
<PG>193-202</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2014-08-17 07:09:30 -0400" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="OTHER">
<AU>Purdue</AU>
<TI>Safety and efficacy of the buprenorphine transdermal delivery system in subjects with osteoarthritis pain</TI>
<SO>clinicaltrials.gov/show/NCT00314652</SO>
<YR>(accessed 16 August 2014)</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NCT00486811" MODIFIED="2014-08-17 07:10:22 -0400" MODIFIED_BY="Anne Lawson" NAME="NCT00486811" YEAR="6811">
<REFERENCE MODIFIED="2014-08-17 07:10:22 -0400" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="OTHER">
<AU>Grünenthal</AU>
<TI>A study to evaluate the efficacy and safety of CG5503 prolonged release (PR) in subjects with moderate to severe chronic pain due to osteoarthritis of the knee</TI>
<SO>clinicaltrials.gov/show/NCT00486811</SO>
<YR>(accessed 16 August 2014)</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NCT00531427" MODIFIED="2014-08-17 07:11:12 -0400" MODIFIED_BY="Anne Lawson" NAME="NCT00531427" YEAR="1427">
<REFERENCE MODIFIED="2014-08-17 07:11:12 -0400" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="OTHER">
<AU>Purdue</AU>
<TI>A study to evaluate the efficacy and safety of CG5503 prolonged release (PR) in subjects with moderate to severe chronic pain due to osteoarthritis of the knee</TI>
<SO>clinicaltrials.gov/show/NCT00531427</SO>
<YR>(accessed 16 August 2014)</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NCT00980798" MODIFIED="2014-08-17 07:12:06 -0400" MODIFIED_BY="Anne Lawson" NAME="NCT00980798" YEAR="0798">
<REFERENCE MODIFIED="2014-08-17 07:12:06 -0400" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="OTHER">
<AU>Janssen-Cilag</AU>
<TI>Placebo-controlled trial with OROS hydromorphone hydrochloride to treat patients with moderate to severe pain induced by osteoarthritis of the hip or the knee</TI>
<SO>clinicaltrials.gov/show/NCT00980798</SO>
<YR>(accessed 16 August 2014)</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Peloso-2000" MODIFIED="2009-07-31 03:00:57 -0400" MODIFIED_BY="[Empty name]" NAME="Peloso 2000" YEAR="2000">
<REFERENCE MODIFIED="2009-07-31 03:00:57 -0400" MODIFIED_BY="[Empty name]" NOTES="Date of Publication: 2000" NOTES_MODIFIED="2009-07-31 03:00:57 -0400" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Peloso PM, Bellamy N, Bensen W, Thomson GTD, Harsanyi Z, Babul N, et al</AU>
<TI>Double blind randomized placebo control trial of controlled release codeine in the treatment of osteoarthritis of the hip or knee</TI>
<SO>Journal of Rheumatology</SO>
<YR>2000</YR>
<VL>27</VL>
<NO>3</NO>
<PG>764-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Quiding-1992" MODIFIED="2012-12-17 12:43:40 -0500" MODIFIED_BY="[Empty name]" NAME="Quiding 1992" YEAR="1992">
<REFERENCE MODIFIED="2009-07-31 03:01:36 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Öhrvik, J</AU>
<TI>Nonparametric methods in crossover trials</TI>
<SO>Biometrical Journal</SO>
<YR>1998</YR>
<VL>7</VL>
<PG>771-89</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2008-10-14 10:56:33 -0400" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Quiding H, Grimstad J, Rusten K, Stubhaug A, Bremnes J, Breivik H</AU>
<TI>Ibuprofen plus codeine, ibuprofen, and placebo in a single- and multidose cross-over comparison for coxarthrosis pain</TI>
<SO>Pain</SO>
<YR>1992</YR>
<VL>50</VL>
<NO>3</NO>
<PG>303-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shannon-2005" MODIFIED="2014-08-18 14:48:01 -0400" MODIFIED_BY="[Empty name]" NAME="Shannon 2005" YEAR="2005">
<REFERENCE MODIFIED="2014-08-18 14:48:01 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Landau CJ, Shannon M, Kivitz AJ, Sessler NE, Xia Y, Ripa SR</AU>
<TI>Buprenorphine transdermal system in chronic pain due to osteoarthritis</TI>
<SO>Arthritis and Rheumatism</SO>
<YR>2008</YR>
<VL>58</VL>
<NO>Suppl 9</NO>
<PG>866</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2014-08-17 07:25:07 -0400" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="OTHER">
<AU>Purdue</AU>
<TI>Safety and efficacy of buprenorphine transdermal system in subjects with moderate to severe osteoarthritis of hip or knee</TI>
<SO>clinicaltrials.gov/show/NCT00313846</SO>
<YR>(accessed 16 August 2014)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2014-08-17 07:13:06 -0400" MODIFIED_BY="Anne Lawson" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Shannon MJ, Kivitz AJ, Landau CJ, Sessler NE, Xia Y, Ripa SR</AU>
<TI>Buprenorphine transdermal system in chronic pain due to osteoarthritis</TI>
<SO>Archives of Physical Medicine and Rehabilitation</SO>
<YR>2005</YR>
<VL>86</VL>
<PG>E32</PG>
<IDENTIFIERS MODIFIED="2013-02-05 05:05:24 -0500" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zautra-2005" MODIFIED="2009-07-31 03:02:12 -0400" MODIFIED_BY="[Empty name]" NAME="Zautra 2005" YEAR="2005">
<REFERENCE MODIFIED="2009-07-31 03:02:12 -0400" MODIFIED_BY="[Empty name]" NOTES="Date of Publication: Nov 2005" NOTES_MODIFIED="2009-07-31 03:02:12 -0400" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zautra AJ, Smith BW</AU>
<TI>Impact of controlled-release oxycodone on efficacy beliefs and coping efforts among osteoarthritis patients with moderate to severe pain</TI>
<SO>Clinical Journal of Pain</SO>
<YR>2005</YR>
<VL>21</VL>
<NO>6</NO>
<PG>471-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2014-08-17 08:23:18 -0400" MODIFIED_BY="Anne Lawson">
<STUDY DATA_SOURCE="PUB" ID="STD-Adams-2006" MODIFIED="2009-07-31 03:03:15 -0400" MODIFIED_BY="[Empty name]" NAME="Adams 2006" YEAR="2006">
<REFERENCE MODIFIED="2009-07-31 03:03:15 -0400" MODIFIED_BY="[Empty name]" NOTES="Date of Publication: May 2006" NOTES_MODIFIED="2009-07-31 03:03:15 -0400" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Adams EH, Breiner S, Cicero TJ, Geller A, Inciardi JA, Schnoll SH, et al</AU>
<TI>A comparison of the abuse liability of tramadol, NSAIDs, and hydrocodone in patients with chronic pain</TI>
<SO>Journal of Pain and Symptom Management</SO>
<YR>2006</YR>
<VL>31</VL>
<NO>5</NO>
<PG>465-76</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Andrei-1984" MODIFIED="2008-09-18 04:00:25 -0400" MODIFIED_BY="[Empty name]" NAME="Andrei 1984" YEAR="1984">
<REFERENCE MODIFIED="2008-09-18 04:00:25 -0400" MODIFIED_BY="[Empty name]" NOTES="Date of Publication: 1984" NOTES_MODIFIED="2008-09-18 04:00:25 -0400" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Andrei A, Schiaroli G, Algeri R, Valentini P</AU>
<TI>Recent data on antiinflammatory and analgesic treatment of degenerative arthropathies. Double-blind controlled clinical trial. [Italian]</TI>
<SO>Archivio di Medicina Interna</SO>
<YR>1984</YR>
<VL>36</VL>
<NO>4</NO>
<PG>245-56</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Boureau-1990" MODIFIED="2008-10-22 11:47:05 -0400" MODIFIED_BY="[Empty name]" NAME="Boureau 1990" YEAR="1990">
<REFERENCE MODIFIED="2008-10-22 11:47:05 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Boureau F, Delecoeuillerie G, Orvain J</AU>
<TI>Comparative study of the efficacy and tolerance of 2 dosages of the paracetamol 400 mg codeine 25 mg association versus paracetamol 1000 mg in non-inflammatory rheumatic pain</TI>
<SO>Rhumatologie Revue International de Rhumatologie</SO>
<YR>1990</YR>
<VL>20</VL>
<NO>1</NO>
<PG>41-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Boyer-2012" MODIFIED="2014-08-17 07:25:36 -0400" MODIFIED_BY="Anne Lawson" NAME="Boyer 2012" YEAR="2012">
<REFERENCE MODIFIED="2014-08-17 07:25:36 -0400" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Boyer KA, Angst MS, Asay J, Giori NJ, Andriacchi TP</AU>
<TI>Sensitivity of gait parameters to the effects of anti-inflammatory and opioid treatments in knee osteoarthritis patients</TI>
<SO>Journal of Orthopaedic Research</SO>
<YR>2012</YR>
<VL>30</VL>
<NO>7</NO>
<PG>1118-24</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Brooks-1982" MODIFIED="2009-07-31 03:03:48 -0400" MODIFIED_BY="[Empty name]" NAME="Brooks 1982" YEAR="1982">
<REFERENCE MODIFIED="2009-07-31 03:03:48 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Brooks PM, Dougan MA, Mugford S, Meffin E</AU>
<TI>Comparative effectiveness of 5 analgesics in patients with rheumatoid arthritis and osteoarthritis</TI>
<SO>Journal of Rheumatology</SO>
<YR>1982</YR>
<VL>9</VL>
<NO>5</NO>
<PG>723-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Burch-2004" MODIFIED="2008-09-18 04:00:25 -0400" MODIFIED_BY="[Empty name]" NAME="Burch 2004" YEAR="2004">
<REFERENCE MODIFIED="2008-09-18 04:00:25 -0400" MODIFIED_BY="[Empty name]" NOTES="Date of Publication: Mar 2004" NOTES_MODIFIED="2008-09-18 04:00:25 -0400" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Burch F, Codding C, Patel N, Sheldon E</AU>
<TI>Lidocaine patch 5% improves pain, stiffness, and physical function in osteoarthritis pain patients. A prospective, multicenter, open-label effectiveness trial</TI>
<SO>Osteoarthritis and Cartilage</SO>
<YR>2004</YR>
<VL>12</VL>
<NO>3</NO>
<PG>253-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Caldwell-1999" MODIFIED="2014-08-17 07:26:02 -0400" MODIFIED_BY="Anne Lawson" NAME="Caldwell 1999" YEAR="1999">
<REFERENCE MODIFIED="2014-08-17 07:26:02 -0400" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Caldwell JR, Hale ME, Boyd RE, Hague JM, Iwan T, Shi M, et al</AU>
<TI>Treatment of osteoarthritis pain with controlled release oxycodone or fixed combination oxycodone plus acetaminophen added to nonsteroidal antiinflammatory drugs: a double blind, randomized, multicenter, placebo controlled trial</TI>
<SO>Journal of Rheumatology</SO>
<YR>1999</YR>
<VL>26</VL>
<NO>4</NO>
<PG>862-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Choquette-2008" MODIFIED="2014-08-17 07:26:14 -0400" MODIFIED_BY="Anne Lawson" NAME="Choquette 2008" YEAR="2008">
<REFERENCE MODIFIED="2014-08-17 07:26:14 -0400" MODIFIED_BY="Anne Lawson" NOTES="Date of Publication: May 2008" NOTES_MODIFIED="2014-08-17 07:26:14 -0400" NOTES_MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Choquette D, McCarthy TG, Rodrigues JFN, Kelly AJ, Camacho F, Horbay GLA, et al</AU>
<TI>Transdermal fentanyl improves pain control and functionality in patients with osteoarthritis: an open-label Canadian trial</TI>
<SO>Clinical Rheumatology</SO>
<YR>2008</YR>
<VL>27</VL>
<NO>5</NO>
<PG>587-95</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Conaghan-2011" MODIFIED="2014-08-17 07:26:39 -0400" MODIFIED_BY="Anne Lawson" NAME="Conaghan 2011" YEAR="2011">
<REFERENCE MODIFIED="2014-08-17 07:26:39 -0400" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Conaghan PG, O'Brien CM, Wilson M, Schofield, JP</AU>
<TI>Transdermal buprenorphine plus oral paracetamol vs an oral codeine-paracetamol combination for osteoarthritis of hip and/or knee: a randomised trial</TI>
<SO>Osteoarthritis &amp; Cartilage</SO>
<YR>2011</YR>
<VL>19</VL>
<NO>8</NO>
<PG>930-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Corsinovi-2009" MODIFIED="2014-08-17 07:26:57 -0400" MODIFIED_BY="Anne Lawson" NAME="Corsinovi 2009" YEAR="2009">
<REFERENCE MODIFIED="2014-08-17 07:26:57 -0400" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Corsinovi L, Martinelli E, Fonte G, Astengo M, Sona, A, Gatti A, et al</AU>
<TI>Efficacy of oxycodone/acetaminophen and codeine/acetaminophen vs. conventional therapy in elderly women with persistent, moderate to severe osteoarthritis-related pain</TI>
<SO>Archives of Gerontology &amp; Geriatrics</SO>
<YR>2009</YR>
<VL>49</VL>
<NO>3</NO>
<PG>378-82</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Doak-1992" MODIFIED="2014-08-17 07:27:26 -0400" MODIFIED_BY="Anne Lawson" NAME="Doak 1992" YEAR="1992">
<REFERENCE MODIFIED="2014-08-17 07:27:26 -0400" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Doak W, Hosie J, Hossain M, James IGV, Reid I, Miller AJ</AU>
<TI>A novel combination of ibuprofen and codeine phosphate in the treatment of osteoarthritis: a double-blind placebo controlled study</TI>
<SO>Journal of Drug Development</SO>
<YR>1992</YR>
<VL>4</VL>
<NO>4</NO>
<PG>179-87</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fancourt-1984" MODIFIED="2009-07-31 03:05:35 -0400" MODIFIED_BY="[Empty name]" NAME="Fancourt 1984" YEAR="1984">
<REFERENCE MODIFIED="2009-07-31 03:05:35 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fancourt GJ, Flavell Matts SG</AU>
<TI>A double-blind comparison of meptazinol versus placebo in chronic rheumatoid arthritis and osteoarthritis</TI>
<SO>Current Medical Research and Opinion</SO>
<YR>1984</YR>
<VL>9</VL>
<NO>3</NO>
<PG>184-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Friedmann-2011b" MODIFIED="2014-08-17 08:23:18 -0400" MODIFIED_BY="Anne Lawson" NAME="Friedmann 2011b" YEAR="2011">
<REFERENCE MODIFIED="2014-08-17 07:27:41 -0400" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Friedmann N, Klutzaritz V, Webster L</AU>
<TI>Long-term safety of Remoxy® (extended-release oxycodone) in patients with moderate to severe chronic osteoarthritis or low back pain</TI>
<SO>Pain Medicine</SO>
<YR>2011</YR>
<VL>12</VL>
<NO>5</NO>
<PG>755-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gazi-2005" MODIFIED="2014-08-17 07:27:57 -0400" MODIFIED_BY="Anne Lawson" NAME="Gazi 2005" YEAR="2005">
<REFERENCE MODIFIED="2014-08-17 07:27:57 -0400" MODIFIED_BY="Anne Lawson" NOTES="Date of Publication: Sep 2005" NOTES_MODIFIED="2014-08-17 07:27:57 -0400" NOTES_MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gazi MCB, Machado Issy A, Kimiko Sakata R</AU>
<TI>Intra-articular bupivacaine and morphine for knee osteoarthritis analgesia. Comparative study</TI>
<SO>Revista Brasileira de Anestesiologia</SO>
<YR>2005</YR>
<VL>55</VL>
<NO>5</NO>
<PG>491-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hale-2007" MODIFIED="2014-08-17 07:28:10 -0400" MODIFIED_BY="Anne Lawson" NAME="Hale 2007" YEAR="2007">
<REFERENCE MODIFIED="2014-08-17 07:28:10 -0400" MODIFIED_BY="Anne Lawson" NOTES="Date of Publication: May 2007" NOTES_MODIFIED="2014-08-17 07:28:10 -0400" NOTES_MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hale M, Tudor IC, Khanna S, Thipphawong J</AU>
<TI>Efficacy and tolerability of once-daily OROS hydromorphone and twice-daily extended-release oxycodone in patients with chronic, moderate to severe osteoarthritis pain: results of a 6-week, randomized, open-label, noninferiority analysis</TI>
<SO>Clinical Therapeutics</SO>
<YR>2007</YR>
<VL>29</VL>
<NO>5</NO>
<PG>874-88</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-James-2010" MODIFIED="2014-08-17 07:28:25 -0400" MODIFIED_BY="Anne Lawson" NAME="James 2010" YEAR="2010">
<REFERENCE MODIFIED="2014-08-17 07:28:25 -0400" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>James IGV, O'Brien CM, McDonald CJ</AU>
<TI>A randomized, double-blind, double-dummy comparison of the efficacy and tolerability of low-dose transdermal buprenorphine (BuTrans seven-day patches) with buprenorphine sublingual tablets (Temgesic) in patients with osteoarthritis pain</TI>
<SO>Journal of Pain &amp; Symptom Management</SO>
<YR>2010</YR>
<VL>40</VL>
<NO>2</NO>
<PG>266-78</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Katz-2010b" MODIFIED="2014-08-17 07:28:36 -0400" MODIFIED_BY="Anne Lawson" NAME="Katz 2010b" YEAR="2010">
<REFERENCE MODIFIED="2014-08-17 07:28:36 -0400" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Katz N, Sun S, Johnson F, Stauffer J</AU>
<TI>ALO-01 (morphine sulfate and naltrexone hydrochloride) extended-release capsules in the treatment of chronic pain of osteoarthritis of the hip or knee: pharmacokinetics, efficacy, and safety</TI>
<SO>Journal of Pain</SO>
<YR>2010</YR>
<VL>11</VL>
<NO>4</NO>
<PG>303-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Le-Loet-2005" MODIFIED="2014-08-17 07:28:46 -0400" MODIFIED_BY="Anne Lawson" NAME="Le Loet 2005" YEAR="2005">
<REFERENCE MODIFIED="2014-08-17 07:28:46 -0400" MODIFIED_BY="Anne Lawson" NOTES="Using Smart Source Parsing" NOTES_MODIFIED="2014-08-17 07:28:46 -0400" NOTES_MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Le Loet X, Pavelka K, Richarz U</AU>
<TI>Transdermal fentanyl for the treatment of pain caused by osteoarthritis of the knee or hip: an open, multicentre study</TI>
<SO>BMC Musculoskeletal Disorders</SO>
<YR>2005</YR>
<VL>6</VL>
<NO>31</NO>
<PG>1-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-McIlwain-2005" MODIFIED="2014-08-17 07:28:58 -0400" MODIFIED_BY="Anne Lawson" NAME="McIlwain 2005" YEAR="2005">
<REFERENCE MODIFIED="2014-08-17 07:28:58 -0400" MODIFIED_BY="Anne Lawson" NOTES="Date of Publication: Mar 2005" NOTES_MODIFIED="2014-08-17 07:28:58 -0400" NOTES_MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>McIlwain H, Ahdieh H</AU>
<TI>Safety, tolerability, and effectiveness of oxymorphone extended release for moderate to severe osteoarthritis pain: a one-year study</TI>
<SO>American Journal of Therapeutics</SO>
<YR>2005</YR>
<VL>12</VL>
<NO>2</NO>
<PG>106-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mitchell-1984" MODIFIED="2009-07-31 03:06:48 -0400" MODIFIED_BY="[Empty name]" NAME="Mitchell 1984" YEAR="1984">
<REFERENCE MODIFIED="2009-07-31 03:06:48 -0400" MODIFIED_BY="[Empty name]" NOTES="Medline" NOTES_MODIFIED="2009-07-31 03:06:48 -0400" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mitchell H, Cunningham TJ, Mathews JD, Muirden KD</AU>
<TI>Further look at dextropropoxyphene with or without paracetamol in the treatment of arthritis</TI>
<SO>Medical Journal of Australia</SO>
<YR>1984</YR>
<VL>140</VL>
<NO>4</NO>
<PG>224-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Neubauer-1983" MODIFIED="2009-07-31 03:07:10 -0400" MODIFIED_BY="[Empty name]" NAME="Neubauer 1983" YEAR="1983">
<REFERENCE MODIFIED="2009-07-31 03:07:10 -0400" MODIFIED_BY="[Empty name]" NOTES="German" NOTES_MODIFIED="2009-07-31 03:07:10 -0400" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Neubauer M, Bach GL</AU>
<TI>Short-term therapy of painful muscular disorders. Results of a multicenter double-blind test of 2 new suppository preparations with and without codeine</TI>
<SO>Fortschritte der Medizin</SO>
<YR>1983</YR>
<VL>101</VL>
<NO>21</NO>
<PG>1009-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rosenthal-2007" MODIFIED="2014-08-17 07:29:25 -0400" MODIFIED_BY="Anne Lawson" NAME="Rosenthal 2007" YEAR="2007">
<REFERENCE MODIFIED="2014-08-17 07:29:25 -0400" MODIFIED_BY="Anne Lawson" NOTES="Date of Publication: May 2007" NOTES_MODIFIED="2014-08-17 07:29:25 -0400" NOTES_MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rosenthal M, Moore P, Groves E, Iwan T, Greenberg Schlosser L, Dziewanowska Z, et al</AU>
<TI>Sleep improves when patients with chronic OA pain are managed with morning dosing of once a day extend-release morphine sulfate (AVINZA): findings from a pilot study</TI>
<SO>Journal of Opioid Management</SO>
<YR>2007</YR>
<VL>3</VL>
<NO>3</NO>
<PG>145-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Roth-2000" MODIFIED="2014-08-17 07:29:35 -0400" MODIFIED_BY="Anne Lawson" NAME="Roth 2000" YEAR="2000">
<REFERENCE MODIFIED="2014-08-17 07:29:35 -0400" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Roth SH, Fleischmann RM, Burch FX, Dietz F, Bockow B, Rapoport RJ, et al</AU>
<TI>Around-the-clock, controlled-release oxycodone therapy for osteoarthritis-related pain: placebo-controlled trial and long-term evaluation</TI>
<SO>Archives of Internal Medicine</SO>
<YR>2000</YR>
<VL>160</VL>
<NO>6</NO>
<PG>853-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Salzman-1983" MODIFIED="2009-07-31 03:08:18 -0400" MODIFIED_BY="[Empty name]" NAME="Salzman 1983" YEAR="1983">
<REFERENCE MODIFIED="2009-07-31 03:08:18 -0400" MODIFIED_BY="[Empty name]" NOTES="Medline" NOTES_MODIFIED="2009-07-31 03:08:18 -0400" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Salzman RT, Brobyn RD</AU>
<TI>Long-term comparison of suprofen and propoxyphene in patients with osteoarthritis</TI>
<SO>Pharmacology</SO>
<YR>1983</YR>
<VL>27 Suppl 1</VL>
<PG>55-64</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tassain-2003" MODIFIED="2008-09-18 04:00:25 -0400" MODIFIED_BY="[Empty name]" NAME="Tassain 2003" YEAR="2003">
<REFERENCE MODIFIED="2008-09-18 04:00:25 -0400" MODIFIED_BY="[Empty name]" NOTES="Date of Publication: Jul 2003" NOTES_MODIFIED="2008-09-18 04:00:25 -0400" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tassain V, Attal N, Fletcher D, Brasseur L, Degieux P, Chauvin M, et al</AU>
<TI>Long term effects of oral sustained release morphine on neuropsychological performance in patients with chronic non-cancer pain</TI>
<SO>Pain</SO>
<YR>2003</YR>
<VL>104</VL>
<NO>1-2</NO>
<PG>389-400</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Torres-2001" MODIFIED="2014-08-17 07:30:05 -0400" MODIFIED_BY="Anne Lawson" NAME="Torres 2001" YEAR="2001">
<REFERENCE MODIFIED="2014-08-17 07:30:05 -0400" MODIFIED_BY="Anne Lawson" NOTES="Date of Publication: Apr 2001" NOTES_MODIFIED="2014-08-17 07:30:05 -0400" NOTES_MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Torres Huerta JC, Hernandez Santos JR, Tenopala Villegas S</AU>
<TI>Transdermal fentanyl in patients with nononcological chronic pain [Spanish]</TI>
<SO>Revista Mexicana de Anestesiologia</SO>
<YR>2001</YR>
<VL>24</VL>
<NO>2</NO>
<PG>65-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vignon-1999" MODIFIED="2014-08-17 07:30:16 -0400" MODIFIED_BY="Anne Lawson" NAME="Vignon 1999" YEAR="1999">
<REFERENCE MODIFIED="2014-08-17 07:30:16 -0400" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vignon E, Bannwarth B, Conrozier T, Derobert E, Verdoncq B</AU>
<TI>Multicenter, double-blind, clinical trial comparing two tablets bid to one tablet qid of the same acetaminophen-dextropropoxyphen-caffeine combination in patients with osteoarthritis [French]</TI>
<SO>Semaine des Hopitaux</SO>
<YR>1999</YR>
<VL>75</VL>
<NO>13-14</NO>
<PG>419-25</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vlok-1987" MODIFIED="2009-07-31 03:11:44 -0400" MODIFIED_BY="[Empty name]" NAME="Vlok 1987" YEAR="1987">
<REFERENCE MODIFIED="2009-07-31 03:11:44 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vlok GJ, van Vuren JP</AU>
<TI>Comparison of a standard ibuprofen treatment regimen with a new ibuprofen/paracetamol/codeine combination in chronic osteo-arthritis</TI>
<SO>South African Medical Journal [Suid Afrikaanse Tydskrif vir Geneeskunde]</SO>
<YR>1987</YR>
<VL>Suppl</VL>
<PG>1, 4-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vorsanger-2011" MODIFIED="2014-08-17 07:30:49 -0400" MODIFIED_BY="Anne Lawson" NAME="Vorsanger 2011" YEAR="2011">
<REFERENCE MODIFIED="2014-08-17 07:30:49 -0400" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vorsanger G, Xiang J, Biondi D, Upmalis D, Delfgaauw J, Allard R, et al</AU>
<TI>Post hoc analyses of data from a 90-day clinical trial evaluating the tolerability and efficacy of tapentadol immediate release and oxycodone immediate release for the relief of moderate to severe pain in elderly and nonelderly patients</TI>
<SO>Pain Research &amp; Management</SO>
<YR>2011</YR>
<VL>16</VL>
<NO>4</NO>
<PG>245-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wallace-1994" MODIFIED="2009-07-31 03:11:11 -0400" MODIFIED_BY="[Empty name]" NAME="Wallace 1994" YEAR="1994">
<REFERENCE MODIFIED="2009-07-31 03:11:11 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wallace WA, Elliott CA, Price VH</AU>
<TI>A combination of ibuprofen and codeine phosphate provides superior analgesia to ibuprofen alone in osteoarthritis</TI>
<SO>British Journal of Clinical Research</SO>
<YR>1994</YR>
<VL>5</VL>
<PG>33-46</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wang-1965" MODIFIED="2009-07-31 03:12:02 -0400" MODIFIED_BY="[Empty name]" NAME="Wang 1965" YEAR="1965">
<REFERENCE MODIFIED="2009-07-31 03:12:02 -0400" MODIFIED_BY="[Empty name]" NOTES="Medline" NOTES_MODIFIED="2009-07-31 03:12:02 -0400" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wang RI</AU>
<TI>Analgesic effectiveness of new propoxyphene preparations</TI>
<SO>Journal of New Drugs</SO>
<YR>1965</YR>
<VL>5</VL>
<NO>3</NO>
<PG>171-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wild-2010" MODIFIED="2014-08-17 07:31:33 -0400" MODIFIED_BY="Anne Lawson" NAME="Wild 2010" YEAR="2010">
<REFERENCE MODIFIED="2014-08-17 07:31:33 -0400" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wild JE, Grond S, Kuperwasser B, Gilbert J, McCann B, Lange B, et al</AU>
<TI>Long-term safety and tolerability of tapentadol extended release for the management of chronic low back pain or osteoarthritis pain</TI>
<SO>Pain Practice</SO>
<YR>2010</YR>
<VL>10</VL>
<NO>5</NO>
<PG>416-27</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2014-08-17 07:31:53 -0400" MODIFIED_BY="Anne Lawson">
<STUDY DATA_SOURCE="PUB" ID="STD-Kroner-1991" MODIFIED="2014-08-17 07:31:53 -0400" MODIFIED_BY="Anne Lawson" NAME="Kroner 1991" YEAR="1991">
<REFERENCE MODIFIED="2014-08-17 07:31:53 -0400" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kroner K, Hansen TB, Harving S, Hvass I, Madsen F, Nafei A, et al</AU>
<TI>Individually dosed codeine plus paracetamol versus paracetamol in long-term treatment of chronic pain due to arthrosis of the hip - a randomised, double blind, multicenter study</TI>
<SO>Acta Orthopaedica Scandinavica, Supplement</SO>
<YR>1991</YR>
<VL>62</VL>
<NO>246</NO>
<PG>43</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</AWAITING_STUDIES>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2014-08-18 14:25:40 -0400" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2014-08-18 14:25:40 -0400" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Altman-1986" MODIFIED="2014-08-17 07:32:31 -0400" MODIFIED_BY="Anne Lawson" NAME="Altman 1986" TYPE="JOURNAL_ARTICLE">
<AU>Altman R, Asch E, Bloch D, Bole G, Borenstein D, Brandt K, et al</AU>
<TI>Development of criteria for the classification and reporting of osteoarthritis: classification of osteoarthritis of the knee</TI>
<SO>Arthritis and Rheumatism</SO>
<YR>1986</YR>
<VL>29</VL>
<PG>1039-49</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Altman-1996" MODIFIED="2009-07-31 03:14:38 -0400" MODIFIED_BY="[Empty name]" NAME="Altman 1996" TYPE="JOURNAL_ARTICLE">
<AU>Altman R, Brandt K, Hochberg M, Moskowitz R, Bellamy N, Bloch DA, et al</AU>
<TI>Design and conduct of clinical trials in patients with osteoarthritis: recommendations from a task force of the Osteoarthritis Research Society. Results from a workshop</TI>
<SO>Osteoarthritis and Cartilage</SO>
<YR>1996</YR>
<VL>4</VL>
<NO>4</NO>
<PG>217-43</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Avouac-2007" MODIFIED="2009-07-31 03:14:51 -0400" MODIFIED_BY="[Empty name]" NAME="Avouac 2007" TYPE="JOURNAL_ARTICLE">
<AU>Avouac J, Gossec L, Dougados M</AU>
<TI>Efficacy and safety of opioids for osteoarthritis: a meta-analysis of randomized controlled trials</TI>
<SO>Osteoarthritis and Cartilage</SO>
<YR>2007</YR>
<VL>15</VL>
<NO>8</NO>
<PG>957-65</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bellamy-1995" MODIFIED="2014-08-17 07:34:23 -0400" MODIFIED_BY="Anne Lawson" NAME="Bellamy 1995" TYPE="JOURNAL_ARTICLE">
<AU>Bellamy N</AU>
<TI>Outcome measurement in osteoarthritis clinical trials</TI>
<SO>Journal of Rheumatology Supplement</SO>
<YR>1995</YR>
<VL>43</VL>
<PG>49-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-British-Pain-Society-2010" MODIFIED="2014-08-17 16:09:51 -0400" MODIFIED_BY="Anne Lawson" NAME="British Pain Society 2010" TYPE="OTHER">
<AU>British Pain Society</AU>
<TI>Opioids for persistent pain: good practice, 2010</TI>
<SO>www.britishpainsociety.org/book_opioid_main.pdf</SO>
<YR>(accessed 16 August 2014)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Caldwell-2005" MODIFIED="2009-03-23 10:30:44 -0400" MODIFIED_BY="[Empty name]" NAME="Caldwell 2005" TYPE="JOURNAL_ARTICLE">
<AU>Caldwell DM, Ades AE, Higgins JP</AU>
<TI>Simultaneous comparison of multiple treatments: combining direct and indirect evidence</TI>
<SO>BMJ</SO>
<YR>2005</YR>
<VL>331</VL>
<NO>7521</NO>
<PG>897-900</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cepeda-2006" MODIFIED="2014-08-17 07:37:55 -0400" MODIFIED_BY="Anne Lawson" NAME="Cepeda 2006" TYPE="COCHRANE_REVIEW">
<AU>Cepeda MS, Camargo F, Zea C, Valencia L</AU>
<TI>Tramadol for osteoarthritis</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2006</YR>
<NO>3</NO>
<IDENTIFIERS MODIFIED="2014-08-17 07:37:55 -0400" MODIFIED_BY="Anne Lawson">
<IDENTIFIER MODIFIED="2014-08-17 07:37:55 -0400" MODIFIED_BY="Anne Lawson" TYPE="DOI" VALUE="10.1002/14651858.CD005522.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Chinn-2000" MODIFIED="2009-07-08 12:24:41 -0400" MODIFIED_BY="[Empty name]" NAME="Chinn 2000" TYPE="JOURNAL_ARTICLE">
<AU>Chinn S</AU>
<TI>A simple method for converting an odds ratio to effect size for use in meta-analysis</TI>
<SO>Statistics in Medicine</SO>
<YR>2000</YR>
<VL>19</VL>
<NO>22</NO>
<PG>3127-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Clegg-2006" MODIFIED="2009-07-31 03:21:16 -0400" MODIFIED_BY="[Empty name]" NAME="Clegg 2006" TYPE="JOURNAL_ARTICLE">
<AU>Clegg DO, Reda DJ, Harris CL, Klein MA, O'Dell JR, Hooper MM, et al</AU>
<TI>Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis</TI>
<SO>New England Journal of Medicine</SO>
<YR>2006</YR>
<VL>354</VL>
<NO>8</NO>
<PG>795-808</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cohen-1988" MODIFIED="2014-08-17 16:11:26 -0400" MODIFIED_BY="Anne Lawson" NAME="Cohen 1988" TYPE="BOOK">
<AU>Cohen J</AU>
<SO>Statistical Power Analysis for the Behavioral Sciences</SO>
<YR>1988</YR>
<EN>2nd</EN>
<PB>Lawrence Erlbaum Associates</PB>
<CY>Hillsdale, NJ</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-da-Costa-2012a" MODIFIED="2014-08-17 16:11:56 -0400" MODIFIED_BY="Anne Lawson" NAME="da Costa 2012a" TYPE="JOURNAL_ARTICLE">
<AU>da Costa BR, Rutjes AWS, Johnston BC, Reichenbach S, Nüesch E, Tonia T, et al</AU>
<TI>Methods to convert continuous outcomes into odds ratios of treatment response and numbers needed to treat: meta-epidemiological study</TI>
<SO>International Journal of Epidemiology</SO>
<YR>2012</YR>
<VL>41</VL>
<NO>5</NO>
<PG>1445-59</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-da-Costa-2012b" MODIFIED="2014-08-17 07:36:42 -0400" MODIFIED_BY="Anne Lawson" NAME="da Costa 2012b" TYPE="COCHRANE_REVIEW">
<AU>da Costa BR, Nüesch E, Reichenbach S, Jüni P, Rutjes AWS</AU>
<TI>Doxycycline for osteoarthritis of the knee or hip</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2012</YR>
<NO>11</NO>
<IDENTIFIERS MODIFIED="2014-08-17 07:36:42 -0400" MODIFIED_BY="Anne Lawson">
<IDENTIFIER MODIFIED="2014-08-17 07:36:42 -0400" MODIFIED_BY="Anne Lawson" TYPE="DOI" VALUE="10.1002/14651858.CD007323.pub3"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-DerSimonian-1986" MODIFIED="2008-05-14 14:30:04 -0400" MODIFIED_BY="[Empty name]" NAME="DerSimonian 1986" TYPE="JOURNAL_ARTICLE">
<AU>DerSimonian R, Laird N</AU>
<TI>Meta-analysis in clinical trials</TI>
<SO>Controlled Clinical Trials</SO>
<YR>1986</YR>
<VL>7</VL>
<NO>3</NO>
<PG>177-88</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dickersin-1994" MODIFIED="2008-05-14 14:11:16 -0400" MODIFIED_BY="[Empty name]" NAME="Dickersin 1994" TYPE="JOURNAL_ARTICLE">
<AU>Dickersin K, Scherer R, Lefebvre C</AU>
<TI>Identifying relevant studies for systematic reviews</TI>
<SO>BMJ</SO>
<YR>1994</YR>
<VL>309</VL>
<NO>6964</NO>
<PG>1286-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Eccles-1998" MODIFIED="2009-07-31 03:22:09 -0400" MODIFIED_BY="[Empty name]" NAME="Eccles 1998" TYPE="JOURNAL_ARTICLE">
<AU>Eccles M, Freemantle N, Mason J</AU>
<TI>North of England Evidence Based Guidelines Development Project: summary guideline for non-steroidal anti-inflammatory drugs versus basic analgesics in treating of pain of degenerative arthritis</TI>
<SO>BMJ</SO>
<YR>1998</YR>
<VL>317</VL>
<PG>526-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Egger-2001" MODIFIED="2009-07-31 03:23:21 -0400" MODIFIED_BY="[Empty name]" NAME="Egger 2001" TYPE="BOOK_SECTION">
<AU>Egger M, Smith GD</AU>
<TI>Principles of and procedures for systematic reviews</TI>
<SO>Systematic Reviews in Health Care: Meta-Analysis in Context</SO>
<YR>2001</YR>
<PG>23-42</PG>
<ED>Egger M, Smith GD, Altman DG</ED>
<PB>BMJ Books</PB>
<CY>London</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Egger-2003" MODIFIED="2009-07-31 03:22:46 -0400" MODIFIED_BY="[Empty name]" NAME="Egger 2003" TYPE="JOURNAL_ARTICLE">
<AU>Egger M, Juni P, Bartlett C, Holenstein F, Sterne J</AU>
<TI>How important are comprehensive literature searches and the assessment of trial quality in systematic reviews? Empirical study</TI>
<SO>Health Technology Assessment (Winchester, England)</SO>
<YR>2003</YR>
<VL>7</VL>
<NO>1</NO>
<PG>1-76</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Eriksen-2006" MODIFIED="2009-07-09 15:32:54 -0400" MODIFIED_BY="[Empty name]" NAME="Eriksen 2006" TYPE="JOURNAL_ARTICLE">
<AU>Eriksen J, Sjøgren P, Bruera E, Ekholm O, Rasmussen NK</AU>
<TI>Critical issues on opioids in chronic non-cancer pain: an epidemiological study</TI>
<SO>Pain</SO>
<YR>2006</YR>
<VL>125</VL>
<NO>1-2</NO>
<PG>172-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Furlan-2006" MODIFIED="2009-07-31 03:23:48 -0400" MODIFIED_BY="[Empty name]" NAME="Furlan 2006" TYPE="JOURNAL_ARTICLE">
<AU>Furlan AD, Sandoval JA, Mailis-Gagnon A, Tunks E</AU>
<TI>Opioids for chronic noncancer pain: a meta-analysis of effectiveness and side effects</TI>
<SO>Canadian Medical Association Journal</SO>
<YR>2006</YR>
<VL>1</VL>
<NO>11</NO>
<PG>1589-94</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gehling-2011" MODIFIED="2013-02-05 10:55:42 -0500" MODIFIED_BY="[Empty name]" NAME="Gehling 2011" TYPE="JOURNAL_ARTICLE">
<AU>Gehling M, Hermann B, Tryba M</AU>
<TI>Meta-analysis of dropout rates in randomized controlled clinical trials: opioid analgesia for osteoarthritis pain</TI>
<SO>Schmerz</SO>
<YR>2011</YR>
<VL>25</VL>
<NO>3</NO>
<PG>296-305</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gossop-1990" MODIFIED="2009-07-31 03:24:12 -0400" MODIFIED_BY="[Empty name]" NAME="Gossop 1990" TYPE="JOURNAL_ARTICLE">
<AU>Gossop M</AU>
<TI>The development of a Short Opiate Withdrawal Scale (SOWS)</TI>
<SO>Addictive Behaviors</SO>
<YR>1990</YR>
<VL>15</VL>
<NO>5</NO>
<PG>487-90</PG>
<IDENTIFIERS MODIFIED="2009-07-09 09:31:22 -0400" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Guyatt-2008" MODIFIED="2014-08-17 07:38:54 -0400" MODIFIED_BY="Anne Lawson" NAME="Guyatt 2008" TYPE="JOURNAL_ARTICLE">
<AU>Guyatt G, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al</AU>
<TI>GRADE: an emerging consensus on rating quality of evidence and strength of recommendations</TI>
<SO>BMJ</SO>
<YR>2008</YR>
<VL>336</VL>
<NO>7650</NO>
<PG>924-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-G_x00f8_tzsche-2007" MODIFIED="2009-03-03 04:59:01 -0500" MODIFIED_BY="[Empty name]" NAME="Gøtzsche 2007" TYPE="JOURNAL_ARTICLE">
<AU>Gøtzsche PC, Hróbjartsson A, Maric K, Tendal B</AU>
<TI>Data extraction errors in meta-analyses that use standardized mean differences</TI>
<SO>JAMA</SO>
<YR>2007</YR>
<VL>298</VL>
<NO>4</NO>
<PG>430-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2003" MODIFIED="2008-05-14 14:30:32 -0400" MODIFIED_BY="[Empty name]" NAME="Higgins 2003" TYPE="JOURNAL_ARTICLE">
<AU>Higgins JP, Thompson SG, Deeks JJ, Altman DG</AU>
<TI>Measuring inconsistency in meta-analyses</TI>
<SO>BMJ</SO>
<YR>2003</YR>
<VL>327</VL>
<NO>7414</NO>
<PG>557-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011" MODIFIED="2014-08-17 07:41:38 -0400" MODIFIED_BY="Anne Lawson" NAME="Higgins 2011" TYPE="OTHER">
<AU>Higgins JPT, Green S (editors)</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011</TI>
<SO>Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hochberg-2012" MODIFIED="2014-08-17 07:42:19 -0400" MODIFIED_BY="Anne Lawson" NAME="Hochberg 2012" TYPE="JOURNAL_ARTICLE">
<AU>Hochberg MC, Altman RD, April KT, Benkhalti M, Guyatt G, McGowan J, et al</AU>
<TI>American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee</TI>
<SO>Arthritis Care and Research</SO>
<YR>2012</YR>
<VL>64</VL>
<NO>4</NO>
<PG>465-74</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-J_x00fc_ni-2001" MODIFIED="2014-08-17 08:29:29 -0400" MODIFIED_BY="Anne Lawson" NAME="Jüni 2001" TYPE="JOURNAL_ARTICLE">
<AU>Jüni P, Altman DG, Egger M</AU>
<TI>Systematic reviews in health care: assessing the quality of controlled clinical trials</TI>
<SO>BMJ</SO>
<YR>2001</YR>
<VL>323</VL>
<NO>7303</NO>
<PG>42-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-J_x00fc_ni-2006" MODIFIED="2014-08-17 08:29:37 -0400" MODIFIED_BY="Anne Lawson" NAME="Jüni 2006" TYPE="JOURNAL_ARTICLE">
<AU>Jüni P, Reichenbach S, Dieppe P</AU>
<TI>Osteoarthritis: rational approach to treating the individual</TI>
<SO>Best Practice &amp; Research. Clinical Rheumatology</SO>
<YR>2006</YR>
<VL>20</VL>
<NO>4</NO>
<PG>721-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kalso-2004" MODIFIED="2009-07-09 15:51:20 -0400" MODIFIED_BY="[Empty name]" NAME="Kalso 2004" TYPE="JOURNAL_ARTICLE">
<AU>Kalso E, Edwards JE, Moore RA, McQuay HJ</AU>
<TI>Opioids in chronic non-cancer pain: systematic review of efficacy and safety</TI>
<SO>Pain</SO>
<YR>2004</YR>
<VL>112</VL>
<NO>3</NO>
<PG>372-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Loeser-2001" MODIFIED="2014-08-17 08:30:28 -0400" MODIFIED_BY="Anne Lawson" NAME="Loeser 2001" TYPE="BOOK">
<AU>Loeser JD, Butler SH, Chapman CR, Turk DC</AU>
<SO>Bonica's Management of Pain</SO>
<YR>2001</YR>
<EN>3rd</EN>
<PB>Lippincott Williams &amp; Wilkins</PB>
<CY>Philadelphia, PA</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Maier-2002" MODIFIED="2009-07-31 03:27:00 -0400" MODIFIED_BY="[Empty name]" NAME="Maier 2002" TYPE="JOURNAL_ARTICLE">
<AU>Maier C, Hildebrandt J, Klinger R, Henrich-Eberl C, Lindena G, MONTAS Study Group</AU>
<TI>Morphine responsiveness, efficacy and tolerability in patients with chronic non-tumor associated pain - results of a double-blind placebo-controlled trial (MONTAS)</TI>
<SO>Pain</SO>
<YR>2002</YR>
<VL>97</VL>
<NO>3</NO>
<PG>223-33</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-NICE-2008" MODIFIED="2014-08-17 07:44:17 -0400" MODIFIED_BY="Anne Lawson" NAME="NICE 2008" TYPE="OTHER">
<AU>NICE clinical guideline 59</AU>
<TI>Osteoarthritis - the care and management of osteoarthritis in adults</TI>
<SO>www.nice.org.uk/nicemedia/pdf/CG59NICEguideline.pdf</SO>
<YR>(accessed 16 August 2014)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-N_x00fc_esch-2009" MODIFIED="2014-08-17 07:44:34 -0400" MODIFIED_BY="Anne Lawson" NAME="Nüesch 2009" TYPE="JOURNAL_ARTICLE">
<AU>Nüesch E, Trelle S, Reichenbach S, Rutjes AWS, Bürgi E, Scherer M, et al</AU>
<TI>The effects of the exclusion of patients from the analysis in randomised controlled trials: meta-epidemiological study</TI>
<SO>BMJ</SO>
<YR>2009</YR>
<VL>339</VL>
<PG>b3244</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-N_x00fc_esch-2010" MODIFIED="2014-08-17 16:14:34 -0400" MODIFIED_BY="Anne Lawson" NAME="Nüesch 2010" TYPE="JOURNAL_ARTICLE">
<AU>Nüesch E, Trelle S, Reichenbach S, Rutjes AW, Tschannen B, Altman DG, et al</AU>
<TI>Small study effects in meta-analyses of osteoarthritis trials: meta-epidemiological study</TI>
<SO>BMJ</SO>
<YR>2010</YR>
<VL>341</VL>
<PG>c3515</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Pham-2004" MODIFIED="2009-07-31 03:28:36 -0400" MODIFIED_BY="[Empty name]" NAME="Pham 2004" TYPE="JOURNAL_ARTICLE">
<AU>Pham T, van der Heijde D, Altman RD, Anderson JJ, Bellamy N, Hochberg M, et al</AU>
<TI>OMERACT-OARSI initiative: Osteoarthritis Research Society International set of responder criteria for osteoarthritis clinical trials revisited</TI>
<SO>Osteoarthritis and Cartilage</SO>
<YR>2004</YR>
<VL>12</VL>
<NO>5</NO>
<PG>389-99</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Reichenbach-2007" MODIFIED="2008-05-14 15:28:48 -0400" MODIFIED_BY="[Empty name]" NAME="Reichenbach 2007" TYPE="JOURNAL_ARTICLE">
<AU>Reichenbach S, Sterchi R, Scherer M, Trelle S, Burgi E, Burgi U, et al</AU>
<TI>Meta-analysis: chondroitin for osteoarthritis of the knee or hip</TI>
<SO>Annals of Internal Medicine</SO>
<YR>2007</YR>
<VL>146</VL>
<NO>8</NO>
<PG>580-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Reichenbach-2010" MODIFIED="2014-08-17 07:46:17 -0400" MODIFIED_BY="Anne Lawson" NAME="Reichenbach 2010" TYPE="COCHRANE_REVIEW">
<AU>Reichenbach S, Rutjes AW, Nüesch E, Trelle S, Jüni P</AU>
<TI>Joint lavage for osteoarthritis of the knee</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2010</YR>
<NO>5</NO>
<IDENTIFIERS MODIFIED="2014-08-17 07:46:06 -0400" MODIFIED_BY="Anne Lawson">
<IDENTIFIER MODIFIED="2014-08-17 07:46:06 -0400" MODIFIED_BY="Anne Lawson" TYPE="DOI" VALUE="10.1002/14651858.CD007320.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-RevMan-2012" MODIFIED="2014-08-17 16:18:16 -0400" MODIFIED_BY="Anne Lawson" NAME="RevMan 2012" TYPE="COMPUTER_PROGRAM">
<TI>Review Manager (RevMan)</TI>
<YR>2012</YR>
<EN>5.2</EN>
<PB>The Nordic Cochrane Centre, The Cochrane Collaboration</PB>
<CY>Copenhagen</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rutjes-2009a" MODIFIED="2014-08-17 16:18:59 -0400" MODIFIED_BY="Anne Lawson" NAME="Rutjes 2009a" TYPE="COCHRANE_REVIEW">
<AU>Rutjes AW, Nüesch E, Sterchi R, Kalichman L, Hendriks E, Osiri M, et al</AU>
<TI>Transcutaneous electrostimulation for osteoarthritis of the knee</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2009</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2014-08-17 16:18:59 -0400" MODIFIED_BY="Anne Lawson">
<IDENTIFIER MODIFIED="2014-08-17 16:18:59 -0400" MODIFIED_BY="Anne Lawson" TYPE="DOI" VALUE="10.1002/14651858.CD002823.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Rutjes-2009b" MODIFIED="2014-08-18 14:25:40 -0400" MODIFIED_BY="[Empty name]" NAME="Rutjes 2009b" TYPE="COCHRANE_REVIEW">
<AU>Rutjes AW, Nuesch E, Reichenbach S, Juni P</AU>
<TI>S-Adenosylmethionine for osteoarthritis of the knee or hip</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2009</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2014-08-17 07:47:57 -0400" MODIFIED_BY="Anne Lawson">
<IDENTIFIER MODIFIED="2014-08-17 07:47:57 -0400" MODIFIED_BY="Anne Lawson" TYPE="DOI" VALUE="10.1002/14651858.CD007321.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Rutjes-2010" MODIFIED="2014-08-17 07:48:48 -0400" MODIFIED_BY="Anne Lawson" NAME="Rutjes 2010" TYPE="COCHRANE_REVIEW">
<AU>Rutjes AW, Nuesch E, Sterchi R, Juni P</AU>
<TI>Therapeutic ultrasound for osteoarthritis of the knee or hip</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2010</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2014-08-17 07:48:48 -0400" MODIFIED_BY="Anne Lawson">
<IDENTIFIER MODIFIED="2014-08-17 07:48:48 -0400" MODIFIED_BY="Anne Lawson" TYPE="DOI" VALUE="10.1002/14651858.CD003132.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Rutjes-2012" MODIFIED="2013-02-05 10:58:03 -0500" MODIFIED_BY="[Empty name]" NAME="Rutjes 2012" TYPE="JOURNAL_ARTICLE">
<AU>Rutjes AW, Jüni P, da Costa BR, Trelle S, Nüesch E, Reichenbach S</AU>
<TI>Viscosupplementation for osteoarthritis of the knee: a systematic review and meta-analysis</TI>
<SO>Annals of Internal Medicine</SO>
<YR>2012</YR>
<VL>157</VL>
<NO>3</NO>
<PG>180-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-R_x00fc_cker-2008" MODIFIED="2014-08-17 08:31:29 -0400" MODIFIED_BY="Anne Lawson" NAME="Rücker 2008" TYPE="JOURNAL_ARTICLE">
<AU>Rücker G, Schwarzer G, Carpenter JR, Schumacher M</AU>
<TI>Undue reliance on I(2) in assessing heterogeneity may mislead</TI>
<SO>BMC Medical Research Methodology</SO>
<YR>2008</YR>
<VL>8</VL>
<NO>1</NO>
<PG>79</PG>
<IDENTIFIERS MODIFIED="2009-07-09 09:31:37 -0400" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Schug-2006" MODIFIED="2014-08-17 07:50:50 -0400" MODIFIED_BY="Anne Lawson" NAME="Schug 2006" TYPE="BOOK_SECTION">
<AU>Schug SA, Gandham N</AU>
<TI>Opioids: clinical use</TI>
<SO>Wall and Melzack's Textbook of Pain</SO>
<YR>2006</YR>
<PG>443-57</PG>
<EN>5th</EN>
<ED>McMahon S, Klotzenburg M</ED>
<PB>Elsevier Limited</PB>
<CY>Oxford</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Shang-2005" MODIFIED="2009-07-31 03:31:30 -0400" MODIFIED_BY="[Empty name]" NAME="Shang 2005" TYPE="JOURNAL_ARTICLE">
<AU>Shang A, Huwiler-Muntener K, Nartey L, Juni P, Dorig S, Sterne JA, et al</AU>
<TI>Are the clinical effects of homoeopathy placebo effects? Comparative study of placebo-controlled trials of homoeopathy and allopathy</TI>
<SO>Lancet</SO>
<YR>2005</YR>
<VL>366</VL>
<NO>9487</NO>
<PG>726-32</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Stein-1996" MODIFIED="2014-08-17 07:51:33 -0400" MODIFIED_BY="Anne Lawson" NAME="Stein 1996" TYPE="JOURNAL_ARTICLE">
<AU>Stein C, Pfluger M, Yassouridis A, Hoelzl J, Lehrberger K, Welte C, et al</AU>
<TI>No tolerance to peripheral morphine analgesia in presence of opioid expression in inflamed synovia</TI>
<SO>Journal of Clinical Investigation</SO>
<YR>1996</YR>
<VL>98</VL>
<PG>793-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sterne-2001" MODIFIED="2008-05-14 15:30:57 -0400" MODIFIED_BY="[Empty name]" NAME="Sterne 2001" TYPE="JOURNAL_ARTICLE">
<AU>Sterne JA, Egger M</AU>
<TI>Funnel plots for detecting bias in meta-analysis: guidelines on choice of axis</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2001</YR>
<VL>54</VL>
<NO>10</NO>
<PG>1046-55</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sterne-2011" MODIFIED="2014-08-17 07:51:49 -0400" MODIFIED_BY="Anne Lawson" NAME="Sterne 2011" TYPE="JOURNAL_ARTICLE">
<AU>Sterne JA, Sutton AJ, Ioannidis JP, Terrin N, Jones DR, Lau J, et al</AU>
<TI>Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials</TI>
<SO>BMJ</SO>
<YR>2011</YR>
<VL>343</VL>
<PG>d4002</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Thompson-1999" MODIFIED="2008-05-14 15:31:10 -0400" MODIFIED_BY="[Empty name]" NAME="Thompson 1999" TYPE="JOURNAL_ARTICLE">
<AU>Thompson SG, Sharp SJ</AU>
<TI>Explaining heterogeneity in meta-analysis: a comparison of methods</TI>
<SO>Statistics in Medicine</SO>
<YR>1999</YR>
<VL>18</VL>
<NO>20</NO>
<PG>2693-708</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Von-Korff-2004" MODIFIED="2008-05-09 07:52:41 -0400" MODIFIED_BY="[Empty name]" NAME="Von Korff 2004" TYPE="JOURNAL_ARTICLE">
<AU>Von Korff M, Deyo RA</AU>
<TI>Potent opioids for chronic musculoskeletal pain: flying blind?</TI>
<SO>Pain</SO>
<YR>2004</YR>
<VL>109</VL>
<NO>3</NO>
<PG>207-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wandel-2010" MODIFIED="2013-02-05 10:58:31 -0500" MODIFIED_BY="[Empty name]" NAME="Wandel 2010" TYPE="JOURNAL_ARTICLE">
<AU>Wandel S, Jüni P, Tendal B, Nüesch E, Villiger PM, Welton NJ, et al</AU>
<TI>Effects of glucosamine, chondroitin, or placebo in patients with osteoarthritis of hip or knee: network meta-analysis</TI>
<SO>BMJ</SO>
<YR>2010</YR>
<VL>341</VL>
<NO>16</NO>
<PG>c4675</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Zhang-2008" MODIFIED="2014-08-17 07:52:19 -0400" MODIFIED_BY="Anne Lawson" NAME="Zhang 2008" TYPE="JOURNAL_ARTICLE">
<AU>Zhang W, Moskowitz RW, Nuki G, Abramson S, Altman RD, Arden N, et al</AU>
<TI>OARSI recommendations for the management of hip and knee osteoarthritis. Part II: OARSI evidence-based, expert consensus guidelines</TI>
<SO>Osteoarthritis and Cartilage</SO>
<YR>2008</YR>
<VL>16</VL>
<NO>2</NO>
<PG>137-62</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES MODIFIED="2009-07-08 12:23:49 -0400" MODIFIED_BY="[Empty name]"/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2014-08-21 15:46:44 -0400" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2014-08-21 15:46:44 -0400" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2014-08-17 16:41:02 -0400" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-Afilalo-2010">
<CHAR_METHODS MODIFIED="2014-08-16 08:29:24 -0400" MODIFIED_BY="Anne Lawson">
<P>Randomised controlled trial<BR/>3-arm parallel group design<BR/>Trial duration: 17 weeks<BR/>Randomisation stratified according by centre<BR/>Multicentre trial with 112 centres<BR/>Power calculation reported<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-08-17 16:41:02 -0400" MODIFIED_BY="Anne Lawson">
<P>Participants with moderate-to-severe joint pain who needed analgesics for at least 3 months and were dissatisfied with their current treatment were eligible<BR/>1030 participants were randomised<BR/>1023 participants with knee osteoarthritis were reported at baseline<BR/>Affected joints: 1023 knees<BR/>Number of females: 618 of 1023 (60%)<BR/>Mean age: 58 years<BR/>Mean BMI: 34 kg/m<SUP>2</SUP>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-08-16 08:39:33 -0400" MODIFIED_BY="Anne Lawson">
<P>
<I>Experimental interventions</I>
</P>
<P>Oral extended-release tapentadol, 100-250 mg twice daily</P>
<P>Oral controlled-release oxycodone, 20-50 mg twice daily</P>
<P>
<I>Control intervention </I>
<BR/>Placebo, twice daily</P>
<P>Treatment duration: 15 weeks<BR/>Analgesics other than study drugs allowed, but it was unclear whether intake was similar between groups<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-08-16 08:33:20 -0400" MODIFIED_BY="Anne Lawson">
<P>Extracted pain outcome: global pain after 17 weeks<BR/>Extracted function outcome: WOMAC disability subscore after 17 weeks<BR/>Primary outcome: change in mean pain intensity</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-08-16 08:33:22 -0400" MODIFIED_BY="Anne Lawson">
<P>Sponsor: Johnson &amp; Johnson, Grünenthal</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-08-17 16:41:38 -0400" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-Breivik-2010">
<CHAR_METHODS MODIFIED="2013-02-04 05:46:50 -0500" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial<BR/>2-arm parallel group design<BR/>Trial duration: 28 weeks<BR/>Multicentre trial with 19 centres<BR/>Power calculation reported<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-08-17 16:41:38 -0400" MODIFIED_BY="Anne Lawson">
<P>Participants with insufficient relief of moderate-to-severe osteoarthritis pain using NSAIDs or COXIBs and without previous exposure to opioids were eligible.</P>
<P>199 participants were randomised<BR/>199 participants with knee or hip osteoarthritis were reported at baseline<BR/>Affected joints: 126 knees, 73 hips<BR/>Number of females: 136 of 199 (68%)<BR/>Mean age: 63 years</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-08-16 08:39:53 -0400" MODIFIED_BY="Anne Lawson">
<P>
<I>Experimental intervention</I>
<BR/>Transdermal buprenorphine (Norspan; BuTrans), 5-20 &#956;g/hour</P>
<P>
<I>Control intervention</I>
<BR/>Placebo, change of patch every 7 days</P>
<P>Treatment duration: 24 weeks</P>
<P>No analgesics other than study drugs allowed<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-08-16 08:40:04 -0400" MODIFIED_BY="Anne Lawson">
<P>Extracted pain outcome: WOMAC pain subscore after 28 weeks<BR/>Extracted function outcome: WOMAC disability subscore after 28 weeks<BR/>Primary outcome: WOMAC pain</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-08-16 08:40:09 -0400" MODIFIED_BY="Anne Lawson">
<P>Sponsor: Norpharma, Mundipharma</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-08-17 16:42:13 -0400" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-Caldwell-2002">
<CHAR_METHODS MODIFIED="2008-12-23 13:54:58 -0500" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial<BR/>4-arm parallel group design<BR/>Trial duration: 4 weeks<BR/>Multicentre trial<BR/>No power calculation reported</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-08-17 16:42:13 -0400" MODIFIED_BY="Anne Lawson">
<P>Participants with prior suboptimal analgesic response to NSAIDs/paracetamol or previous intermittent opioid therapy were eligible<BR/>295 participants with knee or hip (or both) osteoarthritis were reported at baseline<BR/>Number of females: 184 of 295 (62%)<BR/>Mean age: 62 years<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-08-16 08:42:20 -0400" MODIFIED_BY="Anne Lawson">
<P>
<I>Experimental interventions</I>
<BR/>Oral morphine (Avinza), 30 mg once daily in the morning<BR/>Oral morphine (Avinza), 30 mg once daily in the evening<BR/>Oral morphine sulphate (Contin), 15 mg twice daily</P>
<P>
<I>Control intervention</I>
<BR/>Placebo, twice daily</P>
<P>Treatment duration: 4 weeks<BR/>No analgesics other than study drugs allowed</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-07-31 02:37:41 -0400" MODIFIED_BY="[Empty name]">
<P>Extracted pain outcome: global pain after 4 weeks<BR/>Extracted function outcome: WOMAC disability subscore after 4 weeks<BR/>Primary outcome: WOMAC OA index</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-08-16 08:42:32 -0400" MODIFIED_BY="Anne Lawson">
<P>Sponsor: Elan</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-08-17 16:43:26 -0400" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-Chindalore-2005">
<CHAR_METHODS MODIFIED="2008-12-23 13:49:52 -0500" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial<BR/>4-arm parallel group design<BR/>Trial duration: 4 weeks<BR/>Randomisation stratified according to gender<BR/>Multicentre trial with 37 centres<BR/>No power calculation reported</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-08-17 16:43:26 -0400" MODIFIED_BY="Anne Lawson">
<P>Participants with moderate to severe hip or knee pain while taking &#8805;1 oral analgesic medication were eligible<BR/>362 participants were randomised<BR/>360 participants with hip or knee osteoarthritis were reported at baseline<BR/>Number of females: 249 of 360 (69%)<BR/>Average age: 54 years</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-08-16 08:52:32 -0400" MODIFIED_BY="Anne Lawson">
<P>
<I>Experimental interventions</I>
<BR/>Oral oxycodone, 10 mg 4 times daily<BR/>Oral oxycodone, 2.5 mg 4 times daily, plus naltrexone 0.001 mg 4 times daily (Oxytrex)<BR/>Oral oxycodone, 2.5 mg 4 times daily, plus natronex 0.001 mg twice daily (Oxytrex)</P>
<P>
<I>Control intervention </I>
<BR/>Placebo, twice daily</P>
<P>Treatment duration: 3 weeks<BR/>Analgesics other than study drugs allowed, but it was unclear whether intake was similar between groups</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-07-31 02:39:19 -0400" MODIFIED_BY="[Empty name]">
<P>Extracted pain outcome: global pain after 4 weeks<BR/>Extracted function outcome: WOMAC disability subscore after 4 weeks<BR/>Primary outcome: pain intensity during the past 24 hours</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-08-16 08:53:27 -0400" MODIFIED_BY="Anne Lawson">
<P>Sponsor: Pain Therapeutics<BR/>For WOMAC disability, insufficient data were reported to calculate standardised mean differences and it was, therefore, not included in the meta-analysis</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-08-17 16:43:53 -0400" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-Etropolski-2011">
<CHAR_METHODS MODIFIED="2014-08-16 08:54:30 -0400" MODIFIED_BY="Anne Lawson">
<P>Randomised controlled trial<BR/>4-arm parallel group design<BR/>Trial duration: 8 weeks<BR/>Randomisation stratified according to study centre<BR/>Multicentre trial with 84 centres<BR/>No power calculation reported<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-08-17 16:43:53 -0400" MODIFIED_BY="Anne Lawson">
<P>Participants with joint disease requiring surgery and insufficient pain relief by stable analgesic regimens were eligible<BR/>598 participants were randomised<BR/>598 participants with knee or hip osteoarthritis reported at baseline<BR/>Number of females: 349 of 596 (59%)<BR/>Mean age: 59 years</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-08-16 08:55:50 -0400" MODIFIED_BY="Anne Lawson">
<P>
<I>Experimental interventions </I>
<BR/>Oral immediate-release tapentadol, 50 mg 3-6 times daily<BR/>Oral immediate-release tapentadol, 75 mg 3-6 times daily<BR/>Oral immediate-release oxycodone, 10 mg 3-6 times daily</P>
<P>
<I>Control intervention</I>
<BR/>Placebo, 3-6 times daily</P>
<P>Treatment duration: 2 weeks<BR/>Analgesics other than study drugs allowed and intake was similar between groups<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-08-16 08:56:07 -0400" MODIFIED_BY="Anne Lawson">
<P>Extracted pain outcome: global pain after 8 weeks<BR/>No function outcome reported<BR/>Primary outcome: change in pain intensity<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-08-16 08:56:10 -0400" MODIFIED_BY="Anne Lawson">
<P>Sponsor: Johnson &amp; Johnson</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-08-17 16:44:13 -0400" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-Fidelholtz-2011">
<CHAR_METHODS MODIFIED="2013-02-04 05:46:51 -0500" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial<BR/>4-arm parallel group design<BR/>Trial duration unclear <BR/>Multicentre trial with 99 centres<BR/>No power calculation reported<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-08-17 16:44:13 -0400" MODIFIED_BY="Anne Lawson">
<P>Participants with moderate-to-severe osteoarthritis pain of knees or hips were eligible<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-08-16 08:57:31 -0400" MODIFIED_BY="Anne Lawson">
<P>
<I>Experimental intervention</I>
<BR/>Oral oxycodone, 10-40 mg twice daily</P>
<P>
<I>Control intervention</I>
</P>
<P>
<I>P</I>lacebo</P>
<P>Treatment duration: not reported<BR/>Unclear whether analgesics other than study drugs allowed</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-08-16 08:57:40 -0400" MODIFIED_BY="Anne Lawson">
<P>Extracted pain outcome: WOMAC pain subscore after 8 weeks<BR/>No function outcome reported<BR/>Primary outcome: WOMAC pain<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-08-16 08:57:46 -0400" MODIFIED_BY="Anne Lawson">
<P>Sponsor: Pfizer, Pain Solutions<BR/>2 trial arms excluded from review</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-08-17 16:44:29 -0400" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-Friedmann-2011">
<CHAR_METHODS MODIFIED="2013-02-04 05:46:52 -0500" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial<BR/>2-arm parallel group design<BR/>Trial duration: 14 weeks<BR/>Multicentre trial with 61 centres<BR/>Power calculation reported<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-08-17 16:44:29 -0400" MODIFIED_BY="Anne Lawson">
<P>Participants with moderate-to-severe osteoarthritis pain using NSAIDs or opioids were eligible<BR/>412 participants were randomised<BR/>412 participants with knee or hip osteoarthritis were reported at baseline<BR/>Affected joints: 323 knees and 89 hips<BR/>Number of females: 288 of 412 (70%)<BR/>Mean age: 58 years</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-08-16 08:59:44 -0400" MODIFIED_BY="Anne Lawson">
<P>
<I>Experimental intervention</I>
<BR/>Oral extended-release oxycodone (Remoxy), 5-20 mg twice daily</P>
<P>
<I>Control intervention</I>
<BR/>Placebo, twice daily</P>
<P>Treatment duration: 12 weeks<BR/>Unclear whether analgesics other than study drugs allowed</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-08-16 09:00:17 -0400" MODIFIED_BY="Anne Lawson">
<P>Extracted pain outcome: global pain after 14 weeks<BR/>No function outcome reported<BR/>Primary outcome: change in pain intensity score<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-08-16 09:00:37 -0400" MODIFIED_BY="Anne Lawson">
<P>Sponsor: Pain Therapeutics, King, Pfizer</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-08-17 16:44:55 -0400" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-Hartrick-2009">
<CHAR_METHODS MODIFIED="2014-08-16 09:01:50 -0400" MODIFIED_BY="Anne Lawson">
<P>Randomised controlled trial<BR/>4-arm parallel group design<BR/>Trial duration: 2 weeks<BR/>Randomisation stratified according to study centre<BR/>Multicentre trial<BR/>Power calculation reported<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-08-17 16:44:55 -0400" MODIFIED_BY="Anne Lawson">
<P>Participants with insufficient relief of moderate-to-severe osteoarthritis pain who were candidates for joint replacement surgery were eligible<BR/>674 participants were randomised<BR/>659 participants with knee or hip osteoarthritis were reported at baseline<BR/>Number of females: 324 of 659 (49%)<BR/>Mean age: 61 years<BR/>Mean BMI: 33 kg/m<SUP>2</SUP>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-08-16 09:02:40 -0400" MODIFIED_BY="Anne Lawson">
<P>
<I>Experimental interventions</I>
<BR/>Oral immediate-release tapentadol, 50 mg every 4-6 hours<BR/>Oral immediate-release tapentadol, 75 mg every 4-6 hours<BR/>Oral oxycodone, 10 mg every 4-6 hours</P>
<P>
<I>Control intervention</I>
<BR/>Placebo, every 4-6 hours</P>
<P>Treatment duration: 1 week<BR/>Analgesics other than study drugs allowed, but it was unclear whether intake was similar between groups<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-08-16 09:02:52 -0400" MODIFIED_BY="Anne Lawson">
<P>Extracted pain outcome: global pain after 2 weeks<BR/>No function outcome reported<BR/>Primary outcome: sum of pain intensity difference</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-08-16 09:02:54 -0400" MODIFIED_BY="Anne Lawson">
<P>Sponsor: Johnson &amp; Johnson, Grünenthal</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-08-17 16:45:15 -0400" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-Katz-2010">
<CHAR_METHODS MODIFIED="2014-08-16 09:05:14 -0400" MODIFIED_BY="Anne Lawson">
<P>Randomised controlled trial<BR/>2-arm parallel group design<BR/>Trial duration: 14 weeks<BR/>Randomisation stratified according to joint (hip/knee), daily dosage at end of titration, and study site<BR/>Multicentre trial with 81 centres<BR/>Power calculation reported<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-08-17 16:45:15 -0400" MODIFIED_BY="Anne Lawson">
<P>Participants with insufficient pain relief with non-opioids analgesics, tramadol, or other opioids at &#8804; 40-mg morphine equivalent per day were eligible<BR/>344 participants were randomised<BR/>344 participants with knee or hip osteoarthritis were reported at baseline<BR/>Affected joints: 267 knees and 77 hips<BR/>Number of females: 201 of 344 (58%)<BR/>Mean age: 54 years<BR/>Mean BMI: 32 kg/m<SUP>2</SUP>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-08-16 09:06:01 -0400" MODIFIED_BY="Anne Lawson">
<P>
<I>Experimental intervention</I>
<BR/>Oral morphine sulphate and naltrexone hydrochloride (EMBEDA), 20-80 mg twice daily</P>
<P>
<I>Control intervention</I>
<BR/>Placebo, twice daily</P>
<P>Treatment duration: 12 weeks<BR/>Analgesics other than study drugs allowed and intake was similar between groups</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-08-16 09:06:10 -0400" MODIFIED_BY="Anne Lawson">
<P>Extracted pain outcome: global pain after 14 weeks<BR/>Extracted function outcome: WOMAC disability subscore after 14 weeks<BR/>Primary outcome: change in average pain intensity</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-08-16 09:06:12 -0400" MODIFIED_BY="Anne Lawson">
<P>Sponsor: King, Quintiles Medical Communications, Alphapharm</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-08-17 16:45:34 -0400" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-Kivitz-2006">
<CHAR_METHODS MODIFIED="2008-12-23 13:52:41 -0500" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial<BR/>4-arm parallel group design<BR/>Trial duration: 2 weeks<BR/>Multicentre trial<BR/>Power calculation reported</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-08-17 16:45:34 -0400" MODIFIED_BY="Anne Lawson">
<P>Participants with suboptimal analgesic response to NSAIDs/paracetamol or previous opioid therapy were eligible<BR/>370 participants were randomised<BR/>370 participants with knee or hip osteoarthritis were reported at baseline<BR/>Affected joints: 297 knees and 73 hips<BR/>Number of females: 224 of 370 (61%)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-08-16 09:07:52 -0400" MODIFIED_BY="Anne Lawson">
<P>
<I>Experimental interventions</I>
<BR/>Oral extended-release oxymorphone, 10 mg twice daily<BR/>Oral extended-release oxymorphone, 40 mg twice daily<BR/>Oral extended-release oxymorphone, 50 mg twice daily</P>
<P>
<I>Control intervention</I>
<BR/>Placebo, twice daily</P>
<P>Treatment duration: 2 weeks<BR/>No analgesics other than study drugs allowed</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-08-16 09:07:56 -0400" MODIFIED_BY="Anne Lawson">
<P>Extracted pain outcome: global pain after 2 weeks<BR/>Extracted function outcome: WOMAC disability subscore after 2 weeks<BR/>Primary outcome: change in pain intensity</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-08-16 09:07:59 -0400" MODIFIED_BY="Anne Lawson">
<P>Sponsor: Endo Pharmaceuticals Inc, Penwest Pharmaceuticals Co</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-08-17 16:46:04 -0400" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-Kjaersgaard_x002d_Andersen-1990">
<CHAR_METHODS MODIFIED="2008-12-23 13:52:59 -0500" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial<BR/>2-arm parallel group design<BR/>Trial duration: 4 weeks<BR/>Multicentre trial with 7 centres<BR/>Power calculation reported</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-08-17 16:46:02 -0400" MODIFIED_BY="Anne Lawson">
<P>Participants with chronic pain requiring analgesic treatment were eligible<BR/>158 participants with hip osteoarthritis were reported at baseline<BR/>Affected joints: 158 hips<BR/>Number of females: 72 of 158 (46%)<BR/>Mean age: 66 years<BR/>Mean BMI: 26 kg/m<SUP>2</SUP>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-08-16 09:09:06 -0400" MODIFIED_BY="Anne Lawson">
<P>
<I>Experimental intervention</I>
<BR/>Oral codeine 60 mg plus paracetamol 1000 mg, 3 times daily</P>
<P>
<I>Control intervention</I>
<BR/>Paracetamol 1000 mg, 3 times daily</P>
<P>Treatment duration: 4 weeks<BR/>No analgesics other than study drugs allowed</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-08-17 16:46:04 -0400" MODIFIED_BY="Anne Lawson">
<P>Extracted pain outcome: global pain after 4 weeks<BR/>Extracted function outcome: participant's global assessment after 4 weeks</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-08-16 09:09:13 -0400" MODIFIED_BY="Anne Lawson">
<P>No information about source of funding provided</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-08-17 16:46:28 -0400" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-Langford-2006">
<CHAR_METHODS MODIFIED="2008-12-23 13:53:32 -0500" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial<BR/>2-arm parallel group design<BR/>Trial duration: 8 weeks<BR/>Randomisation stratified according to target joint (knee/hip)<BR/>Multicentre trial<BR/>Power calculation reported</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-08-17 16:46:28 -0400" MODIFIED_BY="Anne Lawson">
<P>Participants without adequate pain control under weak opioid treatment (with and without paracetamol) were eligible<BR/>416 participants were randomised<BR/>399 participants with knee or hip osteoarthritis were reported at baseline<BR/>Affected joints: 211 knees and 188 hips<BR/>Number of females: 265 of 399 (66%)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-08-16 09:10:19 -0400" MODIFIED_BY="Anne Lawson">
<P>
<I>Experimental intervention</I>
<BR/>Transdermal fentanyl (Durogesic), median dosage 25 &#956;g/hour</P>
<P>
<I>Control intervention</I>
<BR/>Placebo</P>
<P>Treatment duration: 6 weeks<BR/>Analgesics other than study drugs allowed and intake assessed, but it was unclear whether intake was similar between groups</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-07-31 02:44:10 -0400" MODIFIED_BY="[Empty name]">
<P>Extracted pain outcome: global pain after 8 weeks<BR/>Extracted function outcome: WOMAC disability subscore after 8 weeks<BR/>Primary outcome: pain relief on VAS</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-08-16 09:10:44 -0400" MODIFIED_BY="Anne Lawson">
<P>Sponsor: Janssen-Cilag</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-08-17 16:46:39 -0400" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-Markenson-2005">
<CHAR_METHODS MODIFIED="2008-12-23 13:53:49 -0500" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial<BR/>2-arm parallel group design<BR/>Trial duration: 13 weeks<BR/>Multicentre trial with 9 centres<BR/>Power calculation reported</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-08-17 16:46:39 -0400" MODIFIED_BY="Anne Lawson">
<P>Participants with moderate-to-severe pain while taking NSAIDs/paracetamol, with contraindications to NSAID therapy or with previous oral opioid therapy were eligible<BR/>109 participants were randomised<BR/>107 participants with osteoarthritis were reported at baseline<BR/>Affected joints: 33 knees, 19 hips, and 57 other joints<BR/>Number of females: 78 of 107 (73%)<BR/>Mean age: 63 years</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-08-16 09:11:46 -0400" MODIFIED_BY="Anne Lawson">
<P>
<I>Experimental intervention</I>
<BR/>Oral oxycodone (OxyContin), 10 mg twice daily</P>
<P>
<I>Control intervention</I>
<BR/>Placebo, twice daily</P>
<P>Treatment duration: 13 weeks<BR/>Analgesics other than study drugs allowed and intake assessed, but it was unclear whether intake was similar</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-07-31 02:45:05 -0400" MODIFIED_BY="[Empty name]">
<P>Extracted pain outcome: global pain after 13 weeks<BR/>Extracted function outcome: WOMAC global scale after 13 weeks</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-08-16 09:11:53 -0400" MODIFIED_BY="Anne Lawson">
<P>Sponsor: Purdue Pharma</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-08-17 16:46:58 -0400" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-Matsumoto-2005">
<CHAR_METHODS MODIFIED="2008-12-23 13:54:11 -0500" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial<BR/>4-arm parallel group design<BR/>Trial duration: 4 weeks<BR/>Simple randomisation<BR/>Multicentre trial<BR/>Power calculation reported</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-08-17 16:46:58 -0400" MODIFIED_BY="Anne Lawson">
<P>Participants with suboptimal analgesic response to NSAIDs, paracetamol, or opioids were eligible<BR/>491 participants were randomised<BR/>489 participants with knee or hip osteoarthritis were reported at baseline<BR/>Affected joints: 373 knees and 116 hips<BR/>Number of females: 297 of 489 (61%)<BR/>Mean age: 62 years<BR/>Mean BMI: 34 kg/m<SUP>2</SUP>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-08-16 09:15:24 -0400" MODIFIED_BY="Anne Lawson">
<P>
<I>Experimental interventions</I>
<BR/>Oral extended-release oxymorphone, 20 mg twice daily<BR/>Oral extended-release oxymorphone, 40 mg twice daily<BR/>Oral controlled-release oxycodone, 20 mg twice daily</P>
<P>
<I>Control intervention</I>
<BR/>Placebo, twice daily</P>
<P>Treatment duration: 4 weeks<BR/>No analgesics other than study drugs allowed</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-07-31 02:46:09 -0400" MODIFIED_BY="[Empty name]">
<P>Extracted pain outcome: WOMAC pain subscore after 4 weeks<BR/>Extracted function outcome: WOMAC disability subscore after 4 weeks<BR/>Primary outcome: change in arthritis pain intensity</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-08-16 09:15:35 -0400" MODIFIED_BY="Anne Lawson">
<P>Sponsors: TheraQuest Biosciences, Endo Pharmaceuticals, Penwest Pharmaceuticals Co</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-08-17 16:47:14 -0400" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-Munera-2010">
<CHAR_METHODS MODIFIED="2013-02-04 05:46:54 -0500" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial <BR/>2-arm parallel group design<BR/>Trial duration: 4 weeks<BR/>Multicentre trial with 25 centres<BR/>Power calculation reported<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-08-17 16:47:12 -0400" MODIFIED_BY="Anne Lawson">
<P>Participants with inadequate pain control using NSAIDs were eligible<BR/>315 participants were randomised<BR/>315 participants with knee or hip osteoarthritis were reported at baseline<BR/>Affected joints: 173 knees and 142 hips<BR/>Number of females: 212 of 315 (67%)<BR/>Mean age: 61 years</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-08-16 09:18:03 -0400" MODIFIED_BY="Anne Lawson">
<P>
<I>Experimental intervention</I>
<BR/>Transdermal buprenorphine, 5, 10, or 20 &#956;g/hour</P>
<P>
<I>Control intervention</I>
<BR/>Placebo</P>
<P>Treatment duration: 4 weeks<BR/>No analgesics other than study drugs allowed</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-08-17 16:47:14 -0400" MODIFIED_BY="Anne Lawson">
<P>Extracted pain outcome: global pain after 4 weeks<BR/>Extracted function outcome: participant's global assessment after 4 weeks<BR/>Primary outcome: percentage of participants considered to have achieved treatment success</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-08-16 09:18:21 -0400" MODIFIED_BY="Anne Lawson">
<P>Sponsor: Purdue</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-08-17 16:47:41 -0400" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-NCT00486811">
<CHAR_METHODS MODIFIED="2013-02-04 05:46:54 -0500" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial<BR/>3-arm parallel group design<BR/>Trial duration unclear <BR/>Multicentre trial with 101 centres <BR/>No power calculation reported<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-08-17 16:47:41 -0400" MODIFIED_BY="Anne Lawson">
<P>Participants who were dissatisfied with their prior analgesic therapy were eligible<BR/>987 participants with knee osteoarthritis were reported at baseline<BR/>Number of females: 707 of 987 (72%)<BR/>Mean age: 62 years</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-08-16 09:23:15 -0400" MODIFIED_BY="Anne Lawson">
<P>
<I>Experimental interventions</I>
<BR/>Oral extended-release tapentadol, 100-250 mg twice daily<BR/>Oral controlled-release oxycodone, 20-50 mg twice daily</P>
<P>
<I>Control intervention</I>
<BR/>Placebo, twice daily</P>
<P>Treatment duration: 15 weeks<BR/>Unclear whether analgesics other than study drugs allowed<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-08-16 09:24:07 -0400" MODIFIED_BY="Anne Lawson">
<P>Extracted pain outcome: global pain after 15 weeks</P>
<P>Extracted function outcome: WOMAC global scale after 15 weeks<BR/>Primary outcome: change in mean pain intensity</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-08-16 09:24:10 -0400" MODIFIED_BY="Anne Lawson">
<P>Sponsor: Grünenthal GmbH</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-08-17 16:48:02 -0400" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-NCT00531427">
<CHAR_METHODS MODIFIED="2013-02-04 05:46:55 -0500" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial <BR/>2-arm parallel group design <BR/>Trial duration unclear <BR/>Multicentre trial with 83 centres<BR/>No power calculation reported<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-08-17 16:48:02 -0400" MODIFIED_BY="Anne Lawson">
<P>Participants with suboptimal analgesic response to opioids were eligible<BR/>570 participants were randomised<BR/>570 participants with knee osteoarthritis were reported at baseline<BR/>Affected joints: 567 knees<BR/>Number of females: 356 of 567 (63%)<BR/>Mean age: 59 years</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-08-16 09:25:21 -0400" MODIFIED_BY="Anne Lawson">
<P>
<I>Experimental intervention</I>
<BR/>Transdermal buprenorphine, 10 or 20 &#956;g/hour</P>
<P>
<I>Control intervention</I>
<BR/>Placebo</P>
<P>Treatment duration: 12 weeks<BR/>Analgesics other than study drugs allowed and intake was similar between groups</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-08-16 09:25:32 -0400" MODIFIED_BY="Anne Lawson">
<P>Extracted pain outcome: global pain after 12 weeks.<BR/>No function outcome reported<BR/>Primary outcome: mean pain over the last 24 hours</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-08-16 09:25:35 -0400" MODIFIED_BY="Anne Lawson">
<P>Sponsor: Purdue Pharma</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-08-17 16:48:37 -0400" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-NCT00980798">
<CHAR_METHODS MODIFIED="2013-02-04 05:46:56 -0500" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial <BR/>2-arm parallel group design <BR/>Trial duration unclear<BR/>Power calculation reported<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-08-17 16:48:37 -0400" MODIFIED_BY="Anne Lawson">
<P>Participants with insufficient pain relief using NSAIDs, paracetamol, or a weak opioid were eligible<BR/>88 participants with knee or hip osteoarthritis were reported at baseline<BR/>Number of females: 208 of 288 (72%)<BR/>Mean age: 65 years</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-08-16 09:27:27 -0400" MODIFIED_BY="Anne Lawson">
<P>
<I>Experimental intervention</I>
<BR/>Oral hydromorphone (OROS), 4-32 mg once daily</P>
<P>
<I>Control intervention </I>
<BR/>Placebo, once daily</P>
<P>Treatment duration: 16 weeks<BR/>Analgesics other than study drugs allowed, but it was unclear whether intake was similar between groups</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-08-16 09:27:37 -0400" MODIFIED_BY="Anne Lawson">
<P>Extracted pain outcome: global pain after 16 weeks<BR/>No function outcome reported<BR/>Primary outcome: mean pain (Item 5 of Brief Pain Inventory)<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-08-16 09:27:39 -0400" MODIFIED_BY="Anne Lawson">
<P>Sponsor: Janssen-Cilag</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-08-17 16:48:50 -0400" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-Peloso-2000">
<CHAR_METHODS MODIFIED="2008-12-23 13:54:28 -0500" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial<BR/>2-arm parallel group design<BR/>Trial duration: 4 weeks<BR/>Multicentre trial with 4 centres<BR/>Power calculation reported</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-08-17 16:48:50 -0400" MODIFIED_BY="Anne Lawson">
<P>Participants with osteoarthritis symptoms requiring therapy with paracetamol, anti-inflammatory agents or opioids were eligible<BR/>103 participants were randomised<BR/>103 participants with osteoarthritis were reported at baseline<BR/>Affected joints: 94 knees and 49 hips<BR/>Number of females: 64 of 103 (62%)<BR/>Mean age: 62 years<BR/>Mean BMI: 34 kg/m<SUP>2</SUP>
<BR/>Mean disease duration: 10.3 years</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-08-16 09:30:33 -0400" MODIFIED_BY="Anne Lawson">
<P>
<I>Experimental intervention</I>
<BR/>Oral codeine (Contin), 100 mg twice daily</P>
<P>
<I>Control intervention</I>
<BR/>Placebo, twice daily</P>
<P>Treatment duration: 4 weeks<BR/>Analgesics other than study drugs allowed and intake assessed, but it was unclear whether intake was similar between groups</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-07-31 02:47:28 -0400" MODIFIED_BY="[Empty name]">
<P>Extracted pain outcome: global pain after 4 weeks<BR/>Extracted function outcome: WOMAC disability subscore after 4 weeks<BR/>Primary outcome: WOMAC pain and overall pain intensity</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-08-16 09:30:46 -0400" MODIFIED_BY="Anne Lawson">
<P>Sponsor: Purdue Frederick</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-08-17 16:57:17 -0400" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-Quiding-1992">
<CHAR_METHODS MODIFIED="2014-08-17 16:57:17 -0400" MODIFIED_BY="Anne Lawson">
<P>Randomised controlled trial<BR/>3-arm cross-over design<BR/>Trial duration: 1 week<BR/>No power calculation reported</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-08-17 16:49:10 -0400" MODIFIED_BY="Anne Lawson">
<P>Participants in need of analgesic medication for hip osteoarthritis were eligible<BR/>27 participants were randomised<BR/>26 participants with hip osteoarthritis were reported at baseline<BR/>Affected joints: 26 hips<BR/>Number of females: 22 of 26 (85%)<BR/>Mean age: 53 years</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-08-16 09:33:12 -0400" MODIFIED_BY="Anne Lawson">
<P>
<I>Experimental intervention</I>
<BR/>Oral codeine 30 mg plus ibuprofen 200 mg, 6 times in 32 hours</P>
<P>
<I>Control intervention</I>
<BR/>Ibuprofen 200 mg, 6 times in 32 hours</P>
<P>Treatment duration: 32 hours<BR/>No analgesics other than study drugs allowed</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-07-31 02:50:20 -0400" MODIFIED_BY="[Empty name]">
<P>Extracted pain outcome: global pain after 1 week<BR/>No function outcome reported<BR/>No primary outcome reported</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-08-16 09:33:27 -0400" MODIFIED_BY="Anne Lawson">
<P>No information about source of funding provided<BR/>1 trial arm excluded from review</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-08-21 15:46:44 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Shannon-2005">
<CHAR_METHODS MODIFIED="2013-02-04 05:46:57 -0500" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial<BR/>2-arm parallel group design<BR/>Trial duration: 30 weeks<BR/>Multicentre trial with 41 centres<BR/>No power calculation reported<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-08-21 15:46:44 -0400" MODIFIED_BY="[Empty name]">
<P>Participants with moderate-to-severe pain while taking paracetamol, non-steroidal anti-inflammatory agents or opioids were eligible<BR/>327 participants were randomised<BR/>327 participants with knee or hip osteoarthritis were reported at baseline<BR/>Number of females: 219 of 326 (67%)<BR/>Mean age: 61 years</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-08-16 09:37:29 -0400" MODIFIED_BY="Anne Lawson">
<P>
<I>Experimental intervention</I>
<BR/>Transdermal buprenorphine (Butrans), 5, 10 or 20 &#956;g/hour</P>
<P>
<I>Control intervention</I>
<BR/>Placebo</P>
<P>Treatment duration: 4 weeks<BR/>Analgesics other than study drugs allowed, but it was unclear whether intake was similar between groups</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-08-16 09:38:33 -0400" MODIFIED_BY="Anne Lawson">
<P>Extracted pain outcome: global pain after 30 weeks<BR/>Extracted function outcome: after 30 weeks<BR/>Primary outcome: time to development of inadequate analgesia</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-08-16 09:38:35 -0400" MODIFIED_BY="Anne Lawson">
<P>Sponsor: Purdue Pharma L.P</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-08-17 16:49:36 -0400" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-Zautra-2005">
<CHAR_METHODS MODIFIED="2008-12-23 13:54:47 -0500" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial<BR/>2-arm parallel group design<BR/>Trial duration: 13 weeks<BR/>Multicentre trial with 9 centres<BR/>No power calculation reported</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-08-17 16:49:36 -0400" MODIFIED_BY="Anne Lawson">
<P>107 participants were randomised<BR/>104 participants with knee osteoarthritis were reported at baseline<BR/>Number of females: 76 of 104 (73%)<BR/>Mean age: 63 years</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-08-16 09:39:25 -0400" MODIFIED_BY="Anne Lawson">
<P>
<I>Experimental intervention</I>
<BR/>Oral oxycodone (Oxycontin), 10 mg twice daily</P>
<P>
<I>Control intervention</I>
<BR/>Placebo, twice daily</P>
<P>Treatment duration: 13 weeks<BR/>Analgesics other than study drugs allowed, but it was unclear whether intake was similar between groups</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-07-31 02:51:39 -0400" MODIFIED_BY="[Empty name]">
<P>Extracted pain outcome: global pain after 13 weeks<BR/>No function outcome reported<BR/>Primary outcome: coping efficacy and arthritis helplessness</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-08-16 09:39:34 -0400" MODIFIED_BY="Anne Lawson">
<P>Sponsor: Purdue Pharma</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>BMI: body mass index; COXIB: cyclo-oxygenase inhibitor; NSAID: non-steroidal anti-inflammatory drug; VAS: visual analogue scale; WOMAC: Western Ontario and McMaster Universities Arthritis Index.</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2014-08-17 16:51:30 -0400" MODIFIED_BY="Anne Lawson" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2014-08-16 09:40:27 -0400" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-Adams-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-08-16 09:40:27 -0400" MODIFIED_BY="Anne Lawson">
<P>Only active control interventions</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-08-17 16:51:16 -0400" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-Andrei-1984">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-08-17 16:51:16 -0400" MODIFIED_BY="Anne Lawson">
<P>Percentage of participants with knee or hip osteoarthritis 17% (5/30)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-08-16 09:40:31 -0400" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-Boureau-1990">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-08-16 09:40:31 -0400" MODIFIED_BY="Anne Lawson">
<P>Only active control interventions</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-08-16 09:40:41 -0400" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-Boyer-2012">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-08-16 09:40:41 -0400" MODIFIED_BY="Anne Lawson">
<P>Cross-over trial providing pooled results only</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-08-17 16:51:17 -0400" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-Brooks-1982">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-08-17 16:51:17 -0400" MODIFIED_BY="Anne Lawson">
<P>Percentage of participants with osteoarthritis 50%, no information about joints involved</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-08-16 09:44:25 -0400" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-Burch-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-08-16 09:44:25 -0400" MODIFIED_BY="Anne Lawson">
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-08-17 16:51:18 -0400" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-Caldwell-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-08-17 16:51:18 -0400" MODIFIED_BY="Anne Lawson">
<P>Percentage of participants with knee or hip osteoarthritis likely to be below 50%</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-08-16 09:44:22 -0400" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-Choquette-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-08-16 09:44:22 -0400" MODIFIED_BY="Anne Lawson">
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-08-16 09:44:34 -0400" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-Conaghan-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-08-16 09:44:34 -0400" MODIFIED_BY="Anne Lawson">
<P>Only active control interventions</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-08-16 09:44:36 -0400" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-Corsinovi-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-08-16 09:44:36 -0400" MODIFIED_BY="Anne Lawson">
<P>Only active control interventions</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-08-16 09:44:39 -0400" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-Doak-1992">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-08-16 09:44:39 -0400" MODIFIED_BY="Anne Lawson">
<P>Cross-over trial providing pooled results only</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-08-17 16:51:25 -0400" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-Fancourt-1984">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-08-17 16:51:25 -0400" MODIFIED_BY="Anne Lawson">
<P>Mixed population of rheumatoid arthritis and osteoarthritis, no information about number of participants with osteoarthritis</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-08-17 16:51:26 -0400" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-Friedmann-2011b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-08-17 16:51:26 -0400" MODIFIED_BY="Anne Lawson">
<P>Percentage of participants with knee or hip osteoarthritis 15% (123/827)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-08-16 09:44:46 -0400" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-Gazi-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-08-16 09:44:46 -0400" MODIFIED_BY="Anne Lawson">
<P>Only active control interventions</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-08-16 09:44:46 -0400" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-Hale-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-08-16 09:44:46 -0400" MODIFIED_BY="Anne Lawson">
<P>Only active control interventions</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-08-16 09:44:48 -0400" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-James-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-08-16 09:44:48 -0400" MODIFIED_BY="Anne Lawson">
<P>Only active control interventions</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-08-16 09:44:49 -0400" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-Katz-2010b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-08-16 09:44:49 -0400" MODIFIED_BY="Anne Lawson">
<P>Only active control interventions</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-08-16 09:44:54 -0400" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-Le-Loet-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-08-16 09:44:54 -0400" MODIFIED_BY="Anne Lawson">
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-08-16 09:44:57 -0400" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-McIlwain-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-08-16 09:44:57 -0400" MODIFIED_BY="Anne Lawson">
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-08-17 16:51:27 -0400" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-Mitchell-1984">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-08-17 16:51:27 -0400" MODIFIED_BY="Anne Lawson">
<P>Mixed population of rheumatoid arthritis and osteoarthritis, no information about number of participants with osteoarthritis</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-08-17 16:51:28 -0400" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-Neubauer-1983">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-08-17 16:51:28 -0400" MODIFIED_BY="Anne Lawson">
<P>Percentage of participants with osteoarthritis 15% (5/33)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-08-16 09:45:07 -0400" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-Rosenthal-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-08-16 09:45:07 -0400" MODIFIED_BY="Anne Lawson">
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-08-17 16:51:29 -0400" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-Roth-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-08-17 16:51:29 -0400" MODIFIED_BY="Anne Lawson">
<P>Percentage of participants with knee or hip osteoarthritis likely to be below 50%</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-08-16 09:45:12 -0400" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-Salzman-1983">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-08-16 09:45:12 -0400" MODIFIED_BY="Anne Lawson">
<P>Only active control interventions</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-08-17 16:51:29 -0400" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-Tassain-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-08-17 16:51:29 -0400" MODIFIED_BY="Anne Lawson">
<P>Percentage of participants with osteoarthritis 7% (2/28)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-08-16 09:45:19 -0400" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-Torres-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-08-16 09:45:19 -0400" MODIFIED_BY="Anne Lawson">
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-08-16 09:45:29 -0400" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-Vignon-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-08-16 09:45:29 -0400" MODIFIED_BY="Anne Lawson">
<P>Comparison of combination of dextropropoxyphene, paracetamol, and caffeine with placebo</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-08-16 09:45:34 -0400" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-Vlok-1987">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-08-16 09:45:34 -0400" MODIFIED_BY="Anne Lawson">
<P>Cross-over trial providing pooled results only</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-08-16 09:45:36 -0400" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-Vorsanger-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-08-16 09:45:36 -0400" MODIFIED_BY="Anne Lawson">
<P>Only active control interventions</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-08-16 09:45:40 -0400" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-Wallace-1994">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-08-16 09:45:40 -0400" MODIFIED_BY="Anne Lawson">
<P>Cross-over trial providing pooled results only</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-08-17 16:51:30 -0400" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-Wang-1965">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-08-17 16:51:30 -0400" MODIFIED_BY="Anne Lawson">
<P>Percentage of participants with osteoarthritis 6% (2/34)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-08-16 09:45:43 -0400" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-Wild-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-08-16 09:45:43 -0400" MODIFIED_BY="Anne Lawson">
<P>Only active control interventions</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2014-08-17 16:51:33 -0400" MODIFIED_BY="Anne Lawson" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<AWAITING_CHAR MODIFIED="2014-08-17 16:51:33 -0400" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-Kroner-1991">
<CHAR_METHODS MODIFIED="2008-12-12 10:19:41 -0500" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial<BR/>2-arm parallel group design<BR/>Trial duration: 3 weeks<BR/>Multicentre trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-08-17 16:51:31 -0400" MODIFIED_BY="Anne Lawson">
<P>131 participants with hip osteoarthritis were reported at baseline<BR/>Number of females: 70 of 131 (53%)<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-08-16 09:45:59 -0400" MODIFIED_BY="Anne Lawson">
<P>
<I>Experimental intervention</I>
<BR/>Codeine 30 mg plus paracetamol 500 mg</P>
<P>
<I>Control intervention</I>
<BR/>Paracetamol 500 mg</P>
<P>Treatment duration: 3 weeks<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-08-17 16:51:33 -0400" MODIFIED_BY="Anne Lawson">
<P>Assessed efficacy outcomes: pain intensity, pain relief, participant's evaluation of the effect of treatment<BR/>Assessed safety outcomes: number of participants withdrawn due to adverse events, serious adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-08-16 09:46:05 -0400" MODIFIED_BY="Anne Lawson">
<P>Insufficient data provided in published abstract, no full-text article available. Awaiting author response</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2014-08-21 15:44:23 -0400" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2014-08-17 16:44:59 -0400" MODIFIED_BY="Anne Lawson" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-16 08:33:29 -0400" MODIFIED_BY="Anne Lawson" RESULT="YES" STUDY_ID="STD-Afilalo-2010">
<DESCRIPTION>
<P>Quote: "Randomization was based on a computer-generated randomization list, balanced using permuted blocks, and stratified by study site"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-16 08:40:14 -0400" MODIFIED_BY="Anne Lawson" RESULT="YES" STUDY_ID="STD-Breivik-2010">
<DESCRIPTION>
<P>Quote: "Randomisation was performed using a validated computer system that automates the random assignment of subjects to randomisation numbers"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-16 08:42:47 -0400" MODIFIED_BY="Anne Lawson" RESULT="UNKNOWN" STUDY_ID="STD-Caldwell-2002">
<DESCRIPTION>
<P>The authors' description of the randomisation process does not explain how they generated the random sequence of allocation </P>
<P>Quote: "Eligible participants entered a washout period of up to seven days and were subsequently randomized to one of four treatments"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-16 08:53:34 -0400" MODIFIED_BY="Anne Lawson" RESULT="UNKNOWN" STUDY_ID="STD-Chindalore-2005">
<DESCRIPTION>
<P>Insufficient information provided</P>
<P>Quote: "Qualifying patients were randomly assigned and stratified by sex to 1 of 4 treatments for 3 weeks"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-16 08:56:12 -0400" MODIFIED_BY="Anne Lawson" RESULT="YES" STUDY_ID="STD-Etropolski-2011">
<DESCRIPTION>
<P>Quote: "Randomization was based on a computer-generated randomization schedule, stratified by study center, and implemented using an interactive voice response system"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-17 08:08:07 -0400" MODIFIED_BY="Anne Lawson" RESULT="UNKNOWN" STUDY_ID="STD-Fidelholtz-2011">
<DESCRIPTION>
<P>Method used to generate random sequence of allocation was not reported, so the risk of selection bias was unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-17 08:08:11 -0400" MODIFIED_BY="Anne Lawson" RESULT="UNKNOWN" STUDY_ID="STD-Friedmann-2011">
<DESCRIPTION>
<P>Method used to generate random sequence of allocation was not reported, so the risk of selection bias was unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-17 16:44:59 -0400" MODIFIED_BY="Anne Lawson" RESULT="YES" STUDY_ID="STD-Hartrick-2009">
<DESCRIPTION>
<P>Permuted blocks were used to balance the number of participants across groups, so generation of sequence of random allocation was likely computer-generated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-17 08:08:17 -0400" MODIFIED_BY="Anne Lawson" RESULT="UNKNOWN" STUDY_ID="STD-Katz-2010">
<DESCRIPTION>
<P>Method used to generate random sequence of allocation was not reported, so the risk of selection bias was unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-17 08:07:19 -0400" MODIFIED_BY="Anne Lawson" RESULT="YES" STUDY_ID="STD-Kivitz-2006">
<DESCRIPTION>
<P>Quote: "A computer-generated randomization schedule was used to assign them to 1 of 4 groups"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-17 08:08:18 -0400" MODIFIED_BY="Anne Lawson" RESULT="UNKNOWN" STUDY_ID="STD-Kjaersgaard_x002d_Andersen-1990">
<DESCRIPTION>
<P>Method used to generate random sequence of allocation was not reported, so the risk of selection bias was unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-16 09:10:46 -0400" MODIFIED_BY="Anne Lawson" RESULT="YES" STUDY_ID="STD-Langford-2006">
<DESCRIPTION>
<P>Quote: "Randomization was performed using a computer-generated list"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-16 09:12:01 -0400" MODIFIED_BY="Anne Lawson" RESULT="YES" STUDY_ID="STD-Markenson-2005">
<DESCRIPTION>
<P>Quote: "The computer-generated randomization code and study drug bottles labeled with randomization numbers were supplied by the sponsor"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-16 09:15:40 -0400" MODIFIED_BY="Anne Lawson" RESULT="YES" STUDY_ID="STD-Matsumoto-2005">
<DESCRIPTION>
<P>Quote: "The list of randomization numbers was based on a computer generated randomization schedule"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-17 08:08:21 -0400" MODIFIED_BY="Anne Lawson" RESULT="UNKNOWN" STUDY_ID="STD-Munera-2010">
<DESCRIPTION>
<P>Method used to generate random sequence of allocation was not reported, so the risk of selection bias was unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-17 08:08:22 -0400" MODIFIED_BY="Anne Lawson" RESULT="UNKNOWN" STUDY_ID="STD-NCT00486811">
<DESCRIPTION>
<P>Method used to generate random sequence of allocation was not reported, so the risk of selection bias was unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-17 08:08:25 -0400" MODIFIED_BY="Anne Lawson" RESULT="UNKNOWN" STUDY_ID="STD-NCT00531427">
<DESCRIPTION>
<P>Method used to generate random sequence of allocation was not reported, so the risk of selection bias was unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-17 08:08:27 -0400" MODIFIED_BY="Anne Lawson" RESULT="UNKNOWN" STUDY_ID="STD-NCT00980798">
<DESCRIPTION>
<P>Method used to generate random sequence of allocation was not reported, so the risk of selection bias was unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-17 08:08:28 -0400" MODIFIED_BY="Anne Lawson" RESULT="UNKNOWN" STUDY_ID="STD-Peloso-2000">
<DESCRIPTION>
<P>Method used to generate random sequence of allocation was not reported, so the risk of selection bias was unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-17 08:08:30 -0400" MODIFIED_BY="Anne Lawson" RESULT="UNKNOWN" STUDY_ID="STD-Quiding-1992">
<DESCRIPTION>
<P>Method used to generate random sequence of allocation was not reported, so the risk of selection bias was unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-17 08:08:33 -0400" MODIFIED_BY="Anne Lawson" RESULT="UNKNOWN" STUDY_ID="STD-Shannon-2005">
<DESCRIPTION>
<P>Method used to generate random sequence of allocation was not reported, so the risk of selection bias was unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-16 09:39:36 -0400" MODIFIED_BY="Anne Lawson" RESULT="UNKNOWN" STUDY_ID="STD-Zautra-2005">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2014-08-17 16:42:14 -0400" MODIFIED_BY="Anne Lawson" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-17 16:41:08 -0400" MODIFIED_BY="Anne Lawson" RESULT="YES" STUDY_ID="STD-Afilalo-2010">
<DESCRIPTION>
<P>Quote: "Randomization was implemented through an interactive voice response system (IVRS) to dispense blinded study medication. Placebo tablets and capsules (one for each active treatment) were used to maintain blinded treatments. Investigators were not provided with the randomization codes, and the schedule was maintained with the IVRS. The blinding was not broken until all participants had completed the trial, except in the case of a suspected unexpected serious adverse reaction or if emergency treatment required knowledge of a patient's treatment status"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-16 08:40:23 -0400" MODIFIED_BY="Anne Lawson" RESULT="YES" STUDY_ID="STD-Breivik-2010">
<DESCRIPTION>
<P>Quote: Coded-drugs of identical appearance: drugs "were identical in appearance, packed in a labelled foil pouch, containing coded treatment group identification. The medication codes were not available until the completion of the study and clinical database lock, except in case of emergency." Also: "The randomisation schedule was filed in a secure location in a manner such that blinding was properly maintained throughout the study"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-17 16:42:14 -0400" MODIFIED_BY="Anne Lawson" RESULT="UNKNOWN" STUDY_ID="STD-Caldwell-2002">
<DESCRIPTION>
<P>The authors' description of the randomisation process does not explain whether the random sequence of allocation was concealed from study personnel responsible for participant recruitment</P>
<P>Quote: "Eligible participants entered a washout period of up to seven days and were subsequently randomized to one of four treatments"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-16 08:53:35 -0400" MODIFIED_BY="Anne Lawson" RESULT="UNKNOWN" STUDY_ID="STD-Chindalore-2005">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-16 08:56:13 -0400" MODIFIED_BY="Anne Lawson" RESULT="YES" STUDY_ID="STD-Etropolski-2011">
<DESCRIPTION>
<P>Quote: "Randomization was based on a computer-generated randomization schedule, stratified by study center, and implemented using an interactive voice response system"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-17 08:08:08 -0400" MODIFIED_BY="Anne Lawson" RESULT="UNKNOWN" STUDY_ID="STD-Fidelholtz-2011">
<DESCRIPTION>
<P>Method used to conceal the random sequence of allocation was not reported, so the risk of selection bias was unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-17 08:08:12 -0400" MODIFIED_BY="Anne Lawson" RESULT="UNKNOWN" STUDY_ID="STD-Friedmann-2011">
<DESCRIPTION>
<P>Method used to conceal the random sequence of allocation was not reported, so the risk of selection bias was unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-17 08:08:15 -0400" MODIFIED_BY="Anne Lawson" RESULT="UNKNOWN" STUDY_ID="STD-Hartrick-2009">
<DESCRIPTION>
<P>No information on concealment of allocation was provided, so risk of selection bias was unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-16 09:06:19 -0400" MODIFIED_BY="Anne Lawson" RESULT="YES" STUDY_ID="STD-Katz-2010">
<DESCRIPTION>
<P>Quote: "The outpatient site contacted the Interactive Web Response System to receive a randomization number and treatment assignment"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-16 09:08:11 -0400" MODIFIED_BY="Anne Lawson" RESULT="YES" STUDY_ID="STD-Kivitz-2006">
<DESCRIPTION>
<P>Quote: "The study medications had computer-generated 2-part labels. One part of the label, which contained study and patient information, was attached to the box that contained all 4 bottles of study medication. The other part of the label was a tear-off section containing the same information. This tear-off section was removed at the time of dispensing and was attached to the appropriate page of the case report form; a copy of this page was made and retained in the investigator's study file. The treatment to which a patient had been assigned was concealed by an alcohol-removable-ink overlay on the tear-off part of the label"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-17 08:08:19 -0400" MODIFIED_BY="Anne Lawson" RESULT="UNKNOWN" STUDY_ID="STD-Kjaersgaard_x002d_Andersen-1990">
<DESCRIPTION>
<P>Method used to conceal the random sequence of allocation was not reported, so the risk of selection bias was unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-16 09:10:49 -0400" MODIFIED_BY="Anne Lawson" RESULT="YES" STUDY_ID="STD-Langford-2006">
<DESCRIPTION>
<P>Quote: "Participants were assigned consecutive treatment codes, and investigators were unaware of the treatment allocation"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-16 09:12:05 -0400" MODIFIED_BY="Anne Lawson" RESULT="YES" STUDY_ID="STD-Markenson-2005">
<DESCRIPTION>
<P>Quote: "The computer-generated randomization code and study drug bottles labeled with randomization numbers were supplied by the sponsor"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-17 08:08:20 -0400" MODIFIED_BY="Anne Lawson" RESULT="UNKNOWN" STUDY_ID="STD-Matsumoto-2005">
<DESCRIPTION>
<P>Method used to conceal the random sequence of allocation was not reported, so the risk of selection bias was unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-17 08:08:22 -0400" MODIFIED_BY="Anne Lawson" RESULT="UNKNOWN" STUDY_ID="STD-Munera-2010">
<DESCRIPTION>
<P>Method used to conceal the random sequence of allocation was not reported, so the risk of selection bias was unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-17 08:08:23 -0400" MODIFIED_BY="Anne Lawson" RESULT="UNKNOWN" STUDY_ID="STD-NCT00486811">
<DESCRIPTION>
<P>Method used to conceal the random sequence of allocation was not reported, so the risk of selection bias was unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-17 08:08:26 -0400" MODIFIED_BY="Anne Lawson" RESULT="UNKNOWN" STUDY_ID="STD-NCT00531427">
<DESCRIPTION>
<P>Method used to conceal the random sequence of allocation was not reported, so the risk of selection bias was unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-17 08:08:27 -0400" MODIFIED_BY="Anne Lawson" RESULT="UNKNOWN" STUDY_ID="STD-NCT00980798">
<DESCRIPTION>
<P>Method used to conceal the random sequence of allocation was not reported, so the risk of selection bias was unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-17 08:08:29 -0400" MODIFIED_BY="Anne Lawson" RESULT="UNKNOWN" STUDY_ID="STD-Peloso-2000">
<DESCRIPTION>
<P>Method used to conceal the random sequence of allocation was not reported, so the risk of selection bias was unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-17 08:08:31 -0400" MODIFIED_BY="Anne Lawson" RESULT="UNKNOWN" STUDY_ID="STD-Quiding-1992">
<DESCRIPTION>
<P>Method used to conceal the random sequence of allocation was not reported, so the risk of selection bias was unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-17 08:08:33 -0400" MODIFIED_BY="Anne Lawson" RESULT="UNKNOWN" STUDY_ID="STD-Shannon-2005">
<DESCRIPTION>
<P>Method used to conceal the random sequence of allocation was not reported, so the risk of selection bias was unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-16 09:39:39 -0400" MODIFIED_BY="Anne Lawson" RESULT="YES" STUDY_ID="STD-Zautra-2005">
<DESCRIPTION>
<P>Quote: "The bottles of medication were labeled with a randomization number and dispensed by the investigators"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2008-10-20 10:07:05 -0400" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>Function</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.02" NO="2">
<NAME>Pain</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="STUDY" MODIFIED="2014-08-17 08:06:15 -0400" MODIFIED_BY="Anne Lawson" NO="7">
<NAME>Described as double-blind?</NAME>
<DESCRIPTION/>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-07-23 16:05:42 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Afilalo-2010">
<DESCRIPTION>
<P>Quote: "This was a randomized, double-blind, active- and placebo controlled, parallel-arm, multicentre, phase III study..."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-16 08:40:34 -0400" MODIFIED_BY="Anne Lawson" RESULT="YES" STUDY_ID="STD-Breivik-2010">
<DESCRIPTION>
<P>Quote: "This was a 6 months (24 weeks; 168 days), randomised, double-blind, placebo-controlled, parallel-group, multicentre study"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-16 08:43:22 -0400" MODIFIED_BY="Anne Lawson" RESULT="YES" STUDY_ID="STD-Caldwell-2002">
<DESCRIPTION>
<P>Quote: "The double-blind trial was a 4-week, multicenter, randomized, double-blind, double-dummy, placebo controlled, parallel trial"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-16 08:53:39 -0400" MODIFIED_BY="Anne Lawson" RESULT="YES" STUDY_ID="STD-Chindalore-2005">
<DESCRIPTION>
<P>Quote: "This study was a randomized, double-blind, placebo and active-controlled dose escalation trial"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-16 08:56:15 -0400" MODIFIED_BY="Anne Lawson" RESULT="YES" STUDY_ID="STD-Etropolski-2011">
<DESCRIPTION>
<P>Quote: "In this double-blind study, patients with end-stage joint disease were randomized to tapentadol IR (50 mg or 75 mg), oxycodone HCL IR 10 mg, or placebo"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-07-23 16:52:07 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Fidelholtz-2011">
<DESCRIPTION>
<P>Quote: "A randomized, double-blind, placebo (PBO)- &amp; active-controlled study..."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-07-23 16:59:32 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Friedmann-2011">
<DESCRIPTION>
<P>Quote: "...a double-blind, multicenter, placebo-controlled trial..."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-16 09:04:35 -0400" MODIFIED_BY="Anne Lawson" RESULT="YES" STUDY_ID="STD-Hartrick-2009">
<DESCRIPTION>
<P>Quote: "...randomized, double-blind, active- and placebo-controlled study..."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-16 09:06:20 -0400" MODIFIED_BY="Anne Lawson" RESULT="YES" STUDY_ID="STD-Katz-2010">
<DESCRIPTION>
<P>Quote: "This randomized, double-blind, placebo-controlled, multicenter outpatient study"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-07-23 17:08:17 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kivitz-2006">
<DESCRIPTION>
<P>Quote: "This was a 2-week, multicenter, randomized, double-blind, parallel-group, dose-ranging, Phase lll trial"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-16 09:09:26 -0400" MODIFIED_BY="Anne Lawson" RESULT="YES" STUDY_ID="STD-Kjaersgaard_x002d_Andersen-1990">
<DESCRIPTION>
<P>Quote: "The study was designed as a randomised, double-blind and parallel investigation"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-16 09:11:06 -0400" MODIFIED_BY="Anne Lawson" RESULT="YES" STUDY_ID="STD-Langford-2006">
<DESCRIPTION>
<P>Quote: "The aim of the present trial was therefore to assess pain relief from treatment with TDF [transdermal fentanyl] as compared with placebo in a double-blind study"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-16 09:12:07 -0400" MODIFIED_BY="Anne Lawson" RESULT="YES" STUDY_ID="STD-Markenson-2005">
<DESCRIPTION>
<P>Quote: "This was a double blind, randomized, placebo-controlled, parallel-group study"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-16 09:15:53 -0400" MODIFIED_BY="Anne Lawson" RESULT="YES" STUDY_ID="STD-Matsumoto-2005">
<DESCRIPTION>
<P>Quote: "The study was a multicenter, 4-week, randomized, double-blind, parallel-group study"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-07-23 17:20:49 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Munera-2010">
<DESCRIPTION>
<P>Quote: "&#8230;randomized, placebo-controlled, double-blind, parallel-group investigation"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-16 09:24:44 -0400" MODIFIED_BY="Anne Lawson" RESULT="YES" STUDY_ID="STD-NCT00486811">
<DESCRIPTION>
<P>Quote from ClinicalTrials.gov: "Double Blind (Subject, Investigator)"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-16 09:25:53 -0400" MODIFIED_BY="Anne Lawson" RESULT="YES" STUDY_ID="STD-NCT00531427">
<DESCRIPTION>
<P>Quote from ClinicalTrials.gov: "Double Blind (Subject, Investigator)"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-16 09:27:55 -0400" MODIFIED_BY="Anne Lawson" RESULT="YES" STUDY_ID="STD-NCT00980798">
<DESCRIPTION>
<P>Quote from ClinicalTrials.gov: "Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-17 08:06:08 -0400" MODIFIED_BY="Anne Lawson" RESULT="YES" STUDY_ID="STD-Peloso-2000">
<DESCRIPTION>
<P>Quote: "Randomized, balanced, double blind parallel group assignment"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-16 09:34:27 -0400" MODIFIED_BY="Anne Lawson" RESULT="YES" STUDY_ID="STD-Quiding-1992">
<DESCRIPTION>
<P>Quote: "double-blind, placebo-controlled cross-over design"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-07-23 17:33:11 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Shannon-2005">
<DESCRIPTION>
<P>Quote: "Randomized, double-blind, placebo-controlled"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-17 08:06:15 -0400" MODIFIED_BY="Anne Lawson" RESULT="YES" STUDY_ID="STD-Zautra-2005">
<DESCRIPTION>
<P>Quote: "Double-blind, randomized, placebo-controlled, parallel-group study"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="STUDY" MODIFIED="2014-08-21 15:44:23 -0400" MODIFIED_BY="[Empty name]" NO="8">
<NAME>Blinding of patients?</NAME>
<DESCRIPTION/>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-18 06:45:42 -0400" MODIFIED_BY="Anne Lawson" RESULT="YES" STUDY_ID="STD-Afilalo-2010">
<DESCRIPTION>
<P>Because the study was described as a double-dummy, we considered participants to be blinded</P>
<P>Quote: "Placebo tablets and capsules (one for each active treatment) were used to maintain blinded treatments"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-17 16:41:43 -0400" MODIFIED_BY="Anne Lawson" RESULT="YES" STUDY_ID="STD-Breivik-2010">
<DESCRIPTION>
<P>Because medication was described as identical and participants were explicitly described as blinded, we considered participants to be blinded</P>
<P>Quote: "All patients, investigators, and study centre and Sponsor personnel were blinded to the medication codes"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-21 15:44:23 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Caldwell-2002">
<DESCRIPTION>
<P>Because the study was described as a double-dummy, we considered participants to be blinded</P>
<P>Quote: "Placebo Avinza and placebo MSC [morphine sulphate controlled-release] matched the appearance of the respective active treatments. Avinza capsules and encapsulated MSC tablets did not look identical; therefore, to maintain the study blind, all participants consumed two capsules (one each representing Avinza and MSC) every morning and evening (Table 1)"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-18 06:45:56 -0400" MODIFIED_BY="Anne Lawson" RESULT="YES" STUDY_ID="STD-Chindalore-2005">
<DESCRIPTION>
<P>Because the interventions were described as indistinguishable, we considered participants to be blinded</P>
<P>Quote: "All study medications were identical in appearance, and patients, site personnel, and study monitors were blinded to treatment assignments"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-16 08:56:22 -0400" MODIFIED_BY="Anne Lawson" RESULT="YES" STUDY_ID="STD-Etropolski-2011">
<DESCRIPTION>
<P>Quote: "All study drugs were provided as overencapsulated tablets or capsules and were identical in shape, color, and size"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-17 16:44:17 -0400" MODIFIED_BY="Anne Lawson" RESULT="UNKNOWN" STUDY_ID="STD-Fidelholtz-2011">
<DESCRIPTION>
<P>It was unclear if method used to blind participants was appropriate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-17 16:44:33 -0400" MODIFIED_BY="Anne Lawson" RESULT="UNKNOWN" STUDY_ID="STD-Friedmann-2011">
<DESCRIPTION>
<P>It was unclear if method used to blind participants was appropriate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-17 16:45:05 -0400" MODIFIED_BY="Anne Lawson" RESULT="UNKNOWN" STUDY_ID="STD-Hartrick-2009">
<DESCRIPTION>
<P>It was unclear if method used to blind participants was appropriate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-17 16:45:22 -0400" MODIFIED_BY="Anne Lawson" RESULT="UNKNOWN" STUDY_ID="STD-Katz-2010">
<DESCRIPTION>
<P>It was unclear if method used to blind participants was appropriate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-18 06:46:02 -0400" MODIFIED_BY="Anne Lawson" RESULT="YES" STUDY_ID="STD-Kivitz-2006">
<DESCRIPTION>
<P>Because the study was described as a double-dummy, we considered participants to be blinded</P>
<P>Quote: "Study medications were overencapsulated in gelatin capsules so they were visually indistinguishable, and they were administered in a double-dummy fashion to maintain blinding"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-17 16:46:17 -0400" MODIFIED_BY="Anne Lawson" RESULT="YES" STUDY_ID="STD-Kjaersgaard_x002d_Andersen-1990">
<DESCRIPTION>
<P>Because the study used indistinguishable interventions, we considered participants to be blinded</P>
<P>Quote: "The tablets were identical in weight, appearance and taste"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-18 06:47:35 -0400" MODIFIED_BY="Anne Lawson" RESULT="YES" STUDY_ID="STD-Langford-2006">
<DESCRIPTION>
<P>Because the study used indistinguishable interventions, we considered participants to be blinded</P>
<P>Quote: "TDF and placebo patches were identical"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-18 06:47:40 -0400" MODIFIED_BY="Anne Lawson" RESULT="YES" STUDY_ID="STD-Markenson-2005">
<DESCRIPTION>
<P>Because the study used indistinguishable interventions, we considered participants to be blinded</P>
<P>Quote: "Patients who met the entry criteria were randomly assigned in double blind fashion to receive either 10-mg tablets of CR oxycodone or matching placebo every 12 hours"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-18 06:47:45 -0400" MODIFIED_BY="Anne Lawson" RESULT="YES" STUDY_ID="STD-Matsumoto-2005">
<DESCRIPTION>
<P>Because the study used indistinguishable interventions, we considered participants to be blinded</P>
<P>Quote: "Active study medication tablets were overencapsulated and visually indistinguishable from each other and from the placebo tablets"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-18 06:47:50 -0400" MODIFIED_BY="Anne Lawson" RESULT="YES" STUDY_ID="STD-Munera-2010">
<DESCRIPTION>
<P>Because the study used indistinguishable interventions, we considered participants to be blinded</P>
<P>Quote: "Placebo TDS [transdermal buprenorphine]-treated patients received identical-looking patches for each strength level"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-17 16:47:53 -0400" MODIFIED_BY="Anne Lawson" RESULT="UNKNOWN" STUDY_ID="STD-NCT00486811">
<DESCRIPTION>
<P>It was unclear if method used to blind participants was appropriate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-17 16:48:10 -0400" MODIFIED_BY="Anne Lawson" RESULT="UNKNOWN" STUDY_ID="STD-NCT00531427">
<DESCRIPTION>
<P>It was unclear if method used to blind participants was appropriate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-18 06:47:56 -0400" MODIFIED_BY="Anne Lawson" RESULT="YES" STUDY_ID="STD-NCT00980798">
<DESCRIPTION>
<P>Because the study used indistinguishable interventions, we considered participants to be blinded</P>
<P>Quote from ClinicalTrials.gov: "the control group receives an optically identical tablet with no active ingredient, a so-called placebo."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-18 06:51:10 -0400" MODIFIED_BY="Anne Lawson" RESULT="YES" STUDY_ID="STD-Peloso-2000">
<DESCRIPTION>
<P>Because the study used indistinguishable interventions, we considered participants to be blinded</P>
<P>Quote: "identical appearing placebo"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-18 06:51:14 -0400" MODIFIED_BY="Anne Lawson" RESULT="YES" STUDY_ID="STD-Quiding-1992">
<DESCRIPTION>
<P>Because the study was described as a double-dummy, we considered participants to be blinded</P>
<P>Quote: "a double-dummy technique was used to ensure blindness of the study"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-17 16:49:29 -0400" MODIFIED_BY="Anne Lawson" RESULT="UNKNOWN" STUDY_ID="STD-Shannon-2005">
<DESCRIPTION>
<P>It was unclear if method used to blind participants was appropriate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-17 16:49:45 -0400" MODIFIED_BY="Anne Lawson" RESULT="YES" STUDY_ID="STD-Zautra-2005">
<DESCRIPTION>
<P>Because the study used indistinguishable interventions, we considered participants to be blinded</P>
<P>Quote: "Patients were randomized at each of the 9 participating clinics to receive either oral CR oxycodone (10 mg) or matching placebo"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-09" LEVEL="STUDY" MODIFIED="2014-08-17 08:08:32 -0400" MODIFIED_BY="Anne Lawson" NO="9">
<NAME>Blinding of physicians?</NAME>
<DESCRIPTION/>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-17 08:08:05 -0400" MODIFIED_BY="Anne Lawson" RESULT="UNKNOWN" STUDY_ID="STD-Afilalo-2010">
<DESCRIPTION>
<P>Physicians were not explicitly described as blinded, so the risk of performance bias was unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-16 08:40:52 -0400" MODIFIED_BY="Anne Lawson" RESULT="YES" STUDY_ID="STD-Breivik-2010">
<DESCRIPTION>
<P>Quote: "All patients, investigators, and study centre and Sponsor personnel were blinded to the medication codes"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-17 08:08:06 -0400" MODIFIED_BY="Anne Lawson" RESULT="UNKNOWN" STUDY_ID="STD-Caldwell-2002">
<DESCRIPTION>
<P>Physicians were not explicitly described as blinded, so the risk of performance bias was unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-16 08:53:57 -0400" MODIFIED_BY="Anne Lawson" RESULT="YES" STUDY_ID="STD-Chindalore-2005">
<DESCRIPTION>
<P>Quote: "All study medications were identical in appearance, and patients, site personnel, and study monitors were blinded to treatment assignments"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-07-23 16:21:55 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Etropolski-2011">
<DESCRIPTION>
<P>Quote from ClinicalTrials.gov: "Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-07-23 16:53:32 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Fidelholtz-2011">
<DESCRIPTION>
<P>Quote from ClinicalTrial.gov: "Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-17 08:08:13 -0400" MODIFIED_BY="Anne Lawson" RESULT="UNKNOWN" STUDY_ID="STD-Friedmann-2011">
<DESCRIPTION>
<P>Physicians were not explicitly described as blinded, so the risk of performance bias was unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-16 09:04:41 -0400" MODIFIED_BY="Anne Lawson" RESULT="YES" STUDY_ID="STD-Hartrick-2009">
<DESCRIPTION>
<P>Quote from ClinicalTrials.gov: "This is a double-blind study, i.e., neither patients nor investigators will know what treatment is given"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-16 09:06:30 -0400" MODIFIED_BY="Anne Lawson" RESULT="YES" STUDY_ID="STD-Katz-2010">
<DESCRIPTION>
<P>Quote from ClinicalTrials.gov: "Double Blind (Subject, Investigator)"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-16 09:08:22 -0400" MODIFIED_BY="Anne Lawson" RESULT="YES" STUDY_ID="STD-Kivitz-2006">
<DESCRIPTION>
<P>Quote: "The study patients, study personnel, and investigators were blinded to the identity of the study treatments"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-17 08:08:20 -0400" MODIFIED_BY="Anne Lawson" RESULT="UNKNOWN" STUDY_ID="STD-Kjaersgaard_x002d_Andersen-1990">
<DESCRIPTION>
<P>Physicians were not explicitly described as blinded, so the risk of performance bias was unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-16 09:11:10 -0400" MODIFIED_BY="Anne Lawson" RESULT="YES" STUDY_ID="STD-Langford-2006">
<DESCRIPTION>
<P>Quote: "investigators were unaware of the treatment allocation"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-16 09:12:22 -0400" MODIFIED_BY="Anne Lawson" RESULT="YES" STUDY_ID="STD-Markenson-2005">
<DESCRIPTION>
<P>Because coded labelled bottles were provided by sponsor and drug tables were matching the placebo tablets, physicians were considered blinded as well</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-16 09:16:05 -0400" MODIFIED_BY="Anne Lawson" RESULT="YES" STUDY_ID="STD-Matsumoto-2005">
<DESCRIPTION>
<P>Quote: "Study enrollees, study personnel, and investigators were blinded to the identity of the treatments"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-16 09:22:05 -0400" MODIFIED_BY="Anne Lawson" RESULT="UNKNOWN" STUDY_ID="STD-Munera-2010">
<DESCRIPTION>
<P>Physicians were not explicitly described as blinded, so the risk of performance bias was unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-16 09:24:47 -0400" MODIFIED_BY="Anne Lawson" RESULT="YES" STUDY_ID="STD-NCT00486811">
<DESCRIPTION>
<P>Quote from ClinicalTrials.gov: "Double Blind (Subject, Investigator)"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-16 09:25:54 -0400" MODIFIED_BY="Anne Lawson" RESULT="YES" STUDY_ID="STD-NCT00531427">
<DESCRIPTION>
<P>Quote from ClinicalTrials.gov: "Double Blind (Subject, Investigator)"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-16 09:28:19 -0400" MODIFIED_BY="Anne Lawson" RESULT="YES" STUDY_ID="STD-NCT00980798">
<DESCRIPTION>
<P>Quote from ClinicalTrials.gov: "Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-17 08:08:30 -0400" MODIFIED_BY="Anne Lawson" RESULT="UNKNOWN" STUDY_ID="STD-Peloso-2000">
<DESCRIPTION>
<P>Physicians were not explicitly described as blinded, so the risk of performance bias was unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-17 08:08:32 -0400" MODIFIED_BY="Anne Lawson" RESULT="UNKNOWN" STUDY_ID="STD-Quiding-1992">
<DESCRIPTION>
<P>Physicians were not explicitly described as blinded, so the risk of performance bias was unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-07-23 17:33:32 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Shannon-2005">
<DESCRIPTION>
<P>Quote from ClinicalTrials.gov: "Double Blind (Subject, Investigator)"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-16 09:39:47 -0400" MODIFIED_BY="Anne Lawson" RESULT="UNKNOWN" STUDY_ID="STD-Zautra-2005">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-10" LEVEL="STUDY" MODIFIED="2014-08-17 16:50:22 -0400" MODIFIED_BY="Anne Lawson" NO="10">
<NAME>Blinding of outcome assessors?</NAME>
<DESCRIPTION/>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-17 16:41:21 -0400" MODIFIED_BY="Anne Lawson" RESULT="YES" STUDY_ID="STD-Afilalo-2010">
<DESCRIPTION>
<P>Because participants were blinded and outcomes were participant-reported, the risk of detection bias was considered low</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-17 16:41:49 -0400" MODIFIED_BY="Anne Lawson" RESULT="YES" STUDY_ID="STD-Breivik-2010">
<DESCRIPTION>
<P>Because participants were blinded and outcomes were participant-reported, the risk of detection bias was considered low</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-17 16:42:27 -0400" MODIFIED_BY="Anne Lawson" RESULT="YES" STUDY_ID="STD-Caldwell-2002">
<DESCRIPTION>
<P>Because participants were blinded and outcomes were participant-reported, the risk of detection bias was considered low</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-17 16:43:40 -0400" MODIFIED_BY="Anne Lawson" RESULT="YES" STUDY_ID="STD-Chindalore-2005">
<DESCRIPTION>
<P>Because participants were blinded and outcomes were participant-reported, the risk of detection bias was considered low</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-17 16:44:00 -0400" MODIFIED_BY="Anne Lawson" RESULT="YES" STUDY_ID="STD-Etropolski-2011">
<DESCRIPTION>
<P>Because participants were blinded and outcomes were participant-reported, the risk of detection bias was considered low</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-17 16:44:18 -0400" MODIFIED_BY="Anne Lawson" RESULT="UNKNOWN" STUDY_ID="STD-Fidelholtz-2011">
<DESCRIPTION>
<P>Because outcomes were self reported, and because it was unclear whether participants were properly blinded, it was unclear whether outcome assessors were blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-17 16:44:34 -0400" MODIFIED_BY="Anne Lawson" RESULT="UNKNOWN" STUDY_ID="STD-Friedmann-2011">
<DESCRIPTION>
<P>Because outcomes were self reported, and because it was unclear whether participants were properly blinded, it was unclear whether outcome assessors were blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-17 16:45:09 -0400" MODIFIED_BY="Anne Lawson" RESULT="UNKNOWN" STUDY_ID="STD-Hartrick-2009">
<DESCRIPTION>
<P>Because outcomes were self reported, and because it was unclear whether participants were properly blinded, it was unclear whether outcome assessors were blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-17 16:45:25 -0400" MODIFIED_BY="Anne Lawson" RESULT="UNKNOWN" STUDY_ID="STD-Katz-2010">
<DESCRIPTION>
<P>Because outcomes were self reported, and because it was unclear whether participants were properly blinded, it was unclear whether outcome assessors were blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-17 16:45:50 -0400" MODIFIED_BY="Anne Lawson" RESULT="YES" STUDY_ID="STD-Kivitz-2006">
<DESCRIPTION>
<P>Because participants were blinded and outcomes were participant-reported, the risk of detection bias was considered low</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-17 16:46:21 -0400" MODIFIED_BY="Anne Lawson" RESULT="YES" STUDY_ID="STD-Kjaersgaard_x002d_Andersen-1990">
<DESCRIPTION>
<P>Because participants were blinded and outcomes were participant-reported, the risk of detection bias was considered low</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-17 16:46:36 -0400" MODIFIED_BY="Anne Lawson" RESULT="YES" STUDY_ID="STD-Langford-2006">
<DESCRIPTION>
<P>Because participants were blinded and outcomes were participant-reported, the risk of detection bias was considered low</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-17 16:46:48 -0400" MODIFIED_BY="Anne Lawson" RESULT="YES" STUDY_ID="STD-Markenson-2005">
<DESCRIPTION>
<P>Because participants were blinded and outcomes were participant-reported, the risk of detection bias was considered low</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-17 16:47:04 -0400" MODIFIED_BY="Anne Lawson" RESULT="YES" STUDY_ID="STD-Matsumoto-2005">
<DESCRIPTION>
<P>Because participants were blinded and outcomes were participant-reported, the risk of detection bias was considered low</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-17 16:47:26 -0400" MODIFIED_BY="Anne Lawson" RESULT="YES" STUDY_ID="STD-Munera-2010">
<DESCRIPTION>
<P>Because participants were blinded and outcomes were participant-reported, the risk of detection bias was considered low</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-17 16:47:56 -0400" MODIFIED_BY="Anne Lawson" RESULT="UNKNOWN" STUDY_ID="STD-NCT00486811">
<DESCRIPTION>
<P>Because participants were blinded and outcomes were participant-reported, the risk of detection bias was considered low</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-17 16:48:32 -0400" MODIFIED_BY="Anne Lawson" RESULT="UNKNOWN" STUDY_ID="STD-NCT00531427">
<DESCRIPTION>
<P>Because it was unclear whether participants were blinded and outcomes were participant-reported, the risk of detection bias was considered unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-17 16:48:46 -0400" MODIFIED_BY="Anne Lawson" RESULT="YES" STUDY_ID="STD-NCT00980798">
<DESCRIPTION>
<P>Because participants were blinded and outcomes were participant-reported, the risk of detection bias was considered low</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-17 16:48:57 -0400" MODIFIED_BY="Anne Lawson" RESULT="YES" STUDY_ID="STD-Peloso-2000">
<DESCRIPTION>
<P>Because participants were blinded and outcomes were participant-reported, the risk of detection bias was considered low</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-17 16:49:22 -0400" MODIFIED_BY="Anne Lawson" RESULT="YES" STUDY_ID="STD-Quiding-1992">
<DESCRIPTION>
<P>Because participants were blinded and outcomes were participant-reported, the risk of detection bias was considered low</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-17 16:49:32 -0400" MODIFIED_BY="Anne Lawson" RESULT="UNKNOWN" STUDY_ID="STD-Shannon-2005">
<DESCRIPTION>
<P>Because it was unclear whether participants were blinded and the outcomes are participant-reported, the risk of bias was unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-17 16:50:22 -0400" MODIFIED_BY="Anne Lawson" RESULT="YES" STUDY_ID="STD-Zautra-2005">
<DESCRIPTION>
<P>Because participants were blinded and outcomes were participant-reported, the risk of detection bias was considered low</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-11" LEVEL="STUDY" MODIFIED="2014-08-17 16:42:28 -0400" MODIFIED_BY="Anne Lawson" NO="11">
<NAME>Interventions reported as indistinguishable?</NAME>
<DESCRIPTION/>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-07-23 16:08:02 -0400" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Afilalo-2010">
<DESCRIPTION>
<P>Quote: "Placebo tablets and capsules (one for each active treatment)&#8230;"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-16 08:41:02 -0400" MODIFIED_BY="Anne Lawson" RESULT="YES" STUDY_ID="STD-Breivik-2010">
<DESCRIPTION>
<P>Quote: drugs "were identical in appearance, packed in a labelled foil pouch, containing coded treatment group identification. The medication codes were not available until the completion of the study and clinical database lock, except in case of emergency"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-17 16:42:28 -0400" MODIFIED_BY="Anne Lawson" RESULT="NO" STUDY_ID="STD-Caldwell-2002">
<DESCRIPTION>
<P>Quote: "Placebo Avinza and placebo MSC matched the appearance of the respective active treatments. Avinza capsules and encapsulated MSC tablets did not look identical; therefore, to maintain the study blind, all participants consumed two capsules (one each representing Avinza and MSC) every morning and evening"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-16 08:54:05 -0400" MODIFIED_BY="Anne Lawson" RESULT="YES" STUDY_ID="STD-Chindalore-2005">
<DESCRIPTION>
<P>Quote: "All study medications were identical in appearance, and patients, site personnel, and study monitors were blinded to treatment assignments"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-17 08:05:48 -0400" MODIFIED_BY="Anne Lawson" RESULT="YES" STUDY_ID="STD-Etropolski-2011">
<DESCRIPTION>
<P>Quote: "All study drugs were provided as overencapsulated tablets or capsules and were identical in shape, color, and size"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-17 14:54:00 -0400" MODIFIED_BY="Anne Lawson" RESULT="NO" STUDY_ID="STD-Fidelholtz-2011">
<DESCRIPTION>
<P>Interventions were not reported as indistinguishable</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-17 14:55:14 -0400" MODIFIED_BY="Anne Lawson" RESULT="NO" STUDY_ID="STD-Friedmann-2011">
<DESCRIPTION>
<P>Interventions were not reported as indistinguishable</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-17 14:55:15 -0400" MODIFIED_BY="Anne Lawson" RESULT="NO" STUDY_ID="STD-Hartrick-2009">
<DESCRIPTION>
<P>Interventions were not reported as indistinguishable</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-17 14:55:16 -0400" MODIFIED_BY="Anne Lawson" RESULT="NO" STUDY_ID="STD-Katz-2010">
<DESCRIPTION>
<P>Interventions were not reported as indistinguishable</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-16 09:08:34 -0400" MODIFIED_BY="Anne Lawson" RESULT="NO" STUDY_ID="STD-Kivitz-2006">
<DESCRIPTION>
<P>The authors reported that interventions were only visually indistinguishable, which is probably the reason why double-dummy was implemented</P>
<P>Quote: "Study medications were overencapsulated in gelatin capsules so they were visually indistinguishable, and they were administered in a double-dummy fashion to maintain blinding"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-07-23 17:12:29 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kjaersgaard_x002d_Andersen-1990">
<DESCRIPTION>
<P>Quote: "The tablets were identical in weight, appearance and taste"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-16 09:11:15 -0400" MODIFIED_BY="Anne Lawson" RESULT="YES" STUDY_ID="STD-Langford-2006">
<DESCRIPTION>
<P>Quote: "TDF and placebo patches were identical"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-16 09:12:58 -0400" MODIFIED_BY="Anne Lawson" RESULT="YES" STUDY_ID="STD-Markenson-2005">
<DESCRIPTION>
<P>Quote: "Patients who met the entry criteria were randomly assigned in double blind fashion to receive either 10-mg tablets of CR [controlled release] oxycodone or matching placebo every 12 hours"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-16 09:16:13 -0400" MODIFIED_BY="Anne Lawson" RESULT="YES" STUDY_ID="STD-Matsumoto-2005">
<DESCRIPTION>
<P>Quote: "Active study medication tablets were overencapsulated and visually indistinguishable from each other and from the placebo tablets"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-16 09:22:29 -0400" MODIFIED_BY="Anne Lawson" RESULT="YES" STUDY_ID="STD-Munera-2010">
<DESCRIPTION>
<P>Quote: "Placebo TDS-treated patients received identical-looking patches for each strength level"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-17 14:55:29 -0400" MODIFIED_BY="Anne Lawson" RESULT="NO" STUDY_ID="STD-NCT00486811">
<DESCRIPTION>
<P>Interventions were not reported as indistinguishable</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-17 14:55:30 -0400" MODIFIED_BY="Anne Lawson" RESULT="NO" STUDY_ID="STD-NCT00531427">
<DESCRIPTION>
<P>Interventions were not reported as indistinguishable</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-16 09:28:32 -0400" MODIFIED_BY="Anne Lawson" RESULT="YES" STUDY_ID="STD-NCT00980798">
<DESCRIPTION>
<P>Quote from ClinicalTrials.gov: "the control group receives an optically identical tablet with no active ingredient, a so-called placebo"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-07-23 17:30:21 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Peloso-2000">
<DESCRIPTION>
<P>Quote: "identical appearing placebo"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-17 14:55:31 -0400" MODIFIED_BY="Anne Lawson" RESULT="NO" STUDY_ID="STD-Quiding-1992">
<DESCRIPTION>
<P>Interventions were not reported as indistinguishable</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-17 14:55:32 -0400" MODIFIED_BY="Anne Lawson" RESULT="NO" STUDY_ID="STD-Shannon-2005">
<DESCRIPTION>
<P>Interventions were not reported as indistinguishable</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-16 09:39:51 -0400" MODIFIED_BY="Anne Lawson" RESULT="YES" STUDY_ID="STD-Zautra-2005">
<DESCRIPTION>
<P>Quote: "Patients were randomized at each of the 9 participating clinics to receive either oral CR oxycodone (10 mg) or matching placebo"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-12" LEVEL="STUDY" MODIFIED="2014-08-17 16:42:30 -0400" MODIFIED_BY="Anne Lawson" NO="12">
<NAME>Double-dummy technique used?</NAME>
<DESCRIPTION/>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-16 08:35:36 -0400" MODIFIED_BY="Anne Lawson" RESULT="YES" STUDY_ID="STD-Afilalo-2010">
<DESCRIPTION>
<P>Quote: "Placebo tablets and capsules (one for each active treatment) were used to maintain blinded treatments"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-16 08:41:03 -0400" MODIFIED_BY="Anne Lawson" RESULT="NO" STUDY_ID="STD-Breivik-2010">
<DESCRIPTION>
<P>No double-dummy technique used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-17 16:42:30 -0400" MODIFIED_BY="Anne Lawson" RESULT="YES" STUDY_ID="STD-Caldwell-2002">
<DESCRIPTION>
<P>Quote: "Placebo Avinza and placebo MSC matched the appearance of the respective active treatments. Avinza capsules and encapsulated MSC tablets did not look identical; therefore, to maintain the study blind, all participants consumed two capsules (one each representing Avinza and MSC) every morning and evening"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-16 08:54:07 -0400" MODIFIED_BY="Anne Lawson" RESULT="NO" STUDY_ID="STD-Chindalore-2005">
<DESCRIPTION>
<P>No double-dummy technique used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-16 08:56:39 -0400" MODIFIED_BY="Anne Lawson" RESULT="NO" STUDY_ID="STD-Etropolski-2011">
<DESCRIPTION>
<P>No double-dummy technique used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-16 08:58:26 -0400" MODIFIED_BY="Anne Lawson" RESULT="UNKNOWN" STUDY_ID="STD-Fidelholtz-2011">
<DESCRIPTION>
<P>Description of intervention is not detailed enough to assess whether double-dummy technique was used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-16 09:01:12 -0400" MODIFIED_BY="Anne Lawson" RESULT="UNKNOWN" STUDY_ID="STD-Friedmann-2011">
<DESCRIPTION>
<P>Description of intervention is not detailed enough to assess whether double-dummy technique was used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-16 09:04:51 -0400" MODIFIED_BY="Anne Lawson" RESULT="NO" STUDY_ID="STD-Hartrick-2009">
<DESCRIPTION>
<P>No double-dummy technique used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-16 09:06:37 -0400" MODIFIED_BY="Anne Lawson" RESULT="UNKNOWN" STUDY_ID="STD-Katz-2010">
<DESCRIPTION>
<P>Unclear whether double-dummy technique was used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-16 09:08:37 -0400" MODIFIED_BY="Anne Lawson" RESULT="YES" STUDY_ID="STD-Kivitz-2006">
<DESCRIPTION>
<P>Quote: "Study medications were overencapsulated in gelatin capsules so they were visually indistinguishable, and they were administered in a double-dummy fashion to maintain blinding"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-16 09:09:44 -0400" MODIFIED_BY="Anne Lawson" RESULT="NO" STUDY_ID="STD-Kjaersgaard_x002d_Andersen-1990">
<DESCRIPTION>
<P>No double-dummy technique used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-16 09:11:16 -0400" MODIFIED_BY="Anne Lawson" RESULT="NO" STUDY_ID="STD-Langford-2006">
<DESCRIPTION>
<P>No double-dummy technique used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-16 09:12:36 -0400" MODIFIED_BY="Anne Lawson" RESULT="NO" STUDY_ID="STD-Markenson-2005">
<DESCRIPTION>
<P>No double-dummy technique used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-16 09:16:16 -0400" MODIFIED_BY="Anne Lawson" RESULT="NO" STUDY_ID="STD-Matsumoto-2005">
<DESCRIPTION>
<P>No double-dummy technique used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-16 09:22:30 -0400" MODIFIED_BY="Anne Lawson" RESULT="UNKNOWN" STUDY_ID="STD-Munera-2010">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-16 09:24:56 -0400" MODIFIED_BY="Anne Lawson" RESULT="UNKNOWN" STUDY_ID="STD-NCT00486811">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-16 09:26:35 -0400" MODIFIED_BY="Anne Lawson" RESULT="UNKNOWN" STUDY_ID="STD-NCT00531427">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-16 09:28:41 -0400" MODIFIED_BY="Anne Lawson" RESULT="UNKNOWN" STUDY_ID="STD-NCT00980798">
<DESCRIPTION>
<P>No information available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-16 09:32:12 -0400" MODIFIED_BY="Anne Lawson" RESULT="NO" STUDY_ID="STD-Peloso-2000">
<DESCRIPTION>
<P>No double-dummy technique used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-16 09:35:29 -0400" MODIFIED_BY="Anne Lawson" RESULT="YES" STUDY_ID="STD-Quiding-1992">
<DESCRIPTION>
<P>Quote: "a double-dummy technique was used to ensure blindness of the study"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-16 09:38:56 -0400" MODIFIED_BY="Anne Lawson" RESULT="NO" STUDY_ID="STD-Shannon-2005">
<DESCRIPTION>
<P>No double-dummy technique used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-16 09:39:52 -0400" MODIFIED_BY="Anne Lawson" RESULT="NO" STUDY_ID="STD-Zautra-2005">
<DESCRIPTION>
<P>No double-dummy technique used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-13" LEVEL="GROUP" MODIFIED="2014-08-17 16:51:10 -0400" MODIFIED_BY="Anne Lawson" NO="13">
<NAME>Intention-to-treat analysis performed?</NAME>
<DESCRIPTION/>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-13.02" NO="2">
<NAME>Function</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-13.01" NO="1">
<NAME>Pain</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-13.01" MODIFIED="2014-08-17 16:41:23 -0400" MODIFIED_BY="Anne Lawson" RESULT="NO" STUDY_ID="STD-Afilalo-2010">
<DESCRIPTION>
<P>2 of 346 participants excluded in experimental group. 171 of 339 participants excluded in control group<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-13.02" MODIFIED="2014-08-17 16:41:34 -0400" MODIFIED_BY="Anne Lawson" RESULT="NO" STUDY_ID="STD-Afilalo-2010">
<DESCRIPTION>
<P>197 of 346 participants excluded in experimental group, 260 of 339 participants excluded in control group</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-13.01" MODIFIED="2014-08-17 16:41:59 -0400" MODIFIED_BY="Anne Lawson" RESULT="NO" STUDY_ID="STD-Breivik-2010">
<DESCRIPTION>
<P>5 of 100 participants excluded in experimental group, 0 of 99 participants excluded in control group<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-13.02" MODIFIED="2014-08-17 16:42:11 -0400" MODIFIED_BY="Anne Lawson" RESULT="NO" STUDY_ID="STD-Breivik-2010">
<DESCRIPTION>
<P>6 of 100 participants excluded in experimental group, 3 of 99 participants excluded in control group<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-13.01" MODIFIED="2014-08-17 16:42:30 -0400" MODIFIED_BY="Anne Lawson" RESULT="NO" STUDY_ID="STD-Caldwell-2002">
<DESCRIPTION>
<P>Not all participants randomised were analysed</P>
<P>Quote: "Efficacy and safety analyses for both trials were performed on all patients who received at least one dose of study medication"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-13.02" MODIFIED="2014-08-17 16:43:12 -0400" MODIFIED_BY="Anne Lawson" RESULT="NO" STUDY_ID="STD-Caldwell-2002">
<DESCRIPTION>
<P>Not all participants randomised were analysed</P>
<P>Quote: "Efficacy and safety analyses for both trials were performed on all patients who received at least one dose of study medication"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-13.01" MODIFIED="2014-08-17 16:43:47 -0400" MODIFIED_BY="Anne Lawson" RESULT="NO" STUDY_ID="STD-Chindalore-2005">
<DESCRIPTION>
<P>1 of 310 participants (0.3%) excluded in experimental groups, 1 of 52 participants (1.9%) excluded in control group</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-13.02" MODIFIED="2014-08-17 16:43:50 -0400" MODIFIED_BY="Anne Lawson" RESULT="NO" STUDY_ID="STD-Chindalore-2005">
<DESCRIPTION>
<P>1 of 310 participants (0.3%) excluded in experimental groups, 1 of 52 participants (1.9%) excluded in control group</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-13.01" MODIFIED="2014-08-17 16:44:03 -0400" MODIFIED_BY="Anne Lawson" RESULT="NO" STUDY_ID="STD-Etropolski-2011">
<DESCRIPTION>
<P>2 of 306 participants excluded in experimental group, 74 of 148 participants excluded in control group<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-13.02" MODIFIED="2014-08-16 08:56:43 -0400" MODIFIED_BY="Anne Lawson" RESULT="UNKNOWN" STUDY_ID="STD-Etropolski-2011">
<DESCRIPTION>
<P>Not applicable, no function outcome reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-13.01" MODIFIED="2014-08-17 16:44:24 -0400" MODIFIED_BY="Anne Lawson" RESULT="UNKNOWN" STUDY_ID="STD-Fidelholtz-2011">
<DESCRIPTION>
<P>It was unclear how many participants were randomised in this study, so it was not possible to assess whether all participants randomised were included in the analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-13.02" MODIFIED="2014-08-16 08:58:39 -0400" MODIFIED_BY="Anne Lawson" RESULT="UNKNOWN" STUDY_ID="STD-Fidelholtz-2011">
<DESCRIPTION>
<P>Not applicable, no function outcome reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-13.01" MODIFIED="2014-08-17 16:44:52 -0400" MODIFIED_BY="Anne Lawson" RESULT="NO" STUDY_ID="STD-Friedmann-2011">
<DESCRIPTION>
<P>2 of 205 participants excluded in experimental group, 0 of 207 participants excluded in control group<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-13.02" MODIFIED="2014-08-16 09:01:19 -0400" MODIFIED_BY="Anne Lawson" RESULT="UNKNOWN" STUDY_ID="STD-Friedmann-2011">
<DESCRIPTION>
<P>Not applicable, no function outcome reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-13.01" MODIFIED="2014-08-17 16:45:11 -0400" MODIFIED_BY="Anne Lawson" RESULT="NO" STUDY_ID="STD-Hartrick-2009">
<DESCRIPTION>
<P>0 of 330 participants excluded in experimental group, 86 of 172 participants excluded in control group<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-13.02" MODIFIED="2014-08-16 09:04:59 -0400" MODIFIED_BY="Anne Lawson" RESULT="UNKNOWN" STUDY_ID="STD-Hartrick-2009">
<DESCRIPTION>
<P>Not applicable, no function outcome reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-13.01" MODIFIED="2014-08-17 16:45:28 -0400" MODIFIED_BY="Anne Lawson" RESULT="NO" STUDY_ID="STD-Katz-2010">
<DESCRIPTION>
<P>1 of 171 participants excluded in experimental group, 0 of 173 participants excluded in control group<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-13.02" MODIFIED="2014-08-17 16:45:30 -0400" MODIFIED_BY="Anne Lawson" RESULT="YES" STUDY_ID="STD-Katz-2010">
<DESCRIPTION>
<P>All randomised participants included in the analysis<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-13.01" MODIFIED="2014-08-17 16:45:56 -0400" MODIFIED_BY="Anne Lawson" RESULT="NO" STUDY_ID="STD-Kivitz-2006">
<DESCRIPTION>
<P>9 of 279 participants (0.7%) excluded in experimental groups, 4 of 91 participants (4.4%) excluded in control group</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-13.02" MODIFIED="2014-08-17 16:46:00 -0400" MODIFIED_BY="Anne Lawson" RESULT="NO" STUDY_ID="STD-Kivitz-2006">
<DESCRIPTION>
<P>9 of 279 participants (0.7%) excluded in experimental groups, 4 of 91 participants (4.4%) excluded in control group</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-13.01" MODIFIED="2014-08-17 16:46:23 -0400" MODIFIED_BY="Anne Lawson" RESULT="NO" STUDY_ID="STD-Kjaersgaard_x002d_Andersen-1990">
<DESCRIPTION>
<P>43 of 83 participants (52%) excluded in experimental group, 18 of 75 participants (24%) excluded in control group</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-13.02" MODIFIED="2014-08-17 16:46:25 -0400" MODIFIED_BY="Anne Lawson" RESULT="NO" STUDY_ID="STD-Kjaersgaard_x002d_Andersen-1990">
<DESCRIPTION>
<P>40 of 83 participants (48%) excluded in experimental group, 15 of 75 participants (20%) excluded in control group</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-13.01" MODIFIED="2014-08-16 09:11:17 -0400" MODIFIED_BY="Anne Lawson" RESULT="NO" STUDY_ID="STD-Langford-2006">
<DESCRIPTION>
<P>No information on exclusions available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-13.02" MODIFIED="2014-08-16 09:11:19 -0400" MODIFIED_BY="Anne Lawson" RESULT="NO" STUDY_ID="STD-Langford-2006">
<DESCRIPTION>
<P>No information on exclusions available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-13.01" MODIFIED="2014-08-17 16:46:53 -0400" MODIFIED_BY="Anne Lawson" RESULT="NO" STUDY_ID="STD-Markenson-2005">
<DESCRIPTION>
<P>2 randomised participants who withdrew before receiving treatment were excluded from the analyses</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-13.02" MODIFIED="2014-08-17 16:46:54 -0400" MODIFIED_BY="Anne Lawson" RESULT="NO" STUDY_ID="STD-Markenson-2005">
<DESCRIPTION>
<P>2 randomised participants who withdrew before receiving treatment were excluded from the analyses</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-13.01" MODIFIED="2014-08-17 16:47:07 -0400" MODIFIED_BY="Anne Lawson" RESULT="NO" STUDY_ID="STD-Matsumoto-2005">
<DESCRIPTION>
<P>19 of 367 participants (5.2%) excluded in experimental groups, 5 of 124 (4.0%) participants excluded in control group</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-13.02" MODIFIED="2014-08-17 16:47:10 -0400" MODIFIED_BY="Anne Lawson" RESULT="NO" STUDY_ID="STD-Matsumoto-2005">
<DESCRIPTION>
<P>19 of 367 participants (5.2%) excluded in experimental groups, 5 of 124 (4.0%) participants excluded in control group</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-13.01" MODIFIED="2014-08-17 16:47:31 -0400" MODIFIED_BY="Anne Lawson" RESULT="NO" STUDY_ID="STD-Munera-2010">
<DESCRIPTION>
<P>3 of 152 participants excluded in experimental group, 1 of 163 participants excluded in control group<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-13.02" MODIFIED="2014-08-17 16:47:39 -0400" MODIFIED_BY="Anne Lawson" RESULT="NO" STUDY_ID="STD-Munera-2010">
<DESCRIPTION>
<P>3 of 152 participants excluded in experimental group, 1 of 163 participants excluded in control group</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-13.01" MODIFIED="2014-08-17 16:47:56 -0400" MODIFIED_BY="Anne Lawson" RESULT="UNKNOWN" STUDY_ID="STD-NCT00486811">
<DESCRIPTION>
<P>It was unclear whether all participants randomised were also analysed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-13.02" MODIFIED="2014-08-17 16:47:57 -0400" MODIFIED_BY="Anne Lawson" RESULT="UNKNOWN" STUDY_ID="STD-NCT00486811">
<DESCRIPTION>
<P>It was unclear whether all participants randomised were also analysed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-13.01" MODIFIED="2014-08-17 16:48:35 -0400" MODIFIED_BY="Anne Lawson" RESULT="YES" STUDY_ID="STD-NCT00531427">
<DESCRIPTION>
<P>All randomised participants included in the analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-13.02" MODIFIED="2014-08-16 09:26:44 -0400" MODIFIED_BY="Anne Lawson" RESULT="UNKNOWN" STUDY_ID="STD-NCT00531427">
<DESCRIPTION>
<P>Not applicable, no function outcome reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-13.01" MODIFIED="2014-08-17 16:48:46 -0400" MODIFIED_BY="Anne Lawson" RESULT="NO" STUDY_ID="STD-NCT00980798">
<DESCRIPTION>
<P>13 randomised participants were excluded from the analyses</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-13.02" MODIFIED="2014-08-16 09:29:06 -0400" MODIFIED_BY="Anne Lawson" RESULT="UNKNOWN" STUDY_ID="STD-NCT00980798">
<DESCRIPTION>
<P>Not applicable, no function outcome reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-13.01" MODIFIED="2014-08-17 16:49:00 -0400" MODIFIED_BY="Anne Lawson" RESULT="NO" STUDY_ID="STD-Peloso-2000">
<DESCRIPTION>
<P>20 of 51 participants (39%) excluded in experimental group, 17 of 52 participants (33%) excluded in control group</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-13.02" MODIFIED="2014-08-17 16:49:01 -0400" MODIFIED_BY="Anne Lawson" RESULT="NO" STUDY_ID="STD-Peloso-2000">
<DESCRIPTION>
<P>20 of 51 participants (39%) excluded in experimental group, 17 of 52 participants (33%) excluded in control group</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-13.01" MODIFIED="2014-08-16 09:35:31 -0400" MODIFIED_BY="Anne Lawson" RESULT="UNKNOWN" STUDY_ID="STD-Quiding-1992">
<DESCRIPTION>
<P>No information on exclusions available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-13.02" MODIFIED="2014-08-16 09:35:33 -0400" MODIFIED_BY="Anne Lawson" RESULT="UNKNOWN" STUDY_ID="STD-Quiding-1992">
<DESCRIPTION>
<P>Not applicable, no function outcome reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-13.01" MODIFIED="2014-08-17 16:49:33 -0400" MODIFIED_BY="Anne Lawson" RESULT="NO" STUDY_ID="STD-Shannon-2005">
<DESCRIPTION>
<P>1 of 165 participants excluded in experimental group, 0 of 162 participants excluded in control group<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-13.02" MODIFIED="2014-08-16 09:39:02 -0400" MODIFIED_BY="Anne Lawson" RESULT="UNKNOWN" STUDY_ID="STD-Shannon-2005">
<DESCRIPTION>
<P>Not applicable, no function outcome reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-13.01" MODIFIED="2014-08-17 16:51:10 -0400" MODIFIED_BY="Anne Lawson" RESULT="NO" STUDY_ID="STD-Zautra-2005">
<DESCRIPTION>
<P>1 of 56 participants (1.8%) excluded in experimental group, 2 of 51 participants (3.9%) excluded in control group</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-13.02" MODIFIED="2014-08-16 09:39:57 -0400" MODIFIED_BY="Anne Lawson" RESULT="UNKNOWN" STUDY_ID="STD-Zautra-2005">
<DESCRIPTION>
<P>Not applicable, no function outcome reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-14" LEVEL="GROUP" NO="14">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-15" LEVEL="GROUP" NO="15">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2014-08-17 16:52:14 -0400" MODIFIED_BY="Anne Lawson">
<SOF_TABLE ID="SOF-01" MODIFIED="2014-08-17 16:52:14 -0400" MODIFIED_BY="Anne Lawson" NO="1">
<TITLE MODIFIED="2014-08-16 09:46:21 -0400" MODIFIED_BY="Anne Lawson">Oral or transdermal opioids compared with placebo for osteoarthritis of the knee or hip</TITLE>
<TABLE COLS="7" ROWS="12">
<TR>
<TD COLSPAN="7">
<P>
<B>Oral or transdermal opioids compared with placebo for osteoarthritis of the knee or hip</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population: </B>participants with osteoarthritis of the knee or hip</P>
<P>
<B>Settings:</B> various orthopaedic or rheumatology clinics</P>
<P>
<B>Intervention: o</B>ral or transdermal opioids</P>
<P>
<B>Comparison: p</B>lacebo</P>
</TD>
</TR>
<TR>
<TH ALIGN="CENTER" ROWSPAN="3" VALIGN="MIDDLE">
<P>Outcomes</P>
</TH>
<TH ALIGN="CENTER" COLSPAN="2" VALIGN="MIDDLE">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="CENTER" ROWSPAN="3" VALIGN="MIDDLE">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="CENTER" ROWSPAN="3" VALIGN="MIDDLE">
<P>No of participants<BR/>(studies)</P>
</TH>
<TH ALIGN="CENTER" ROWSPAN="3" VALIGN="MIDDLE">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="CENTER" ROWSPAN="3" VALIGN="MIDDLE">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="CENTER" VALIGN="MIDDLE">
<P>Assumed risk</P>
</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="CENTER" VALIGN="MIDDLE">
<P>Placebo</P>
</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE">
<P>Opioids</P>
</TH>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<B>Pain intensity</B>
</P>
<P>Various pain scales.</P>
<P>(median follow-up: 4 weeks)</P>
</TD>
<TD ALIGN="CENTER">
<P>
<B>-1.8 cm change </B>
<BR/>on 10-cm VAS<SUP>1</SUP>
</P>
<P>29% improvement</P>
</TD>
<TD ALIGN="CENTER">
<P>
<B>-2.5 cm change</B>
<BR/>(&#916; -0.7 cm, -0.9 to -0.5)<SUP>2</SUP>
</P>
<P>
<B>41% improvement</B>
<BR/>(&#916; 12%, 9% to 15%)<SUP>3</SUP>
</P>
</TD>
<TD ALIGN="CENTER">
<P>SMD -0.28 (-0.35 to -0.20)</P>
</TD>
<TD ALIGN="CENTER">
<P>8275<BR/>(22)</P>
</TD>
<TD ALIGN="CENTER">
<P>++++<BR/>high</P>
</TD>
<TD ALIGN="CENTER">
<P>NNTB 10 (95% CI 8 to 14)<SUP>4</SUP>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<B>Function</B>
</P>
<P>Various validated function scales.</P>
<P>(median follow-up: 5 weeks)</P>
</TD>
<TD ALIGN="CENTER">
<P>
<B>-1.2 units </B>
<BR/>on WOMAC (range 0 to 10)<SUP>1</SUP>
</P>
<P>21% improvement</P>
</TD>
<TD ALIGN="CENTER">
<P>
<B>-1.8 units on WOMAC</B>
<BR/>(&#916; -0.6, -0.8 to -0.4)<SUP>5</SUP>
</P>
<P>
<B>32% improvement</B>
<BR/>(&#916; 11%, 7% to 14%)<SUP>6</SUP>
</P>
</TD>
<TD ALIGN="CENTER">
<P>SMD -0.26 (-0.35 to -0.17)</P>
</TD>
<TD ALIGN="CENTER">
<P>3553<BR/>(12)</P>
</TD>
<TD ALIGN="CENTER">
<P>++++<BR/>high</P>
</TD>
<TD ALIGN="CENTER">
<P>NNTB 12 (95% CI 10 to 18)<SUP>7</SUP>
<BR/>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>
<B>Number of participants experiencing any adverse event</B>
</P>
<P>(median follow-up: 8 weeks)</P>
</TD>
<TD ALIGN="CENTER" ROWSPAN="1" VALIGN="MIDDLE">
<P>150 per 1000 participant-years<SUP>8</SUP>
</P>
</TD>
<TD ALIGN="CENTER" ROWSPAN="1" VALIGN="MIDDLE">
<P>224 per 1000 participant-years<BR/>(203 to 245)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>RR 1.49 (1.35 to 1.63)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>4898<BR/>(9)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>+++O<BR/>moderate<SUP>9</SUP>
</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>NNTH 14 (95% CI 11 to 19)</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>
<B>Number of participants who withdrew because of adverse events</B>
</P>
<P>(median follow-up: 6 weeks)</P>
</TD>
<TD ALIGN="CENTER" ROWSPAN="1" VALIGN="MIDDLE">
<P>17 per 1000 participant-years<SUP>8</SUP>
</P>
</TD>
<TD ALIGN="CENTER" ROWSPAN="1" VALIGN="MIDDLE">
<P>64 per 1000 participant-years<BR/>(50 to 82)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>RR 3.76 (2.93 to 4.82)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>7712<BR/>(19)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>++++<BR/>high</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>NNTH 21 (95% CI 15 to 30)</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>
<B>Number of participants experiencing any serious adverse event</B>
</P>
<P>(median follow-up: 8 weeks)</P>
</TD>
<TD ALIGN="CENTER" ROWSPAN="1" VALIGN="MIDDLE">
<P>4 per 1000 participant-years<SUP>8</SUP>
</P>
</TD>
<TD ALIGN="CENTER" ROWSPAN="1" VALIGN="MIDDLE">
<P>13 per 1000 participant-years<BR/>(3 to 54)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>RR 3.35 (0.83 to 13.56)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>681<BR/>(3)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>++OO<BR/>low<SUP>10</SUP>
</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>Little evidence of harmful effect (NNTH not statistically significant)</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<B>Withdrawal symptoms</B>
</P>
<P>(median follow-up: 16 weeks)</P>
</TD>
<TD ALIGN="CENTER">
<P>9 per 1000 participant-years<SUP>11</SUP>
</P>
</TD>
<TD ALIGN="CENTER">
<P>24 per 100<BR/>participant-years<BR/>(18 to 33)<BR/>
</P>
</TD>
<TD ALIGN="CENTER">
<P>OR 2.67 (2.02 to 3.77)</P>
</TD>
<TD ALIGN="CENTER">
<P>1151<BR/>(3)</P>
</TD>
<TD ALIGN="CENTER">
<P>+++O<BR/>moderate<SUP>12</SUP>
</P>
</TD>
<TD ALIGN="CENTER">
<P>NNTH 65 (95% CI 42 to 110)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>CI: confidence interval; GRADE: GRADE Working Group grades of evidence (see explanations); NNTB: number needed to treat for an additional beneficial outcome; NNTH: number needed to treat for an additional harmful outcome; OR: odds ratio; RR: risk ratio; SMD: standardised mean difference; WOMAC: Western Ontario and McMaster Universities Arthritis Index.</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality (++++):</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality (+++O):</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality (++OO):</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality (+OOO):</B> We are very uncertain about the estimate.</P>
<P>
<SUP>1</SUP> Median reduction as observed across placebo groups in large osteoarthritis trials (see methods section, <LINK REF="REF-N_x00fc_esch-2009" TYPE="REFERENCE">Nüesch 2009</LINK>).<BR/>
<SUP>2</SUP> SMDs were back-transformed onto a 10-cm visual analogue scale (VAS) on the basis of a typical pooled standard deviation (SD) of 2.5 cm in large trials that assessed pain using a VAS and expressed as change based on an assumed standardised reduction of 0.72 |SD units in the control group.<BR/>
<SUP>3</SUP> Percentage of improvement was calculated based on median observed pain at baseline across control groups of large osteoarthritis trials of 6.1 cm on 10-cm VAS (<LINK REF="REF-N_x00fc_esch-2009" TYPE="REFERENCE">Nüesch 2009</LINK>).<BR/>
<SUP>4</SUP> Absolute response risks for pain in the control groups were assumed 31% (see methods section).<BR/>
<SUP>5</SUP> SMDs were back-transformed onto a standardised WOMAC disability score ranging from 0 to 10 on the basis of a typical pooled SD of 2.1 in trials that assessed function using WOMAC disability scores and expressed as change based on an assumed standardised reduction of 0.58 standard deviation units in the control group.<BR/>
<SUP>6 </SUP>Percentage of improvement was calculated based on median observed WOMAC function scores at baseline across control groups of large osteoarthritis trials of 5.6 units (<LINK REF="REF-N_x00fc_esch-2009" TYPE="REFERENCE">Nüesch 2009</LINK>).<BR/>
<SUP>7</SUP> Absolute response risks for function in the control groups were assumed 26% (see methods section).<BR/>
<SUP>8 </SUP>Median control risk across placebo groups in large osteoarthritis trials (see methods section, <LINK REF="REF-N_x00fc_esch-2009" TYPE="REFERENCE">Nüesch 2009</LINK>).<BR/>
<SUP>9</SUP> Downgraded (1 level) because: 9 out of 19 studies reported this outcome, possibly leading to selective outcome reporting bias.<BR/>
<SUP>10 </SUP>Downgraded (2 levels) because: 3 out of 19 studies reported this outcome, possibly leading to selective outcome reporting bias, the CI of the pooled estimate is wide and crossed no difference.<BR/>
<SUP>11</SUP> Median risk across control groups in included trials.<BR/>
<SUP>12</SUP> Downgraded (1 level) because 3 out of 22 studies reported this outcome, possible leading to selective outcome reporting bias.</P>
</FOOTNOTES>
</SOF_TABLE>
</SOF_TABLES>
<ADDITIONAL_TABLES MODIFIED="2014-08-21 15:53:15 -0400" MODIFIED_BY="[Empty name]">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2014-08-21 15:48:19 -0400" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2009-07-31 02:56:51 -0400" MODIFIED_BY="[Empty name]">Stratified analyses: pain</TITLE>
<TABLE COLS="7" ROWS="33">
<TR>
<TD>
<P>
<B>Variable</B>
</P>
</TD>
<TD>
<P>
<B>Number of </B>
<BR/>
<B>studies</B>
</P>
</TD>
<TD>
<P>
<B>N of participants </B>
<BR/>
<B>opioids</B>
</P>
</TD>
<TD>
<P>
<B>N of participants </B>
<BR/>
<B>control </B>
<BR/>
</P>
</TD>
<TD>
<P>
<B>Pain intensity</B>
<BR/>SMD (95% CI)</P>
</TD>
<TD>
<P>
<B>Heterogeneity</B>
<BR/>I<SUP>2</SUP> (%)</P>
</TD>
<TD>
<P>
<B>P value*</B>
</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>All trials</B>
</P>
</TD>
<TD>
<P>22</P>
</TD>
<TD>
<P>5180</P>
</TD>
<TD>
<P>3095</P>
</TD>
<TD>
<P>-0.28 (-0.35 to -0.20)</P>
</TD>
<TD>
<P>58%</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD COLSPAN="6">
<P>
<B>Analgesic potency</B>
</P>
</TD>
<TD>
<P>0.32</P>
</TD>
</TR>
<TR>
<TD>
<P>Weak</P>
</TD>
<TD>
<P>3</P>
</TD>
<TD>
<P>79</P>
</TD>
<TD>
<P>100</P>
</TD>
<TD>
<P>-0.51 (-1.01 to -0.01)</P>
</TD>
<TD>
<P>55%</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Strong</P>
</TD>
<TD>
<P>19</P>
</TD>
<TD>
<P>5101</P>
</TD>
<TD>
<P>2995</P>
</TD>
<TD>
<P>-0.26 (-0.35 to -0.18)</P>
</TD>
<TD>
<P>64%</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD COLSPAN="6">
<P>
<B>Route of administration</B>
</P>
</TD>
<TD>
<P>0.36</P>
</TD>
</TR>
<TR>
<TD>
<P>Oral</P>
</TD>
<TD>
<P>17</P>
</TD>
<TD>
<P>4287</P>
</TD>
<TD>
<P>2188</P>
</TD>
<TD>
<P>-0.30 (-0.41 to -0.20)</P>
</TD>
<TD>
<P>70%</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Transdermal</P>
</TD>
<TD>
<P>5</P>
</TD>
<TD>
<P>893</P>
</TD>
<TD>
<P>907</P>
</TD>
<TD>
<P>-0.20 (-0.29 to -0.11)</P>
</TD>
<TD>
<P>0%</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD COLSPAN="6">
<P>
<B>Allocation concealment</B>
</P>
</TD>
<TD>
<P>0.31</P>
</TD>
</TR>
<TR>
<TD>
<P>Adequate</P>
</TD>
<TD>
<P>8</P>
</TD>
<TD>
<P>1981</P>
</TD>
<TD>
<P>1141</P>
</TD>
<TD>
<P>-0.32 (-0.44 to -0.21)</P>
</TD>
<TD>
<P>48%</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Inadequate or unclear</P>
</TD>
<TD>
<P>14</P>
</TD>
<TD>
<P>3199</P>
</TD>
<TD>
<P>1954</P>
</TD>
<TD>
<P>-0.24 (-0.35 to -0.13)</P>
</TD>
<TD>
<P>67%</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD COLSPAN="6">
<P>
<B>Blinding of participants</B>
</P>
</TD>
<TD>
<P>0.23</P>
</TD>
</TR>
<TR>
<TD>
<P>Adequate</P>
</TD>
<TD>
<P>15</P>
</TD>
<TD>
<P>3050</P>
</TD>
<TD>
<P>1616</P>
</TD>
<TD>
<P>-0.32 (-0.42 to -0.22)</P>
</TD>
<TD>
<P>53%</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Inadequate or unclear</P>
</TD>
<TD>
<P>7</P>
</TD>
<TD>
<P>2130</P>
</TD>
<TD>
<P>1479</P>
</TD>
<TD>
<P>-0.21 (-0.34 to -0.08)</P>
</TD>
<TD>
<P>73%</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD COLSPAN="6">
<P>
<B>Intention-to-treat analysis</B>
</P>
</TD>
<TD>
<P>0.43</P>
</TD>
</TR>
<TR>
<TD>
<P>Yes</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>283</P>
</TD>
<TD>
<P>287</P>
</TD>
<TD>
<P>-0.14 (-0.30 to 0.02)</P>
</TD>
<TD>
<P>N/A</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>No or unclear</P>
</TD>
<TD>
<P>21</P>
</TD>
<TD>
<P>4897</P>
</TD>
<TD>
<P>2808</P>
</TD>
<TD>
<P>-0.29 (-0.37 to -0.20)</P>
</TD>
<TD>
<P>63%</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD COLSPAN="6">
<P>
<B>Type of control intervention</B>
</P>
</TD>
<TD>
<P>0.97</P>
</TD>
</TR>
<TR>
<TD>
<P>Placebo</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>5132</P>
</TD>
<TD>
<P>3030</P>
</TD>
<TD>
<P>-0.28 (-0.36 to -0.19)</P>
</TD>
<TD>
<P>65%</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>No intervention</P>
</TD>
<TD>
<P>2</P>
</TD>
<TD>
<P>48</P>
</TD>
<TD>
<P>65</P>
</TD>
<TD>
<P>-0.33 (-0.93 to 0.28)</P>
</TD>
<TD>
<P>35%</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD COLSPAN="6">
<P>
<B>Number of participants randomised</B>
</P>
</TD>
<TD>
<P>0.08</P>
</TD>
</TR>
<TR>
<TD>
<P>&gt; 200</P>
</TD>
<TD>
<P>16</P>
</TD>
<TD>
<P>4895</P>
</TD>
<TD>
<P>2796</P>
</TD>
<TD>
<P>-0.24 (-0.33 to -0.16)</P>
</TD>
<TD>
<P>64%</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>&#8804; 200</P>
</TD>
<TD>
<P>6</P>
</TD>
<TD>
<P>285</P>
</TD>
<TD>
<P>299</P>
</TD>
<TD>
<P>-0.47 (-0.71 to -0.23)</P>
</TD>
<TD>
<P>48%</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD COLSPAN="6">
<P>
<B>Duration of treatment</B>
</P>
</TD>
<TD>
<P>0.001</P>
</TD>
</TR>
<TR>
<TD>
<P>&gt; 1 month</P>
</TD>
<TD>
<P>10</P>
</TD>
<TD>
<P>2635</P>
</TD>
<TD>
<P>1972</P>
</TD>
<TD>
<P>-0.15 (-0.22 to -0.08)</P>
</TD>
<TD>
<P>25%</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>&#8804; 1 month</P>
</TD>
<TD>
<P>12</P>
</TD>
<TD>
<P>2545</P>
</TD>
<TD>
<P>1123</P>
</TD>
<TD>
<P>-0.40 (-0.50 to -0.30)</P>
</TD>
<TD>
<P>37%</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD COLSPAN="6">
<P>
<B>Use of analgesic co-interventions</B>
</P>
</TD>
<TD>
<P>0.59</P>
</TD>
</TR>
<TR>
<TD>
<P>Similar between groups</P>
</TD>
<TD>
<P>6</P>
</TD>
<TD>
<P>1189</P>
</TD>
<TD>
<P>891</P>
</TD>
<TD>
<P>-0.31 (-0.46 to -0.16)</P>
</TD>
<TD>
<P>60%</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Unclear</P>
</TD>
<TD>
<P>16</P>
</TD>
<TD>
<P>3991</P>
</TD>
<TD>
<P>2204</P>
</TD>
<TD>
<P>-0.26 (-0.36 to -0.16)</P>
</TD>
<TD>
<P>65%</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD COLSPAN="6">
<P>
<B>Type of osteoarthritis</B>
</P>
</TD>
<TD>
<P>0.77</P>
</TD>
</TR>
<TR>
<TD>
<P>Hip only</P>
</TD>
<TD>
<P>2</P>
</TD>
<TD>
<P>48</P>
</TD>
<TD>
<P>65</P>
</TD>
<TD>
<P>-0.33 (-0.93 to 0.28)</P>
</TD>
<TD>
<P>35%</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Knee only</P>
</TD>
<TD>
<P>4</P>
</TD>
<TD>
<P>1674</P>
</TD>
<TD>
<P>1010</P>
</TD>
<TD>
<P>-0.22 (-0.41 to -0.04)</P>
</TD>
<TD>
<P>78%</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Knee and hip</P>
</TD>
<TD>
<P>16</P>
</TD>
<TD>
<P>3458</P>
</TD>
<TD>
<P>2020</P>
</TD>
<TD>
<P>-0.29 (-0.38 to -0.20)</P>
</TD>
<TD>
<P>56%</P>
</TD>
<TD>
<P/>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>*P value for interaction. N/A: not available.</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-02" MODIFIED="2014-08-21 15:53:15 -0400" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2009-07-31 02:57:09 -0400" MODIFIED_BY="[Empty name]">Stratified analyses: function</TITLE>
<TABLE COLS="7" ROWS="33">
<TR>
<TD>
<P>
<B>Variable</B>
</P>
</TD>
<TD>
<P>
<B>Number of </B>
<BR/>
<B>studies</B>
</P>
</TD>
<TD>
<P>
<B>N of participants </B>
<BR/>
<B>opioids</B>
</P>
</TD>
<TD>
<P>
<B>N of participants </B>
<BR/>
<B>control</B>
</P>
</TD>
<TD>
<P>
<B>Function </B>
<BR/>SMD (95% CI)</P>
</TD>
<TD>
<P>
<B>Heterogeneity</B>
<BR/>I<SUP>2</SUP> (%)</P>
</TD>
<TD>
<P>
<B>P value*</B>
</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>All trials</B>
</P>
</TD>
<TD>
<P>12</P>
</TD>
<TD>
<P>2124</P>
</TD>
<TD>
<P>1429</P>
</TD>
<TD>
<P>-0.26 (-0.35 to -0.17)</P>
</TD>
<TD>
<P>32%</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD COLSPAN="6">
<P>
<B>Analgesic potency</B>
</P>
</TD>
<TD>
<P>0.42</P>
</TD>
</TR>
<TR>
<TD>
<P>Weak</P>
</TD>
<TD>
<P>2</P>
</TD>
<TD>
<P>74</P>
</TD>
<TD>
<P>95</P>
</TD>
<TD>
<P>-0.42 (-0.74 to -0.10)</P>
</TD>
<TD>
<P>6%</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Strong</P>
</TD>
<TD>
<P>10</P>
</TD>
<TD>
<P>2050</P>
</TD>
<TD>
<P>1334</P>
</TD>
<TD>
<P>-0.26 (-0.36 to -0.16)</P>
</TD>
<TD>
<P>48%</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD COLSPAN="6">
<P>
<B>Route of administration</B>
</P>
</TD>
<TD>
<P>0.76</P>
</TD>
</TR>
<TR>
<TD>
<P>Oral</P>
</TD>
<TD>
<P>9</P>
</TD>
<TD>
<P>1679</P>
</TD>
<TD>
<P>974</P>
</TD>
<TD>
<P>-0.30 (-0.43 to -0.16)</P>
</TD>
<TD>
<P>58%</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Transdermal</P>
</TD>
<TD>
<P>3</P>
</TD>
<TD>
<P>445</P>
</TD>
<TD>
<P>455</P>
</TD>
<TD>
<P>-0.25 (-0.38 to -0.12)</P>
</TD>
<TD>
<P>0%</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD COLSPAN="6">
<P>
<B>Allocation concealment</B>
</P>
</TD>
<TD>
<P>0.43</P>
</TD>
</TR>
<TR>
<TD>
<P>Adequate</P>
</TD>
<TD>
<P>6</P>
</TD>
<TD>
<P>1034</P>
</TD>
<TD>
<P>762</P>
</TD>
<TD>
<P>-0.32 (-0.45 to -0.18)</P>
</TD>
<TD>
<P>47%</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Inadequate or unclear</P>
</TD>
<TD>
<P>6</P>
</TD>
<TD>
<P>1090</P>
</TD>
<TD>
<P>667</P>
</TD>
<TD>
<P>-0.23 (-0.37 to -0.09)</P>
</TD>
<TD>
<P>39%</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD COLSPAN="6">
<P>
<B>Blinding of participants</B>
</P>
</TD>
<TD>
<P>0.008</P>
</TD>
</TR>
<TR>
<TD>
<P>Adequate</P>
</TD>
<TD>
<P>10</P>
</TD>
<TD>
<P>1656</P>
</TD>
<TD>
<P>1038</P>
</TD>
<TD>
<P>-0.32 (-0.40 to -0.24)</P>
</TD>
<TD>
<P>0%</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Inadequate or unclear</P>
</TD>
<TD>
<P>2</P>
</TD>
<TD>
<P>468</P>
</TD>
<TD>
<P>391</P>
</TD>
<TD>
<P>-0.07 (-0.20 to 0.07)</P>
</TD>
<TD>
<P>0%</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD COLSPAN="6">
<P>
<B>Intention-to-treat analysis</B>
</P>
</TD>
<TD>
<P>0.34</P>
</TD>
</TR>
<TR>
<TD>
<P>Yes</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>171</P>
</TD>
<TD>
<P>173</P>
</TD>
<TD>
<P>-0.13 (-0.34 to 0.08)</P>
</TD>
<TD>
<P>N/A</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>No or unclear</P>
</TD>
<TD>
<P>11</P>
</TD>
<TD>
<P>1953</P>
</TD>
<TD>
<P>1256</P>
</TD>
<TD>
<P>-0.29 (-0.40 to -0.19)</P>
</TD>
<TD>
<P>44%</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD COLSPAN="6">
<P>
<B>Type of control intervention</B>
</P>
</TD>
<TD>
<P>0.96</P>
</TD>
</TR>
<TR>
<TD>
<P>Placebo</P>
</TD>
<TD>
<P>11</P>
</TD>
<TD>
<P>2081</P>
</TD>
<TD>
<P>1369</P>
</TD>
<TD>
<P>-0.28 (-0.38 to -0.18)</P>
</TD>
<TD>
<P>49%</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>No intervention</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>43</P>
</TD>
<TD>
<P>60</P>
</TD>
<TD>
<P>-0.29 (-0.68 to 0.11)</P>
</TD>
<TD>
<P>N/A</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD COLSPAN="6">
<P>
<B>Number of participants randomised</B>
</P>
</TD>
<TD>
<P>0.11</P>
</TD>
</TR>
<TR>
<TD>
<P>&gt; 200</P>
</TD>
<TD>
<P>8</P>
</TD>
<TD>
<P>1900</P>
</TD>
<TD>
<P>1187</P>
</TD>
<TD>
<P>-0.23 (-0.32 to -0.14)</P>
</TD>
<TD>
<P>26%</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>&#8804; 200</P>
</TD>
<TD>
<P>4</P>
</TD>
<TD>
<P>224</P>
</TD>
<TD>
<P>242</P>
</TD>
<TD>
<P>-0.46 (-0.73 to -0.19)</P>
</TD>
<TD>
<P>51%</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD COLSPAN="6">
<P>
<B>Duration of treatment</B>
</P>
</TD>
<TD>
<P>0.41</P>
</TD>
</TR>
<TR>
<TD>
<P>&gt; 1 month</P>
</TD>
<TD>
<P>6</P>
</TD>
<TD>
<P>1061</P>
</TD>
<TD>
<P>893</P>
</TD>
<TD>
<P>-0.25 (-0.41 to -0.09)</P>
</TD>
<TD>
<P>66%</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>&#8804; 1 month</P>
</TD>
<TD>
<P>6</P>
</TD>
<TD>
<P>1063</P>
</TD>
<TD>
<P>536</P>
</TD>
<TD>
<P>-0.31 (-0.42 to -0.20)</P>
</TD>
<TD>
<P>0%</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD COLSPAN="6">
<P>
<B>Use of analgesic co-interventions</B>
</P>
</TD>
<TD>
<P>0.38</P>
</TD>
</TR>
<TR>
<TD>
<P>Similar between groups</P>
</TD>
<TD>
<P>4</P>
</TD>
<TD>
<P>460</P>
</TD>
<TD>
<P>456</P>
</TD>
<TD>
<P>-0.40 (-0.67 to -0.13)</P>
</TD>
<TD>
<P>71%</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Unclear</P>
</TD>
<TD>
<P>8</P>
</TD>
<TD>
<P>1664</P>
</TD>
<TD>
<P>973</P>
</TD>
<TD>
<P>-0.24 (-0.33 to -0.15)</P>
</TD>
<TD>
<P>16%</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD COLSPAN="6">
<P>
<B>Type of osteoarthritis</B>
</P>
</TD>
<TD>
<P>0.45</P>
</TD>
</TR>
<TR>
<TD>
<P>Hip only</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>43</P>
</TD>
<TD>
<P>60</P>
</TD>
<TD>
<P>-0.29 (-0.68 to 0.11)</P>
</TD>
<TD>
<P>N/A</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Knee only</P>
</TD>
<TD>
<P>2</P>
</TD>
<TD>
<P>538</P>
</TD>
<TD>
<P>376</P>
</TD>
<TD>
<P>-0.16 (-0.43 to 0.11)</P>
</TD>
<TD>
<P>76%</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Knee and hip</P>
</TD>
<TD>
<P>9</P>
</TD>
<TD>
<P>1543</P>
</TD>
<TD>
<P>993</P>
</TD>
<TD>
<P>-0.31 (-0.41 to -0.20)</P>
</TD>
<TD>
<P>31%</P>
</TD>
<TD>
<P/>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>*P value for interaction. N/A: not available.</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2014-08-17 16:23:56 -0400" MODIFIED_BY="Anne Lawson">
<COMPARISON ID="CMP-001" MODIFIED="2014-08-17 16:23:56 -0400" MODIFIED_BY="Anne Lawson" NO="1">
<NAME>Opioids versus placebo</NAME>
<IV_OUTCOME CHI2="62.17036819858042" CI_END="-0.2019842537625883" CI_START="-0.35129553850383377" CI_STUDY="95" CI_TOTAL="95" DF="26" EFFECT_SIZE="-0.27663989613321105" ESTIMABLE="YES" I2="58.1794337827427" I2_Q="39.500628732108865" ID="CMP-001.01" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_DATA="NO" LOG_EFFECT_SIZE="NaN" MODIFIED="2014-08-17 07:52:44 -0400" MODIFIED_BY="Anne Lawson" NO="1" NOTES="&lt;p&gt;For Matsumoto 2005, in the control group standard errors were inflated and the number of patients was halfed to avoid duplicate counting of patients when including two different comparisons in the overall meta-analysis.&lt;/p&gt;" NOTES_MODIFIED="2014-08-17 07:52:44 -0400" NOTES_MODIFIED_BY="Anne Lawson" P_CHI2="8.507390845913232E-5" P_Q="0.11560260254924548" P_Z="3.7933742492579175E-13" Q="11.570368176231137" RANDOM="YES" SCALE="2.25" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="22" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.021156146522302865" TOTALS="YES" TOTAL_1="5180" TOTAL_2="3095" WEIGHT="100.0" Z="7.262736156180398">
<NAME>Pain</NAME>
<GROUP_LABEL_1>Opioids</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours opioids</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Std. Mean Difference</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="2.216999167609096" CI_END="-0.08834965977107989" CI_START="-0.2988993137852133" DF="3" EFFECT_SIZE="-0.1936244867781466" ESTIMABLE="YES" I2="0.0" ID="CMP-001.01.01" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" MODIFIED="2014-08-17 07:52:30 -0400" MODIFIED_BY="Anne Lawson" NO="1" P_CHI2="0.5286079218903343" P_Z="3.123668521620245E-4" STUDIES="4" TAU2="0.0" TOTAL_1="691" TOTAL_2="710" WEIGHT="17.159571056893416" Z="3.604822077596433">
<NAME>Buprenorphine</NAME>
<IV_DATA CI_END="0.04023481377376781" CI_START="-0.5242348137737678" EFFECT_SIZE="-0.242" ESTIMABLE="YES" ESTIMATE="-0.242" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2012-11-30 09:31:42 -0500" MODIFIED_BY="[Empty name]" ORDER="41" SE="0.144" STUDY_ID="STD-Breivik-2010" TOTAL_1="95" TOTAL_2="99" WEIGHT="3.4633507549420792"/>
<IV_DATA CI_END="0.09643589423756618" CI_START="-0.35043589423756616" EFFECT_SIZE="-0.127" ESTIMABLE="YES" ESTIMATE="-0.127" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2012-11-30 09:32:10 -0500" MODIFIED_BY="[Empty name]" ORDER="42" SE="0.114" STUDY_ID="STD-Munera-2010" TOTAL_1="149" TOTAL_2="162" WEIGHT="4.248259979483675"/>
<IV_DATA CI_END="0.024636974701364556" CI_START="-0.3046369747013646" EFFECT_SIZE="-0.14" ESTIMABLE="YES" ESTIMATE="-0.14" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2012-11-30 09:32:40 -0500" MODIFIED_BY="[Empty name]" ORDER="43" SE="0.084" STUDY_ID="STD-NCT00531427" TOTAL_1="283" TOTAL_2="287" WEIGHT="5.142720961322968"/>
<IV_DATA CI_END="-0.10448403373151394" CI_START="-0.5435159662684861" EFFECT_SIZE="-0.324" ESTIMABLE="YES" ESTIMATE="-0.324" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2012-11-30 09:31:19 -0500" MODIFIED_BY="[Empty name]" ORDER="40" SE="0.112" STUDY_ID="STD-Shannon-2005" TOTAL_1="164" TOTAL_2="162" WEIGHT="4.305239361144695"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="4.444676874497564" CI_END="-0.00899411352328583" CI_START="-1.0098426582231197" DF="2" EFFECT_SIZE="-0.5094183858732028" ESTIMABLE="YES" I2="55.00235323122147" ID="CMP-001.01.02" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" MODIFIED="2012-12-17 12:43:40 -0500" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.10835553434610357" P_Z="0.04602212089265871" STUDIES="3" TAU2="0.10402901185776413" TOTAL_1="79" TOTAL_2="100" WEIGHT="4.429265506361799" Z="1.9951903705339344">
<NAME>Codeine</NAME>
<IV_DATA CI_END="0.2627125447997912" CI_START="-0.5487125447997911" EFFECT_SIZE="-0.143" ESTIMABLE="YES" ESTIMATE="-0.143" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2008-12-12 09:10:18 -0500" MODIFIED_BY="[Empty name]" ORDER="102" SE="0.207" STUDY_ID="STD-Kjaersgaard_x002d_Andersen-1990" TOTAL_1="40" TOTAL_2="57" WEIGHT="2.2668051737621684"/>
<IV_DATA CI_END="-0.2812492199577461" CI_START="-1.284750780042254" EFFECT_SIZE="-0.783" ESTIMABLE="YES" ESTIMATE="-0.783" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2008-12-12 09:09:58 -0500" MODIFIED_BY="[Empty name]" ORDER="107" SE="0.256" STUDY_ID="STD-Peloso-2000" TOTAL_1="31" TOTAL_2="35" WEIGHT="1.673591012616534"/>
<IV_DATA CI_END="0.18498109188352851" CI_START="-1.8729810918835286" EFFECT_SIZE="-0.844" ESTIMABLE="YES" ESTIMATE="-0.844" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2008-12-12 09:10:07 -0500" MODIFIED_BY="[Empty name]" ORDER="108" SE="0.525" STUDY_ID="STD-Quiding-1992" TOTAL_1="8" TOTAL_2="8" WEIGHT="0.4888693199830961"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="0.0" CI_END="-0.02700360154599457" CI_START="-0.41899639845400544" DF="0" EFFECT_SIZE="-0.223" ESTIMABLE="YES" I2="0.0" ID="CMP-001.01.03" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" MODIFIED="2012-11-30 09:38:21 -0500" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.025747442877233385" STUDIES="1" TAU2="0.0" TOTAL_1="202" TOTAL_2="197" WEIGHT="4.656776061195576" Z="2.23">
<NAME>Fentanyl</NAME>
<IV_DATA CI_END="-0.02700360154599457" CI_START="-0.41899639845400544" EFFECT_SIZE="-0.223" ESTIMABLE="YES" ESTIMATE="-0.223" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2008-12-12 09:10:48 -0500" MODIFIED_BY="[Empty name]" ORDER="103" SE="0.1" STUDY_ID="STD-Langford-2006" TOTAL_1="202" TOTAL_2="197" WEIGHT="4.656776061195576"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="0.0" CI_END="0.2811556421293466" CI_START="-0.19315564212934655" DF="0" EFFECT_SIZE="0.044" ESTIMABLE="YES" I2="0.0" ID="CMP-001.01.04" LOG_CI_END="-0.551053196803147" LOG_CI_START="NaN" LOG_EFFECT_SIZE="-1.3565473235138126" MODIFIED="2014-08-17 07:52:36 -0400" MODIFIED_BY="Anne Lawson" NO="4" P_CHI2="1.0" P_Z="0.7161295695881675" STUDIES="1" TAU2="0.0" TOTAL_1="132" TOTAL_2="143" WEIGHT="4.053038059717063" Z="0.36363636363636365">
<NAME>Hydromorphone</NAME>
<IV_DATA CI_END="0.2811556421293466" CI_START="-0.19315564212934655" EFFECT_SIZE="0.044" ESTIMABLE="YES" ESTIMATE="0.044" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2012-11-30 09:33:37 -0500" MODIFIED_BY="[Empty name]" ORDER="44" SE="0.121" STUDY_ID="STD-NCT00980798" TOTAL_1="132" TOTAL_2="143" WEIGHT="4.053038059717063"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="0.7560013262599465" CI_END="-0.08763148932418222" CI_START="-0.41916320563602993" DF="1" EFFECT_SIZE="-0.25339734748010606" ESTIMABLE="YES" I2="0.0" ID="CMP-001.01.05" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" MODIFIED="2012-11-30 09:38:36 -0500" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.38458283622614664" P_Z="0.002734643841259048" STUDIES="2" TAU2="0.0" TOTAL_1="392" TOTAL_2="246" WEIGHT="8.07967470732671" Z="2.9960914772439287">
<NAME>Morphine</NAME>
<IV_DATA CI_END="-0.07944489810255256" CI_START="-0.6125551018974473" EFFECT_SIZE="-0.346" ESTIMABLE="YES" ESTIMATE="-0.346" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2012-11-30 09:34:51 -0500" MODIFIED_BY="[Empty name]" ORDER="99" SE="0.136" STUDY_ID="STD-Caldwell-2002" TOTAL_1="222" TOTAL_2="73" WEIGHT="3.6589998274760642"/>
<IV_DATA CI_END="0.016676110330325844" CI_START="-0.40667611033032586" EFFECT_SIZE="-0.195" ESTIMABLE="YES" ESTIMATE="-0.195" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2012-11-30 09:34:07 -0500" MODIFIED_BY="[Empty name]" ORDER="45" SE="0.108" STUDY_ID="STD-Katz-2010" TOTAL_1="170" TOTAL_2="173" WEIGHT="4.420674879850646"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="37.084063641287244" CI_END="-0.14583641422683966" CI_START="-0.4736216039252886" DF="9" EFFECT_SIZE="-0.30972900907606415" ESTIMABLE="YES" I2="75.73081502864233" ID="CMP-001.01.06" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" MODIFIED="2012-11-30 09:42:06 -0500" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="2.5424645805349755E-5" P_Z="2.1222865033556477E-4" STUDIES="10" TAU2="0.05060462888438928" TOTAL_1="1889" TOTAL_2="1054" WEIGHT="36.7746493512903" Z="3.7039971410229815">
<NAME>Oxycodone</NAME>
<IV_DATA CI_END="0.055236614546765095" CI_START="-0.3132366145467651" EFFECT_SIZE="-0.129" ESTIMABLE="YES" ESTIMATE="-0.129" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2012-11-30 09:40:38 -0500" MODIFIED_BY="[Empty name]" ORDER="50" SE="0.094" STUDY_ID="STD-Afilalo-2010" TOTAL_1="342" TOTAL_2="168" WEIGHT="4.837506284395869"/>
<IV_DATA CI_END="-0.018085474349911757" CI_START="-0.6139145256500882" EFFECT_SIZE="-0.316" ESTIMABLE="YES" ESTIMATE="-0.316" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2008-12-12 09:12:04 -0500" MODIFIED_BY="[Empty name]" ORDER="100" SE="0.152" STUDY_ID="STD-Chindalore-2005" TOTAL_1="309" TOTAL_2="51" WEIGHT="3.2780550604605834"/>
<IV_DATA CI_END="-0.3968852942726121" CI_START="-0.973114705727388" EFFECT_SIZE="-0.685" ESTIMABLE="YES" ESTIMATE="-0.685" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2012-11-30 09:40:52 -0500" MODIFIED_BY="[Empty name]" ORDER="51" SE="0.147" STUDY_ID="STD-Etropolski-2011" TOTAL_1="143" TOTAL_2="74" WEIGHT="3.3926505363075514"/>
<IV_DATA CI_END="0.2273558222066463" CI_START="-0.2273558222066463" EFFECT_SIZE="0.0" ESTIMABLE="YES" ESTIMATE="0.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2012-11-30 09:41:04 -0500" MODIFIED_BY="[Empty name]" ORDER="52" SE="0.116" STUDY_ID="STD-Fidelholtz-2011" TOTAL_1="158" TOTAL_2="141" WEIGHT="4.191800043105465"/>
<IV_DATA CI_END="-0.06896356553053462" CI_START="-0.4570364344694654" EFFECT_SIZE="-0.263" ESTIMABLE="YES" ESTIMATE="-0.263" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2012-11-30 09:41:19 -0500" MODIFIED_BY="[Empty name]" ORDER="53" SE="0.099" STUDY_ID="STD-Friedmann-2011" TOTAL_1="203" TOTAL_2="207" WEIGHT="4.686710940222953"/>
<IV_DATA CI_END="-0.24736482607163274" CI_START="-0.7726351739283672" EFFECT_SIZE="-0.51" ESTIMABLE="YES" ESTIMATE="-0.51" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2012-11-30 09:41:35 -0500" MODIFIED_BY="[Empty name]" ORDER="54" SE="0.134" STUDY_ID="STD-Hartrick-2009" TOTAL_1="172" TOTAL_2="86" WEIGHT="3.7095176354340187"/>
<IV_DATA CI_END="-0.04684705903014935" CI_START="-0.8151529409698506" EFFECT_SIZE="-0.431" ESTIMABLE="YES" ESTIMATE="-0.431" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2008-12-12 09:11:36 -0500" MODIFIED_BY="[Empty name]" ORDER="104" SE="0.196" STUDY_ID="STD-Markenson-2005" TOTAL_1="56" TOTAL_2="51" WEIGHT="2.4354871488446945"/>
<IV_DATA CI_END="0.026634273541868647" CI_START="-0.5966342735418686" EFFECT_SIZE="-0.285" ESTIMABLE="YES" ESTIMATE="-0.285" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2012-11-30 09:42:06 -0500" MODIFIED_BY="[Empty name]" ORDER="106" SE="0.159" STUDY_ID="STD-Matsumoto-2005" TOTAL_1="120" TOTAL_2="59" WEIGHT="3.1243779635443194"/>
<IV_DATA CI_END="0.23319657853130515" CI_START="-0.13919657853130518" EFFECT_SIZE="0.047" ESTIMABLE="YES" ESTIMATE="0.047" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2012-11-30 09:40:05 -0500" MODIFIED_BY="[Empty name]" ORDER="55" SE="0.095" STUDY_ID="STD-NCT00486811" TOTAL_1="331" TOTAL_2="168" WEIGHT="4.807212912768148"/>
<IV_DATA CI_END="-0.407167347153829" CI_START="-1.206832652846171" EFFECT_SIZE="-0.807" ESTIMABLE="YES" ESTIMATE="-0.807" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2008-12-12 09:11:52 -0500" MODIFIED_BY="[Empty name]" ORDER="109" SE="0.204" STUDY_ID="STD-Zautra-2005" TOTAL_1="55" TOTAL_2="49" WEIGHT="2.3113308262066923"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="4.3260781397864084E-4" CI_END="-0.20689349267898677" CI_START="-0.5784323961948812" DF="1" EFFECT_SIZE="-0.39266294443693395" ESTIMABLE="YES" I2="0.0" ID="CMP-001.01.07" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" MODIFIED="2012-11-30 09:38:30 -0500" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.9834058151500129" P_Z="3.430947987013114E-5" STUDIES="2" TAU2="0.0" TOTAL_1="498" TOTAL_2="147" WEIGHT="7.364144442245603" Z="4.142797547589358">
<NAME>Oxymorphone</NAME>
<IV_DATA CI_END="-0.1479644659170333" CI_START="-0.6340355340829668" EFFECT_SIZE="-0.391" ESTIMABLE="YES" ESTIMATE="-0.391" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2008-12-12 09:11:16 -0500" MODIFIED_BY="[Empty name]" ORDER="101" SE="0.124" STUDY_ID="STD-Kivitz-2006" TOTAL_1="270" TOTAL_2="87" WEIGHT="3.9714939059380514"/>
<IV_DATA CI_END="-0.10688529427261206" CI_START="-0.683114705727388" EFFECT_SIZE="-0.395" ESTIMABLE="YES" ESTIMATE="-0.395" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2008-12-13 05:00:48 -0500" MODIFIED_BY="[Empty name]" ORDER="105" SE="0.147" STUDY_ID="STD-Matsumoto-2005" TOTAL_1="228" TOTAL_2="60" WEIGHT="3.3926505363075514"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="5.973173497062828" CI_END="-0.16335695255371946" CI_START="-0.4639034151795472" DF="3" EFFECT_SIZE="-0.3136301838666333" ESTIMABLE="YES" I2="49.77544179027812" ID="CMP-001.01.08" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" MODIFIED="2014-08-17 07:52:44 -0400" MODIFIED_BY="Anne Lawson" NO="8" P_CHI2="0.11292276130550027" P_Z="4.303057486719731E-5" STUDIES="4" TAU2="0.011620723978060236" TOTAL_1="1297" TOTAL_2="498" WEIGHT="17.482880814969526" Z="4.09057461181013">
<NAME>Tapentadol</NAME>
<IV_DATA CI_END="-0.11176338545323489" CI_START="-0.4802366145467651" EFFECT_SIZE="-0.296" ESTIMABLE="YES" ESTIMATE="-0.296" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2012-11-30 09:36:02 -0500" MODIFIED_BY="[Empty name]" ORDER="46" SE="0.094" STUDY_ID="STD-Afilalo-2010" TOTAL_1="344" TOTAL_2="169" WEIGHT="4.837506284395869"/>
<IV_DATA CI_END="-0.10920468200979294" CI_START="-0.618795317990207" EFFECT_SIZE="-0.364" ESTIMABLE="YES" ESTIMATE="-0.364" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2012-11-30 09:36:21 -0500" MODIFIED_BY="[Empty name]" ORDER="47" SE="0.13" STUDY_ID="STD-Etropolski-2011" TOTAL_1="304" TOTAL_2="74" WEIGHT="3.8124510898425625"/>
<IV_DATA CI_END="-0.2708843938861134" CI_START="-0.7491156061138866" EFFECT_SIZE="-0.51" ESTIMABLE="YES" ESTIMATE="-0.51" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2012-11-30 09:35:47 -0500" MODIFIED_BY="[Empty name]" ORDER="48" SE="0.122" STUDY_ID="STD-Hartrick-2009" TOTAL_1="330" TOTAL_2="86" WEIGHT="4.025710527962946"/>
<IV_DATA CI_END="0.04419657853130518" CI_START="-0.3281965785313051" EFFECT_SIZE="-0.142" ESTIMABLE="YES" ESTIMATE="-0.142" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2012-11-30 09:40:11 -0500" MODIFIED_BY="[Empty name]" ORDER="49" SE="0.095" STUDY_ID="STD-NCT00486811" TOTAL_1="319" TOTAL_2="169" WEIGHT="4.807212912768148"/>
</IV_SUBGROUP>
</IV_OUTCOME>
<IV_OUTCOME CHI2="20.496298335553366" CI_END="-0.17316087656167764" CI_START="-0.3450108852959981" CI_STUDY="95" CI_TOTAL="95" DF="14" EFFECT_SIZE="-0.2590858809288379" ESTIMABLE="YES" I2="31.69498330478891" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_DATA="NO" LOG_EFFECT_SIZE="NaN" MODIFIED="2014-08-17 07:53:05 -0400" MODIFIED_BY="Anne Lawson" NO="2" NOTES="&lt;p&gt;For Matsumoto 2005, in the control group standard errors were inflated and the number of patients in the control group was halfed to avoid duplicate counting of patients when including two different comparisons in the overall meta-analysis.&lt;/p&gt;" NOTES_MODIFIED="2014-08-17 07:53:05 -0400" NOTES_MODIFIED_BY="Anne Lawson" P_CHI2="0.115254633187307" P_Q="0.717660549774865" P_Z="3.4253774678879057E-9" Q="3.6965624692847334" RANDOM="YES" SCALE="1.24" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="12" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.008861077109775033" TOTALS="YES" TOTAL_1="2124" TOTAL_2="1429" WEIGHT="99.99999999999999" Z="5.909793072031909">
<NAME>Function</NAME>
<GROUP_LABEL_1>Opioids</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours opioids</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Std. Mean Difference</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="0.014105852179995326" CI_END="-0.05122321261360738" CI_START="-0.40344221056195806" DF="1" EFFECT_SIZE="-0.22733271158778273" ESTIMABLE="YES" I2="0.0" ID="CMP-001.02.01" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" MODIFIED="2014-08-17 07:52:51 -0400" MODIFIED_BY="Anne Lawson" NO="1" P_CHI2="0.9054591161352267" P_Z="0.011404979981320033" STUDIES="2" TAU2="0.0" TOTAL_1="243" TOTAL_2="258" WEIGHT="15.162198795676805" Z="2.5300391507287348">
<NAME>Buprenorphine</NAME>
<IV_DATA CI_END="0.04515474174284789" CI_START="-0.5271547417428479" EFFECT_SIZE="-0.241" ESTIMABLE="YES" ESTIMATE="-0.241" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2012-11-30 09:49:44 -0500" MODIFIED_BY="[Empty name]" ORDER="56" SE="0.146" STUDY_ID="STD-Breivik-2010" TOTAL_1="94" TOTAL_2="96" WEIGHT="6.36891966827306"/>
<IV_DATA CI_END="0.004435894237566185" CI_START="-0.4424358942375662" EFFECT_SIZE="-0.219" ESTIMABLE="YES" ESTIMATE="-0.219" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2012-11-30 09:49:32 -0500" MODIFIED_BY="[Empty name]" ORDER="57" SE="0.114" STUDY_ID="STD-Munera-2010" TOTAL_1="149" TOTAL_2="162" WEIGHT="8.793279127403745"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="1.0620534431567858" CI_END="-0.10019991248961607" CI_START="-0.7379051926154889" DF="1" EFFECT_SIZE="-0.4190525525525525" ESTIMABLE="YES" I2="5.8427797166536" ID="CMP-001.02.02" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" MODIFIED="2012-11-30 09:49:56 -0500" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.3027476966506738" P_Z="0.009998373270879348" STUDIES="2" TAU2="0.0032395000000000054" TOTAL_1="74" TOTAL_2="95" WEIGHT="6.538995106977614" Z="2.575885557888008">
<NAME>Codeine</NAME>
<IV_DATA CI_END="0.10595276089255096" CI_START="-0.6819527608925509" EFFECT_SIZE="-0.288" ESTIMABLE="YES" ESTIMATE="-0.288" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2008-12-12 09:19:33 -0500" MODIFIED_BY="[Empty name]" ORDER="113" SE="0.201" STUDY_ID="STD-Kjaersgaard_x002d_Andersen-1990" TOTAL_1="43" TOTAL_2="60" WEIGHT="3.90148753791183"/>
<IV_DATA CI_END="-0.12512911191136628" CI_START="-1.1168708880886338" EFFECT_SIZE="-0.621" ESTIMABLE="YES" ESTIMATE="-0.621" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2008-12-12 09:19:33 -0500" MODIFIED_BY="[Empty name]" ORDER="112" SE="0.253" STUDY_ID="STD-Peloso-2000" TOTAL_1="31" TOTAL_2="35" WEIGHT="2.6375075690657837"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="0.0" CI_END="-0.08504363756145447" CI_START="-0.48095636243854545" DF="0" EFFECT_SIZE="-0.283" ESTIMABLE="YES" I2="0.0" ID="CMP-001.02.03" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" MODIFIED="2012-11-30 09:49:54 -0500" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.005078999103861107" STUDIES="1" TAU2="0.0" TOTAL_1="202" TOTAL_2="197" WEIGHT="10.08260426335602" Z="2.8019801980198014">
<NAME>Fentanyl</NAME>
<IV_DATA CI_END="-0.08504363756145447" CI_START="-0.48095636243854545" EFFECT_SIZE="-0.283" ESTIMABLE="YES" ESTIMATE="-0.283" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2008-12-12 09:20:11 -0500" MODIFIED_BY="[Empty name]" ORDER="114" SE="0.101" STUDY_ID="STD-Langford-2006" TOTAL_1="202" TOTAL_2="197" WEIGHT="10.08260426335602"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="1.1225464190981431" CI_END="-0.023827641668952765" CI_START="-0.3770419235484386" DF="1" EFFECT_SIZE="-0.20043478260869566" ESTIMABLE="YES" I2="10.916824196597345" ID="CMP-001.02.04" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" MODIFIED="2012-11-30 09:50:41 -0500" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.28937084155521564" P_Z="0.026121532119537928" STUDIES="2" TAU2="0.0018479999999999987" TOTAL_1="393" TOTAL_2="246" WEIGHT="16.389365210541413" Z="2.2244001747143094">
<NAME>Morphine</NAME>
<IV_DATA CI_END="-0.04444489810255259" CI_START="-0.5775551018974474" EFFECT_SIZE="-0.311" ESTIMABLE="YES" ESTIMATE="-0.311" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2012-11-30 09:50:24 -0500" MODIFIED_BY="[Empty name]" ORDER="115" SE="0.136" STUDY_ID="STD-Caldwell-2002" TOTAL_1="222" TOTAL_2="73" WEIGHT="7.025435471933698"/>
<IV_DATA CI_END="0.08467611033032585" CI_START="-0.33867611033032585" EFFECT_SIZE="-0.127" ESTIMABLE="YES" ESTIMATE="-0.127" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2012-11-30 09:50:41 -0500" MODIFIED_BY="[Empty name]" ORDER="58" SE="0.108" STUDY_ID="STD-Katz-2010" TOTAL_1="171" TOTAL_2="173" WEIGHT="9.363929738607716"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="10.271929764574798" CI_END="-0.005345694514343691" CI_START="-0.5847714384898239" DF="3" EFFECT_SIZE="-0.2950585665020838" ESTIMABLE="YES" I2="70.79419282688035" ID="CMP-001.02.05" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" MODIFIED="2012-11-30 09:54:00 -0500" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.01639065245667637" P_Z="0.04591992139288658" STUDIES="4" TAU2="0.06128976109124616" TOTAL_1="382" TOTAL_2="298" WEIGHT="22.59738436336725" Z="1.9961286487076522">
<NAME>Oxycodone</NAME>
<IV_DATA CI_END="0.009834453619168348" CI_START="-0.5938344536191683" EFFECT_SIZE="-0.292" ESTIMABLE="YES" ESTIMATE="-0.292" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2012-11-30 09:51:31 -0500" MODIFIED_BY="[Empty name]" ORDER="59" SE="0.154" STUDY_ID="STD-Afilalo-2010" TOTAL_1="92" TOTAL_2="79" WEIGHT="5.899712220583751"/>
<IV_DATA CI_END="-0.4040472391074491" CI_START="-1.1919527608925509" EFFECT_SIZE="-0.798" ESTIMABLE="YES" ESTIMATE="-0.798" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2008-12-12 09:21:35 -0500" MODIFIED_BY="[Empty name]" ORDER="117" SE="0.201" STUDY_ID="STD-Markenson-2005" TOTAL_1="56" TOTAL_2="51" WEIGHT="3.90148753791183"/>
<IV_DATA CI_END="0.17063427354186864" CI_START="-0.4526342735418686" EFFECT_SIZE="-0.141" ESTIMABLE="YES" ESTIMATE="-0.141" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2012-11-30 09:54:00 -0500" MODIFIED_BY="[Empty name]" ORDER="118" SE="0.159" STUDY_ID="STD-Matsumoto-2005" TOTAL_1="120" TOTAL_2="59" WEIGHT="5.629281994691897"/>
<IV_DATA CI_END="0.21563517392836729" CI_START="-0.30963517392836726" EFFECT_SIZE="-0.047" ESTIMABLE="YES" ESTIMATE="-0.047" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2012-11-30 09:51:16 -0500" MODIFIED_BY="[Empty name]" ORDER="60" SE="0.134" STUDY_ID="STD-NCT00486811" TOTAL_1="114" TOTAL_2="109" WEIGHT="7.166902610179773"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="0.03731058541371424" CI_END="-0.19425400638351878" CI_START="-0.564735855166683" DF="1" EFFECT_SIZE="-0.3794949307751009" ESTIMABLE="YES" I2="0.0" ID="CMP-001.02.06" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" MODIFIED="2012-11-30 09:54:29 -0500" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.8468341450740209" P_Z="5.937224784756353E-5" STUDIES="2" TAU2="0.0" TOTAL_1="498" TOTAL_2="147" WEIGHT="14.298728162298307" Z="4.015291972212373">
<NAME>Oxymorphone</NAME>
<IV_DATA CI_END="-0.1519644659170333" CI_START="-0.6380355340829668" EFFECT_SIZE="-0.395" ESTIMABLE="YES" ESTIMATE="-0.395" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2012-11-30 09:54:29 -0500" MODIFIED_BY="[Empty name]" ORDER="116" SE="0.124" STUDY_ID="STD-Kivitz-2006" TOTAL_1="270" TOTAL_2="87" WEIGHT="7.929808494025247"/>
<IV_DATA CI_END="-0.0718452582571521" CI_START="-0.6441547417428479" EFFECT_SIZE="-0.358" ESTIMABLE="YES" ESTIMATE="-0.358" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2012-11-30 09:54:18 -0500" MODIFIED_BY="[Empty name]" ORDER="119" SE="0.146" STUDY_ID="STD-Matsumoto-2005" TOTAL_1="228" TOTAL_2="60" WEIGHT="6.36891966827306"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="2.770479834116994" CI_END="0.15547209093581885" CI_START="-0.4473714415851695" DF="1" EFFECT_SIZE="-0.14594967532467532" ESTIMABLE="YES" I2="63.90516950581886" ID="CMP-001.02.07" LOG_CI_END="-0.8083475605947804" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" MODIFIED="2014-08-17 07:53:05 -0400" MODIFIED_BY="Anne Lawson" NO="7" P_CHI2="0.0960174616873345" P_Z="0.3426090638349667" STUDIES="2" TAU2="0.030311499999999995" TOTAL_1="332" TOTAL_2="188" WEIGHT="14.930724097782589" Z="0.9490227289838883">
<NAME>Tapentadol</NAME>
<IV_DATA CI_END="-0.03360504216439236" CI_START="-0.5823949578356076" EFFECT_SIZE="-0.308" ESTIMABLE="YES" ESTIMATE="-0.308" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2012-11-30 09:52:49 -0500" MODIFIED_BY="[Empty name]" ORDER="61" SE="0.14" STUDY_ID="STD-Afilalo-2010" TOTAL_1="149" TOTAL_2="79" WEIGHT="6.75292010889598"/>
<IV_DATA CI_END="0.23715564212934656" CI_START="-0.23715564212934656" EFFECT_SIZE="0.0" ESTIMABLE="YES" ESTIMATE="0.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2012-11-30 09:52:29 -0500" MODIFIED_BY="[Empty name]" ORDER="62" SE="0.121" STUDY_ID="STD-NCT00486811" TOTAL_1="183" TOTAL_2="109" WEIGHT="8.177803988886609"/>
</IV_SUBGROUP>
</IV_OUTCOME>
<DICH_OUTCOME CHI2="47.90882715033738" CI_END="1.6310617552735134" CI_START="1.3548358498787816" CI_STUDY="95" CI_TOTAL="95" DF="14" EFFECT_MEASURE="RR" EFFECT_SIZE="1.4865466489184818" ESTIMABLE="YES" EVENTS_1="2490" EVENTS_2="891" I2="70.77782773502646" I2_Q="67.45543360897241" ID="CMP-001.03" LOG_CI_END="0.21247040461279562" LOG_CI_START="0.13188667985223648" LOG_EFFECT_SIZE="0.17217854223251605" METHOD="IV" MODIFIED="2014-08-17 07:53:47 -0400" MODIFIED_BY="Anne Lawson" NO="3" NOTES="&lt;p&gt;For Matsumoto 2005, the number of patients and events in the control group was halfed to avoid duplicate counting of patients when including two different comparisons in the overall meta-analysis.&lt;/p&gt;" NOTES_MODIFIED="2014-08-17 07:53:47 -0400" NOTES_MODIFIED_BY="Anne Lawson" P_CHI2="1.3610357726179245E-5" P_Q="0.0052296324123976" P_Z="5.499861525647582E-17" Q="18.43625730915922" RANDOM="YES" SCALE="2.57" SORT_BY="STUDY" STUDIES="10" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0218276340381733" TOTALS="YES" TOTAL_1="3222" TOTAL_2="1676" WEIGHT="100.0" Z="8.375481344131376">
<NAME>Number of participants experiencing any adverse event</NAME>
<GROUP_LABEL_1>Opioids</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours opioids</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.4223023372990646" CI_START="1.0944814365588535" DF="0" EFFECT_SIZE="1.2476712328767123" ESTIMABLE="YES" EVENTS_1="92" EVENTS_2="73" I2="0.0" ID="CMP-001.03.01" LOG_CI_END="0.15299192372437614" LOG_CI_START="0.03920839992092242" LOG_EFFECT_SIZE="0.09610016182264929" MODIFIED="2014-08-17 07:53:32 -0400" MODIFIED_BY="Anne Lawson" NO="1" P_CHI2="1.0" P_Z="9.30553235771752E-4" STUDIES="1" TAU2="0.0" TOTAL_1="100" TOTAL_2="99" WEIGHT="8.521179005436641" Z="3.3107228495791516">
<NAME>Buprenorphine</NAME>
<DICH_DATA CI_END="1.4223023372990646" CI_START="1.0944814365588535" EFFECT_SIZE="1.2476712328767123" ESTIMABLE="YES" EVENTS_1="92" EVENTS_2="73" LOG_CI_END="0.15299192372437614" LOG_CI_START="0.03920839992092242" LOG_EFFECT_SIZE="0.09610016182264929" MODIFIED="2012-11-30 09:57:16 -0500" MODIFIED_BY="[Empty name]" ORDER="63" O_E="0.0" SE="0.0668370051196753" STUDY_ID="STD-Breivik-2010" TOTAL_1="100" TOTAL_2="99" VAR="0.004467185253367503" WEIGHT="8.521179005436641"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.7450078574293708" CI_START="0.9433002942016635" DF="0" EFFECT_SIZE="1.282991202346041" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="22" I2="0.0" ID="CMP-001.03.02" LOG_CI_END="0.24179738684278318" LOG_CI_START="-0.02535003011111454" LOG_EFFECT_SIZE="0.10822367836583432" MODIFIED="2012-11-30 09:57:03 -0500" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.11228724852631898" STUDIES="1" TAU2="0.0" TOTAL_1="31" TOTAL_2="35" WEIGHT="4.8234640327267115" Z="1.5879959783259823">
<NAME>Codeine</NAME>
<DICH_DATA CI_END="1.7450078574293708" CI_START="0.9433002942016635" EFFECT_SIZE="1.282991202346041" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="22" LOG_CI_END="0.24179738684278318" LOG_CI_START="-0.02535003011111454" LOG_EFFECT_SIZE="0.10822367836583432" MODIFIED="2008-12-12 09:33:12 -0500" MODIFIED_BY="[Empty name]" ORDER="127" O_E="0.0" SE="0.1569237151197608" STUDY_ID="STD-Peloso-2000" TOTAL_1="31" TOTAL_2="35" VAR="0.024625052366987848" WEIGHT="4.8234640327267115"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="4.9793614550052076E-31" CI_END="1.807603499449554" CI_START="1.3279446611612653" DF="0" EFFECT_SIZE="1.5493215988265494" ESTIMABLE="YES" EVENTS_1="169" EVENTS_2="101" I2="100.0" ID="CMP-001.03.03" LOG_CI_END="0.25710317343707956" LOG_CI_START="0.12317997725108304" LOG_EFFECT_SIZE="0.1901415753440813" MODIFIED="2012-11-30 09:57:58 -0500" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="2.6149436539647644E-8" STUDIES="1" TAU2="0.0" TOTAL_1="216" TOTAL_2="200" WEIGHT="7.9976309357998305" Z="5.565438254931318">
<NAME>Fentanyl</NAME>
<DICH_DATA CI_END="1.807603499449554" CI_START="1.3279446611612653" EFFECT_SIZE="1.5493215988265494" ESTIMABLE="YES" EVENTS_1="169" EVENTS_2="101" LOG_CI_END="0.25710317343707956" LOG_CI_START="0.12317997725108304" LOG_EFFECT_SIZE="0.1901415753440813" MODIFIED="2008-12-12 09:33:19 -0500" MODIFIED_BY="[Empty name]" ORDER="129" O_E="0.0" SE="0.07866714837016708" STUDY_ID="STD-Langford-2006" TOTAL_1="216" TOTAL_2="200" VAR="0.006188520232693882" WEIGHT="7.9976309357998305"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.3494528708820066" CI_START="0.8901567233237588" DF="0" EFFECT_SIZE="1.0960038986354776" ESTIMABLE="YES" EVENTS_1="91" EVENTS_2="84" I2="0.0" ID="CMP-001.03.04" LOG_CI_END="0.13015772159109465" LOG_CI_START="-0.050533523599387536" LOG_EFFECT_SIZE="0.03981209899585354" MODIFIED="2014-08-17 07:53:39 -0400" MODIFIED_BY="Anne Lawson" NO="4" P_CHI2="1.0" P_Z="0.38776022814433686" STUDIES="1" TAU2="0.0" TOTAL_1="171" TOTAL_2="173" WEIGHT="6.770680758725864" Z="0.8636863407361852">
<NAME>Morphine</NAME>
<DICH_DATA CI_END="1.3494528708820066" CI_START="0.8901567233237588" EFFECT_SIZE="1.0960038986354776" ESTIMABLE="YES" EVENTS_1="91" EVENTS_2="84" LOG_CI_END="0.13015772159109465" LOG_CI_START="-0.050533523599387536" LOG_EFFECT_SIZE="0.03981209899585354" MODIFIED="2012-11-30 09:57:50 -0500" MODIFIED_BY="[Empty name]" ORDER="64" O_E="0.0" SE="0.10613893186097823" STUDY_ID="STD-Katz-2010" TOTAL_1="171" TOTAL_2="173" VAR="0.011265472856589378" WEIGHT="6.770680758725864"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="13.9901603799753" CI_END="1.9484621878605604" CI_START="1.4708403110765036" DF="5" EFFECT_SIZE="1.692890052694986" ESTIMABLE="YES" EVENTS_1="1013" EVENTS_2="319" I2="64.26059556002869" ID="CMP-001.03.05" LOG_CI_END="0.28969198222886483" LOG_CI_START="0.1675655239967832" LOG_EFFECT_SIZE="0.2286287531128241" MODIFIED="2012-11-30 09:59:45 -0500" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.01567205392225779" P_Z="2.1622258857460858E-13" STUDIES="6" TAU2="0.018379332692765225" TOTAL_1="1169" TOTAL_2="610" WEIGHT="38.932864501401646" Z="7.338362684356004">
<NAME>Oxycodone</NAME>
<DICH_DATA CI_END="1.629063531853054" CI_START="1.2631388786422444" EFFECT_SIZE="1.4344802134786805" ESTIMABLE="YES" EVENTS_1="299" EVENTS_2="103" LOG_CI_END="0.21193802169044818" LOG_CI_START="0.10145110266314371" LOG_EFFECT_SIZE="0.15669456217679595" MODIFIED="2012-11-30 09:58:56 -0500" MODIFIED_BY="[Empty name]" ORDER="65" O_E="0.0" SE="0.06490056315570841" STUDY_ID="STD-Afilalo-2010" TOTAL_1="342" TOTAL_2="169" VAR="0.0042120830979280955" WEIGHT="8.604658066280903"/>
<DICH_DATA CI_END="2.5198930585697097" CI_START="1.4371283917168913" EFFECT_SIZE="1.9030002255808707" ESTIMABLE="YES" EVENTS_1="114" EVENTS_2="31" LOG_CI_END="0.4013821102027484" LOG_CI_START="0.15749556933348022" LOG_EFFECT_SIZE="0.2794388397681143" MODIFIED="2012-11-30 09:59:07 -0500" MODIFIED_BY="[Empty name]" ORDER="66" O_E="0.0" SE="0.14326016136445585" STUDY_ID="STD-Etropolski-2011" TOTAL_1="143" TOTAL_2="74" VAR="0.020523473834169928" WEIGHT="5.290602143731614"/>
<DICH_DATA CI_END="3.6241025586779685" CI_START="1.9168050027046835" EFFECT_SIZE="2.635658914728682" ESTIMABLE="YES" EVENTS_1="144" EVENTS_2="27" LOG_CI_END="0.5592004793021479" LOG_CI_START="0.2825779341838644" LOG_EFFECT_SIZE="0.4208892067430061" MODIFIED="2012-11-30 09:59:25 -0500" MODIFIED_BY="[Empty name]" ORDER="67" O_E="0.0" SE="0.16248945230616188" STUDY_ID="STD-Hartrick-2009" TOTAL_1="172" TOTAL_2="85" VAR="0.026402822110756452" WEIGHT="4.645671635510749"/>
<DICH_DATA CI_END="2.1916272925364018" CI_START="1.3052335325876767" EFFECT_SIZE="1.691326530612245" ESTIMABLE="YES" EVENTS_1="52" EVENTS_2="28" LOG_CI_END="0.3407667001055052" LOG_CI_START="0.11568822266312662" LOG_EFFECT_SIZE="0.2282274613843159" MODIFIED="2008-12-12 09:33:30 -0500" MODIFIED_BY="[Empty name]" ORDER="125" O_E="0.0" SE="0.1322122118060854" STUDY_ID="STD-Markenson-2005" TOTAL_1="56" TOTAL_2="51" VAR="0.017480068950657186" WEIGHT="5.700227819531878"/>
<DICH_DATA CI_END="1.9580731918129672" CI_START="1.2410340951488033" EFFECT_SIZE="1.558857142857143" ESTIMABLE="YES" EVENTS_1="110" EVENTS_2="35" LOG_CI_END="0.2918289214846866" LOG_CI_START="0.09378371311160719" LOG_EFFECT_SIZE="0.1928063172981469" MODIFIED="2008-12-13 05:04:27 -0500" MODIFIED_BY="[Empty name]" ORDER="126" O_E="0.0" SE="0.11633273573793898" STUDY_ID="STD-Matsumoto-2005" TOTAL_1="125" TOTAL_2="62" VAR="0.013533305404273145" WEIGHT="6.3364510567801275"/>
<DICH_DATA CI_END="1.8147109111374433" CI_START="1.3758067043419628" EFFECT_SIZE="1.5800922245190014" ESTIMABLE="YES" EVENTS_1="294" EVENTS_2="95" LOG_CI_END="0.25880745047544934" LOG_CI_START="0.13855742144707933" LOG_EFFECT_SIZE="0.19868243596126434" MODIFIED="2012-11-30 09:59:45 -0500" MODIFIED_BY="[Empty name]" ORDER="68" O_E="0.0" SE="0.07063546229850828" STUDY_ID="STD-NCT00486811" TOTAL_1="331" TOTAL_2="169" VAR="0.004989368534123985" WEIGHT="8.355253779566368"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.567731334690923E-31" CI_END="1.9670994870448413" CI_START="1.2803569005189628" DF="0" EFFECT_SIZE="1.5870064279155187" ESTIMABLE="YES" EVENTS_1="223" EVENTS_2="36" I2="100.0" ID="CMP-001.03.06" LOG_CI_END="0.29382632513640705" LOG_CI_START="0.10733104646098489" LOG_EFFECT_SIZE="0.20057868579869598" MODIFIED="2012-11-30 09:57:52 -0500" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.0" P_Z="2.48733419341647E-5" STUDIES="1" TAU2="0.0" TOTAL_1="242" TOTAL_2="62" WEIGHT="6.623503047314542" Z="4.215945872989321">
<NAME>Oxymorphone</NAME>
<DICH_DATA CI_END="1.9670994870448413" CI_START="1.2803569005189628" EFFECT_SIZE="1.5870064279155187" ESTIMABLE="YES" EVENTS_1="223" EVENTS_2="36" LOG_CI_END="0.29382632513640705" LOG_CI_START="0.10733104646098489" LOG_EFFECT_SIZE="0.20057868579869598" MODIFIED="2008-12-13 05:04:29 -0500" MODIFIED_BY="[Empty name]" ORDER="128" O_E="0.0" SE="0.10954824986046106" STUDY_ID="STD-Matsumoto-2005" TOTAL_1="242" TOTAL_2="62" VAR="0.012000819047490008" WEIGHT="6.623503047314542"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="8.940375263914786" CI_END="1.6564559914901344" CI_START="1.1663784139969944" DF="3" EFFECT_SIZE="1.3899836373893333" ESTIMABLE="YES" EVENTS_1="877" EVENTS_2="256" I2="66.4443615458892" ID="CMP-001.03.07" LOG_CI_END="0.21917990209127766" LOG_CI_START="0.06683947362072801" LOG_EFFECT_SIZE="0.14300968785600282" MODIFIED="2014-08-17 07:53:47 -0400" MODIFIED_BY="Anne Lawson" NO="7" P_CHI2="0.030094252048077474" P_Z="2.3338470504204173E-4" STUDIES="4" TAU2="0.01994821800945353" TOTAL_1="1293" TOTAL_2="497" WEIGHT="26.330677718594764" Z="3.6798352276167696">
<NAME>Tapentadol</NAME>
<DICH_DATA CI_END="1.4242503802565318" CI_START="1.0881198807969783" EFFECT_SIZE="1.2448916233912848" ESTIMABLE="YES" EVENTS_1="261" EVENTS_2="103" LOG_CI_END="0.15358634407977353" LOG_CI_START="0.03667674527073088" LOG_EFFECT_SIZE="0.09513154467525221" MODIFIED="2012-11-30 10:00:45 -0500" MODIFIED_BY="[Empty name]" ORDER="69" O_E="0.0" SE="0.06867327705227912" STUDY_ID="STD-Afilalo-2010" TOTAL_1="344" TOTAL_2="169" VAR="0.004716018981099085" WEIGHT="8.441297131790563"/>
<DICH_DATA CI_END="2.061911333524091" CI_START="1.176458305634707" EFFECT_SIZE="1.5574828133262824" ESTIMABLE="YES" EVENTS_1="199" EVENTS_2="31" LOG_CI_END="0.31426998578301973" LOG_CI_START="0.07057654013622888" LOG_EFFECT_SIZE="0.1924232629596243" MODIFIED="2012-11-30 10:00:56 -0500" MODIFIED_BY="[Empty name]" ORDER="70" O_E="0.0" SE="0.14314673627493593" STUDY_ID="STD-Etropolski-2011" TOTAL_1="305" TOTAL_2="74" VAR="0.020490988106166057" WEIGHT="5.294663454178624"/>
<DICH_DATA CI_END="2.6895247723265436" CI_START="1.4094840550009538" EFFECT_SIZE="1.947008547008547" ESTIMABLE="YES" EVENTS_1="201" EVENTS_2="27" LOG_CI_END="0.42967554877966935" LOG_CI_START="0.1490601672141705" LOG_EFFECT_SIZE="0.2893678579969199" MODIFIED="2012-11-30 10:01:09 -0500" MODIFIED_BY="[Empty name]" ORDER="71" O_E="0.0" SE="0.16483486420011537" STUDY_ID="STD-Hartrick-2009" TOTAL_1="325" TOTAL_2="85" VAR="0.02717053245587047" WEIGHT="4.572882581760789"/>
<DICH_DATA CI_END="1.4038763859652272" CI_START="1.0335309008312623" EFFECT_SIZE="1.2045537040092393" ESTIMABLE="YES" EVENTS_1="216" EVENTS_2="95" LOG_CI_END="0.1473288690070004" LOG_CI_START="0.014323465830150652" LOG_EFFECT_SIZE="0.08082616741857551" MODIFIED="2012-11-30 10:01:26 -0500" MODIFIED_BY="[Empty name]" ORDER="72" O_E="0.0" SE="0.07812803221344557" STUDY_ID="STD-NCT00486811" TOTAL_1="319" TOTAL_2="169" VAR="0.006103989417545189" WEIGHT="8.021834550864787"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="58.596984413132574" CI_END="4.821178927604933" CI_START="2.9305934562131006" CI_STUDY="95" CI_TOTAL="95" DF="24" EFFECT_MEASURE="RR" EFFECT_SIZE="3.7588449577591665" ESTIMABLE="YES" EVENTS_1="1326" EVENTS_2="211" I2="59.042260893853786" I2_Q="37.49102360552626" ID="CMP-001.04" LOG_CI_END="0.6831532496803719" LOG_CI_START="0.466955575528413" LOG_EFFECT_SIZE="0.5750544126043925" METHOD="IV" MODIFIED="2014-08-17 16:23:56 -0400" MODIFIED_BY="Anne Lawson" NO="4" NOTES="&lt;p&gt;For Matsumoto 2005, the number of patients and events in the control group was halfed to avoid duplicate counting of patients when including two different comparisons in the overall meta-analysis.&lt;/p&gt;" NOTES_MODIFIED="2014-08-17 16:23:56 -0400" NOTES_MODIFIED_BY="Anne Lawson" P_CHI2="1.0051485430373486E-4" P_Q="0.13019639720807452" P_Z="1.877947021705486E-25" Q="11.198391661103656" RANDOM="YES" SCALE="77.67" SORT_BY="STUDY" STUDIES="21" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.2021884191958348" TOTALS="YES" TOTAL_1="5125" TOTAL_2="3003" WEIGHT="100.00000000000001" Z="10.42643906578986">
<NAME>Number of participants who withdrew because of adverse events</NAME>
<GROUP_LABEL_1>Opioids</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours opioids</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="11.703745775794753" CI_END="6.938250981114399" CI_START="1.3840487219284836" DF="3" EFFECT_SIZE="3.0988509810622435" ESTIMABLE="YES" EVENTS_1="119" EVENTS_2="51" I2="74.3671807516147" ID="CMP-001.04.01" LOG_CI_END="0.8412500057599426" LOG_CI_START="0.14115137862669822" LOG_EFFECT_SIZE="0.49120069219332035" MODIFIED="2014-08-17 16:23:56 -0400" MODIFIED_BY="Anne Lawson" NO="1" P_CHI2="0.008470103087800607" P_Z="0.005954330139707294" STUDIES="4" TAU2="0.4183164591780254" TOTAL_1="698" TOTAL_2="709" WEIGHT="15.816537393081463" Z="2.750285827076256">
<NAME>Buprenorphine</NAME>
<DICH_DATA CI_END="62.392235276581246" CI_START="3.7740116852069683" EFFECT_SIZE="15.345" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="2" LOG_CI_END="1.7951305450292268" LOG_CI_START="0.5768032405064563" LOG_EFFECT_SIZE="1.1859668927678415" MODIFIED="2012-11-30 10:11:10 -0500" MODIFIED_BY="[Empty name]" ORDER="73" O_E="0.0" SE="0.7156514894940965" STUDY_ID="STD-Breivik-2010" TOTAL_1="100" TOTAL_2="99" VAR="0.5121570544151189" WEIGHT="2.2577140822490893"/>
<DICH_DATA CI_END="3.610563465290108" CI_START="1.2740105986515475" EFFECT_SIZE="2.1447368421052633" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="18" LOG_CI_END="0.55757498328253" LOG_CI_START="0.10517304096380295" LOG_EFFECT_SIZE="0.3313740121231665" MODIFIED="2012-11-30 10:11:00 -0500" MODIFIED_BY="[Empty name]" ORDER="74" O_E="0.0" SE="0.2657431403437517" STUDY_ID="STD-Munera-2010" TOTAL_1="152" TOTAL_2="163" VAR="0.07061941663975889" WEIGHT="5.911809059378648"/>
<DICH_DATA CI_END="2.287492574882982" CI_START="0.9604939947204834" EFFECT_SIZE="1.4822695035460993" ESTIMABLE="YES" EVENTS_1="44" EVENTS_2="30" LOG_CI_END="0.3593596930368107" LOG_CI_START="-0.017505346125462465" LOG_EFFECT_SIZE="0.1709271734556741" MODIFIED="2012-11-30 10:10:48 -0500" MODIFIED_BY="[Empty name]" ORDER="75" O_E="0.0" SE="0.2213723895159497" STUDY_ID="STD-NCT00531427" TOTAL_1="282" TOTAL_2="285" VAR="0.04900573484000136" WEIGHT="6.420483157949051"/>
<DICH_DATA CI_END="62.46828819915927" CI_START="0.9996839089796967" EFFECT_SIZE="7.902439024390244" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="1" LOG_CI_END="1.795659605260171" LOG_CI_START="-1.3729828641794576E-4" LOG_EFFECT_SIZE="0.8977611534868767" MODIFIED="2012-11-30 10:10:35 -0500" MODIFIED_BY="[Empty name]" ORDER="76" O_E="0.0" SE="1.0548599904813043" STUDY_ID="STD-Shannon-2005" TOTAL_1="164" TOTAL_2="162" VAR="1.1127295995182174" WEIGHT="1.226531093504674"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.00837746335153099" CI_END="6.237121786501495" CI_START="2.1577095597735596" DF="1" EFFECT_SIZE="3.6685006888654415" ESTIMABLE="YES" EVENTS_1="55" EVENTS_2="14" I2="0.0" ID="CMP-001.04.02" LOG_CI_END="0.7949842242001115" LOG_CI_START="0.33399298572379493" LOG_EFFECT_SIZE="0.5644886049619532" MODIFIED="2012-12-17 12:43:40 -0500" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.9270726748078363" P_Z="1.586712569580661E-6" STUDIES="3" TAU2="0.0" TOTAL_1="142" TOTAL_2="135" WEIGHT="8.70363337069573" Z="4.79999289819703">
<NAME>Codeine</NAME>
<DICH_DATA CI_END="6.709694556809573" CI_START="1.947079006922904" EFFECT_SIZE="3.6144578313253013" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="10" LOG_CI_END="0.8267027503759318" LOG_CI_START="0.28938357431124523" LOG_EFFECT_SIZE="0.5580431623435885" MODIFIED="2008-12-12 09:38:33 -0500" MODIFIED_BY="[Empty name]" ORDER="130" O_E="0.0" SE="0.3156239437932147" STUDY_ID="STD-Kjaersgaard_x002d_Andersen-1990" TOTAL_1="83" TOTAL_2="75" VAR="0.09961847389558233" WEIGHT="5.343774023325018"/>
<DICH_DATA CI_END="10.743050984751042" CI_START="1.3608217240503535" EFFECT_SIZE="3.823529411764706" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="4" LOG_CI_END="1.0311276368265572" LOG_CI_START="0.13380123370260624" LOG_EFFECT_SIZE="0.5824644352645817" MODIFIED="2008-12-12 09:37:16 -0500" MODIFIED_BY="[Empty name]" ORDER="131" O_E="0.0" SE="0.5270939710323412" STUDY_ID="STD-Peloso-2000" TOTAL_1="51" TOTAL_2="52" VAR="0.27782805429864255" WEIGHT="3.359859347370713"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2008-12-12 09:38:40 -0500" MODIFIED_BY="[Empty name]" ORDER="132" O_E="0.0" SE="0.0" STUDY_ID="STD-Quiding-1992" TOTAL_1="8" TOTAL_2="8" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.230020981549549" CI_START="1.639134986566019" DF="0" EFFECT_SIZE="2.633168316831683" ESTIMABLE="YES" EVENTS_1="54" EVENTS_2="20" I2="0.0" ID="CMP-001.04.03" LOG_CI_END="0.6263425215472863" LOG_CI_START="0.21461472020062658" LOG_EFFECT_SIZE="0.42047862087395643" MODIFIED="2012-11-30 10:06:25 -0500" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="6.248040963158729E-5" STUDIES="1" TAU2="0.0" TOTAL_1="202" TOTAL_2="197" WEIGHT="6.186842013246001" Z="4.003241707198417">
<NAME>Fentanyl</NAME>
<DICH_DATA CI_END="4.230020981549549" CI_START="1.639134986566019" EFFECT_SIZE="2.633168316831683" ESTIMABLE="YES" EVENTS_1="54" EVENTS_2="20" LOG_CI_END="0.6263425215472863" LOG_CI_START="0.21461472020062658" LOG_EFFECT_SIZE="0.42047862087395643" MODIFIED="2008-12-12 09:37:52 -0500" MODIFIED_BY="[Empty name]" ORDER="133" O_E="0.0" SE="0.24185094859651443" STUDY_ID="STD-Langford-2006" TOTAL_1="202" TOTAL_2="197" VAR="0.05849188133703387" WEIGHT="6.186842013246001"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="11.977288495968754" CI_START="2.537425776392715" DF="0" EFFECT_SIZE="5.51284686536485" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="7" I2="0.0" ID="CMP-001.04.04" LOG_CI_END="1.0783585104970217" LOG_CI_START="0.4043933473253968" LOG_EFFECT_SIZE="0.7413759289112093" MODIFIED="2014-08-17 07:54:12 -0400" MODIFIED_BY="Anne Lawson" NO="4" P_CHI2="1.0" P_Z="1.6178176719849376E-5" STUDIES="1" TAU2="0.0" TOTAL_1="139" TOTAL_2="149" WEIGHT="4.493475521081298" Z="4.312003643728018">
<NAME>Hydromorphone</NAME>
<DICH_DATA CI_END="11.977288495968754" CI_START="2.537425776392715" EFFECT_SIZE="5.512846865364851" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="7" LOG_CI_END="1.0783585104970217" LOG_CI_START="0.4043933473253968" LOG_EFFECT_SIZE="0.7413759289112094" MODIFIED="2012-11-30 10:11:56 -0500" MODIFIED_BY="[Empty name]" ORDER="77" O_E="0.0" SE="0.39589047302837554" STUDY_ID="STD-NCT00980798" TOTAL_1="139" TOTAL_2="149" VAR="0.15672926663463094" WEIGHT="4.493475521081298"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.5846011228167844" CI_END="5.146273158910222" CI_START="0.869234856292104" DF="1" EFFECT_SIZE="2.1150224608086883" ESTIMABLE="YES" EVENTS_1="71" EVENTS_2="18" I2="61.3093103159312" ID="CMP-001.04.05" LOG_CI_END="0.7114928343925787" LOG_CI_START="-0.06086286680641215" LOG_EFFECT_SIZE="0.3253149837930833" MODIFIED="2012-11-30 10:12:14 -0500" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.1079079720986954" P_Z="0.09872481723773417" STUDIES="2" TAU2="0.2547366119219684" TOTAL_1="393" TOTAL_2="246" WEIGHT="8.995965367559641" Z="1.6510673796435176">
<NAME>Morphine</NAME>
<DICH_DATA CI_END="8.386423520327714" CI_START="1.4486874941378174" EFFECT_SIZE="3.4855855855855857" ESTIMABLE="YES" EVENTS_1="53" EVENTS_2="5" LOG_CI_END="0.9235767908003016" LOG_CI_START="0.1609747110688734" LOG_EFFECT_SIZE="0.5422757509345876" MODIFIED="2008-12-12 09:38:15 -0500" MODIFIED_BY="[Empty name]" ORDER="134" O_E="0.0" SE="0.4479562365754171" STUDY_ID="STD-Caldwell-2002" TOTAL_1="222" TOTAL_2="73" VAR="0.20066478988681108" WEIGHT="4.0034131514923095"/>
<DICH_DATA CI_END="2.768770039548859" CI_START="0.7087146401072852" EFFECT_SIZE="1.4008097165991902" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="13" LOG_CI_END="0.44228688687513357" LOG_CI_START="-0.14952859580891192" LOG_EFFECT_SIZE="0.14637914553311085" MODIFIED="2012-11-30 10:12:14 -0500" MODIFIED_BY="[Empty name]" ORDER="78" O_E="0.0" SE="0.3476353440624946" STUDY_ID="STD-Katz-2010" TOTAL_1="171" TOTAL_2="173" VAR="0.12085033244144897" WEIGHT="4.992552216067332"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="18.39074250392644" CI_END="8.865929290462606" CI_START="3.4683048903778397" DF="8" EFFECT_SIZE="5.545245343161616" ESTIMABLE="YES" EVENTS_1="561" EVENTS_2="59" I2="56.49985312832262" ID="CMP-001.04.06" LOG_CI_END="0.9477242632948784" LOG_CI_START="0.5401172682702887" LOG_EFFECT_SIZE="0.7439207657825836" MODIFIED="2012-11-30 10:13:33 -0500" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.018480422137604036" P_Z="8.414144040451454E-13" STUDIES="9" TAU2="0.2417206214292017" TOTAL_1="1736" TOTAL_2="917" WEIGHT="31.13630023368348" Z="7.154233985593702">
<NAME>Oxycodone</NAME>
<DICH_DATA CI_END="11.766317092517244" CI_START="3.6559562524574005" EFFECT_SIZE="6.558745348219032" ESTIMABLE="YES" EVENTS_1="146" EVENTS_2="11" LOG_CI_END="1.0706405480863477" LOG_CI_START="0.5630009902811535" LOG_EFFECT_SIZE="0.8168207691837506" MODIFIED="2012-11-30 10:13:33 -0500" MODIFIED_BY="[Empty name]" ORDER="79" O_E="0.0" SE="0.298189989111109" STUDY_ID="STD-Afilalo-2010" TOTAL_1="342" TOTAL_2="169" VAR="0.08891726960608332" WEIGHT="5.540214078261321"/>
<DICH_DATA CI_END="423.4899777450644" CI_START="1.6797104008907167" EFFECT_SIZE="26.670967741935485" ESTIMABLE="YES" EVENTS_1="79" EVENTS_2="0" LOG_CI_END="2.626843136835513" LOG_CI_START="0.22523441140644246" LOG_EFFECT_SIZE="1.426038774120978" MODIFIED="2008-12-12 09:38:07 -0500" MODIFIED_BY="[Empty name]" ORDER="135" O_E="0.0" SE="1.410716853471957" STUDY_ID="STD-Chindalore-2005" TOTAL_1="309" TOTAL_2="51" VAR="1.990122040669819" WEIGHT="0.735656680423437"/>
<DICH_DATA CI_END="36.61498722216945" CI_START="2.2397965687322" EFFECT_SIZE="9.055944055944057" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="2" LOG_CI_END="1.5636588869136108" LOG_CI_START="0.3502085749908068" LOG_EFFECT_SIZE="0.9569337309522089" MODIFIED="2012-11-30 10:13:19 -0500" MODIFIED_BY="[Empty name]" ORDER="80" O_E="0.0" SE="0.7127867198993736" STUDY_ID="STD-Etropolski-2011" TOTAL_1="143" TOTAL_2="74" VAR="0.5080649080649081" WEIGHT="2.2707219712471276"/>
<DICH_DATA CI_END="3.2389815826588326" CI_START="1.2509260800245645" EFFECT_SIZE="2.0128900949796473" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="22" LOG_CI_END="0.5104084785528195" LOG_CI_START="0.09723164703479889" LOG_EFFECT_SIZE="0.3038200627938092" MODIFIED="2012-11-30 10:13:08 -0500" MODIFIED_BY="[Empty name]" ORDER="81" O_E="0.0" SE="0.2427021160919868" STUDY_ID="STD-Friedmann-2011" TOTAL_1="201" TOTAL_2="207" VAR="0.058904317155528234" WEIGHT="6.177068952205365"/>
<DICH_DATA CI_END="26.633630812429786" CI_START="2.754956590098594" EFFECT_SIZE="8.565891472868216" ESTIMABLE="YES" EVENTS_1="52" EVENTS_2="3" LOG_CI_END="1.4254303753881425" LOG_CI_START="0.44011476005561845" LOG_EFFECT_SIZE="0.9327725677218806" MODIFIED="2012-11-30 10:12:56 -0500" MODIFIED_BY="[Empty name]" ORDER="82" O_E="0.0" SE="0.5787792698372821" STUDY_ID="STD-Hartrick-2009" TOTAL_1="172" TOTAL_2="85" VAR="0.3349854431933775" WEIGHT="3.0023572408923194"/>
<DICH_DATA CI_END="37.0484918766615" CI_START="2.2386889943192494" EFFECT_SIZE="9.107142857142858" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="2" LOG_CI_END="1.5687705339624562" LOG_CI_START="0.34999376422101586" LOG_EFFECT_SIZE="0.959382149091736" MODIFIED="2008-12-12 09:37:45 -0500" MODIFIED_BY="[Empty name]" ORDER="136" O_E="0.0" SE="0.7159155075884319" STUDY_ID="STD-Markenson-2005" TOTAL_1="56" TOTAL_2="51" VAR="0.5125350140056022" WEIGHT="2.256520159326858"/>
<DICH_DATA CI_END="16.11090271168218" CI_START="1.630513339189233" EFFECT_SIZE="5.125333333333334" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="3" LOG_CI_END="1.207119875100709" LOG_CI_START="0.21232435610890626" LOG_EFFECT_SIZE="0.7097221156048077" MODIFIED="2008-12-13 05:03:56 -0500" MODIFIED_BY="[Empty name]" ORDER="137" O_E="0.0" SE="0.5843478121730225" STUDY_ID="STD-Matsumoto-2005" TOTAL_1="125" TOTAL_2="62" VAR="0.34146236559139787" WEIGHT="2.9665878915148416"/>
<DICH_DATA CI_END="8.217117613001538" CI_START="2.9145862028776897" EFFECT_SIZE="4.8938223938223935" ESTIMABLE="YES" EVENTS_1="135" EVENTS_2="14" LOG_CI_END="0.9147195031488724" LOG_CI_START="0.464576904699371" LOG_EFFECT_SIZE="0.6896482039241217" MODIFIED="2012-11-30 10:12:47 -0500" MODIFIED_BY="[Empty name]" ORDER="83" O_E="0.0" SE="0.26441599057103604" STUDY_ID="STD-NCT00486811" TOTAL_1="333" TOTAL_2="169" VAR="0.06991581606966221" WEIGHT="5.927095672688519"/>
<DICH_DATA CI_END="36.18700292279748" CI_START="2.1933814468078725" EFFECT_SIZE="8.909090909090908" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="2" LOG_CI_END="1.5585526154930986" LOG_CI_START="0.3411141655754409" LOG_EFFECT_SIZE="0.9498333905342697" MODIFIED="2008-12-12 09:37:59 -0500" MODIFIED_BY="[Empty name]" ORDER="138" O_E="0.0" SE="0.715129371899152" STUDY_ID="STD-Zautra-2005" TOTAL_1="55" TOTAL_2="49" VAR="0.5114100185528757" WEIGHT="2.2600775871236976"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.1067764821877568" CI_END="9.680772184576432" CI_START="2.9259755968047374" DF="1" EFFECT_SIZE="5.322189696947746" ESTIMABLE="YES" EVENTS_1="225" EVENTS_2="12" I2="9.647519974104666" ID="CMP-001.04.07" LOG_CI_END="0.9859100000899456" LOG_CI_START="0.4662706997054784" LOG_EFFECT_SIZE="0.726090349897712" MODIFIED="2012-11-30 10:06:53 -0500" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.29278377816295575" P_Z="4.318575038236155E-8" STUDIES="2" TAU2="0.0228242952239777" TOTAL_1="521" TOTAL_2="153" WEIGHT="8.326855238549818" Z="5.47730294559584">
<NAME>Oxymorphone</NAME>
<DICH_DATA CI_END="8.337320916006282" CI_START="2.344674186329252" EFFECT_SIZE="4.421346077260056" ESTIMABLE="YES" EVENTS_1="122" EVENTS_2="9" LOG_CI_END="0.9210265184657676" LOG_CI_START="0.37008250210007126" LOG_EFFECT_SIZE="0.6455545102829194" MODIFIED="2008-12-12 09:38:25 -0500" MODIFIED_BY="[Empty name]" ORDER="139" O_E="0.0" SE="0.32362724243007496" STUDY_ID="STD-Kivitz-2006" TOTAL_1="279" TOTAL_2="91" VAR="0.10473459204289451" WEIGHT="5.254698332501029"/>
<DICH_DATA CI_END="26.78503703590014" CI_START="2.88863278340568" EFFECT_SIZE="8.796143250688706" ESTIMABLE="YES" EVENTS_1="103" EVENTS_2="3" LOG_CI_END="1.4278922512119934" LOG_CI_START="0.4606923357946712" LOG_EFFECT_SIZE="0.9442922935033324" MODIFIED="2008-12-13 05:03:51 -0500" MODIFIED_BY="[Empty name]" ORDER="140" O_E="0.0" SE="0.5681380180329317" STUDY_ID="STD-Matsumoto-2005" TOTAL_1="242" TOTAL_2="62" VAR="0.3227808075343878" WEIGHT="3.0721569060487885"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.3276876163610172" CI_END="3.997272016536873" CI_START="1.9010078984267862" DF="3" EFFECT_SIZE="2.7566003837330073" ESTIMABLE="YES" EVENTS_1="205" EVENTS_2="30" I2="0.0" ID="CMP-001.04.08" LOG_CI_END="0.6017637032416595" LOG_CI_START="0.27898392130313004" LOG_EFFECT_SIZE="0.44037381227239486" MODIFIED="2014-08-17 07:54:20 -0400" MODIFIED_BY="Anne Lawson" NO="8" P_CHI2="0.7225692557737157" P_Z="8.892028066892418E-8" STUDIES="4" TAU2="0.0" TOTAL_1="1294" TOTAL_2="497" WEIGHT="16.340390862102574" Z="5.348022770229577">
<NAME>Tapentadol</NAME>
<DICH_DATA CI_END="5.431348507003637" CI_START="1.5997471837596535" EFFECT_SIZE="2.947674418604651" ESTIMABLE="YES" EVENTS_1="66" EVENTS_2="11" LOG_CI_END="0.7349076705541044" LOG_CI_START="0.20405135429746962" LOG_EFFECT_SIZE="0.46947951242578706" MODIFIED="2012-11-30 10:14:42 -0500" MODIFIED_BY="[Empty name]" ORDER="84" O_E="0.0" SE="0.31182762795029306" STUDY_ID="STD-Afilalo-2010" TOTAL_1="344" TOTAL_2="169" VAR="0.0972364695531064" WEIGHT="5.386285161867824"/>
<DICH_DATA CI_END="13.465432151644238" CI_START="0.796729690764889" EFFECT_SIZE="3.275409836065574" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="2" LOG_CI_END="1.1292202959623634" LOG_CI_START="-0.09868899820397059" LOG_EFFECT_SIZE="0.5152656488791965" MODIFIED="2012-11-30 10:14:58 -0500" MODIFIED_BY="[Empty name]" ORDER="85" O_E="0.0" SE="0.7212799976423395" STUDY_ID="STD-Etropolski-2011" TOTAL_1="305" TOTAL_2="74" VAR="0.5202448349989334" WEIGHT="2.2324385346297166"/>
<DICH_DATA CI_END="14.160677124373096" CI_START="1.4512802552173811" EFFECT_SIZE="4.533333333333333" ESTIMABLE="YES" EVENTS_1="52" EVENTS_2="3" LOG_CI_END="1.151084020609954" LOG_CI_START="0.16175128669115624" LOG_EFFECT_SIZE="0.656417653650555" MODIFIED="2012-11-30 10:14:26 -0500" MODIFIED_BY="[Empty name]" ORDER="86" O_E="0.0" SE="0.5811389451799169" STUDY_ID="STD-Hartrick-2009" TOTAL_1="325" TOTAL_2="85" VAR="0.3377224736048265" WEIGHT="2.9871370569991402"/>
<DICH_DATA CI_END="3.9272359554309273" CI_START="1.30446636868886" EFFECT_SIZE="2.263392857142857" ESTIMABLE="YES" EVENTS_1="60" EVENTS_2="14" LOG_CI_END="0.5940869952513578" LOG_CI_START="0.11543288674698872" LOG_EFFECT_SIZE="0.3547599409991732" MODIFIED="2012-11-30 10:14:10 -0500" MODIFIED_BY="[Empty name]" ORDER="87" O_E="0.0" SE="0.28116379271151626" STUDY_ID="STD-NCT00486811" TOTAL_1="320" TOTAL_2="169" VAR="0.07905307833192447" WEIGHT="5.7345301086058935"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.23846552360793277" CI_END="13.564781011299297" CI_START="0.8288282972864751" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="3.3530395686092205" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-001.05" LOG_CI_END="1.1324127869400773" LOG_CI_START="-0.08153542996180163" LOG_EFFECT_SIZE="0.5254386784891378" METHOD="IV" MODIFIED="2014-08-17 07:54:37 -0400" MODIFIED_BY="Anne Lawson" NO="5" P_CHI2="0.6253166237960399" P_Q="0.6253166237960399" P_Z="0.0897571585302153" Q="0.23846552360793277" RANDOM="YES" SCALE="328.31" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="355" TOTAL_2="326" WEIGHT="100.0" Z="1.6966800915961495">
<NAME>Number of participants experiencing any serious adverse event</NAME>
<GROUP_LABEL_1>Opioids</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours opioids</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-001.05.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2008-12-12 09:41:33 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="83" TOTAL_2="75" WEIGHT="0.0" Z="0.0">
<NAME>Codeine</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2008-12-12 09:41:33 -0500" MODIFIED_BY="[Empty name]" ORDER="143" O_E="0.0" SE="0.0" STUDY_ID="STD-Kjaersgaard_x002d_Andersen-1990" TOTAL_1="83" TOTAL_2="75" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="13.60388411719791" CI_START="0.5671945832706328" DF="0" EFFECT_SIZE="2.7777777777777777" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="2" I2="0.0" ID="CMP-001.05.02" LOG_CI_END="1.1336629237990667" LOG_CI_START="-0.2462679253336414" LOG_EFFECT_SIZE="0.44369749923271273" MODIFIED="2008-12-12 09:41:23 -0500" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.2075258071797036" STUDIES="1" TAU2="0.0" TOTAL_1="216" TOTAL_2="200" WEIGHT="77.39014774541387" Z="1.2603981120839087">
<NAME>Fentanyl</NAME>
<DICH_DATA CI_END="13.60388411719791" CI_START="0.5671945832706328" EFFECT_SIZE="2.7777777777777777" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="2" LOG_CI_END="1.1336629237990667" LOG_CI_START="-0.2462679253336414" LOG_EFFECT_SIZE="0.44369749923271273" MODIFIED="2008-12-12 09:41:23 -0500" MODIFIED_BY="[Empty name]" ORDER="142" O_E="0.0" SE="0.8105782115484211" STUDY_ID="STD-Langford-2006" TOTAL_1="216" TOTAL_2="200" VAR="0.657037037037037" WEIGHT="77.39014774541387"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="120.70574812046438" CI_START="0.33785091841841086" DF="0" EFFECT_SIZE="6.385964912280702" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" I2="0.0" ID="CMP-001.05.03" LOG_CI_END="2.0817279520986594" LOG_CI_START="-0.4712748961455304" LOG_EFFECT_SIZE="0.8052265279765646" MODIFIED="2008-12-12 09:41:02 -0500" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.216324890377546" STUDIES="1" TAU2="0.0" TOTAL_1="56" TOTAL_2="51" WEIGHT="22.609852254586126" Z="1.236359759892714">
<NAME>Oxycodone</NAME>
<DICH_DATA CI_END="120.70574812046438" CI_START="0.33785091841841086" EFFECT_SIZE="6.385964912280702" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="2.0817279520986594" LOG_CI_START="-0.4712748961455304" LOG_EFFECT_SIZE="0.8052265279765646" MODIFIED="2008-12-12 09:41:02 -0500" MODIFIED_BY="[Empty name]" ORDER="141" O_E="0.0" SE="1.4996465106265522" STUDY_ID="STD-Markenson-2005" TOTAL_1="56" TOTAL_2="51" VAR="2.2489396568343936" WEIGHT="22.609852254586126"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<IV_OUTCOME CHI2="2.417683991618074" CI_END="3.768831155215528" CI_START="2.023541090062668" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_SIZE="2.7615909733497777" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.06" LOG_CI_END="0.5762066813602613" LOG_CI_START="0.30611202760887735" LOG_DATA="YES" LOG_EFFECT_SIZE="0.44115935448456933" MODIFIED="2014-08-17 07:55:07 -0400" MODIFIED_BY="Anne Lawson" NO="6" P_CHI2="0.490351448058009" P_Q="0.490351448058009" P_Z="1.5273499702205264E-10" Q="2.417683991618074" RANDOM="YES" SCALE="100.0" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="397" TOTAL_2="255" WEIGHT="100.0" Z="6.402618002417713">
<NAME>Withdrawal symptoms</NAME>
<GROUP_LABEL_1>Opioids</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours opioids</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Odds Ratio</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="0.0" CI_END="7.813839980976964" CI_START="0.6065934280144555" DF="0" EFFECT_SIZE="2.1771136810045597" ESTIMABLE="YES" I2="0.0" ID="CMP-001.06.01" LOG_CI_END="0.892864513096816" LOG_CI_START="-0.21710229925535615" LOG_EFFECT_SIZE="0.3378811069207299" MODIFIED="2014-08-17 07:54:53 -0400" MODIFIED_BY="Anne Lawson" NO="1" P_CHI2="1.0" P_Z="0.23277089901669257" STUDIES="1" TAU2="0.0" TOTAL_1="121" TOTAL_2="41" WEIGHT="5.9212307832229065" Z="1.1932515337423313">
<NAME>Oxycodone</NAME>
<IV_DATA CI_END="7.813839980976964" CI_START="0.6065934280144555" EFFECT_SIZE="2.1771136810045597" ESTIMABLE="YES" ESTIMATE="0.778" LOG_CI_END="0.892864513096816" LOG_CI_START="-0.21710229925535615" LOG_EFFECT_SIZE="0.3378811069207299" MODIFIED="2013-01-28 05:50:50 -0500" MODIFIED_BY="[Empty name]" ORDER="94" SE="0.652" STUDY_ID="STD-Afilalo-2010" TOTAL_1="121" TOTAL_2="41" WEIGHT="5.9212307832229065"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="0.0" CI_END="75.5247972473173" CI_START="0.12338311075852293" DF="0" EFFECT_SIZE="3.0526192726543444" ESTIMABLE="YES" I2="0.0" ID="CMP-001.06.02" LOG_CI_END="1.8780895680467482" LOG_CI_START="-0.90874428443869" LOG_EFFECT_SIZE="0.48467264180402914" MODIFIED="2014-08-17 07:55:00 -0400" MODIFIED_BY="Anne Lawson" NO="2" P_CHI2="1.0" P_Z="0.49540661177253387" STUDIES="1" TAU2="0.0" TOTAL_1="171" TOTAL_2="173" WEIGHT="0.9393118925068507" Z="0.681734880879658">
<NAME>Morphine</NAME>
<IV_DATA CI_END="75.5247972473173" CI_START="0.12338311075852293" EFFECT_SIZE="3.0526192726543444" ESTIMABLE="YES" ESTIMATE="1.116" LOG_CI_END="1.8780895680467482" LOG_CI_START="-0.90874428443869" LOG_EFFECT_SIZE="0.48467264180402914" MODIFIED="2013-01-28 05:25:55 -0500" MODIFIED_BY="[Empty name]" ORDER="95" SE="1.637" STUDY_ID="STD-Katz-2010" TOTAL_1="171" TOTAL_2="173" WEIGHT="0.9393118925068507"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="0.0" CI_END="3.973369459321586" CI_START="0.2466920540216048" DF="0" EFFECT_SIZE="0.9900498337491681" ESTIMABLE="YES" I2="0.0" ID="CMP-001.06.03" LOG_CI_END="0.5991589493203003" LOG_CI_START="-0.6078448389583654" LOG_EFFECT_SIZE="-0.004342944819032495" MODIFIED="2014-08-17 07:55:07 -0400" MODIFIED_BY="Anne Lawson" NO="3" P_CHI2="1.0" P_Z="0.9887467121668558" STUDIES="1" TAU2="0.0" TOTAL_1="105" TOTAL_2="41" WEIGHT="5.007427953058085" Z="0.014104372355430184">
<NAME>Tapentadol</NAME>
<IV_DATA CI_END="3.973369459321586" CI_START="0.2466920540216048" EFFECT_SIZE="0.9900498337491681" ESTIMABLE="YES" ESTIMATE="-0.01" LOG_CI_END="0.5991589493203003" LOG_CI_START="-0.6078448389583654" LOG_EFFECT_SIZE="-0.004342944819032495" MODIFIED="2013-01-28 05:50:38 -0500" MODIFIED_BY="[Empty name]" ORDER="92" SE="0.709" STUDY_ID="STD-Afilalo-2010" TOTAL_1="105" TOTAL_2="41" WEIGHT="5.007427953058085"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="0.0" CI_END="4.138088281298189" CI_START="2.1335048280451585" DF="0" EFFECT_SIZE="2.97130128513195" ESTIMABLE="YES" I2="0.0" ID="CMP-001.06.04" LOG_CI_END="0.616799751595952" LOG_CI_START="0.3290936299893305" LOG_EFFECT_SIZE="0.47294669079264123" MODIFIED="2013-01-28 05:25:07 -0500" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="1.1652860971124722E-10" STUDIES="1" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="88.13202937121216" Z="6.44378698224852">
<NAME>Fentanyl</NAME>
<IV_DATA CI_END="4.138088281298189" CI_START="2.1335048280451585" EFFECT_SIZE="2.97130128513195" ESTIMABLE="YES" ESTIMATE="1.089" LOG_CI_END="0.616799751595952" LOG_CI_START="0.3290936299893305" LOG_EFFECT_SIZE="0.47294669079264123" MODIFIED="2013-01-28 05:25:07 -0500" MODIFIED_BY="[Empty name]" ORDER="93" SE="0.169" STUDY_ID="STD-Langford-2006" TOTAL_1="0" TOTAL_2="0" WEIGHT="88.13202937121216"/>
</IV_SUBGROUP>
</IV_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2014-08-21 15:44:24 -0400" MODIFIED_BY="[Empty name]">
<FIGURE FILENAME="flowchart_small.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2014-08-17 07:56:11 -0400" MODIFIED_BY="Anne Lawson" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Study flow chart.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAtUAAALYCAYAAACzLQ61AACAAElEQVR42uydB7geRfm35yQhPaSQ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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2014-08-21 15:44:24 -0400" MODIFIED_BY="[Empty name]" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>Methodological characteristics of included trials. (+) indicates low risk of bias, (?) unclear, and (-) a high risk of bias on a specific item.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAeEAAAOvCAIAAAB05etsAABPlklEQVR42u2dv07rSrv/LSEhihSr
4Aq4hlTIooKKe2KXLiKxytwF4hKO4JwSqOgQZydHQJFisXd3eHeUn01erZ+PPTMe2/Pfn6+spSwn
fBkmM588fjKeJ8sQQgiFrB1CCKHwBKMRQghGI4QQgtEIIQSjEUIIwWiEEILRMBohhGA0QgghGI0Q
QjAaIYQQjEYIoQipauhGbhiNEEImAU0cjYKIDugQhGA0CojOOicRQmbnBYxGowYcgwchxeUm+WiE
EJoA9OkIpB9QM2YQgtEoXEA3HiCEBFQ19O06jEYwGiHzM0VxBkYjGI0QjEaTvIID0AjBaIQQijua
IR+NEEKTIT4dgfpGBwwbhGA0Cmig1B8wZhASzhHuM0RBMBpMI0QcjWA0QrHOFMUZGI2sY5oxg/4P
QRgPkiwHuQ6EUBAxIxix1A8wGiFkhke/YQJSYDRyPQ+NX8EhYkYuL2A0QshFlEc/KKBMPhohhIay
z/R1IYxGoYxpOgSlFO0GO1OYb8hPdICS/PyOZWBENHphNILRyMzYiOv+plgGMIxGQ8Y0YwZFzWir
65S4hwX5H80MGxR7HB1LeM5kQwgZ/iDnEwtGI4TQcIbaznXAaIQQiuCSgnw0QigsHoEUK51MRyCE
Jv4BA6MRYxqhUAZz/YHVhXfkOpDTMY1QJ5iiY7S9Ec694AhGo+DGRhT3sLhh9I49lRCYRjB6JKZt
b7EEo5Hri1mGDZJhiHtY2PcOIRTuJzdIsdLJdARCaGofLTAapRw00SEo0mEsfGzWGUYjnyPb6ohE
CXx+hzw23DDa/IJrBhmC0Wjk2IiiDguMRjB6bBRGb0fN6MAxDaPRVK5nDXrqnEQw2sYwNr9IjnvB
UcKxuaU4HbnENG+clQ8VOgIhhGA0ijVEclO3gtGIEIxG4V4mNx6gyDjCF78wGnknqeIMjGZsIBiN
/IdIxpd2wGgYnV7MYcoZRiP/87A+CBmNDA8EoxFCEVxjIRiNBsZKjBmUwEdLFM4wGg28mLVappMO
R9GFGtwLjtJkdFw78qDONzGiPZXqDTZyL7gNZxiNBka7Nqa3jegGuQR0+O9gsLVlYTRihiPeQbvB
vg1nGI24UkZ8ygZ//UpHIN2xQtYYKeNHxgaMRsRKCI0NNdg/GsFoLU/ugEB+h/Qu7EV4TAlEHI0m
9ynLfh0o/YtEOgSlEUTDaISgP5rQqLOS5uYNQ+lFNMgL7ECKle6lI1CvGWhj/2gYneqHLoLRKJ1Z
zWgE046Dj52FdR1mtwGB0SjNCB3B6M4WGl+nZNyZKYH8xx0osc/aiD5FYDRKLTJifTRiPMNoBKMR
chr+B+sMoxGMRiaRxJcKVrqXjkAe4w6UzEc4n+IwGk0iEKNPIgV0/UwUO/1bKi3Evnco5RmOYHS8
o446LMj/sLZUzxAlcyUU/jsLo1HKgDY+FhmBCEzDaBQoo1kSgNQDw03sTz4awWgE74aEojaaTa4D
JTvPAXTUF/Wx8K7haXwTAhiN0PAojA6Bdw6GAflolOYMNz4c2T86XhjZxrTL5Eyw36/AaDRwtpga
OTDa1zsYPu8QjEb+MxIwGqV0bUE+GkF/NLkh4SY4CNOZWYHQ5IJHs3kqZyS1uoSZfDRCKBRA2w4k
7QWkE4QVjEaeZyDfOMXOaHskhdEwGiEYbfi63up91ebZRx0WlNrnuYX8HbGSy3fQeCfH+H5FFPvD
aORtHjqIwhCC0QhGTy4K4x2UmdvLG9iO/WE0YpKjNN9BB99GWkrRkI9GSU3v6NbAIjfvYFyMju6K
EEaj4II7BmSk72BEjLa3Vx/3giMYjQIN0m28fc5uBTR14yX3GaJQLpajcEb0s8u8BHE0ItpFvIMw
GiFmOO+gtqeb75NtXL1FgWkYjfwz2tIaWBT7p2yM1ejJRyOfE8Z2oESEHuM7GCOj43vXGL6IeYiM
xIxRrLyG0QgxD6f4Ju7sZGPtOdvIsJl1htFIa/pFuv8kkn0cTrwiZUT33TArUOKX4XSFMyrBaBiN
griYDX8esgGISyrtbH6fzB4jMBoNmScmN/Sy49z+RTvu2rDGaF+BQoCfKzv2vUMJTA9a6/HjNuou
Yl0HQgnyCLm/2ILRMBqlMw+5z5BrLPfoJ9eB0pyH9qoWsT7a5ZtIzVlLfwW1slAQjN4Fv4871Wxd
fhYm8PUjjEbMcM/sYMdke+9gjJ+FVu+NNOgMo5HnK+Wd/d2awPSOnJKrKy3jzjAapU8lGN3+cGXW
R/ZxQkegvryLMVzifbQxKtzs5TLZzxXGLvKPaXtZFJTGkGNvUmYF6heQskdw1G9iLJ3M2IDRKPF5
yNq7qHkHo2E0SnkeMrAT4J3VuwHrvyJYZxiN/F8pW1pvwMAmJvUYGbA3KWKGg+n0Y1IYDaORtzGt
drB0NwFvZVy8Y49/Bi7yOaaFw48xydhwcFVku5qt4VCDcYb8XikT6jqGaaQ7F7KuA6F0YESuwxlJ
nd1lDqMRQjA60Es3U+k1S5/flpxhNPI5YRCMRjAaTe4akz3+HWck6GcYjZJlNDuIJhahW72V33jS
Y8d9hghME+327ZCoGb2LoZIO66NRsviwdzeBg2bH8hFoe31xLGvvHFQdhNEIBRT4hzzUG20zvjWK
m2g3lmpnMBqhUUE6jI4rIxHjlRD3GaJkSbqLZ3e6uOqCW52MrL2Le97REcj7taHVwJw1YTtqzjr5
OLS1UwIMQh6jMEYgEg4J25+y9j65za4RhNHIcxxNtCvrauam03xCkLBmSqCBMI2RelyvGN+hIuqc
Uru1xiOP8c4wGk0oMp349UojjWCph6O4y5x8NEIDgw5L15swOuo7TZgddAQaeFUb+NV9vF1tI9EB
o3c28zOWnGE0GnU9a7CqodUMLOjfWd5FyHY1W+JohIbESiEzmgg9yas3GI2QU0bbi8LSuPuZ6Rld
P5PrQEGM6fCpZ7WWeRSlr92PjYg+CI2HGpacYTSa3OeKKYZOfAmKm+sV2/ttse8dQkld3dveQTRG
TMe1lwuMRihlJDnYQdRBnnQX7ao+S5imVhZCTueh7Tp4ZCTUHT7Zj3CLH9uQAhFKT6STY/m+l91l
YTQK4kp5x2ozJ70R432GMfbzjrV3KLEoLNKas27qtwZ+N2C80a6DbyOJoxGM9hbfcW+ky09ZG78I
RiMY7X/CwOj0YtIJYhpGI895A9urzaxOb9sb1MWS94/xU9bqztTkoxHqPU9sfLTEEuraDhudff82
3cHMrEYo+alOJ8BoNJVJzqoA4wR0UAmbma4efmE6w2jkjUpeMh6T/VxxSSUbbd6FvTudPWcYjZJl
tL0GR30veERjI+rqjuyphDxHYVHEdzGyNYEVwTAaRqMEI3QHO8RHtK9xRJiOkdE79r1DKISIJrov
32JcEezyGmu616+QAnmPHLmzDiohGI0CpZKlq85IOwTZvqqA0QhGhxj727ukiHHtXcjO7B8No1H6
mI4rCrN9D4uDb/YcOIc/Now7w2jkP3K0fZ8CCYpIGe1sJId8fxOMRqGwI676IPaq0sR4VWFpTXeM
F4XsH41g9PDQJpY21xtvL4QMPzJFMBoFlJGIce0de/w7GHLOkh5hOsNolGy0C6PTCw4svYPsqYRg
tJ9ZHd2ddc5qkkWxO509WLNfB4LRYTU7ooDUUoWXSHfVEKLZ1G7dMBqleclp78Jzx9o7Jx9XsTDa
zSaI7KmEkGd2GI+/bFcsjetTlhy6i9iIjkDpMXoX7f5E8TY43r3FYTRKKtEx8drPzrIoNr4ls91m
q/1sqW9D/gYVRqPgJk90n1VWi/iN73DbbY6xbg7fGSIwzd8+fELGGJPG5QyjEZwaFejRvbFfWwQ+
NmA0Sn8eTjwej5FK0X0WRlrvxsp2ejAIpToPbeQQHNxJHHW3T/zz28pnCR2B0puKMe6q4XIyThnT
7E2K0s91WN0ZfbKMJpR2MzYiwjSMRkNG3sR3p9tZyKI4WCHHF7NuIgP2JkVBXHJGVGU1ogbHPjzg
ia2PEzoCeWQ08V0ygLY9NiZYgZdZgTyTNOoIPfyVWy7fwSi+QaXmLELhRugTjMJcOke0yoV1HQgF
x4649suPyHlnM+8PnWA06h2T7qztE0bdqR0VD5xcCUUUUMNo5J930bU5upym1c9Cl9dYE0x6wGiU
LKN3rAmLPNqF0TAaJZ43QLFHu4wHGI08XylTGRZG64fnUazKZ987lPgMD3lAshosjWiXe1gQCiKi
sTS3Ld1bEZ2zg2gXRsNo1HvwTXzMOFt3EYWz+66G0Qh1ADqKjARVVmNPR9j+E8hHIxgd1qxmnDv7
UIwF0zH1LYMMpcfoSPfqi3dPpYiuBsh1oGQ/zyMNoic7w2N3dpaaZ987hJxOxUgjR5x9fX4H6wyj
UbKzhQjdGUmp0mA9gqEjEIwOhEoxOju4tGLfO4TSvPC0tJ8qcj827N3gA6MR6hcxmZ0klJ21iqEY
7zSB0WgSMI0lBIPRyVxgsT4aIdfhBoyGpPqRQRQxB2vvUGqM5luyZC6t4t1TKVhnxi7yPKwjXV3L
tkppXGPBaJRy0DRZRu8k6w2MIy8W5xiRGgumYTQKbkDHe5+hkfuJo3PeRVi92+paFPLRKClG7xK6
Y3uajKbOi4vrVxiE0psn7iN0GzFp+M4ABEajYAZKbMsk2D869s9ve3eKssc/QloTO6JdIpHjz297
K9zZPxqhyYFpys62w3MYDaORt2tDdh+O3RlGw2gUIpVCzki43+tn4owma2zPGUaj4OKOSDtkss7s
i+Li+pWOQGQkRl4BTNkZRsNoFMxYiW0HMt44Z5+FZtdcR5cHs+QMo1FYM9zqMgaGenSf34g+RQlG
YbZbS3yXzKgzfsnFug7kOUQim4mEIySWCN1qFsWGM4xGQwIE4/loS7Ode8Hdf5ZHGu3aazO5DhT3
tWFcbY4uCts5vzOevcVhNILR/tvs4KoiImdLcbTt3qCeIUrzYjaijEQyO1MH7uxmD/5p3ikKoxER
OowOlHcu30EYjVA6jN6xjwSYduUMo9Hwy8+I2ME4dzkwJn5nPPlolFTQ4aDNrLxmEEb/Ecjbj2B0
mFcVU97jH0zDaBTE9LC9+sLBDvFRdLKDdIeDXxR+m806w2g0MASL4j4F46W1YbTjz8J4P79NOcNo
FFx4Hl3F8Yk7x5j3h9EIpcxo1hvAaBiNIgCTJWcbbd6xqMPh2MCZeobIc9wRVzqCtXdcY0X/+cdo
QFzP6nuyx78bkuIMo5Fn3lE9IKUURxT0Z49/NAlMxzJmKA3lJSMR/jvInkoIETmm74zcDTk6AqV3
pYw8vpVTbjO5DuRtNDu7wiXRQa5jF+dmquQ6kM8ZWF8hYHVa2pgqxm8G2ZkuEBWj887+7Ys2fhGM
Rsky2mqhUtt7Hplax6Z+PB1nq2Cy/YvY4x8lG0dbQrOD6Qejbbyb9tZ028Mfe/wjGN17HsLoeONo
Z6Eo9xkiRBwNo2E0jEbRDRHLK+QcXG9OdhUzzlE7w2gU4kcC/YAQjEYIIRiNEEIIRiOEEIxGCCEE
oxFCCMFotFOuGUIIuRGMRipG44wzzmE6w2jEbMEZZxiNYDTOOOMMoxFjGmecYTSC0TjjjDOMRjAa
Z5xhNIyG0eoX/PrXr2JV5E/5j//8kf1HNrufzR/mf/z3H5uvDc4GnbfbX5+fxcdHvl7/+PPPbLWa
vb/Pf/36Y7sNt83/+vVrVRRPef6fP378R5bdz2YP8/l///HH12aKbbbhDKNRx8hbvi2P/+u4nCTt
o5w8P//nJ85GnP/+e7leH5dobh8lsv/6K8Q2vy2X/3V8LDLOSkj9z89ptdmSM4xGqvFRhi3CeVI/
ytfgPNK5DJaFdK4f5WuCanMZHnYZZ+VrJtJme84wGknHRxnLdE6V/SGLa3DWcS4j6E5A7w9ZNO2+
zWXMqGecyeLHlNpszxlGm6db485Odd/q97zwhlHZXaSdrdJpxq9//ZJdbAovPz/+9wPnAc7b7a96
iuPuLjs7y46OquPyMnt8bCY9/vnHf5v/9euX7KJeeJn/vx8pt9meM4w2A2h1gTgjjBb+CkWROkUt
V+FvFJ4sVoXmVFFce+Lc6fz5WdQpfHJSvX23t9nNTfXg9FQr4+G4zaui6GMsvsZPps32nGG0YUYL
y6e26alma+d7oWa0sHjrMEbnT7lgfO0lGnrzhznOA5w/PnJhWuPlpfI+PGyef3/33+anPO9FpYd5
ym225wyjLcbRigf6zw5gdOd/9Rm9X/CkP1tm9zOcBzjvl9k1jufn7Py88r6+bj61Wvlv835hmf5x
P0u5zfacYbSxTLQmmsczWhGDG2e0eJ7U1Rp9OA9wFgbRFxeV5dWV+JtD721uc+e4wzjlNttzhtFj
Gd3e+7UTvp2vD4fRRLse4+iDg8r49VUAaOJo4mhkJY4en+vQJy/56ATy0bKDfDT5aNQP0LLvDxUP
BjBavWLEBqNZfeHGubGuY3/spX8nC+s6PLaZdR2JMLpOZ81VH+q8yo710Uk4N9ZHqxnN+mjWRyM+
cv6/uBvQjTP3GcbeZu4zRH4YvWNXDVfO7NcRe5vZrwP5YfQ+rhF/2/59sblYL3A24vy9790P+b53
Iba5jB9lqxrK8+vFtNpsyRlGo+E7+QqzgTgPdpbtHy3MQQfSZtmOycKsa/JttuEMoxEVMXDGOVxn
GI2YLTjjDKMRjMYZZ5xhNGJM44wzjEYwGmeccYbRCEbjjDOMhtEwGiHkVzAaEdHgjDNxNILROOOM
M4xGjGmccYbRCEbjjDPOMBrBaJxxxhlGI2YLzjjDaJQao2U7kG2+NjjjbMlZtofc12ZazjAade/k
KytfVE5LWS0MnHEe4/y2XMoKUJX4k1UzSdIZRiOqpeAclnOM1VKow4I8MJqqgzhTddCvM4wegjOd
2zf13wNhjXDF7+08uaMuOM7ROsdYvZu64EGHnAa7Tv0mqZneeKxopPC3CE8Wq0JzEiquanHGuZfz
qij6GIuzB8k4w2iTjN4/qP+30bGNFwh/pBevFeA2wuj8KReMr71EQ2/+MMcZ55HOT3nei3cP85Sd
YbRhRvelp4zRnUmPTvIaYbS4KrN8Hs7uZzjjPNJZVldbdtzPUnaG0Sbz0Z2PFRG3IgTWSXpYYrR4
BtbVGn044zzSuU204w7jlJ1htPlch4LjOozufC9cMpr4DmfiaOLoZBndmaNQpDg0V1/YZjR5UpzJ
R5OPTp/RA16giVHbjGa9Ac471nV4dYbRtvLRO/m6jgEQV/9S1kfjvGN9dKLOMBp1jA/uf8OZ+wz9
OsNo1DE+2EcCZ/fO7NcBo5Hu+NhHTOLv8b8vYxfrBc44G3cuI1PZeony/HoxIWcYjYbvESzMM+KM
sxFn2V7Mwnxuws4wGlERA2ecw3WG0YjZgjPOMBrBaJxxxhlGI8Y0zjjDaASjccYZZxiNYDTOOMNo
GA2jEUJ+BaMREQ3OOBNHIxiNM844w2jEmMYZZxiNYDTOOOMMoxGMxhlnnGE0YrbgjDOMRqkxerv9
9flZfHzk6/WPP//MVqvZ+/v8168/tttNsM6y/dg2X+E6x9gbsp3evjZTbLMNZxiNOkbe338v1+vj
Ehnto0TJX3/9DNB5+baUFXMqJ7ysMohf5xh74225lJWJKiElqzmSapstOcNopBofZRAnpEb9KF8T
lHOMlUdi7A17lUeo8AKjkdb4KCO7TnDsD1mU5945xgp+MfaGvQp+VEqE0d3A0uwT4WsGd6awQLi6
VSNPqtu83f6qX3rf3WVnZ9nRUXVcXmaPj82L8X/++fDuHGMl7Bh7w14lbCqOw+ge2O3sFmeMFrZq
5MnONn9+FnU6nJxU4+T2Nru5qR6cnmpdiTt2LlaF5vRWXC87do6xN1ZF0cdYfI2fTJvtOcPo7m5q
0K3RV+1nf59UvKzTTf122MCx8OTHRy683H55qZp9eNg8//4+9+6cP+WCObGXaLrMH/w7x9gbT3ne
i0oP85TbbM8ZRvfrJgUQG+TtZLSmm19G75d/NY7n5+z8vPobr6+bT61WM+/O4hrV8hk+u/fvHGNv
yKpfy477WcpttucMowemKdRUbZwUBteDGa0TnmteFnSeFwZ3FxfVaLm6En+j5d1ZPLfras0Y784x
9kabO8cdxim32Z4zjO7H6PZOr2MYrenmkdHC+O7goGrw66sAHCPjaCPOycTRgfcGcTRxdHD5aP3I
t28crZ+Pbi/V6MVoTfR35kllx/h89HjnlPLRIfcG+Wjy0UFgWvFdX2c+WtNNP9cxZrGHfo67rsZ6
g/2xl/4dFo6dE1jXEUVvsK7DjTOM7shpCM8rgKi5okP2W9Rr74Q1dTSXQneW5NFZt6tmx5j10Qad
E1gfHUVvsD7ajTOMRh3jg/sM3Thzn2HsbeY+Q+SH0Tv263DlzH4dsbeZ/TqQH0bv/r0f2w/5fmyL
AJ3LWEy8QuD7AnmxDtE5xt4o40fZqoby/HoxrTZbcobRaPi+xsLcaCDOst2HhRnMQJxj7A3ZjsnC
rGvybbbhDKMRFTFwxjlcZxiNmC044wyjEYzGGWecYTRiTOOMM4xGMBpnnHGG0QhG44wzjIbRMBoh
5FcwGhHR4IwzcTSC0TjjjDOMRoxpnHGG0QhG44wzzjAawWicccYZRiNmC844w2iUGqNl+7Ftt5tg
nWW7pm2+cI7DWbaH3NdmWs4wGunsa3ws39f4Z4DOy7elrORSiRJZ/Q6cw3F+Wy5lBahK/MmqmSTp
DKMRdVhwDss5xmop1GFBHhhNPUOcqTro13lajJZV0R6QddJ8pcGO1SwB3nlycF3wu7vs7Cw7OqqO
y8vs8dFYXXCDzjHWBce5kc+Nrno3dcHNh4qyx8YzuaY6Vthg/ZPD2vn5WdRZeXJSjZPb2+zmpnpw
eqqVl3DsXKwKTXAorsRx9ui8Koo+xuLsQTLOE2J0+w9sQK3RCepn62caPyXzUTxb/10678UARut7
1vXxkQuTDy8vVSMPD5vn39/n3p3zp1wwJ/YSTZf5A85hOT/leS/ePcxTdp40o9u0FUJtwLOyVwqf
7Yx/TTFa/QEgPC+sUf38nJ2fVz7X182nVquZd2dxJWk5O2b3OIflLKurLTvuZyk7w+jhbNVMZxvP
S3T+yMgG1yUMdS8uqtFydSX+fs+7s5gadbVmDM5BObeJdtxhnLIzjDbM6Ha42stHcyfZAYwe9h2p
MNo9OKia9/oqwOjIONqIMzEpcTRxdJr56PGMthGPq/8K24yWZY1lx/h89Hhncrvko8lHp4Bp/Wi0
89m+KezBuQ7Fx4ylXEdj9cX+2Ev/fhPHzqyRiN2ZdR3TZfROY320Jlt3ynUdndkMRVysWL8szISM
XDStHh+NVcxqko5ZH23QmbXGsTuzPnrSjEZ98/XcZ4gz9xn6dYbRqGN8sF8Hzu6d2a8DRiPd8bH7
9+50P+S70y0CdC6jPPHag+9L78Ua59Cdy8hUtl6iPL9eTMgZRqPhuzwLM8WBOMv2NRbmRnEO0Fm2
F7Mwn5uwM4xGVMTAGedwnWE0YrbgjDOMRjAaZ5xxhtGIMY0zzjAawWicccYZRiMYjTPOMBpGw2iE
kF/BaEREgzPOxNEIRuOMM84wGjGmccYZRiMYjTPOOMNoBKNxxhlnGI2YLTjjDKNRaoyW7W22+drg
jLMlZ9kecl+bcJ1l+zhut8OdYTTq3iNYVhipnJayKhs44zzG+W25lBWgKsEqq2bi1/l7P/Rj+X7o
A51hNKI+CM5hOcdYLcVeXSEYjaizhzP1DEc526vPOV1Gy27EtNEVas/2s+rS4J0nFQ69Wki9apx3
1AXXcG7Uub+7y87OsqOj6ri8zB4fh9e5nzqjh30n4IDR6tcIP04aj4XU7svoYlVoTkLFVS3OOPdy
XhVFH2NxXsKx8+dnUafwyUk1125vs5ub6sHpqVbGA0Zr9Ug9LK3/K4xYf7+gM7ZtA1TxrD7TFeBu
N2lAHJ0/5YKRu5doUM8f5jjjPNL5Kc97kfRh7t/54yMXpjVeXqr+ODxsnn9/n8NoA3G0LAGifoE6
4NV8dgyjDeY6xPWe5fNwdj/DGeeRzrK62rLjfubfWVjb/vk5Oz+v+uP6uvnUajWD0Qby0epQd9hJ
BToVwO1MelhitHgG1tUa1zjjPNK5zcrjDmP/zsIg+uKi8ry6En9zCKPNxNHGGS3LdSiyHx4ZTXyH
M3H04Dj64KDqjNdXAaCJo4Nm9JhchwLENhhNnhRn8tFj8tGyg3y0O0a7zEerF9jZYDTrDXDesa5D
w7mxrmN/7KV/JwuM7pGPli2N8LiuQ1ZTh/XROCfmnMD6aDWjWR/tPxJP6W/h/jecuc9Qx5n7DGG0
t7+FfSRwdu/Mfh0wGvX4vCkjJvH3+N+XsYv1AmecjTuXMa9sJUZ5fr0I0fl737sf8n3vBjrDaDR8
j2BhnhFnnI04y3Z5FmaKA3GW7R8tzEHDaOQ/b4MzzjiPdIbRiNmCM84wGsFonHHGGUYjxjTOOMNo
BKNxxhlnGI1gNM44w2gYDaMRQn4FoxERDc44E0cjGI0zzjjDaMSYxhlnGI1gNM444wyjEYzGGWec
YTRituCMM4xGqTFatpvXdrsJ1lm2H9vmizabbLNsD7mvzWaCo86GM4xGOrviHst3xf0ZoPPybSkr
5lTiT1YZhDb3dX5bLmUFqEpky6qZpDrqLDnDaOSnuoQ9Z3v1QWhzXTHWNInRGUYjD1Xa7Dnbq7NH
mxsRdHS1AWN0htE7WXXwvpc56p8d/yPCG0at1gVvVDu+u8vOzrKjo+q4vMweH4dXO7bnbK9eNW1u
5KDd1NiOYtTZc4bRA5HqntH1Fwh/qvFYSO2+jP78LOpj6+Skcri9zW5uqgenp1rXcY6di1WhCTtF
9oA2dzqviqJPk8UZj2RGnT1nGK0Vcv7un/ZJBTp1Yt76K3ttsNIJ7vavHhBHf3zkwou1l5eqeYeH
zfPv73PvzvlTLiDEXiJ4zB9o85A2P+V5L0Y/zOcJjzp7zjC6m9H1BzpwlL2y80dGBuw6Dn0ZLaxw
/PycnZ9Xf+D1dfOp1Wrm3Vlco1rOu9k9bR7SZlldbdlxP5slPOrsOcPoZj66V6yqA1zjjFbkN4wz
WhgaXFxUHXV1Jf4+xLuzmHR1tfhBmwe0uU3h444mZwmPOnvOMLpHHN2OlGVfM5rCundGC6ODg4Pq
T359FQy7kXGHEWfHMelk2+w4jg581NlzhtHDGT3mRxSM1ge0A0bLsmyyY3z+bryz+9zuNNvsPh8d
8qiz5wyjbeWjbTBavcDOBqMb31bvj7301+c7dna2RmLibXa2riOKUWfPGUZr4WzYug6Zj07yRLEm
pO3gbH20euSNWU9q0NnZWuOJt9nZ+ugoRp09ZxiNOsYH9xnSZu4z9OsMo1HH+GC/Dtose4r9Otw4
w2iks5vXD/luXosAncvIVLxe4jtdsFjTZjNtLqNp2RqP8vx6sZjUqLPkDKPR8F1xhZm1QJxlezEL
87m0ebCzbP9oYQ46+VFnwxlGIypi4IxzuM4wGjFbcMYZRiMYjTPOOMNoxJjGGWcYjWA0zjjjDKMR
jMYZZxgNo2E0QsivYDQiosEZZ+JoBKNxxhlnGI0Y0zjjDKMRjMYZZ5xhNILROOOMM4xGzBaccYbR
KDVGy3bz2m43wTrL9pDbfG0m2Bv2nGX73n1taLOZNsNopLMr7rF8V9yfATov35ayAlQlsmXVTFLt
DXvOb8ulrGhWiT9ZBRbaDKORMUZThyX23qAOS+xthtGIeobJ9gb1DGNv84QY3XnbpX4neOkudb1w
nRaOrAt+d5ednWVHR9VxeZk9Phqro2zQ2VmN7Sh6w56zs7rgE2/z5BgdoNWA3/j7sfDk73dU+Db3
+os+P4v62Do5qRxub7Obm+rB6anWdZxj52JVaAJakfFIpjfsOa+Kok83i7MHtBlG64aW9X87g9Y2
Jeuv1Al12z8lO6n+QxTgbrdhQBz98ZELL9ZeXqpGHh42z7+/z70750+5YLbtJZqI84d5wr1hz/kp
z3vx7mFOm4e0GUY38aoTtMqI3Muq03Ywow3mOoQVjp+fs/PzqqnX182nVquZd2dxXW05o2f3s4R7
w56zrBa47Lif0eYhbZ5uPnpADqFvtmFY/NsLprYZLQwNLi6qDry6En8f4t1ZTOe6WnMx4d6w59wm
2nFHN9PmIW0mjlbFuQ2gD2b0SCuPjBZGBwcH1R/y+ioYdiPjOyPOjuPowHvDnrPjmHSybYbR3bgc
/K2dqZBc8SfYZrQsyyY7xudJxzu7z0eH3Bv2nN3ndqfZZhg9hKGdEfGwn9JPlThjdOPb6v2xl/76
fMfOztZ1RNEb9pydrZGYeJthdHeCQvgF44Bcx8g4Wra42+X6aPXIG7Nu16Czs/XRUfSGPWdna40n
3uZpMRr1/QDbcZ9h/L3BPXuxtxlGo47xwX4dsfcGe1/E3mYYjXR28/oh381rEaBzGU2L13h8pzgW
68WkesOecxmZytZLlOfXC9psoM0wGg3fFVeYWQvEWbZ/tDAHnXxv2HOW7cUszOfSZhiNrDAaZ5xx
3lGHBcFonHHGGUYjZgvOOMNoBKNxxhlnGI0Y0zjjDKMRjMYZZ5xhNPLEaISQX8FoRESDM87E0QhG
44wzzjAaMaZxxhlGIxiNM844w2gEo3HGGWcYjZgtOOMMo1FqjJbtIbf52ox0lu0Ttt1uaHMUbZbt
Ife1maKzjX6G0ah7L2ZZAaoSJbJqJjrO3/vtHsv32/1JmwNv89tyKStAVeJPVs0kVWdL/QyjUWo1
TWizmzbbq2kSozN1WJAHRsdYG5A2u2mzvdqAMTpTzzAgeOn3lZHi3M33SVSqfPBJ9a92VmP77i47
O8uOjqrj8jJ7fIygLvjE22yvxnaMzvb6GUZ7YPTghFT78ciTnb+6WBWa4FBciQudPz+L+qg9OalG
4O1tdnNTPTg91bpCpM0e27wqij5NFmcPknG2188weiyj28Hp/nFjn5T2v/UfV4NY0STbjM6fcsHI
3Us0qOcPc03nj49ceBn48lJ5Hx42z7+/z2lzUG1+yvNevHuYp+xsr59h9ChGy2jYfoHsZOcDv4wW
19WWs2N2P9N0FtZOfn7Ozs8r7+vr5lOr1Yw2B9VmWV1t2XE/S9nZXj/DaC1G62whOJKbjRhc8zNj
wO/qbP//OSmkRl2tca3pLAw6Li4qy6sr8TcttDmoNreJdtzR5JSd7fUzjDaW6zDF6M73Yhij63QO
No4+OKiMX18FAzrYmHSybSaOdtPPMNpKrmNkHK14t9pLNUylNQLJk8qOkHO702wz+Wg3/QyjzTB6
ZBytmY/ujOiNg9vZeoP9sZf+yn/a7LHNrOtw088w2kyuQ0FD4VqO9gs6SSpLiKexPlo9psNcazzx
NrM+2k0/w2jUMT64Z482c5+h336G0ahjfLD3BW2WPcV+HW76GUaj7v3YxGsPvi+9F+vFYOfvfcJ+
yPcJW9DmwNtcRqay9RLl+fViWs6W+hlGo+H7Ggtzo72cZfvtCnN2tDnANsv2Yhbmc5N3ttHPMBpR
EQNnnMN1htGI2YIzzjAawWicccYZRiPGNM44w2gEo3HGGWcYjWA0zjjDaBgNoxFCfgWjERENzjgT
RyMYjTPOOMNoxJjGGWcYjWA0zjjjDKMRjMYZZ5xhNGK24IwzjEapMVq2m9d2uxnpLNvpbfMVrnOM
vWGvzbI95L42U2yzjXcQRiOdXXGP5bvi/hzsvHxbyspElUNcVnPEr3OMvWGvzW/LpawAVYk/WTWT
VNts6R2E0Si1yiPUYXHT5hhrmthrs713EEajpCr4Uc/QTZtjrA1or8323kEY7Y566vdAx1C/2rfw
TN+64I1qx3d32dlZdnRUHZeX2eNjiJWwndXYjqI37LXZWY3tKNps7x2E0e4Yre7hzv6vv+D3Y+HJ
3+9o5493NuDzs6jPh5OTyvb2Nru5qR6cnmpdewqdi1WhOaAVV4iOnWPsDXttXhVFnyaLswfJtNne
OwijHTFaHfwO2GClE9xGGP3xkQsvMF9equYdHjbPv7/PNZ3zp1wwdvcSjen5g3/nGHvDXpuf8rwX
7x7mKbfZ3jsIo10wWgeXw4Ju9cfAeEYLKxw/P2fn59WAub5uPrVazTSdxdWv5WN6du/fOcbesNdm
WV1t2XE/S7nN9t5BGG2d0QNoq5+5ts1oYThzcVGNlqsr8Xc4ms7i0VxXa1h7d46xN+y1uU2e444m
p9xme+8gjLbLaBmm2wmNToZ6YbQwojk4qJr9+iqYKhOMowPvDXttdhxHB95m4uik8tHqXEevrxZt
M1qWGZQd08xHh9wb9trsPh8dcpvJR0fPaBmOezFavcDOBqMb37Dvj7307ylIdV1HFL1hr83O1nVE
0WbWdaTAaCGd1Us7ZOmR9jI7N+uj1bNlauujo+gNe212tj46ijazPhp5+ETZi/sMY+8N7jN002bu
M0R+GL1jv474e4P9Oty0mf06kB9G7/69A9kP+Q5ki8HOZfQh/k78+5JwsQ7ROcbesNfmMjKVrZco
z68X02qzpXcQRqPhO/kKs4G9nGX77QpzdoE4x9gb9tos24tZmM9Nvs023kEYjaiIgTPO4TrDaMRs
wRlnGI1gNM444wyjEWMaZ5xhNILROOOMM4xGMBpnnGE0jIbRCCG/gtGIiAZnnImjEYzGGWecYTRi
TOOMM4xGMBpnnHGG0QhG44wzzjAaMVtwxhlGo9QYLdvNa/O1wXnizrI95L42U2yzDWcYjbp3xZWV
Aionj6yuBM5TcH5bLmUFqEpIyaqZpNpmS84wGqVWLQVnN84x1jSx12Z7zjAaJVV1EGc3zjHWBrTX
ZnvOMNou6Rr1v2Wv1+l/db3wYSfV4yPG6t04u3GOsca2vTbbc4bRdhmt36udr6y/QEj2ASc7G1Cs
Cs2porj2xDlJ51VR9DEWX+Mn02Z7zjDaIqPbj2VnBmywMobR+h8S+VMuGF97iYbe/GGO80Scn/K8
F5Ue5im32Z4zjLbFaGFAraB2rwB8MKP75jrEFY7ls2V2P8N5Is6yutqy436WcpvtOcNoK4yWZaUV
aNZntDpUV5xUx9Tik8J5Uldr9OE8Eec2d447jFNusz1nGG2e0UJM92K0ZhDtIB9N5IgzcTRx9ITy
0TqM1ge0A0aTgcWZfDT56GQZrYPIXoxWpFB2rOvAmXUd/trMuo5YGa34tlCYL1as65A9xfponL04
sz7ajTOMRh3jgzvrcOY+Q7/OMBp1jA92qMBZ9hT7dbhxhtGoewcy8bft3xebi/UC58k6l/GjbFVD
eX69mFabLTnDaDR8J19hNhDnSTnLdkwWZl2Tb7MNZxiNqIiBM87hOsNoxGzBGWcYjWA0zjjjDKMR
YxpnnGE0gtE444wzjEYwGmecYTSMhtEIIb+C0YiIBmeciaMRjMYZZ5xhNGJM44wzjEYwGmeccYbR
CEbjjDPOMBoxW3DGGUaj1Bi93f76/Cw+PvL1+seff2ar1ez9ff7r1x/b7SZYZ9muaZuvcJ3pjbpk
e8h9bablDKNRx8j7++/len1cIqN9lCj566+fATov35aykkslSmT1O/w60xt1vS2XsgJUJf5k1UyS
dIbRSDU+yiBOSI36Ub4mKOcYa5rQG3XFWC2FOizIA6PLyK4THPtDFuW5d46xNiC90YhGo6s66L+e
oU7F63hDxb5/ha+/Wvgu2KsLvt3+ql96391lZ2fZ0VF1XF5mj4/Ni/F//vnw7hxjjW16o5HPja56
dxB1wdsTPplQccCHjZc/X4jd9mP9k51/0ednUafDyUnVgNvb7OamenB6qnUl7ti5WBWa4FBciTt2
pjfqWhVFH2Nx9iAZ54GMVjzWCd8aTFT8lEH/Xoz+fWZYq/T/QJ1fqvggsc3oj49ceLn98lI18vCw
ef79fe7dOX/KBXNiL9F0mT/4d6Y36nrK8168e5in7DyE0TJM9OKF5k/pv7Lzpzov89vYHdMqg92i
eTVjg9H75V+N4/k5Oz+vmnp93XxqtZp5dxZXkpazY3bv35neqEtWV1t23M9Sdu7NaFlWWgfow3ih
D5ROf/3fZePksF+qyejOj6VhXSoM7i4uKturK/E3Wt6dxdSoqzVjvDvTG3W1iXbcYZyycz9G61xu
Ny7hhbujal716/jLfqnCqm8LdYLfAX+gfrN1vjOUXQfYiKMPDirz11cBOEbG0Uack4mjJ9sbxNG2
8tGdJ/UBZCmMtR1HD/sD9Zu66780xVI+WnaMz0ePd04pHz3N3iAfbXhdh6kksr7VsOt64d+os6DQ
6h9oKtfhZl3H/thL/w4Lx84JrOuYeG+wrsMMo9Vftekse9BZraHvr/5WUz+ZrmC0jT+wV8i/870+
Ws2OMeujDTonsD564r3B+uiBjO51iW1Q3ADpRtxn6NeZ3qiL+wyNMdoSQHWKMCJnn4Xs1+HGmd6o
i/06jMXRKHlG7/69H9sP+X5siwCdyyhPvPbg+9J7sQ7Rmd5oRKay9RLl+fViQs4wGg3f11iYGw3E
WbavsTA3GogzvdHI8wr3YhbmcxN2htGIihg44xyuM4xGzBaccYbRCEbjjDPOMBoxpnHGGUYjGI0z
zjjDaASjccYZRsNoGI0Q8isYjYhocMaZOBrBaJxxxhlGI8Y0zjjDaASjccYZZxiNYDTOOOMMoxGz
BWecYTRKjdGyvc02XxuccbbkLNtD7mszLWcYjbr3CJYVRiqnpazKBs44j3F+Wy5lBahK/MmqmSTp
DKNRalU8cI7dmTosMBppjY8Yq+HhHLsz9Qxh9MBM02Dbvs7C148sAT6gLniMVaVxjt2ZuuAw2imj
TRXzrZ/5/Xjkyc52FqtCcxIqrmpxxrmX86oo+hiLswfJOMNorT5qR6D7x7JYtfGCOihlPsIf72zn
MEbr/+35Uy4YX3uJht78YY4zziOdn/K8F+8e5ik7w2itDIMQeW38aT6r80pLjO6b6xDXe5bPw9n9
DGecRzrL6mrLjvtZys4wul9eYkwA2ysFoX63hiVA1DG1+KRwBtbVGn044zzSuU204w7jlJ1hdL9c
R9SMHpCPJr7DmTiaODrWXIcXRrfT31YZTZ4UZ/LR5KOjYbR+HN0rH63+Rermsa4D5/ScWdcBo3cd
HSHKbLQXYMhAqX6lcF2H4sdlbVN47lgfjXPMzqyPhtFBfP0YS4O5/w1n7jP06wyjrYThKX2osI8E
zu6d2a8DRqMegX8ZMYm/x/++jF2sFzjjbNy5jExl6yXK8+vFhJxhNBq+R7Awz4gzzkacZXsxC/O5
CTvDaERFDJxxDtcZRiNmC844w2gEo3HGGWcYjRjTOOMMoxGMxhlnnGE0gtE44wyjYTSMRgj5FYxG
RDQ440wcjWA0zjjjDKMRYxpnnGE0gtE444wzjEYwGmeccYbRiNmCM84wGqXGaNneZpuvDc44W3KW
7SH3tZmWM4xG3XsEywojldNSVmUDZ5zHOL8tl7ICVCX+ZNVMknSG0Yj6IDiH5UwdFhiNtMYHdfZw
pp6hX+epMFpYadtUrtbZnzCmBLj6llPqVeNMXXDqgvsHnOy/4TO60fi+Jzv/CuGzxarQnISKq1qc
ce7lvCqKPsbi7EEyzjBaGnjuH9f/baNQ9iPDQl3Zjyvey2Hg1md0/pQLxtdeoqE3f5jjjPNI56c8
78W7h3nKzpPLdQjJq0CwjHQDfmTYjxtktHpvLeF5cb1n+Tyc3c9wxnmks6yutuy4n6XsDKN74K8z
h6AfwPbKUej87OAESMdJ4QysqzX6cMZ5pHObaMcdxik7w2jp92mdmZDOH+lMa7hkdPeUI77DmTia
ODquXIfipH50PDJHoX4XbTOaPCnO5KPJRztldOeDAYy2elL9FtrOdbDeAOcd6zq8OsPoXYPO+ivY
NDMYu57rOhQ4Fn7vN3LRtHp8sG4X5x3ro706T4jRSPMzrCHuf8OZ+wz9OsNo1DE+2EcCZ/fO7NcB
o5Hu+NhHTOLv8b8vYxfrBc44G3cuI1PZeony/HoxIWcYjYbvESzMM+KMsxFn2V7Mwnxuws4wGlER
A2ecw3WG0YjZgjPOMBrBaJxxxhlGI8Y0zjjDaASjccYZZxiNYDTOOMNoGA2jEUJ+BaMREQ3OOBNH
IxiNM844w2jEmMYZZxiNYDTOOOMMoxGMxhlnnGE0YrbgjDOMRqkxWra32eZrM9J5u/31+Vl8fOTr
9Y8//8xWq9n7+/zXrz+2202wbcbZjbNsD7mvzbScYTTq3iNYVhipnJayKhs6zn//vVyvj0s0t48S
2X/99TPANuPsxvltuZQVoCrxJ6tmkqQzjEZ+am2UwbKQzvWjfE1QbcbZjTN1WGA00hof9mrWlRF0
J6D3hyyapjZgqs7UM5wio4WVtsdknZwlgpvv09AS4OpbTh3Xft5uf9VTHHd32dlZdnRUHZeX2eNj
M+nxzz/U2KYuOHXBU2d0/W/s/JNDY3Sj8X1PDvtMKlaF5iRUXNUKnT8/izqFT06qt+P2Nru5qR6c
nmplPBy3GWc3zqui6GMszh4k4wyjxYGn+r9qOLZ/UBHhdv4iNU+HgVuf0flTLhhfe4mG3vxhrun8
8ZEL0xovL5X34WHz/Pv73HubcXbj/JTnvXj3ME/ZeXK5jva/nVDrxUHZ48G/yCCj1R8AwvPies/y
eTi7n2k675fZNY7n5+z8vPK+vm4+tVrNvLcZZzfOsrrasuN+lrIzjO7GX2f2Vj/JYITRI3+Lzl/0
/08KZ2BdrdGn6SwMoi8uKsurK/E3h97bjLMb5zbRjjuMU3aG0dLv0xSZkBgZ3T3lAoijDw4q49dX
AaCJo4mjiaPJdfQIn30xup3dtspo9/lo2UE+mnw0+eiprL1TPxiQRHbGaPXyQRu5DmfrOvbHXvp3
srBGIkln1nXAaGk2Q/0FoHCFxq7nojdh2kRnXYesps7IRdPq8eFsfbSa0ayPZn0066O5z3Dq4j5D
nLnPkPsMUXyM3rFfB87s1+HbGUaj7r3NxN/jf1/GLtaLwc7f+979kO97twiwzTi7cS4jU9l6ifL8
ejEhZxiNhu8RLMwz9nKW7R8tzEEH0mac3TjL9mIW5nMTdobRiIoYOOMcrjOMRswWnHGG0QhG44wz
zjAaMaZxxhlGIxiNM844w2gEo3HGGUbDaBiNEPIrGI2IaHDGmTgawWicccYZRiPGNM44w2gEo3HG
GWcYjWA0zjjjDKMRswVnnGE0So3Rst3ptttNsM6y/dg2X+E60xtuekO2O93XJkRnGI10dnk+lu/y
/DNA5+XbUlbMqUSJrDKIX2d6w01vvC2XstJWJVhldVI8OsNo5KdaCnVY6A33vUEdFpQUo+1VHaSe
Ib3hvjeoZzgVfnnprl7VvoVn+tYFb1TvvrvLzs6yo6PquLzMHh+HV++25xxjJWx6w01vUBc8ZUbX
+8dLdzUaoDgpbKHsleqTn59FfT6cnFS2t7fZzU314PRU69rTsXOxKjTBobgSd+xMb7jpjVVR9Gmy
OC/h2BlGj2W0Ap06Me/vV+qEupqMbniOYfTHRy68wHx5qRp5eNg8//4+9+6cP+WCObGXaLrMH/w7
0xtueuMpz3uR9GHu3xlG94hh2/8qKNl+gf4rO3MpOj9ihNHCit3Pz9n5edXs6+vmU6vVzLuzuEa1
nB2ze//O9Iab3pBV7JYd9zP/zjDaFqMHnNR/t3TIa4TRwnDm4qIaLVdX4u9wvDuLqVFXa8Z4d6Y3
3PRGm5XHHU327wyjnTK6vVGsLBkSCKOFEc3BQdW811fBVBkZRxtxTiZypDeM9wZxNIzuHTJrAncA
ea3mo2XH+Hz0eOeUMrD0htneIB+dOKM7HxhMgGhi1DajG9+w74+99O8pcOycwEoGesNSb7CuY4qM
riNVc0mcGqzCVRmyVMnO7fpo9WwZsz7aoHMCK4LpDUu9wfpolMLnUEPcZ+jGmd5w0xvcZ4hSY/SO
/TpcOdMbbnqD/TpQaoze/XsHsh/yHcgWATqXUZ547cH3pfdiHaIzveGmN8qYV7YSozy/XgTnDKPR
8J18hdnAQJxl+xoLc6OBONMbbnpDtsuzMFPs3RlGIypi4IxzuM4wGjFbcMYZRiMYjTPOOMNoxJjG
GWcYjWA0zjjjDKMRjMYZZxgNo2E0QsivYDQiosEZZ+JoBKNxxhlnGI0Y0zjjDKMRjMYZZ5xhNILR
OOOMM4xGzBaccYbRKDVGy3Yg2243wTrL9mPbfNFmk22W7fT2tdlMcNTZcIbRSGcn32P5Tr4/A3Re
vi1lxZxK/Mkqg9Dmvs5vy6WsTFSJbFnNkVRHnSVnGI2ow0KbhzjbqzwS46iz5wyjEfUMaXNAtQFj
HHX2nGG0tIOERbuFNbnbd3MKb+5U3PGp88penjq/pfOpRoXmu7vs7Cw7OqqOy8vs8dFYXXCDzs7q
VU+8zfYqYcc46uw5w+hmL8i6TPZYRtj2Y4VDG/2aP674KWEj+zL687Ooj62Tk8rh9ja7uakenJ5q
Xcc5di5WhSbsFNkD2tzpvCqKPk0WZzySGXX2nGF0s4M6UdgJZQeM1nmlsEl9Gf3xkQsv1l5eqgYf
HjbPv7/PvTvnT7mAEHuJ4DF/oM1D2vyU570Y/TCfJzzq7DnD6IGMNhhHK36vkLya0b2RXIewKvPz
c3Z+XjXj+rr51Go18+4srlEt593snjYPabOs+rXsuJ/NEh519pxh9E4BU1+MVuS+ZWkNS/loYWhw
cVH9uqsr8fch3p3FpKurxQ/aPKDNbQofdzQ5S3jU2XOG0TsdbtpjtCbBh+VPLMXRBwfVaHl9FQy7
kXGHEWfHMelk2+w4jg581NlzhtEDGW0qHy1bExIIo2VZNtkxPn833tl9bneabXafjw551NlzhtG7
Md/jmfrOMNg4uvFt9f7YS399vmNnZ2skJt5mZ+s6ohh19pxh9K4XeTVXN+8SXR+tHnlj1pMadHa2
1njibXa2PjqKUWfPGUajjvHBfYa0mfsM/TrDaNQxPtivgzbLnmK/DjfOMBrp7Ob1Q76b1yJA5zIy
Fa+X+E4XLNa02Uyby2hatsajPL9eLCY16iw5w2g0fFdcYWYtEGfZXszCfC5tHuws2z9amINOftTZ
cIbRiIoYOOMcrjOMRswWnHGG0QhG44wzzjAaMaZxxhlGIxiNM844w2gEo3HGGUbDaBiNEPIrGI2I
aHDGmTgawWicccYZRiPGNM44w2gEo3HGGWcYjWA0zjjjDKMRswVnnGE0So3Rst28tttNsM6yPeQ2
X7TZZJtl+959behnM22G0UhnV9xj+a64PwN0Xr4tZQWoymkpq2ZCm/s6vy2XsqJZJbJlFVjoZxiN
jDGaOiy0WfZUjHVYYuxnGI2oZ0ibJ1HPMMZ+htHSDuqswK24m3NAYW+hs+a72LepmuOjUe347i47
O8uOjqrj8jJ7fDRWR9mgs7Ma2xNvs7O64BPvZxjd7AVZl8keyxDZfjzMrc3ZzparzXud/Pws6mPr
5KT6Rbe32c1N9eD0VOs6zrFzsSo0J6HiqpY2dzqviqJPk8UZD/oZRveOozvx2gnlXozu7PbGK3UY
3eviQH3+4yMXXqy9vFS/8fCwef79fe7dOX/KBfNtL9E8nD/Q5iFtfsrzXox+mNPPQ9oMowcy2lQc
3bnllfrDQM1unR9XPyWscPz8nJ2fVw2+vm4+tVrNvDuL62rL5+HsnjYPabOsFrjsuJ/Rz0PaDKN3
Cpi6YbQ6p6wZF2umL/oyWhgaXFxUDbu6En8f4t1ZPAPrak1F2jygzW2mHXc0mX4e0mYYrQKrA0b3
TRPL/muJ0cLo4OCgGi2vr4JhNzKONuLsOFaabJsdx9GT7WcYPZDRpvLR4xkty5b0AnTfLJvsGJ+P
Hu/sPuc4zTa7z0dPs59h9E4z1WBpXceABMjgvPMARje+rd4fe+mvz3fs7Oy7+4m32dm6jon3M4ze
9SKv/uLiAeujdX6XDqNlwfUARjdWfapH3pj10Qadna2BnXibna2Pnng/w2jUMT64z5A2c5+h3zbD
aNQxPtivgzbLnmK/DjdthtFIZzevH/LdvBYBOpcRk/h7/O/L2MWaNptpcxlNy9Z4lOfXC/rZQJth
NBq+K64wsxaIs2yPYGGekTYPdpbtHy3MQdPPMBpZYTTOOOO8ow4LgtE444wzjEbMFpxxhtEIRuOM
M84wGjGmccYZRiMYjTPOOMNo5InRCCG/gtGIiAZnnImjEYzGGWecYTRiTOOMM4xGMBpnnHGG0QhG
44wzzjAaMVtwxhlGo9QYLdvNa7vdBOss29ts84VzHM72xoZsr76vTYhthtFIZ1fcY/muuD8DdF6+
LWWFkUqUyKps4ByOs72x8bZcygp9lciWVY3x2GYYjajDgnNYztSOgdFIa3xQzxBnajD6bTOMlnZQ
Z61uxd2cNuqCdzZggKd6fDSqHd/dZWdn2dFRdVxeZo+PxuqCG3S2V/sZZzfO9saGs1rmBtsMo5u9
IOsy2WMZzduPbZwU/tKRP17X52dRH1snJ1UX3d5mNzfVg9NTres4x87FqtAEh+JKHGePzvbGxqoo
+jRZnPFw3GYY3eygTsB1QtkLozs/ToYx+uMjF16svbxUA+bwsHn+/X3u3Tl/ygWzbS/RRJw/4ByW
s72x8ZTnvRj9MPffZhg9kNFBxdGDf3vn+BBWOH5+zs7PqwFzfd18arWaeXcW13uWs2N2j3NYzvbG
hqx+uey4n/lvM4xW5QpcMrozoTyA0TpJavX4EIYGFxeVydWV+PsQ785iatTVmos4B+Vsb2y0KXzc
0WT/bYbRKrA6YHSdpKbiaH3PYdHBwUFl/voqGHYj42gjzsSkScbRRsaG4zjaSJth9EBGW8029EV8
r4sDI/lo2TE+Hz3emdxuqvno8WPDfT56fJthtIqzUazr0Pz+0Mi6jv2xl/76fMfOrJGI3dne2HC2
rsNgm2H0rhd5ZR0lyzbYXh+tAK6N9dHqkTdmfbRBZ9Yax+5sb2w4Wx9tsM0wGnWMD+4zxJn7DP22
GUajjvHBfh04u3dmvw4YjXTHx+7fu3n9kO/mtQjQuYzyxGsPvi+9F2ucQ3e2NzbKaFq2xqM8v14E
12YYjYbviivMrAXiLNvXWJgbxTlAZ3tjQ7Z/tDAH7b3NMBpREQNnnMN1htGI2YIzzjAawWicccYZ
RiPGNM44w2gEo3HGGWcYjWA0zjjDaBgNoxFCfgWjERENzjgTRyMYjTPOOMNoxJjGGWcYjWA0zjjj
DKMRjMYZZ5xhNGK24IwzjEapMVq2m9d2uwnWWbYf2+YrXGd6oy7Z7nRfm2k5w2iksyvusXxX3J8B
Oi/flrJiTiVKZJVB/DrTG3W9LZey0lYl/mR1UpJ0htGIOiz+nemNuuxVS4nRGUYj6hl6dqY3GtGo
paqDMTrD6B4U07lrUzNpNaYBBk+qG9yodnx3l52dZUdH1XF5mT0+GqsLbtA5gUrYE+8Ne9W7Y3SG
0cMjTXWPGe/PuuHvxyNPdjb487Oo0+HkpBont7fZzU314PRU60rcsXOxKjTBobgSd+xMb9S1Koo+
xuLsQTLOMNoMo9shqvrZYaGue0Z/fOTCy+2Xl6qRh4fN8+/vc+/O+VMumBN7iabL/MG/M71R11Oe
9+LdwzxlZxhtgNFqJhrEqHtGCyscPz9n5+fVgLm+bj61Ws28O4trVMvZMbv370xv1CWr2C077mcp
O8NoA/nokYxW++i/zAajhcHdxUX1519dib/R8u4spkZdrRnj3ZneqKtNtOMO45SdYfTwOFrN7k44
arLeL6OF8d3BQdXs11cBOEbG0Uack4mjJ9sbxNEw2jyj+6Yjhr2yMyfuLB8tO8bno8c7p5SPnmZv
kI+G0RYZbTUf3T7peF3H/thL/w4Lx84JrOuYeG+wrgNGG2b0zsm6DkU23Nn6aDU7xqyPNuicwPro
ifcG66NhNOrxCcR9hm6c6Y26uM8QRqMe44P9Otw40xt1sV8HjEa642P37/3Yfsj3Y1sE6FxGeeK1
B9+X3ot1iM70RiMyla2XKM+vFxNyhtFo+L7GwtxoIM6yfY2FudFAnOmNRp5XuBezMJ+bsDOMRlTE
wBnncJ1hNGK24IwzjEYwGmeccYbRiDGNM84wGsFonHHGGUYjGI0zzjAaRsNohJBfwWhERIMzzsTR
CEbjjDPOMBoxpnHGGUYjGI0zzjjDaASjccYZZxiNmC044wyjUWqMlu3Htt1ugnWW7ce2+QrXOcbe
kO309rWZYj/bcIbRSGdf42P5vsY/A3Revi1lxZzKCS+rDOLXOcbeeFsuZWWiSmTLao6k2s+WnGE0
og6Lf+cYe8Ne5ZEY+9meM4xG1DP07Bxjb9ir4BdjP9tzhtFa/NLsIllJb81M1gB/l3XB7+6ys7Ps
6Kg6Li+zx0djdcENOidQFzyK3rBXCTvGfrbnDKP7YXFYL5nqWyF21Z8E6pOdjfz8LOpj6+SkasDt
bXZzUz04PdW6jnPsXKwKzemtuF527Bxjb6yKoo+xOOORTD/bc4bRQ+JWfRTu/9t+9vd5Yair+L2D
Ga0f7Nf18ZELL9ZeXqp2Hh42z7+/z70750+5YCbvJZrh8wf/zjH2xlOe92L0wzzlfrbnDKNtMbr+
QP+kLF6Wtcc2o4U1qp+fs/PzqoXX182nVquZd2dxjWr5DJ/d+3eOsTdk1a9lx/0s5X625wyjrTN6
wLOKd0vG6M5Pgr7OewlDg4uLyvbqSvx9iHdn8dyuqzXJvTvH2BttWh53GKfcz/acYXTcjJalRzpz
JmOig4ODyvz1VTDsRsYdRpyTiaMD741k4ujAxzOM1mW0Irnsl9G9Mhh9f1yWZZMd4/N3451TykeH
3Bsp5aNDHs8wul8oLWPrgHy0muA28tHqt1jn2+r9sZf++nzHzgms64iiNxJY1xHFeIbRupjWTCn0
Wteh8yOauY7OpdCdJXl0Vn2qR96Y9aQGnRNYHx1FbySwPjqK8Qyjo8mD+/qN3Gfoxpn7DGPvZ+4z
nFC07uW9YL8O787s1xF7P7NfB/IWuX/v5vVDvpvXIkDnMhYTrxD4vkBerEN0jrE3ymhatsajPL9e
TKufLTnDaDR8V1xhZi0QZ9nuw8IMZiDOMfaGbP9oYQ46+X624QyjERUxcMY5XGcYjZgtOOMMoxGM
xhlnnGE0YkzjjDOMRjAaZ5xxhtEIRuOMM4yG0TAaIeRXMBoR0eCMM3E0gtE444wzjEaMaZxxhtEI
RuOMM84wGsFonHHGGUYjZgvOOMNolBqjZbt5bbebYJ1lu6ZtvmizyTbL9r372kzR2UY/w2iksyvu
sXxX3J8BOi/flrKSSyX+ZPU7aHNf57flUlY0q8SfrAJLqs6W+hlGI+qw0OYhzvbqsMToTB0W5IHR
1DOkze7rGcboTD1DR5wSVtQOrXkjTw6uC353l52dZUdH1XF5mT0+GqujbNDZWVXpibfZXl3wGJ3t
9TOMlnbQ7/8G0jPCjw39k51/iPDZz8+iPrZOTqpxcnub3dxUD05Pta7jHDsXq0ITdorsAW3udF4V
RZ8mi7MHyTjb62cYrctonVhV+MqRP65u6jBw6zP64yMXXqy9vFSNPDxsnn9/n3t3zp9ywWzbSzQR
5w+0eUibn/K8F+8e5ik72+tnGN3dQfXO6eSg8JVjftwgo9V7awnPCyscPz9n5+eVz/V186nVaubd
WVxJWs672T1tHtJmWS1w2XE/S9nZXj/D6H75aHUmd2Q6QjMv0dm2YebCk8LQ4OKi6p+rK/H3Id6d
xaSrqzUXafOANreJdtzR5JSd7fUzjB4YqwqBHjKjuzGhHR0cHFR/8uurYNiNjKONODuOSSfbZuJo
N/0Mo/t9Z+j+pGYjLTFalmWTHePz0eOd3ed2p9lm8tFu+hlGj2W0yzi6fdJ2rqPxbfX+2Et/fb5j
Z2drJCbeZtZ1uOlnGD08H/37ZYNXwvVKfMtq6oxcNK0eH41Vn+qRN2Z9tEFnZ2uNJ95m1ke76WcY
jTrGB/cZ0mbuM/TbzzAadYwP9uugzbKn2K/DTT/DaKSzm9cP+W5eiwCdy8hUvF7iO12wWNNmM20u
I1PZeony/HoxLWdL/Qyj0fBdcYWZtUCcZXsxC/O5tHmws2wvZmE+N3lnG/0MoxEVMXDGOVxnGI2Y
LTjjDKMRjMYZZ5xhNGJM44wzjEYwGmeccYbRCEbjjDOMhtEwGiHkVzAaEdHgjDNxNILROOOMM4xG
jGmccYbRCEbjjDPOMBrBaJxxxhlGI2YLzjjDaJQao2W7eW23m5HOsp3eNl9TdKaf65LtTve1CdfZ
xjsIo5HOrrjH8l1xfw52Xr4tZWWiygkvqzmSqjP9XNfbcikrbVWCVVYnxa+zpXcQRqPUKo/E6Ew/
10UdFhiNtMZHjBX8YnSmnxtxLvUMYfRYomnexDkspaX+pSNPCn+7TrXju7vs7Cw7OqqOy8vs8THE
StgxOtPPjUxx7HXBDb6DMNp6JtfGj/x+rH+y85cKn/38LOpj6+SkGie3t9nNTfXg9FTrOk7oXKwK
zemtuF5Oxpl+rmtVFH2MxXkJx8723kEYbRjQ7UC1/bj+mvq/svhX8UuHgVuf0R8fufBi7eWlauTh
YfP8+/tc0zl/ygVzYi/RdJk/pOxMP9f1lOe9SPow9+9s7x2E0SYZPYCY9Z4fEPP2+o3qDwDheWGF
4+fn7Py88rm+bj61Ws00ncXVr+UzfHafsjP9XJesYrfsuJ/5d7b3DsJoW1kOfUYPdjaSAFGfFIYG
FxfVaLm6En8fouksntt1tWZMws70c11tVh53GPt3tvcOwmjDgG6Hq70YrbmT7ABG67RcMzo4OKia
9/oqGHbE0Qbj6Mn2czJxtJF3EEabZPSwXEev7/faTLfKaFmWTXaQjzabj55mP6eUjx7/DsJow0G0
IsssO6n+ceOfCr0Y3fi2en/spb8+n3Ud9PPU1nUYfAdh9EBAy9ZHNxZsyE4KX6Y43/6l7fPCF3ee
VI+PxqpP9chjfbSp9dET7+cE1kcbfAdhNOoYH9z/5saZfq6L+wxhNOoxPthHwo0z/VwX+3XAaKQ7
Pnb/3s3rh3w3r8Vg5zIWE68Q+L5AXqyn5Uw/N2Je2UqM8vx6EaKzpXcQRqPhu+IKM2u9nGW7Dwsz
mMk708+NDLJwl2dhpjgQZxvvIIxGVMTAGedwnWE0YrbgjDOMRjAaZ5xxhtGIMY0zzjAawWicccYZ
RiMYjTPOMBpGw2iEkF/BaIQQijaEoiMQQghGI4QQgtEIIQSjEUIIwWiEEILRCCGEYDRCCKF+jEYI
IRSm/h8hVzUcvA3hPQAAAABJRU5ErkJggg==
</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2014-08-21 15:44:24 -0400" MODIFIED_BY="[Empty name]" NO="3" REF_ID="CMP-001.01" SETTINGS="SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;SHOW_ROB_TABLE:NO;SHOW_MORE_DECIMALS:NO;SHOW_RAW_DATA_COLUMNS:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of 22 trials comparing the effects of any type of opioids and control (placebo or no intervention) on knee or hip pain. Values on x-axis denote standardised mean differences. The plot is stratified according to type of opioids. Matsumoto 2005, Hartrick 2009, Afilalo 2010, Etropolski 2011, and NCT00486811 contributed with two comparisons and the standard error was inflated and the number of participants in the placebo group was halved to avoid duplicate counting of participants when including both comparisons in the overall meta-analysis. Data relating to the 3, 3, 3, 2, 2, and 2 active intervention arms in Caldwell 2002, Chindalore 2005, Kivitz 2006, Matsumoto 2005, Hartrick 2009, and Etropolski 2011, respectively, were pooled.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAA5IAAASQCAMAAAC5wIClAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA
AMAAwMD/gADAwMD/gICA/4CAgP/g4OBAAAAAQAAAAECAgID///8AAAALCwsWFhYhISEsLCw3NzdC
QkJNTU1YWFhjY2Nubm55eXmEhISPj4+ampqlpaWwsLC7u7vGxsbR0dHc3Nzn5+cAAAAAADMAAGYA
AJkAAMwAAP8AMwAAMzMAM2YAM5kAM8wAM/8AZgAAZjMAZmYAZpkAZswAZv8AmQAAmTMAmWYAmZkA
mcwAmf8AzAAAzDMAzGYAzJkAzMwAzP8A/wAA/zMA/2YA/5kA/8wA//8zAAAzADMzAGYzAJkzAMwz
AP8zMwAzMzMzM2YzM5kzM8wzM/8zZgAzZjMzZmYzZpkzZswzZv8zmQAzmTMzmWYzmZkzmcwzmf8z
zAAzzDMzzGYzzJkzzMwzzP8z/wAz/zMz/2Yz/5kz/8wz//9mAABmADNmAGZmAJlmAMxmAP9mMwBm
MzNmM2ZmM5lmM8xmM/9mZgBmZjNmZmZmZplmZsxmZv9mmQBmmTNmmWZmmZlmmcxmmf9mzABmzDNm
zGZmzJlmzMxmzP9m/wBm/zNm/2Zm/5lm/8xm//+ZAACZADOZAGaZAJmZAMyZAP+ZMwCZMzOZM2aZ
M5mZM8yZM/+ZZgCZZjOZZmaZZpmZZsyZZv+ZmQCZmTOZmWaZmZmZmcyZmf+ZzACZzDOZzGaZzJmZ
zMyZzP+Z/wCZ/zOZ/2aZ/5mZ/8yZ///MAADMADPMAGbMAJnMAMzMAP/MMwDMMzPMM2bMM5nMM8zM
M//MZgDMZjPMZmbMZpnMZszMZv/MmQDMmTPMmWbMmZnMmczMmf/MzADMzDPMzGbMzJnMzMzMzP/M
/wDM/zPM/2bM/5nM/8zM////AAD/ADP/AGb/AJn/AMz/AP//MwD/MzP/M2b/M5n/M8z/M///ZgD/
ZjP/Zmb/Zpn/Zsz/Zv//mQD/mTP/mWb/mZn/mcz/mf//zAD/zDP/zGb/zJn/zMz/zP///wD//zP/
/2b//5n//8z///9BjlLGAACAAElEQVR42uy9e3RkV3kn+pWkOvVSS9rVEu7u2KbV3bFzCXCDWrS6
JfV4KDU4pCdhLa7hzkouPYY/HO4dJsxd6UWCw42BhAuehBm8VgLYZJbjeAiQZQjD0OCAJQx62F20
5Xsdh7tspJbsfqhBUh2pW6VSVUmqu/d57vM+px5SVen72a3a55xv77Nfv72/fc7+zhcigEAg6gct
WAUIBFISgUAgJREIpCRiPCEI8aJ2mEqZQvoJDt0xQThfNKcUNx7bxvSPdGkkHEkUoTtuSi6VSqWh
O+WSPL0mRB+XopBIJM7+7Xo9FzsEQWjvofVtLU4Rxj2LQ+TiRIUEiYYTSMnmxcKZrRtZaNfoNTZm
DVnQc7P1xup0l+nsQyermrN3jPy34srAPnirTbL3wtfdI4/daHuymxVhbWjhKvu36xVN+rOF0RP9
8NCA9dpt8DtexWl5W44VJzt440p28BdXkJLNiwNDP0yGl4e66BBMIrGMNHifj0Q6pDG5GI+w5909
dE5M8HNibjiajI1lAToEWTIXiyYFGqDBRIyejgidlU8r8CaIjW1IyWZi7+YfvE9lYGSK/mbY/TOQ
jgvheI7eOxmPPK6IJKOwTs8Ip+G+2+i/ZIbm6XxGzp8WluQzpYiQ6FHTqhkK0A2nx74fYcVR6lVF
pACFiFQcKV89VG+JdtPsPR6LqmLJBLAzwjDcd2CYFee8ECmxIrTT4qhhSZ6Vg2o9SlpIycZDFH6d
Ugw2aXArfupJdqpzOn6hX6JU28n4Fv25dWqhc6DTwJZXpd+u/kSsv4MN8+2D6wU6mNPg01ehs/9C
4nhXpTlrhbfFxllXpsk+eer5bX5I+H2I5uhvb38i0X8Y7lkurJ9knXdrduh/V2VehS2QYxdZCof7
L7RP98r56+3/oRyW5A+PxLMDa2paNUMbHKc8gzzLjFKvmsa/CVvjUnGkfK1FCq8N3qLH/7F9MKfK
vAK/pxRHqpDe6fYfjrDcLl5j4bgUluRpOTpOdujlRUo2GkqQpGMw/QGYn4WPsVN5mO1gXYcO3zA7
T3+G4H/bfGqdizTEIjFqwOxleDsNPLMIKmV+fT+N2zELuUpz9uMpOPVQIi2FPwazc9yl5EzPEKPg
BszO0MzkLp3vkAg4d1DLhlImbpLqmKHySv6icliSfzvMhsdyalo1w2oEBt+qLBCUelURHiwOhqWK
l/KVa+n4kJT5uUW+OE/wqW3AzJsZQSGXZOFZKSzJ03Is0uJo5a0BWmPImxqi9c4XHobMP1zZ6oUP
P9z7Ov2Za73zw1/pnd+moXvYOZhbuXzo4PQcx7HrLBIb+e+k1ydonAeh9845Kgk0FYDQGx98uJel
OFdJzr7yyz+av+P2P9tkySgZkS/0wkvHXj7y0jGYa7vzH/4Bfrz1zJ99O3HbG+fYvWk2JIk5pUxK
puZonp75B5BKCXL49S1FXjrFKkJKq3YVnf745Tt/ZbloU5yxby3fPvYtmFPyRX7j6i9vu9O9OFJu
WRt9GPgwlb9HLo5SXpwlGw95+BeAGFWrqDqagZB8MpOBM+x3koUAxIUL75nJ8sM63AWapLWBzrDT
oYqzlly9Pq1ME0pGtPtPClNhKfTUGFXkzsKVVyyx76Kar0ENpqJ5LlzQFqYgJR0ynKwBkuLCNBTs
inNwsjh5UM9XFl5/1RJ7n9REGqTcFq1hKW1zeZGSDYUbk9/ILCcn2EuC/UfhP8nLy6PTMCUrWEfZ
GiV238r/YaCYOL6RyaUSTPIIREydgQWmj9JrFeIjqVzyf9COOEGTDcsZ0V4UtJ1uVXK6kGJaVP6o
OXZmEf6JPxZguieVsIbZ0dEiTSSiplUjxGhx2ujNWC1FTMUJD4e5fLXAvmlLcQgsGR8B0NzGrWGQ
yxE1lREp2UA4uO/xAwdD2UVW09nnT7FTc5eyZy+tstByJMu6/s2LhxPPt/OzVOfWgc5LKzDXlz0u
SzIkJn5FDsxfOpt9YaXSnJ1L/5vwmfSP4NGJ22HsuXVDP/jPIPVhev83Pv9jSBw7bNbQUgdiHzjN
n5gfPbt6ccUaZrnNJtI3YV5Oq2a4+eZO4WbfCsQnb1frlZvC27h8xScTT1uKc/pFw3BB2+jwxVUu
/KxWHFaOn5jKWF2EcNv5jiAFY1gJCKRk/UCAAlYCwg/asAp2BEhIBK4lEQikJAKBQEoiEEhJBAJR
e0pm2iPCSCIN3cY3ui6WZunSiBDRjRgqtOALCnN+g1n8RaJJKUoyKsTYv+rlJyUB3G7OXe+O+6hp
Y5TxhH0UWuqMkBIykE5FLdeV0HjC8RaxFGvJiVRMryMh3m0r6lwHiYjQUYSinF8idAG0K1sFx+Ph
SHu6tp0klYqmeuhvj1oBzBZSiBWDFaJYEkZKtC7lQnQxs5v2pNJasYhQKta2ENwe10NrK7d+9o5P
b568w7B50mUv5d+f/up/WnvHb77gLVkLmPPLbWuEv9gQDoJzdnphbPEL/X/3+NwcbA39f0v/91D6
Dx+uWn5o4nNzLjUxN8ck1KOTt89517QxymsOUXr/YuOTZ+DOfxd+6uBHnlYjmiS5uOYq+eWh1TzA
U4d+mVfraIscv7xpJ+pYur8e+OfuvpV84a70K/TWpewHXygKSmf+m9br/9c75D21NUMvLB28SrPf
dmhxQyvEWuqXwQrRMrLyyLXP5R87ePFVVn/zf7mV/q+3FLKGr737NXkn7U7Mkh+DTWZBF5YN82SL
vgQzKYvRkacojzuqrV+7xGTZ5u4xVRqg8910RErHo10plkQ8rtr2KQKp1OOReLFaWefzm45FeXOl
qS3YnGSDtmzrVqRjWyzJbBYTEXV7d/Jp+E3ZRO5e2USuRMf3jJxrLSzJM9s4qgooaXnmx3f+pbqU
7BWV/HmD5Qtkm8CEEGHGVcY5Cg7CBP2XgU8p9olSG0a6pMbpjkWTUlwH/FCyTynQXw1LsGWyL1Rt
EdV2JXGhqysSUXNShNgMTeI2eftPKfwE7Fd2BG4MrSRjY7laj9O/lOwz8rCon4rBtsnmU7UPVe1R
k7FIZ9cDUbUFIrDURwuxDdJosnWwBGeUiatrOJo8PZbdMcW1BfpYIxdB32jSNhDPsNfcRXhS2myp
2fotXpOmWNnmjusyz5/6Irz95HflUWn5isW276OJk23Vy7qe39Sp7/IWf20F+F3WKRS7t45MPnuK
mT9tx4c+qsr8umTFqJnIHR6Jr/YzC7jlVT0syff2/zA70KnbzXnkxy/kupTureXPK8rIhUR/p2QT
2Pn9wppsfwl85yvAX9B//wFadfvEtoHEp6SrizcHc3lw3kV04uLgOHQPPn9CPzUObSb7QsUWUWvX
7dnhvu35oXeqHYBtxC3R3rz+QGIZ7qcD2b+9LF/5Xbi1E6pT+PmhccgNPR/mC9FqsPn8sGofqtmj
bt4cOr7914NqC4RYIc7R7pGNJDLQ0tNSLMzKVzbh1R1dS97kLOi08WLmpwA3aCt/RBoyNlRbv5w0
ovzYHGN+Fr4DUegQpaOc1bZvfkbfR10p+PwOQN883zCD3TNh0Ozecnd0fEQyephb1O3iTBZ/b4fZ
nFy0sB6W5PPw5vDYum43550f97WkAt1uUs+fB/qhb1ax0ltv6egw2vgBTA4WNydOTWwWfzaxqNsn
0jaU9taCGAZ3a6IwDNPUBW659dDFhMm+ULFF1Np1jq4PlnU7SgH+O5uUSpMdpwY+BccTsd5vHBGk
IXkGkjtBSfhrOEsn6f/CF+L5HxtsPkuqfahujxqW/qm10wbHYqxuJyfiA3dAbDXaEzkiPMquDO1E
IThKhq9PT8HAPfzVYUjSMTM2ubmwObUoDYL0eEvqz9K4ev0FY4xkko5J23AirHR6KnvCUAgqEKra
gMjlt8RSNqovv5RO33cfzUPXW//sW7QsUo6GdC3PkJNxJroty/DhIRiUS6uk5Sc/Y2Nj3jtatboE
PX8eGNdLSf50+7LZJDgMbcPCCWGYWURIuR1VKv2E2hzu97g8EcsUJy5rx2MXJrZeAfLW7Z+qlTfM
egTLgtauSem+WsJi+vd7Jlogm198D3wZfr9wubC08Zo0iGiGLDXGeyb/bSY/8SG9EC+NwzF45qEv
tcNptRBDaj1K/ZX2Y/mfupH+ysW1JF32ZPMnZum8uFK4vDH3/uwf7Fgh+JcgyZXrLyqdZFJSCJnl
DstDePhXh6XB837N1k+JIdvcTYCSVcmQrxUy2nqxVT41rgqkq1kkLr9TJou/qYJk8afYuq3DB+ws
/tqMFaEb9LUYjPsinMVf0Wd+/D2iVevSNn+2jaWVMguvW9SNNprVNlrlUfpPt08MGavGLf/C4OGh
MDe0xWKDh032hYotYquDzWZ4rbAWalX1P4Bj6+HBg9vyeLFvRyiZbJu5c6iN01uX2k8eNtl8agaV
tvaokMwWciWucxwVkjPhklzDd+0oJaOpZPI7bNaWJpCFbkk/OcbWI9+jY4hUom9otn5KDNnm7n7o
lhdZvUdp1edgWiuPINv2tUKPLHDmWPUUVz6/9J69/JPth4elJ6iKrdv9cJfV4m8DDC8+BDhSVM3i
+LBkn9hDj4x2cy758Zt9uS6ZvaJd/uyg1CYbq1vg7mk7xXMRlugkEObsEyNw7ElDb3TTXPul502a
1r06tbFgtC9UbBEFi82mHCkWWUgOLUNM6HlZaujcJkz2SH3s55NdmZ+kduDrkku0s0b5QojP5YpG
m0/FPtRoj6oXIv5AkdApiJZF7q35V2CyeL90ZUK2ZN0pSt66mBU+mX4Wnpq4A8TJD7GBZvP5tUdY
3idg6qD0TF2z9ZPwE8nmbgVOTa7JK5DW9akxWgWfJ2zilNaOl85mL62AOHXre/Lt1i4uVyvrfH5/
+txnDcPdQ3J/UezeTk3+z+aOmDq4+f8YrFbnLx1PpFetYcXObtVkN+eSH59rSaUumb2iTf5sMX/p
s9kXViWbwPjU6nvNlxcnIRKmGgJMvsrZJy4/n42qzQFSXEfMTsDErKwjqePG8K8a7QuXI+utervy
kG6RCB1efzEG7eHVd16ia87xljBdi0m9/uAz27d9anQHvi6ZC8HkjJofeSQ73bUyydt8KvahRntU
vRD/dCWRmxahvfXwGitENxyEWOK4VMOjmwe7RldqWwA/xlkZODT40pLvJIX45Zk/vmj3pBiNBncB
kejcvnufC/L2oedWGR966s7m6qrYZeWnrJLvBiUjpZZ4gDXg+Lu2IBxftFW80EZpx5Hc2ITWH58I
ECMRWwp+m8RSfX1Yraz8JGy7bR1SEoFAIBCIncH/Umf5acNZErHHUWcUQOMsBAIpiUAg/FEyob1O
i6dM51KpVLhcMw43X4oIBMKJksX4gBY6aTkHY8VnTnZUcq8xfCuJQASh5L2uIWD7crd100fFX2Ii
CpptHvODaLCplKSYbQSz1ZOjSTKetocIBFISIK15n01ftZ4DZs3CbWtU/CV+/7ruO5D5QTTZVG5d
OMXUVWarJ0eTZDT/fQgEwpmSa/u1UNJ6js5wZ5/jtnUo/hLfnNR9B0p+EPMGm8r5DmCar26r94zs
pU/x34dAIIwIYOM/BslTk7oDL6qIlkCxnLwPJNu8EwDDY8zLaUqzqaThn8jhYXklqcjcB7CFtY9A
uM6SnmCrP802ssgZzBl9B/I2lVSq1ZqQt+0hAoGU1PRTa0hbS7ZQNnXLPtpVf4mcH0L1iLOp3P+y
nQ9vT9tDBAIp6YlUuOv5m/DlyTXZZFv1l6j5IVRgtKlseefzojUp3n8fAoHgVcgyN/j5M31EA0lE
3SNVZ3203E84TviTCmGLIxA7QslCFaUQCEQ5a0kEAoGURCCQkggEAimJQCCQkggEUhKBQLiCfwki
bbMxbh0QifYrEk6O6D/KBbHuPitUNvSiaCGR2BWRO8FVFH8Y4HYi+K9BUwt4l4IFRekPqbgalJTs
b8FlyD6+CPgBNv+UlJuZmM+YiSoSjaIiUYisHTUDI7WiaCHRtojcCZEf1fTDQLcjQaO41jl/kWij
qkgqrga9O9jdQs+QQ3wi7nb7rgB0NQwltcqURjN5UBW1v2DbdcTdr+OagbgcVbsSqj2ekeqlTPxm
vk6HZJP1xLfMZ+ps22ebQw3bjsB2jbsX1BBPxhGjYFkMrZ3mz2mQpEbVIPoj7u6M3mPuZ+p6j6u6
nOFrl+jaDrea3DPrAWNJa1RudREfbKHnpSFrqzY5ZcoH+n+ZSzmvnBmU1DpHV53nz3EtKTr1gqYm
oO1g77ublfFsBxSqBGKKGkV0XZmpT+SIsXV95M67GkwSpBq0Rrgorva1TEAkTV65xL4bierjCeLd
l5UnXgGqiJSdz6Ax/WqOHtXgcmfXYotISz9o8VSOiK8lZTOrrYQQ8MVIRVCVr5oKWk4UsYrajbEa
XG7mWkPBqgVnScNaUtaNrPVHlEfZ0jWjBGme95JEfdisllSrHbO6JgZdAbrcLkgF+omiZ45wL5CJ
GPQmlmpwuYUiqDDYmgGEH6B/SUS1H/a4X647HavenrjihjpEGZzclah7UXFFIHzptBVcRq0MZ0kE
AimJQCCQkggEUhKBQFQbBnvJILsUm9ho0mIGqb51A1PxrPaSwfY3GaT91Z2hnj2iiMTUVOXaS5pb
19Ze0mLzaR8f7SWDUJIzf/TVNZrUaNJiBqmcMFgM2gqazSa9+7z+66/uRLvK90peky7TXtLaumZ7
STubT4f4dWPLV7dmk22ufBO5wZizooQ9YjSpFMvb9LAso6wyKo2LQnwrJKTq1eB0C4fqqZ/ewecj
pB5+szq1VBtKSoZYooGa/EzoPC43qS7ie3OvaTO2vz5IgvdYTikk5TC+PBWmLF23LnsHMc6S8mFD
+QSxWNXvhPFg3SqzOzqGe2Yn2MKfQGX2kp4Dgaga2jZMr6hbs8m2YF2lybdDVefxVLBeqS7PRChj
tgySiUrtJQ3medbxWkQ7j52jJLF9/tOMk6S7GaAY4ANywZ5siqS8scDtLqL1+W/Z9pJ7ZaVSFzC+
l9SfyIlOE2UzM7JKamsww0BFWqxyvrhMVKmpRM9LuKW8ZrOkUYnizN30C01sNGkxg/S2F6zeXQPl
0IeizZs7lmsv6ZRDi0WkIYp3fIQt0F4SUW2tAe0lq6i4IhAV6rA1jLqXFVcEwlWnreAyamU4SyIQ
SEkEAoGURCCQkggEotpwsJfkLARlIzfePs/kTNDG6s/LcqAh4Ow90iphNmD09aTfUqskWBT3WuZs
F1VzxQrtJd39S1rKYH8V7SWDUNLiG5BwH97n7UAMNnJ2Vn8W08JGZKSj90irhLmCxAA38Gf8aBfF
4068LTFA5faSLv4l7crgcLVeDLXq18uk2ThLpyZxNg7kW9y4b7KKXg3riZw16Ua+vVe6CDnXMu/m
TKx1+cvL/C6pPjI0c0n4Zp3N221lVKFxE519uzXTFtjAho07ZrPrse3cYm1emb1kMxiqE26WVML1
bS/pT7HR1TMSsJs0OQLv4hR5zx7+VlmiX/8hZkW4CvaSrrMPqXAI2WHUr5fJNgjMSX0fcbM6gS3X
zSS3aCpjzeo/op91J7E9UyP/kkEyjyhfcQ3Ysww+GBu7fYh7EX3XRQ0mDUOUoPErtJf04V+yYSbJ
OkaLje4l/3GsP1vjON8+GBuYqH7NIP0KGulV5U4t7mT5RWRkDWdJjZPEskay/TG3TdMYxXlbQzrZ
C/omDW9y6iuurZWq7+xXaC/pu/wO/iWbqG/UFGgviai2Aor2klVVXBGImmrFaC8ZWHFFIDx12gou
o1aGsyQCgZREIBBISQQCKYlAIKoNo3EWlPFhUlurP7GRF/K+zSCd/Ev6ff9mdttYP/4lXarAzlYS
iJ/aQXvJwJQUy9l+42D118D17tsM0sm/pF83myZpEQJGqZ1/STdLSGIpIzHez6l26sBecqWet5vb
zpJcaxr8SnI/xpNO3GuSrVO+N3Qa/Uv63jxuMgkOGmUn/Et6V4FYllu9HdV5NISMh6QxKKnbC1j9
SlpPeis+TQTnrlXWZmyTs0g/HXd3/Ev6XLl41c7ujqvqLFn/3ZKnJFFXBcb5z7a/eRgkkCaZKcUg
39Ips++LpJzkg1jciFCBf0nPKmigtu5qhEy22cyQdlN++SNTYz7Y0QpSe5PQMkgf0L8k0bzledPf
2xLSJGHzpTDcXl7Vxzum9XmVZ4TGWDw6FFEM5PW4jOEgcDSf/iWDLOqI561qZU2JkNHie2kcpFs0
yd5ioy9N/24jy2FkMKeU3vfR0xOrVwUuEuXkH+F7LakdWkdVi6merdVfQ7sS9G3o52RRGMwwsIy6
CuZfknAf3PVpL+ldBRYJ62SK/iXLA9pLIqo2M4PfDxTVFdBeEtEc2vzuRN9jiisC4a3TVnS5TlTX
zpVQ/dYwzpKIPYfk/ApBSiIQ9YKe/wng5ngjUDLTHhFGEmlt1ZuSfrrjmsB4AkwXkzFItwvC+SIU
UwzQJTwK8IhS3PF3CyPtaSYbTWJHsKpwkUisW60/ikTKK0ZKrmRFlrVXqWgryC7rwuMJQaDt2hWm
bZPw7oqGdOM0hWJJGCmllQxIZ+mZSHtG6h407VjRmpfieUFoT3OySjnVFHYRxcx3AZbeV6zXftEa
04KH1lZu/ewdn95UDnthjv2cvH1OFXhND8oXMxev5b92IhOGlXzhrtH5uTk4Nzm6tfDbj0kyC31X
rz14/M+LVDbx/h8+jBw0IvevMrGNzU2l/qAnNABzHlHm5ub+7tmLRehpYbKH1pYigzSmtc/tO0kv
U+Gf3fU863hf38wuXPxM8dwUbZsvPOaZMS5dOaWWkZVHrn0uLzW7/HTyj2LL4f7zBTakFztfTf9i
63OnTXkhocy3L3+crdjIsCSrlHOu17OUNUbmkUXYn4MlstGq9OW5+uoY3Cz5MdiE2NiGNANKY1lX
NJYWaBigFBE6IMKCxYQQiakj7dH8BShAZpb+OSCv258Il+DXIvLVA0OxZGZsXSL+zBHkoAn7JzOL
+Zxaf/CWLV/96Z0TVGt5izRsPg2XZ1hMC+5Vhcn4sxL5C+EIFA1t4wYuXTmlCCz1GW/0VzA7C6dZ
aK2wOAOt8FvmvBRgpg9ickiSVcu56zhIK3p5P8Av9mXqXnFtgb6YQa3Z/sGpFK3EMegcuZDo78xL
we8X1k49qQjk4U1wP9CSlSibc0JimY6r92fyl+WrUXhFTWkGishBE7b+XeKBRFGtP3jPdT+RjgxG
FwEuSrJ3QDLJYlqQvqIKx0+o8eh9+LZxA5du+ir7G2JZPMeLlJjIHUozPzS1CqPmvEgS57TQqFbO
3cYjN2gvBfZv4Y66p+TNKTj1kL6WBJiPwoAU6Ie+WdiQgustHR3whNqrYD8lXuwYq+rQWvvAGyGW
OH4k0huRdtwPAbeCREqaMTQTOTXQpdXfR/0stzMbx56hP9mkPM6BfSdf2y8L56ZUlWx8HU4Z2sYN
XLpr0o3a4FhMa3M57+zP38rh6//r4B/CsDkvksQTWgi0cu42/oQfNuqdkuHr01MwcI9+InkCfiK3
KBvolDXCn25fVmtZKtPn0x35yRBkR8NMc1kpvG9jKd8h0XcCNM0gCSHkoLXvv4fWmFJ//vAvg18/
oR1MyDOYI44N5ZRWGz8z/OIHDW3jBku6Vy6uJScNIvxR8n3wZWucSa3PK7KByllDrB1kiwb278DV
uqckJFeuv0hnvkl1TstklMstLCgjC6/ryxGm0YTXitlSi3pMO0JbeHBRWhcJcLc2uiP/7Ht+i6H+
PDHNb+0YgUzRjZIfUhQbKL6z9JK0aUZvGyewB6KWdJPZQq7UxouEWIcY4frBCDsR4iRol0nLvUeR
DVTOWuLWAVlvbRlP1j0lo6lk8ju0zUOw0C2dOPwybVQ21wkwfZRqHpPAOHr3tBajjY6DsUhPcjgG
8Qe6j7EHQJATYWpBSjUmfCKTTEnvUPZBGDloQgyOHqP1q9SfP/yxrFWqE9H0G2jTOGJD4i+lx/5z
nUvSmVxMbRsnjI2NqenqbyviDxTJsMCLRODYNHyPicQe6DlKDydZD1HjMIkwHL0XHmYnFNlA5awl
wms97Off5E5A3VPy1sWs8Mn0syBOfkgmUOu7nvspPDpxO8xf+mz2hVWIT94O8anV93IP3uKQaFnN
fiADia/efNvoPNWRWsMQOSxV/eI/Pn0gm5ae+W3ixj0LVi9ls2lRrT+fj4T45fl8+mx2dNlZ+DF1
HMzPvEV6HTjeugjRw560sKT7T1cSuWnD3tSl0bWzaelM+1dX+y7d1OJMqBLLfbR0pzjZQOWsLSd/
xGacV+p2kqjIEiRzSLjpS7Art4CbBZoAKXC3mui5tVFpEjsBsrp8RB9i6s0SpDLjrOTGui+56Jc+
iP25CSCESq6vFhPxRa8UoFQHD987HvhLaFJKIhCNP/WjvSQCgUBKIhBISQQCgZREIJCSCAQCKYlA
NCmsXzuv4Iv75s/bq1/dNQpZzrh4MzScVL/UHzwF9dPtLg4Q7X1eWbwoiqYv8rvlRmwa1yiIXaJk
xSDWY2uPJC6eCG0dJ5rcKJLgKdiPMLwDRGJxiGK5NZc8MTrccMhNEIeOCIS74iqKovKFaynEB+mP
1AW1CyLwR6DLm9MD5Z/ot5vqnkKVz66LTikQc8g0HdrlKdjnC0WLN01RTx1ph6jxLKnPBfY+Jrn5
w+h1klJH8VlAnCYb1Z2L6E0Ls38mVS/2n4KuT0tZA4dIIrGOBMRRhZWLCb7Kg2xFVERJ0Z9KynsK
sXEtadXWiM1BOZ5sXGdC8xJYJHZZNpGP2KxxidPNRQI2zlaJc0WU59ARgZQ09i7RwE3RXav0JrOf
y7sFYlyj+pqxA/hn9efQEYHw8XjHR0clAdZldp4qfaudjhqgIQX3STLQbQPmzC2WH4eOCIQPSoLr
uxB7n4PaEXHxOCkGf7hCRIdXCcS32srdl3iv84hLdYg+hygEoqqUJNqbQM4noO46UgqZHneYpyvz
Sk6JYztrWHwVGl0T+vBLKGrvC9UQ/wLR4b56uo6vKtxy5sLO4A4dEQgVZdlLVuxjsCq3qWIKQe8k
4h6A5kG92UsG3iog+lo5NhgCvtFHNiLqiJKkChJVu1XVUiDBk0VaImoC3HaOQCAlEQgEUhKBQEoi
EIig4B7v2Fo3au8ZAz3OsGwjEy0v6Pht6BDI/tGXbSOx/8FnpYgGoqTbu7YKu7LbTk93O0Wr/aO3
baPFdEX/QftFRCMqriJnA6kYR5pMJ/WrYG9UaUxLVIwsdYtL2bTSkfBBNtD6BFIR0XCzpGm64acV
k+kkGPevWI0qTWkRg1Wl9D9vceimwVpUZj+2jW7MxGkS0XCU9JhajJtXidG8yWd/tzV1tDdltNV5
PWwbHbRnnCkRDUpJZeoRffd40TZoPRb9r1OJLVEr0kLx4Q6iUSmp28n77MPEqKg6kof4IHYw1ojl
MxSBaCTF1a8xPBGtJsSus6D5w5S8naXHxFnZdIkzJKJhKWk0DdQ/muhkIQlGo0qDaaIhEmdxKaWr
fMvG5i2jk50ilGHbaGuDiUDUKxrPv2RlpEJKIkxA/5KVoqLP2SAjEfWOBtzjSnYpLgKBlEQgkJII
BAIpiUAgkJIIBFISgUAgJREIpCQCgUBKIhBISQQCgZREIJCSCAQCKYlAICURCARSEoFAICURCKQk
AoFASiIQSEkEAlEtSiZSaiguh7rjEeEPilJwPB6OtKd56VTKGkIgEFWjZDE+oIVOyoG1rY7sy9IH
a7rPhH6xcuIe+1TGxrAmEYiqU/Jea2gjv3gLClJoaCUZG8sBlCJCByNthDE10xERzmfYLJlKPR6L
EnpCiHRksF4RiCpQMn1FC13Vzx6VZX4XbkmHHSMXEv2d0HYyvkWPDvdfaJ/ulQX/Y/tgDnr7E4n+
w1ivCEQVKLm2XwsltZPdWYix3xmQz70d+mZhAyIwO0+PCtAxQ48kzC3CNg3PzsAQ1isCUSaMXztP
wZgp1H1r6MEzLBAZekripDA8BqmJArtO/4VP01OTeRpSTgjD9MREASsW0ShosK+dp2/BBYmREIZ9
SoRMBkIwyX4AWuGpsbE8T3F2AhmJQFSPkoZXG28Pzcfkg59PdmV+koqDANNHIUoV16NsxUiPelIJ
LjY9v5CKYb0iELWZJaODv5eSOXrwme3bPjV6FeYvfTb7wiosR9Zb6dn50bOrF1e4CPN92Tc+/2Os
VwSiKmtJBALXkvU9SyIQCKQkAoGURCAQSEkEAoGURCCQkggEAimJQCAlEQhExWjjwiKR/4rlbh/Q
IppT8JuikgMAYvnZQXB3VDMu2uZEP2HIq8jOkKD1FqSconQD9/vYZI74bwmXalBSMt9CLTlxrx0R
cHOKf0qqtV5xnZXLalFrd/rP+LOTjCRc3+MyZsmJfsKYV8LF9F3sYOUk6h/RuxR65gK1i1M16OMA
n2Xjj0vtEBFJF4ySakUah33WlPpY63TdMjWK+uhsn5RyRmviOmsuY4aIB0PKUQsq1EZc7kP85Luc
anDJkENuCFQvL+WO8xaEoKSEvunVmLtLSV5D4aYow6QlOl0XrQ1liWEz/ylBqD+Nhvjuk5UwsoyR
SNUJgzK/vJHCRzX4W2TsitLqcMsV7UK97XFts28yYlss+YeIFj1Fv6DqviwlLRG+KYmfkVN0HeB2
b9Z06VI7qlz7U3L1pT2LwJQRsVasUDLkmC95tUx2eAnihq7GUFy5tYaFFMQ4AjqQhnu+4axAENF1
HST3HfVntx7s2A9UNehSZSRJAsurI6Q/VnhUg1WC+MoXPtcJTklldgNtOWmazIxrGFEXM9W6LSuJ
3Zjq1nT1o+SI3sSxPPcJNA6UyXT3aCIpV0X2roYdUZj3KFqsU5RpVrPMh6LTPCly9W9ofMekbCfK
utNaCSGOc3/lfU5JvQpPLBzV1qpWAwRvMmRkBY93QJkndeVRm7PkoFGr5JRLRz3TLSnbJjZeJjv+
XpKI9osiS050QVHW5CrJa5C4fmSVLIlcruQwqbAa7CSMbaU8rKtm7ewlhEjwQQ0HvT0Ojw4QVJ/e
ZdT3E1fvOhNxmY6ohFa4U6AMSpIyVv6IvYRKnqxiB/ICbjtHIJCSCAQCKYlAICURCERQGOwljctv
t8dqtiaNzfLeSSuHWiFO5bOzCOTkA94uuCmj++NvkYCpFP7tv5yqgNvny29FCGBNivaSQSip7oL0
0WJ2Jh07b9lYI0bqb7tB3zZIfNhLctzyXxGcOVzgHHq9rgJjKXzbSzpVATdmi/Z9waV20F6yDEq6
j2/c+b0z0Im+7A5JEGGnuGLwKK4ZF8GXwhOkCuySJ36zW2VFxhEh0Ewhdyo7Naekk7V8s0yDlXZH
Hzpo8HYn5XVM4ic9xw+wlF8Fu9wN3G6/0uBTRpt57CE+K2EPcZP4YZqqSBqMsv0yiwQnI3c736Uo
317SfX+qSCqXqB66Gry7tdnRTgzUIM00KToaCiqME33tTAlYV2WYYZIyvpHkz17SowqqJIEIuJYk
NidMldmcdVu+KlDP9SEG+WCJdxV4f2iINFLt1B1a/KyfRcA69mMvKVY7WfcoYp0xviHHq8aYJXU9
1cl00WgBt2uWjTVdOorEdMK3vWSwiiij2gLcRzR+xtGnvaRTFdglbyy7JQraSwYFemFGVHNObMAp
E70wI5pXf6999D2quCIQzjptRZdRdcVZEoFASiIQCKQkAoGURCAQ1YfJJ4jFHRm4bMKqD2+Q1YfF
EMbJNZSdf0VvO0bPu1Ynik3myvUvaakGB5tJo8GtxT8l2ksGp6RpF6KHqVF9eIOsASOtZpD222Us
/hV92TF63rU6UewyV6Z/SXM1ONpMEptz5p6C9pJBKKl859zIL323ssj7l3TYMLlHR0CTdS+px8zV
ImF/Oy2DeuurhLQhd1tJO3yzzrpvm2dzilyQdyNJ9hLjRI+uZXErVk+1I1ZpsDCX3++H8oObuZSP
leCxG+Br5+YKMlOQiPajmliXc0Ql8L8r06DkQTnae/lbXX1mrnx7Se/7+MrJjuxx7Wr8XtdWhW67
W94gazmfmNfJ7mMNqXyUr/Za0pqdsv1L2lhl20tUvYT4eKeSL1RU8i2J+pkWHbso51BzV9ZtNVv8
Ba8GNwlkXOVoMU14xPCQzHaxLbporU3ZKIpjRW//ipWYTdZ06q9mNSB2cpaUNVDCaaEWfdTuBO9a
sAleTFrcJvoWrMQwsNprSZtSlOtf0iNrFgmzf8mdXEs2AUJV+2YZYs8A/Uvu4FrSlxaEjERO7roa
vTfWkj4XFMjIvQ6PLkAqiFtt9HQk2sKxroUmV1wRiEZAd6FYXATYv8zCQuv3T4YbQnFFSxBEU9Kx
FB36+WvXKSOBMRKWrl95cyTSTjINpbhm2iPCSCKtDR4puWxxTWA8AaaLyRik2wXhfBGKKQboEh4F
eGRckX+3MNKeZrLRJHYSp4cLcsUVS8JIKe0tHqcVXzwvCLReWXuVii6yxZGUGorQUFeYtk1i3PMW
erppOW8UiZSaWVWqXQ4pedFF1Dtq52nJIu0ZNe9cCjVD7rzQ+vOVhe+azy/fuHI5JMQ7u+u7R7TG
tOChtZVbP3vHpzeVw16YYz8nb59TBV7Tg/LFzMVr+a+dyIRhJV+4a3R+bg7OTY5uLfz2Y5LMQt/V
aw8e//MilU28/4cPI/tsMTc393fPXiy2jKw8cu1zeQ/h4r6TtOJJKPPtyx8PHVpbigyuuERJHgSl
wZIDNHRuirbNFx7zzJGe7jcPvOdLtFGhp2VATqkXFCVv4cvKGSUvSs64JaNynoaGl8P95wtQbD9F
JeZ6DWLVRrHQ1bK0ORZdlg/35yy/2VsrmfZYYeLzWofsnauvHsHNkh+DTYiNbUgzoDSWdUVjaYGG
AUoRoQMiLFhMCJGYOtIezV+AAmRm6Z8D8qL+iXAJfi0iXz0wFEtmxtYl4s8cQfI5zkrvnIjTyl3q
o9XogXulvwWY6YMYPA2XZ9yipDW2FvPmtnGDnu4WfFI685ZNs8zvbSsBJS9KznSo51lodhZOU4lQ
jesxTUrhyMbVG/vpfLif8c/xd+la65tDkY461WJb+GBfzKDWbP/gVIo2zRh0jlxI9HfmpeD3C2un
nlQE8vAmuB8yzHnYJuSEBB2bivdn8pflq1F4RU1pBopIPSccGYwuQohV4znPXneV/S1BMkll72A/
LqZIKW3J8UU5xLWNG/R0Pw3vi8Rpvi5eN8u855oSUPIC6StGAfW8EhqlEqs1rMOerkfCv3p55ZfL
ytrRx78brzEttg6fxXKUvDkFpx5KcOuZ+SgMSIF+6JuFDSm43tLRAU8oAlt0xIlC7BhrwNBa+8Ab
IZY4fiTSG5H24w8Bt4JESjpOkhuTz7D3w8diWr06Yi0pVyyb8+g4B26eFHu21Emg+2kpxLeNG/R0
/2Tyr+Mn7wDIWh4FfFQ9o+QF1vYbBdTzSojlPVzLWiz9SamcWFCarWdKhq9PT8HAPdxa5AT8RH5O
wwY6ZY3wp9uXtVpmtfD5dEd+MgTZ0TDTdlYK79tYyndI9J0ATTFIQgi554B/GYycALhyMZuc9Blj
Uq77CfbjXK85rfY3HpR++LZxg57uWj48C5t+8uJyfnInKnFxdW1z48gdt8n6qa9/B37laHtxfXW4
nikJyZXrL9KZb1Kd0zIZ5XILC8rIwuv6coRpW+G1YrbUoh4DHGsLDy5usSMB7tZmAmSeI35T2kGV
zOZzpTa/bSa1zAhkii6UPHE2JT0HoKGHlJDeNo7KbiplTrdkI2LIS9r8Jo1J6OdDLLcjO1CRB8W1
ws+P3NG2X9FNnX97wp+JlvLrmXBddgiuNqOpZPI7tH+EYEF+THz4ZaqtsrlOgOmjVEOdBNYT7p7W
YrTR9opFepLDMYg/0H2MPQCCnAhTC1KqMeETmaS8oNkHYeSeA7YlTTH+QJEMC/5iCHD0KPwX2hzT
bwDnKGNjY2zxT+mhhGjbxNS2cYukpEsjxiLdMYjZpatyj7br0XvhYe6EIqGcpycicGwavrdDlXmC
0jL/8t8dAGXNaP1976+0v7qZ/8tY/b6W4xro1sWs8Mn0syBOfkgmUOu7nvspPDpxO8xf+mz2hVWI
T94O8anV92ox/grikGhZzX4gA4mv3nzb6DzVcVvDEDksNePiPz59IEvTo9hERweO2JKW3P90JZGb
9rn/c6kvm00fh/n02ezocoA7jbcuQvRwzEtMT/fHrTc7+9xfESyzvJwyKr3G80uja2fTO7mzNXz6
o3ny8mcOWF8/Hrj9SPuP1m8O1HeHqGhDXeaQcNOXYFduATcLNAFS4L75rOfWRqVJVBHdhaEfLEmh
/cvdYaFtxr4P1tuGusr2uCY31n3JRb/0QezPTQAhVHJ9d5qIL3oq3aUdffjeXSz0XI2EnznhMkg0
FSURiMaf+nHbOQKBQEoiEEhJBAKBlEQgkJIIBAIpiUA0KSyes7ivjwX+Dpn58/a2Dn1svnFn74nQ
fFnzA2D7lTxLto25172AOdxWBNtULZ9xN31G3zY3urfJcvw6IpCSVQOxHlu7InHz0yjadHuL10vi
+gl2e1+QNiMMf1tiYL1zzhSvprycXW4q8euIQMXVbroTReXb3VKID9IfqQtqF0Tgj0CXN6cHyj/R
uX+aZjb9HFFv7ZWCQ3Fs8hTsc7TWqVf3bWpHZMCJEVHFWVL1l6t7VTb4gRW5+UPzOqk5jBWt/d0w
z+k+b6y0cPZAxbt9sklBd0Bj4wtSzjLhHAkT75GAOM97ipcG5/JYnMQjOxHlUVL0p5LyTkGsfY1Y
1TTi3LnL0YvLSEHLMnHkorYmJGXlilgV9kr9OiKQkprfJ9GbpSL4I7OfyxXD49lOWQvhipfUwf06
IhBOj3eId0cN4uVUtHkEIgbjgU2HNqmKIjHpkbYcMNzWniViWQx1iyUS9ISBqIyS4PouxN6XpHZk
+3jR8hzUd5cnTt57iUVTNOuMNtM0cad5+dMlwcc7iNpRkmhvAjmfgLojScUROj+XWp5kGPqjh/N0
J0+EKst8+yW0Dh6Eu711lFATdnxHYckZP+17uXYs068jYo+jLHvJivwLVu02VUwh6J1EfPnfPGh0
/5I+HEw2YF8N+Cof2YioI0qSKkhU7VZVS4EETxZpiagJcNs5AoGURCAQSEkEAimJQCCCgnu8Y2vd
qG+KCfI4w7J/TLS8meO3oYOLBaVlC7cP20Y9DqBZFKJxKen2rq3Cju22xdPdTtFohqKe8RVHFkNO
IhpfcRU5G0jFONJkOqlfBXujSmNaomJkqVtcyqaVjoSvCouQi4gGnyVN041uNClPNZyFJBj3r1iN
Kk1pEYNVpfQ/b3HopsF6EM01jrqvDamJaGxKesxWxs2rxPAJDr/Tm63VIvE/x/mzbcRdb4gmoaQy
9fje7c0bXonOl5zMJmtl24hsRDQLJUnQSYYYFVVHXhAfxA72aQwRyYfYG4qrXyt4IlooJLrOguYP
U/J2lmXMnMT3qhOBaFhKmsz9RKO9JFiPjEaVBtNEQyTO4lJKV/k+lc1bRsWUUTY0NNge+rFtNMZB
ZiIaCo3nX7Ic20YEwhHoX7JSBPyODTIS0VhowD2upIbSCARSEoFAICURCKQkAoFASiIQSEkEAoGU
RCCQkggEAimJQCAlEQgEUhKBQEoiEAikJAKBQEoiEEhJBAKBlEQgkJIIBAIpiUAgJREIRG1g/EJd
YkD9NFD8pBTqyW6V2uJLNJRih6YPB3Wvr9smmoIxrFkEomJKFjsHtNBJObC+tW/h3ik5bKXZW5F6
CEQNFdd7raFsfuk2COkimY6IcD4DqVQyHnlcYPNhMRYRYkl6hiQiuWiqB3pSMaxWBKIalExf0UJX
tZMP/MbUNV3kcP+F9uleGtiaHfpwgc2cHZl89hTTX7djQx+NwMNQBAGrFYGoBiXX9muhpHbyc9OD
dygrxFQKCtAxAxv0YO4glKSzuTs69sE2O7MET3wX/j0VCWO1IhDVWEvaIpm5b1NfS27BHyunAYal
hWTXWy/uk4L0zNBpAYqbk3msVgSiGrOkD7TCU2NjBsqtw5VX9KP8cNfwf8BaRSCqSMlUigtFIwvH
IKpfFGC6J5VQjyYgA/fD3Ue5ORUG4G+xVhGIWs2St1oPr11a1Y/nR8+uXlxRjx6duB1OTb41o1+f
HYepJaxVBKJsVNdzVmZfx6mXkJKIRkK9ec6qLiWFUCiewUZGICXLR1tVUyuA9IYEgUDUaC2JQCCQ
kggEUhKBQCAlEQgEUhKBQEoiEAjf4F+CiG7vKEUwXVWkRZAu2P40KPTcByoVd1kkAe4TqM7klGVZ
kQWJl6wmJrWgv5w5VoHeD/jsirb5t09DbOSeseOU9O4K9ufpP9ufRmWklvtApeIui0HuE6jORD4m
cb+VekkRk+7hl5EOVaCPAXx2RfMJtzSIuOsNvALQ1WCUVMZgIiqtSViQ1al6nhvrHJu4GcZCYvfj
p0OLAVIPUl+WlANQrBpV4Ls0ddgj9JoLGUYy0gCUVIc3eWBTqMiNlNrJIGruXgLZsZRF4ou+IqmY
mpWPQPXTKiv1PWG0Oeddy7apyonppE07KwRuAojEsIQjNUm9DMIEZwFTesRyimCogorm4joZqLvq
u8u1VaW5m0Vr9XjEUi8DjcyuoPwgvsZK76dMJgm7EdkhjaYZqHdFcS13pG8yldP3DLGzkyTxEUO0
5t6PiuldBcThRs4SiCBo8aEWiW4iTT3umdTWemGkn5wQQqpCDc9BSb2RD7UVEXiWlN9gGdUi/Yjo
+oh+UpS1FOWa8adRp0r1ybJaOGMZvaP5JhafrBjgZW6A+uWzI0o3IxVUgUtpVUFilWiKXrFz8GXC
jCsAhM++UIWHQDuNhjNhFnFtgKgipVB9rZiSSEdEgP5A6r8/Fbu2boUbmZIIRFOhs/P/BejarF9S
oiUIYi+h+MA8ZSSsxDobgZKZ9ogwkkhrq175E8vdcU1gPAGmi8kYpNsF4XwRiikG6BIeBXhkXJF/
tzDSnpa+0JzEzmBGd0KI0NpOt4+w+htPCIJe986I04ovloSREqtXqcpdut9ISmksuW3CtG0S4563
YP2gVGShibggtPN5U+9HcxBpVz5FWIykWC+JCH9Q5O99nkZNc7JFmlaiB9xzXHN0RB6WA4vzwnid
doxW3fPcobWVWz97x6cVDyDQC3Ps5+Ttc6rAa3pQvpi5eC3/tROZMKzkC3eNzs/NwbnJ0a2F335M
klnou3rtweN/XqSyiff/8GEkoRGlYpdAa+ex0w9+m9bf1zezCxc/U/Qa4/edpBXfMrLyyLXP5efm
5m7dli44SycPyk1IBX9218XiuSnaNl94zDNjh9aWIoMrzMvE17Zfe7xvuajnrVdxKPpHseVw/3n5
1skBepft7Y5MR4bLCwllvn3548wNIhmWZDu2XvvMPXfOzCndalcw/vfXclJgP/3JfnH/eqvUl+fq
q2Nws+THYBNiYxvSDCiNZV3RWFryIQmliNABEcmdJB3bY+r4cjR/AQqQmaV/Dsjr9ifCJfi1iHz1
wFAsmRmT/DS3zhxBDpqQKy6+ClsQgz5Wf7lCOAJejFT8fkZgqY99nxMytyZdfHmmdd8tmfdOrBja
xg1Pw+UZKXnI5Q++Ypu3v4LZWTgtjxLSXTbyi7eAHx0KMNMHMTkkyWbzB2+DZ3ezwtPt99xgvuHo
v2Xp91q0ox4/OtzCB/tihsl8+wenUpIPyc6RC4n+zrwU/H5h7dSTikAe3gT3Ay1WibI5JySWaQvd
n8lflq9GQfPfM+Pd2/YipiEE5yCZlP0CTtO69OpVkt/PEKvyc2x8H4ouOgun9CXHkXwsbGgbN9yh
5YiNuiDNJEeMeSsxEdnH4RfjmmSLWeKcFhpl/eE3jl3bxcpODl5ZBtpDuX9Lr70hV9eUvDkFpx7i
1zPzUZA9pfezkVz+ZvJ6S0cHPKEIbNERJwqxY6wBQ2vtA2+EWOL4kUhvRNprPwTcChIpaTNPnoU4
Ha2kbku1qt+CU14xZL+fbXAsxtog0z/ponP1bGlTQCbHBPm2cYOWI5apLDDKja8b8zbE/vyttCJ+
WrlLdxZiZokntBDD9emZO3extre77c4erGtKhq9PT8HAPdy4cgJ+IjcMG+iUNcKfbl/Wapm12+fT
HfnJEGRHw0zbWSm8b2Mp3yHRl/nVUlPinasjZCx0Db2YobUkzXswfmb4xQ/6i3jl4lpykv7GShGX
x2Y5XSk7NrRBBfm2cYOaI0brkeHpjE3eJrXQxoMKI28NPyiaJUoG2eTlXR2YV67cDoreqv3ryq3U
NSUhuXL9RTrzTapzWiajXG5hQRlZeF1fjjANKrxWzJZa1GPa/G3hwcUtdiTA3dowjQS0PqrphU+J
zGOnVLfFd8JLfje2JLOFXKmNEkZWKh1w4mxKeg4gqWgTMjW1tnFUdlMpGIFMUaZk5mbLhRWWtxKX
NyYSYpkeke7ykHSX9C24cIaXoF0mLfceXXaXEc5G2VTP1pGS3rr/UHuoHt9OcpSMppLJ71CtKAQL
8hx/+GWqrbK5ToDpo1RDnQTG0buntRhtdByMRXqSwzGIP9B9jD0AgpwIUwtSqjHhE5mkvKDZh87S
LdhfWmMPSMJw9Bit5v3n1nx7HIs/UCTDAls3zLpIjY2NscU/e1AXo2t+aeKMqW3jFmkSpt9Am5xG
/AbsY8ro/nOdS0aRCBybhu8xEeUubw/Nx0B9N8bO0WLdCw+zE4rsRyLdBk+lu4HY/7hD4SPFbV25
+uyUXAPdupgVPpl+FsTJD8l5bX3Xcz+VfEjOX/ps9oVViE/eDvGp1fdyD97ikGhZzX4gA4mv3nzb
6DzVcVrDEDksrSoW//HpA9m09JBtE3cJWZAfupdNJ8+ks2t9m5Cfudf3K7t/upLITYusVn2+7i1J
Whptm0WIHo55Sc+nz2ZHpX77fw69hWUqP/MWU96WRtfOpvlJPTr4e5LIhHpiuS+bTZ/iZM+13lzr
W93lOk+uJQ8oA+LhG/WqulXkzC5zSLjpS7Art4CbBZoAKXC3mui5tVFpEjVH55u/C/ujV/X+2Fz+
JZMb677kol/6IPbnJoAQKhXcrifii14pQGm3H76n/1XpmdP8INHULl8RiMab+uuMkrjtHIFASiIQ
CKQkAoGURCAQSEkEAimJQCBqQUmR+2sM+YRo/1FmXymK1qtimdlAIHCWlGHrHaKS6AgEUlJmkigq
36+WQnyQ/khE0y6IwB+BLi+xTLSkaI6rJgFKsroAaFe0EwhEs8N2O7jqL9fsU5JzLWlxQil/cpeo
nmCIU4qWuAZvTsbktCuN7dYZgSiXkqI/nZK4+rAlBvfbdq64TQ4sieUqQU0WgZTUKCCCrwcyPpxr
OXLSUwkVK1qTIhDNprhy0xPxNW8Gm888HVhaBXC+ROwVtHhPVI5TlsNEaZoXbd2MilwM0S510XIF
J0rE3p0lVU+A7IEM71NS8RIohQzOArkjq4tQXlx5BiTzVHF2yPs8lMMmAXRNiNhDKMtesmIfgw7k
RSB2Hg3nX9JO5awKIxEIRDUoSaogYZBDAiMQHHDbOQKBlEQgEEhJBAIpiUAggoJ7vKMabxgF1FcV
gR7D8DvJ1eimFPSd5rZ31d9zKi80dRFlZ7slP/Zx8PkvomEp6WZtUWHHFl2oQWyS1y0/jBYj6pkA
cQhyEtHwiqvIGS0qxpEm00n9KtgbVRrTEhUjS93iUjatdCS8ZY9tObRCKiIafJY0TTf8JGMynQSj
BaPV/tGUFjGYQUr/s1NWZdUHkcwKsWccnCYRjU5Jj4mGGLu7aJjRfPZ+Yscy4kA9ZQzgr2tbiDz2
EeFMiWgKSipTj/+t3qJt0HosVrBONaxGfTMfZ0hEM1BSX7/57NHEqKg6zofEB7GJ/STpJw4C0byK
q+hzgiGilUKus6C+ErVcJm5qK/GvWQebfRGIuqekbhhpeNngaCEJRqNKg8myIRJncSmlK8ovD23e
MoraO0UlpKfj+LRGERGJqQDITERDofH8SwalGFIS4Qr0L1kpiIiMRDQxGnCPK6mhNAKBlEQgEEhJ
BAIpiUAgkJIIBFISgUAgJREIpCQCgUBKIhBISQQCgZREIJCSCAQCKYlAIJCSCARSEoFAICURCKQk
AoFASiIQSEkEArETlEyk1FBcDaUjciiVUv+oMBx4IZAwAoGUZCjGB7TQSfXkmSGsJARidyh5r02o
WDDKx1I90JOKpmPRLmnuS8QAOiJCJwuTuNDVFXlgHKAUETrYmXic/nk8Ei9S2VwiktNlk/HI45Bh
chlsBATCnpLpK1roqhpq+4FRXoAi/S+SOvXdben46avQ2X8hcZwRdGt2uG97fuYMdI5cSPRT5sHy
Kv3z0cRJ9gHnaHzoo7zs0Ifh8Eh8tb8XGwGBsKfk2n4tlFQCPR/+V9xykK4Hb0CB/icMQN+8dPLX
90MeOmaBToAwf5CS8CCUoB/6ZmGDzYxhdnoGIvRHXIQndNk5Jvd2mM3RUwgEQoPxa+cpGDOG4vEl
JST90D+RUrY9tMGO6D/pZPg0DU/mlVPsnzCsnZFPTRSUK0ZZYZgmPFHAVkDsIurta+fu/iXhpCXP
4RPpE5c2pgYzcJ9y5kyehkPGqVe/SrXgY/rVVuBlW+CpJHYJBMJJcVX1Uy40NkbpaBhFvgcn4ALV
Pae1NeAkTB+FqHHByZ85c0xSYm2uCHCkmIpjIyAQbpT0QHQCpk7DT5/7rBZz/tLZ7AsrvMz8pc9m
X1jVbrF2cZOXvbSiHx1PpFexERAIp7WkNzL79g2+tBREU4cxrGUEriVrRslIqSUe6E2iUCpiqyOQ
kr7RFlA+D/rC0BfweSoCUdO1JAKBQEoiEEhJBAKBlEQgkJJYBQgEUhKBQDiAfwkiEu2vCECkvwxE
OXT7EWVB07XGhJ55LSQafqyCat0pJ0R/hTdE8ldlasqijyiiOXPEd848qkE9dCq/fXxR7koEWeeb
ksY2pP/UJlQO3X6UKjeebFBGEn50Uvs+6D9WQeWKekL03echYJWJ/K9HFNFyH5EEYaRjNfAEtS2/
fXz5h4h11+ArAF31SknCTwYkKKfEvTv8iUTUe6p6FCwSCRAFAkTxnZ0qlN8Bddgv+Ox+M2QaREkd
UbKimmxiRio9zrnjkXIqroz6IgFYpsmQarWR3/I3APgMp75VXwUwUtLvzChKsvYlcbu2F+bLcoZs
UmbcIAsz2ib0/1ov5UTnaqnbTtFVX9lpg8CclNvWfiXjdq3RaVazApGgSWviLjGtFwhoS7qKRxt7
dimt77k4RZSpuDpWH3GRbsoqF7WnNl5dqpIuF+xhqKe0jUyFq0ouRRJMgUUmBkCLdaBT/jiPv8H1
lsYGIdITZeWn+mpr4LhKTkQfMtWvhjJaHxlZ0SxJbNaCyqHbj61kgzJQedNKvIqhC2pdsoxyq6kE
j+unlkXjwx3ify3pXQ2W8htO6AdK0fbuA4ZgCGElIaqsYrtfrrsps95MmHFDHaJ8ZXtno+7RtSQC
4WNV6X65gri7gJ9EI+OouCIQdYLxM8VlgIPxDFISgagDQr7ruhI6sBKrP8U10x4RRhJpbdUrf2K5
W//08XgCTBeTMUi3C8L5IhRTDNAlPArwiKIHjL9bGGlPM9koftTcDu0p5jdQEBI9tG7pT9o7iuz3
s8icfvbEI0K820W2OKJ9JZs5Du0K07ZJ+NPRWF+QPy2Ybh9h7avcExTXMOy4JETaM1z6mURE6FA/
R1g8LwjtUnm6E0KElixNC9he1GLXBR6PvlllJNzYqJdO2qqPDYfWVm797B2fVj+D3Atz7Ofk7XOq
wGt6UL6YuXgt/7UTmTCs5At3jc7PzcG5ydGthd9+TJJZ6Lt67cHjf16kson3//BhZKAJC18eoLXY
sfXaZ+65c+brm9mFi5/x+r5mcd9JqeKTLGZoa1/mX89uOksnD8pNCD0tTP7cFG2bLzzmK2+fO70U
GVxhHpQeO/3gt4GFpHtKTS8/oSTDy+H+8wU9/UNr/9zdt6p4XSKhzLcvf5y5migVuwTaC/7byX9+
Q99ycU7pVnWA3L6/Ye4VGfaz3zWx69nH62uW/BhsQmxsQ5oBpbGsKxpLC+zjyLK/yAgLFumYF1NH
2qP5C1CAzCz9c0Be1D8RLsGvRRRVYCiWzIytS8SfOYIUNOP3JHeA2fzB2+BZyBXCEfD84q3i97OY
l2Mu3QYhZ+G05pPsLZvmtvHCb8HlGfl7nzHmBa2g3pNDAWZn4TSX/scgNqP5QSvATB9Iw32uuPgq
bNH/Ykv19AXR7khiAZaZrzj6T/m98eZorq4o2QJ9MYNas/2DU6kCcwki+4vMS8HvF9ZOPakI5OFN
cD9Q5aVE2ZwTEnSdXLw/k78sX43CK2pKM4DfV7bgPdeUevqNY1JomtalBxS/n19UFhMP/MbUNWdh
3dvKRVk949rGC6OQTNJWpTinhL5o9t1SYhdGufRLck/grp5TDqbpyPEXMN5dP5Qcj/78Bu2tYP63
sPFAro4oeXMKTj3Er2fmoyB7Stf8RQKst3R0wBOKwBYdWaIQO8YaIrTWPvBGiCWOH4n0RqS99UPA
KedISQs+qlTP9emZO1kv+S045RVF9vvZ/bSyhPvc9OAdjrI9W9pDxKwUjW8bLwzLtJJGUymk3VPD
kB6U0xfgv8dgm7+q9JPcWYjDqamH3hrarJe6/51tpytPHKojSoavT0/BwD3cWuQE/EQeU9iQp6wR
/nT7stYarM0+n+7IT4YgOxpmms5K4X0bS/kOib4ToLVi0k3B2utIXmYD1viZ4Rc/6C/CxoN6TOdO
njNziG8bL0ywPyEupN1Tw6T5hJj+/e6JFv6qPGUudA29mIF3DF54qVQ3j/fFwpEDss5q/PeGIwti
HVESkivXX6Qz36Q6p2UyyuUWFlQGRHhdX46EKOnCa8VsqUU9BjjWFh5c3JJHzbu1B3hIPK8HN++E
l/x2hhMPpaQVvofUWYuU3jZeGGEtLlGyVW574z3Zc9MQuzDCxQmvFbKhVq1fZdJy7yn2wqdE1qXo
WrKOPG6L+aO3yfrqflB/b+v4hbj7j105SkZTyeR3oI3W9YL8aP3wy1RbZXOd4hVyEhhH757WYrTR
cTAW6UkOxyD+QPcxyf95ToSpBSnVmPCJTFJe0OyDMLLOHh+J0IqLwv5za779kSlOP6ORhWNGv552
UvxLh1xMbRsvSD5DBRY5DEeZf1Cjo1F2FIFj0/A9Lv1YZCE5tKycoNHuhYfZwf7S2mmJ2rnu+uoF
mcILbKaU+Cj15qM3VurhPQjXQLcuZoVPpp8FcfJDctW1vuu5n8KjE7er/iLjk7dDfGr1vVqMv6Jr
hETLavYDGUh89ebbRuep/tUahshh6VHb4j8+fSBL06PYDOwOaM/gXOvNtb5VyM/cG/SV3b7Ww2uX
gnjnHG9dhOhhX2/E59Nns6NSX30mnV3rs1OPl0bXzqb5iT0ROrz+YkxRdZf7stm0tDbOD0kl+3G6
82a9+RI9w2ZKBQeO3MjUx4vJinbvZA4JN30JduUWcLNAk8DLYWjPrY1Kou80SPYXdA3Zsm+2bjpo
ZRvqkhvrvuSiX/og9uUmQbil5PouI55YdLkqQN35G73zBsQv19GMgXtcEXt92kd7SQQCgZREIJCS
CAQCKYlAICURCARSEoHYA5QUub/GkE+I5jgBUhStV8Uys4FA4Cwpg9gRrZLoCARSUmaSKCrf35ZC
fJD+SETTLojAH4EuL7FMtKRojqsmAUqyugBoV7QTCESzw3Y7uOovV/cNbPC6LAKYLmhOkYjqCYY4
pWiJa/DmZExOu4JOlxB7k5KiP52S979k5QkxuN+2845HjL/EcpWgJotASmoUEMHXAxnR55rRjpOe
SqhY0ZoUgWg2xZV3heVr3gw2n4lejtisAjhfIvYKWrwnKscpy2GiNM2Ltm5GRS6GaJe6aLmCEyVi
786SqidA9kBGX/JpriOlkJ1bSXWGA8PDGF5ceQakebEk+o8qSywCgK4JEXsHZdlLVuRf0CyGT1IR
u4p6s5cM/E0c0XNlhxxDIHaQkqQKEgY5JDACwQG3nSMQSEkEAoGURCCQkggEIii4xzuq8YZRQH1V
EegxDL+TXI1uSkHfaW57V/09p/JCUxdRdrZb8qOJqJelE/j8F9GwlHSztqiwY4su1CA2yeuWH0aL
EfWMexyFwgbrEwSigRVXkTNaVIwjTaaT+lWwN6o0piUqRpa6xaVsWumD8MQ26GcMwLcriEafJU3T
DT/JmEwnwWjBaLV/NKVFDGaQ0v/slFVZdSGeqveaFWJ7HZZnMk6TiAanJLhPTPw5k22k75mJ2BGI
uHHRqPpqW4iI92SJQDQ8JZWpx/9Wb9E2aD0Wy+ENsdFCkWmIPUVJfaebz1mGGBVVR/IQH8QOxjb7
OCLBSRLRZIqr6PPtAbH2ftF1FtRXopbLpKwpFNVWRNNTUjeMNLxscLSQBKNRpcFk2RCJs7iU0hXl
txU2bxkVSfYIyJgZl6c1ehxtbMAXk4jGQ+P5lwxKMaQkwhXoX7JSEBEZiWhiNOAeV1JDaQQCKYlA
IJCSCARSEoFAICURCKQkAoFASiIQSEkEAoGURCCQkggEAimJQCAlEQgEUhKBQCAlEQikJAKBQEoi
EEhJBAKBlEQgkJIIBKI2aI3xR4nTc0ooLocyP+2lYMFUb++rreOvyQdmpOSzKduLCEQ9o946Lf/R
yGLngBY6KQeOvu1iVrt+W+Z33uaa2Bi2LwJRRcX1XmtoGwTtZKQAhQgLdESETjolpuJx+icpJIr0
3Hg8Mk6P6P8kEclBhsqcz2D1IhCVUDJ9RQtdVQKbkBXiCrXGN2FrnP529l9IHO+igWUm/5nEAJtp
z84OvVNhcWzoo3C4/0L7dC9WLwJRCSXX9muhpBqanEicvEMOhgeLg2H6m4eOWcjRQI7JH58FNnXO
H6QzqoS5JXgCCtAxAxtYvQhEJZS0QTZ/YpZOlRJ+Bl30H8AWnJAZK/2l4ZAcHgb17BCV+eP7sHIR
iOBo8y96MFKaPJgCOJPPwH0h9SwN28i2wlNJrFwEohqzZCrFhWKRhRhElePwcFjSZWH6qHYOyDFJ
cTVBgOmeVAKrF4GosuJ6s/Vw56U5beqT5tT5S2ezL6yoEo+tXVy2xpsfPbt6cQWrF4EIigo9Z6Xw
XSSiwVFvnrPaKos+WcImRSDqiJJ5rEEEYifXkggEAimJQCAlEQgEUhKBQCAlEQikJAKB8A3jSxAR
gNs6IBL+xyBHtItyDNufRoWefS0k2haLOyFXR7Dyl11pIvtDPKLoedekiW1j+qoCEZQzIhCHSjIn
bZcG0eIjfFFS9N9mxhi2Pw3LSC37Wki0rR3uhGhTG2XVnS8oWXKNol/UpUXil5HWKiD8ze0kRK80
5B8i7l7LrgB0NRYl5aoXiXGAI1ytE/PATJx6TFOA+C2aSETTVeI7dVJWpbHmIL7zXv4ASXwlQLQq
qDt9h0fIcobUOSW56uUGOLGyebQZoHY3R6WLWLoCqXWOypIuv+ncdGSptHXZKYhllmyAvtvmWRLa
HYmo/Oe7dzQLbUXT2tqrXLK8D0G71XrwSnOlvmjTjmUMFnIMl6HYb2nJrj9i6GqIPtfmZ8L3daU5
GGjqNITvcL6UUXEnZwxXMpgv+hss7KuAuEgQn1Pq3tSwqkFJdSHuc3nVVJMkceymNSlR2ZNk2Xqr
WG4VVFkC4YwWk2ZhfISohpjOqumt4h5SW+V6IcRfLxN3iJF+bidWtQpEZMruzJKqti8vO8AQsl8P
iLKSopxWfsTGfjGploKYSmtZC+mCxhM+F02i+qKO/ykjo16l4IcA4m8taakCl7IbL1kqwyUNhC1C
WEmIsrTgclXqulOh6u2rArihDlFFdbnm0fea4opAeOq0FV1G1RVnSQQCKYlAIJCSCARSEoFAVB8W
SxD7Pcommz6DdWDTwcUM0mRgUZm9JGf4RfxGChJFb0AlVrAdbfb2jgB2NpOWzgNoL1kNSlqIaDjJ
2fQZrAObj5EOZpCW/l+hvaQSyY/xY1lRjBuwAtlLGktnLRaxdADRdMu6tJfUUNeGk20Oo7CynUSp
fpMxPdkjL5eMBXXr/eXUiB7JN1GMUXZqOCTl1VfZydRM99FgMJz8JqlrSopEG9WIFq6zut05OH65
oio1QiAoIwNF4ekbmPvlDS+kURrTYDhZ3z5B9C9DgC+Fds9AW73Vl2FgkIVZufaS1Wz9eulEdW04
afr2jvaUYm8S0Z5Lyt57EqTj7UzFEfdv7xhD/o2rvQtrtj7ARzY1oqRigWV8grOXKr2aemktpw6f
D4/0Z0/qcxaxvGqw3I843qwRJsn6RouN0gX2nxvb21prHW6Yds2QbuTp29yzfCr5uwUysoy1pMRJ
ohpJitwbJd4scseXTDs8Vfo1g6zQXrLiBaifKOXZSxpLZ9v6YGuSyT+RMNtLioAGk36A9pKIas+a
7pfRXjKg4opAVKgy1yzqHl1LIhDeOq3nh5bLjlt7ZGKJIlISgagXjPfkrya6kZIIRF0gU/rjpWX4
RV0/++UomWmPCCOJtLbqTUk/3XF9gEmA6WIyBul2QThfhGKKAbqERwEeGVfk3y2MtKeZbDSJvcGM
noQQifeo9TeeEAS97h0wEReEdqZ1FSOs/rveLcTGHYWLNH0txQSV7wrTtkmMe3db2g9KRe5+SttK
zS63e7EkRNozyn1YXrrjEeEPeH2weJ5GTXOySjnVFHYH3QdWvst+ly6rua9DtMa04KG1lVs/e8en
N5XDXphjPydvn1MFXtOD8sXMxWv5r53IhGElX7hrdH5uDs5Njm4t/PZjksxC39VrDx7/8yKVTbz/
hw8jCU2DYbEj869ntpT6+/pmduHiZzwWOV/bfu3xvmUqlByg9U/6Xhj7r19zjNIx8Pi5n/+Z1Jo9
LUz+3BRtmy885pmxQ2tLkcGVvH4/pW2lZpefTv5RbDncf74gD8ss7e3tjkxHpsAtGUOZb1/+eIiF
hiVZpZxzSrfaFXS0X5YD+3M3H11Ue2TvXJ11DD34MdiE2NiGNANKY1lXNJYWaBigFBE6IMKCbOzV
huaj+QtQgMws/XNAXtQ/ES7Br0XkqweGYsnM2LpE/JkjyEET1gpLz0ObWn+5QjgCXo8dcvmDr1BZ
KOal6Wcic6KQdRQuwOnTsC0F37Jpbhs3PA2XZ6DA3e+A5YHNX8HsLJyWp0MpLxv5xVtQMNx9pg9i
ckiSVcq5i0hHXntpP+MjwPJ+uNFTrwvKFj7YZ9SDtn9wKkUrcQw6Ry4k+jvzUvD7hbVTTyoCeXgT
3A9UBShRNueExDJtofszeWUoisIrakozUEQOWhB96LnX1fqjmKZhTxyFVoAvSouJ3w3FIwln/SsC
3eMQloIXr8vs0dvGDXdAMinnSLmf1LaGBiwxkTuk4BfjmmSLWeKcFhrlyrlLIKduUC6C9m/p5111
T8mbU3DqIX49Mx+FASnQD32zsCEF11s6OuAJRWCLjjhRiB1jVR1aax94I8QSx49EeiNSYYeAW0Ei
Ja24/uKpN2r1B+O/Bac8o4xnIQ7dT0tEnBn668TAHY6ir0+99aHJ16VgVmoIvm3cMCMTSb+f1LZ/
yIsMsT9/K63OnlYGhe4sxMwST2gh0Mu5W9i2nBHrnpLh69NTMHCPfiJ5An4iNwwb6JSx5k+3L6u1
LNXw59Md+ckQZEfDTNtZKbxvYynfIdF3ArQhPMmMRhEmJGepnqHUH4yfGX7xg56PhEaGpzOw8aBy
+J4Z2HSeFQZf+tQQz1i+bVwfIrE/Ie5+Utt+mReZ1EJqXrpvDT8omiVKnKxazl3D6tUDoOit0r+e
F0J1T0lIrlx/kc58k+qclskol1tYUEYWXteXIyFKuvBaMVtqUY8BjrWFBxe32JEAd2sP8ZB/Dk/X
1PorvhNe8hy1MzdbLqwAnHiIrfa5Xm8LAZZOmxirt40T2APREcgUZUoq9wOdo4pIiHWIEXak5CV9
Cy6c4SVol0nLvUeR5fvJ7uBg/o2Szrpf0ltv6zpT/2vJaCqZ/A600TpckFe+h1+m2iqb6wSYPko1
j0lgHL17WovRRntELNKTHI5B/IHuY+wBEOREmFqQUo0Jn8gkU9JSY5+yqEHoiAk9L9MaU+pv/7m1
Jc8o34B9TDkcGxtjy/oITMdoqzghDOM5Snn+pUMupraNE1jSkzD9BtrkNKJyP61tNZEIHJuG7zER
JS9vD83HQH03xs6F4ei98DA7ocgq5dxV3Hy5R1lLwu3ZpXrtGNxLkNxyvnUu/aOv3Fp86cZtMNcL
v3j86tRX/uaLXygufOzyzOIqdFz+QrHj8sY3D4HyKPuxl+4Pd23min/ydeiazg2M3ngYxv9+CxJ/
GWPa0fo/h/998caPvkJlC3f9YgNJaFIst9ef/OVNUOoP2o/19no9jh8duk0RYvWfX/67yM+zrU7C
65nHYwvPfkVuKenv+N+vQLvcNm5YOP9kgaZLoyj361TaVnsxBmuvbf/9jV88rKcdHfoWk+ydUOfg
tfdPFG98gt1dkVXLuZsvQeDxpb+5JQV6b+n1Vm8vQSqyBMkcEm76EuzKLeBmgSZACtytJnpubVSa
RM1HwluL0EMW+RyNNRElIbmx7ksu+qUPYn9uAgihkuurxUR80SsFKO3yw/fi7/zoumF+aC5KIhCN
P/WjvSQCgUBKIhBISQQCgZREIJCSCAQCKYlANClc/EsG/7yf+fP2yqZNk98tcPF/Y+ugUdQ+ni/f
xC0FJ9eL8hfcbbzRAZeozWe+7X0kEjBGtM9NUIeOCATYfFq5Eth8pt7aI4nFKsbNkyFYXGwQ1xRc
XC+KNl/N5y7Z+Qlz9JFIfJQnqENHBMJZcRVFUfk6tRTig/RH6oLaBRH4I9DlzemB+gV1v92U80tC
1Fv7SIF3S6Pe3iZPweYv4pA7CFAeBKLcWVKfCzSvPYQf+7n5Q50NNOoQ0dqFDXOWyPsBIn5pwLt9
ck9BNDrvVuIBEN2nOJh89onEyjX3nIm6DwzX3CBbERVRUvQ3SfD+l4hddzV3RGJzUEZfJQFSMC1r
tSy7+xEnLiKig7sP4lwRFTh0RCAltW4lgsXNvbNW6U1mP5drAFL1GMS6yvWRoj+HjgiEx+Md4t1R
SYD+LBIb93jBmCM6LeYCqoo+biuWxWnbWH4dOiIQHpQE13chov0SjHALLad5Ugw+jRGnmYkEJoy/
SOX5hcepEFFDShLtTSC3dtKdJ0ohJ1eT2ttDy6pK/XG6ne6J0Oi40IcbRSdPj5qnQ/fZyvFVhVvO
nEmqZTiYQ0cEgqEse8mK/AtW7TZVTCHonUTcA9A8qDd7ycBbBURfK8cGQ8A3+shGRB1RklRBomq3
qloKJHiySEtETYDbzhEIpCQCgUBKIhBISQQCERTc4x1b60abXdw+YNlGJlpe0PHb0CGQBWUw20ar
iSMC0SCUdHvXVmGPdtvpGcBOUbsWJI6NiSMC0ViKq8jZQCrGkSbTSf0q2BtVGtMSFSNL3eJSNq10
JHw16YNURDTqLGmabvjZxWQ6Ccb9K1ajSlNaxGBVKf3PWxy6abAe87X/LeI4TSIalpIeM4xx8yox
fILD75RE7FhmXny68RKCvK/HbaaIBqekMvWIvhkm2gatx6L/dar7A5mgm21whkQ0NCV1O3mfXdn4
yQzRkTwVmzJWJQ4C0YCKq19jeCIS81Qnus6C5g9T8naWHhNnmdMlzpCIRqek0TRQ/+Cbk4UkGI0q
DaaJhkicxaWUrvJ9Kpu3jE52ilCGbaPFlhKBqGc0nn/JMrmFlETYA/1LVoryPmeDjEQ0CBpwjyvZ
sUgIBFISgUBKIhAIpCQCgUBKIhBISQQCgZREIJCSCAQCKYlAICURCARSEoFASiIQCKQkAoFASiIQ
SEkEAoGURCCQkggEAimJQCAlEQhEbSiZSKmhuBLqercQG5dC3QkhEu/xTDCVwkpFIKpDyWJ8QAud
lAOk72J2614W6rm1fWMNVotYZQjETlHyXmuoOJEJF9ZZ6JdDiWR4eZgUw3HIRCPRVA/0pKKZjkg4
QWl6PhLpAMjE3i19dqpDYEepVC4WTULmvBApZbCmEYjAlExf0UJXlUAhFBMSEp9+H14FyAFl5EnS
OxiNQJH+Fzncf6FroBM6p+MX+jvhyVPPbzNltz8R66echNvaB9ehd7o9PnIYaxqBCEzJtf1aKKkE
hoe+2D5wBws9AfRcEkowN7W+MTV3Awr0P6EAfYtj67ABsx2Qh4/B7Bww4s5ehrfTwDOLsE2vzcxS
UQQC4QfGr52nYMwYSsFTcN9knoYiQ09RJZSFO4/DC6sQKWXbQxuKmDA8BqnxIjui/yJD9GeioBwJ
w1RgHNegiDpFg33tfJL9KbE/G/AvAMcgDMX81GQuDeFhMiTAFEha7f2QycAZKp2RF430R0s4BE+N
jSEjEYhyKam/xaChCEz/C0TZwY3Jd2aKuWMi7B+MXxhOwffgBFwAAaZ7UnH4BhydpvQMw1G2aIzC
0SM0pgJ6tEBFEAhEFWbJm5fOjowus9DBfa0H2kP/GC72P5c589yJ7ugETJ2G+dGzqxdXYe5S9uyl
VRh7bp2lN9eXPU6PFNBrhy8+izWNQJSxlvSPzL59gy8tYf0hcC1ZJ5SMlFri+LIRgZSsOtrKjJdn
D3wQCMQOryURCARSEoFASiIQCKQkAoFASiIQSEkEAuEbxpcgovSWUgQgSlA/qR2xi9oPH6NpwJXG
UDxLKfUTZgmRBLmPSHzXoXuG7GQ5aeIzY+7VoKRkV35D8va1IzZTT6k9JUUierWaIqDKifzJZmGk
XhrRrsw2gmYJMdB9RP916J4hO1leWm7fCquBgdiX31Buh9ohYp008wpAVwPMknL9ay1nHQXN00Td
VHCNyClay1w1EJcj9wzVMFPlVQPx2x12fdzWMxhSD74J9aXjWSmpj6TWUbDuari2IJX14epL64sJ
77zZJVueKkOqJVgHSivhZ0n5oJ431NEGM2g2xH2Jspdg0OD8jcK+hmxSXsXKaiDxt/xUxOgP/b8i
VrhE9pOuSOqp73TVa19rc+tP4p5jnlsfl/u0R+dnEr77HSm3lxLvJbzx8Rz7R3yzwqkaiPmJkd2l
OtZaG/Dxjt0CfU9Nku79m/iNLwZ9simS6lesTSb8qsgEkF27hxZTvzM12t5ipLva6ltrJYT4ep9h
lK5yxfrMRFlPRipT1xEBZklHTY1wr6SkoHEZQ5rqvaRSGk7zsyuzQVBfrgWoB6O0GODlboDb8UtO
OUzKrQbv8ht1ispqZ+8ihJWEKE9rKPNy3alZDfaFOgSiuooq6riVKK4IhL1OW8Fl1MpwlkQgkJII
BAIpiUAgJREIRLVhspcE/q216LAD03kTl8GMT/9psDW9kxmgi70kt5uA+DYfta0uvzn03F5gY67o
34bOxRLUl62kcxpoLxmIkqZNk0HrzmjGpyXWaE3w/7f3/sFxHPe94HcB7C52FwTQS0KiFFIhRMZO
pRTfBaT5C2QcAbZVejyfrnzPuatKmafnP/RydanzXYWVXPRyoX8kZ6tSqYtzfralqytH5+fnSp7t
2L7Qlh0TJRkEHK5puE7P8T07AEFLImEJwDYAAlwsFuBez++emZ6Znpld7M7i+5GInd3p7ulfn+5v
z/Rnvl4yQB+9pHlr31c3I1ddUgjeBS+SK0rrJb2VoHJaSZ80WivnW2nf3eZCSuo76vgRlerbPfSx
zTnwqW3soaUMmlITALcM0FMcQ7myklCpRxw0IGDLKmnAdazIwY892lIr6cpSyv0TaWdKWlm0BAPG
8KoWRTA0Bg/vyd9GFaxSJLtcVn2HWlQuNzw3pE3bmLhnyfbviz2yQ6x4hyIJbvNEvwTERsJgZZNt
yAqZepiNLZIvBSE2zkTUS9Kg1wmFEJi1vCMMJqDP9YRsHtkf29cukLurYeY+zNo6bFmJfVO39DKL
hEydhNBLBishXbvPO9Awai9K+r1gSSigJJ2xcGzk+BFdltzcEUeC9MGSaNKANBDe4J9LEupTbdRv
SqTeVZ7kbcY0YnhZszXqtWioMLQRVdAINiEjw8+Snoo23aoSCSg9tZSJVcl5yQB99IKOH+Qst+j1
JBNWUAp5vaQrsqtI/lpJuTQQQqBeEtHIqU7irhPqJeUNVwSi8dZ8By1kWmC4IhCBNm2s02i54iyJ
QCAlEQgEUhKBQEoiEIjGw6YE0dffvpvIHapJu48th3Quoc+GvcSCLuWnSy/JbXCSEkxykcI8tLMu
4O/Lzt5WzdVLugstyADqJUNSEuJ6p3BI5xJ6v9tbLEi8AlqbXIw6CbPBJoR/SavSaUAN8+kZF2im
XtJVaFEGdlEvuZKMPeZBlDTqT2k6UwhpSSZdzibNNhZ6newM55OijSmCLky9jAmQjETCjxuS+W5g
FcTMU5NNGxtS7p9IYilJnHMesY+TNEiCRBJVAwENTcSWmLixDZZJdU7ixWfp3i8Z0woWhTTSlqZ3
4rsxOBP3LJnQDtgjXqNAgJtJNyM7ck+x3Y9jk5WftOFudZw7cqPoJU05V8K89AwmttNFWEsSKr9c
SuyNHcFKWe5tOhEnPJBz0RjmcsRhy0TTSxKOz8IQAqGnIwQqQOIarjI2giaJpaTDqp3EpzQNPZfS
8LVn3VSiJMQFYuglfawm4uoBJH4J9zC6pFo00EzZCzUu0Z2j+HTUI0WwOXwvR+PlSr7sTaoWnCVt
a0mbg0BdY2fJ4vgj8x6s2ANjMqdKD8eIwXrJBly1CaXgx82oesmQviWFGUD/knJIJU/fhmiprYB6
ydYbrghEKEO1mdH3muHalFseiI4C6iVxlkQgkJIIBAIpiUAgkJIIRLvBpZckbrGjaxeW44eOEkv6
INi/pJcjSq8EwzultEksA+qYRvcvaS+FtI9J+yNK9C8Zm5IQyhebreU7RiwZXE7hD7ZCy+6pi+CU
0iaxDKhj6mofab2kPUPSmklbGdrSv6QbK/DVwTamJFeXTn+SYBdNUvMVBB0tlpTvvs5CkxCRQl9H
+M0TuzAr+cvx2k6sx1ebU1dJ2pGSumXqmAbsokndMSxJQP3vBpyFlrLOIjiltEssSQj6QocuJuI0
lz5Ltltf7fFaLDkaNO42qj0FGkpnJdoq2gSbO6p/yRCX8B6L/M+2EoNtt6HOXy9JkYhxR2HZwGFE
XZRECUNCDxYyt36c1/BLnmCXiWy4SvUt58vqELu5GAqsc+q8PdvIBT4JN0pgBwmBrqAlsEQjYoU3
6l6DLCEkBIhcmF1oH/93gQS+KQQROEta/iSFKjljEDYeN3WQWNKvk8vqJcPVRHP9cKo36qhptRIa
1omllGbS3gVsclvXWUQA0L8kIuKcGPE06iWjGq4IRCON7QZE3dOGKwLhZ9PGOI1WGc6SCARSEoFA
ICURCKQkAoFoNAR6SfXQqY+UQafoJn38S5JoAWXqSyqSLWyQH0teOEaa51/Syz+m2AMl6iXDUBK8
XyEv1Ywdopv0kgH66CUDAsrUl1Qke9gAxyy8HJM2z7+kl39MDw+ULRfttb3jSaFeUms6Xoyue5nk
RZO630lqjnudp5u0O8IgzUtddhAMubU0bLDAKgibvcblI77hY8AmkCTJoKRrfDSd+AJx+530Ehd0
lG6yXa0tfxf21BUsBiW8q8B0qgmkXRnJ56ztHU+K9JKiPZvcCeJNug583w4vaZJgZjhz3W7pyS1A
o1ZxZL0klfSClxDpVds7nvTRS1IJK6DTCOjj4BaC9X7Wbv0o5npju3RUvWRAFYCn90gpd9WIaIZr
gJ1NPV2vJX6SJDFLFNJaj1Bf8p6vqfuedyT/kpQEhHCLNwl0ZvfYHXRJmGFUcp7sULNV3jgIeZM5
ZOrhqrhRTh0p2aULIQJnSUsl53wNj4dd1imyOC+hX7CPxXDSx4DUoSFVHNe/pNcVvbxHin5AoWQo
oF4S0chZE/1LNtlwRSDkFi27FX1PG64IhMimjXUaLVicJREIpCQCgUBKIhBISQQC0XjY9JICn4Xu
DSDmGZHar5OeQNn0fiByS+TyL0nFelPPK5jyKhKu6mRqm1M4Qjy9pK3sLr2k4ZVUv4pHGkZJUS8Z
ipI+IMLu5FL7UdI5e3j4sticSIpCOBxLUtl+D7ycMZRPkKDatk7G0ku6y07EybuK7dJL6tKFXX8K
spKArebBlLQUkbp6kvM5yVXvHoFpKXhvxCdBCn/vSPoFItYnkToRfZgMLjsEvj9i9/wg2MY6AynX
EEmSR0m3IhI4EcHe2z1MgyTMxItsUmyKQZgwDtijXYkGy7dl3+iya6sa4pwlE9Vje0Sji5ci0sFI
YRt04u6MMGuwGK1PQ7rrCJBaUdeu1Ch6ycYsRQzDqhXD+WDCeptbL0lB6o0uXn2lExyiO4ZzEqYD
74aS1zBdSHBeHMUIrZckUSY7cQi8rRPXcA1saNqx1U7iUzoELWmz11rx9JKBIdx2a1zZ6d5GV5jJ
kAZVc2fuKaYhA0ZTEDa429I2Sgb9S8aeJXn70+wp1pvoqNurZHOdJLZmqgzU+3lJBCP2ffnIMrUt
cH4ZRS8pXXbXwIL+JSMC9ZKIRk7mqJdsmuGKQDTFlEXzNZLhikB42rSxTqPpirMkAoGURCAQSEkE
AimJQCAaD0m9pBy8JJQJW9N7uk6U1UuGewCnV1BIvaRQwBlQiih6Saf3SLd/yTDeN1EvGY6Svhvp
ZNpRrJ1MWhN4uk6U1UuGVY0S51UlowANWYpIekmn90inXlLa+2ar9JKJpqRjgDNaUPNnx/mStPsC
9nAwGWWabU+Ye1CD9JLuOJLdP2QkGREjaUYVxAqxSz1BXCcpqO9GPTWckppa2aaXBHC7lHS6WybS
BlTSYOv08nrJcBIo0ywO+6IPEroUkfwC0QaSZRd6gvgSK8nphD1+pXItoIQDeoAvp05494c8Wyg3
iMn3IYmRLUKd0kboJQOrgEi/cKiVPSFBosmeoMlf4Dwr1P5hkizqiQcYSbYY2/VDlZmEr6iwLxSx
YoXWSwqqQBCCEonpEG/rxKAkfy+DCMSynsNd0qfDYNeJCRp/LJmktQShDagCEjgpI/nioMsxzBPP
RTINWEBD50kodeFjWL1kI25HxI9izW9xHEDKV4HMq3cQkdeStvd1MJ7aTVUvuV6HSCilZZBeAcMV
OUIkmbB6Y8TVS3pd0aWodF3Py/smIgCol0REM4cjzpWolwxnuCIQTbHO0XyNabgiEJ42bazTaLri
LIlAICURCARSEoFASiIQiMbDTy8Zehtlx+klA0oi0kuGkT5GFlnKXEeQuXCbTL0VkXKaSfFZ1EuG
oSTqJfliAASVxKWXDCl9jCGyDL6OSMwprZf0rwY5zaTHWdRLhqKkfYCjvFDSaFJznHMGgQ7USxLZ
kuibR8OVNZJTSuk6Jc7rNKoaIodqRUdwl9wtnPxKm00aPnpJ4h67qUZIbsgLHt47ZxuVd0lIlLKS
ZuTE/zrNGx/b1B51Z8otnGy33Ts9wQVxSCNlvH86oid4pqTc5szgkpBoLmlC14/UdRrjX9JdDR7n
Ze48tAFv2184GaCXjL9VOMl6SfuqSPplF033sil3nWj+JQOrQRhC1rZFr3YRKcnd5iGRXCV2xuIx
coFCRopca2Hjya4qg6sBmdU8BOglJUSSAX0r0TfY7K9ck72ZQJvNSJnr0GZVQwNvtSDk15K6RWQK
Jd0mkmHR8lrKjtNLCgskCmj/IVyRI3hfbLp/Sb9qEIWwZ0i7JuolIwL1kohGz5qUxIi8+0C9JKID
OInm6y4brgiEr00b4zRaZThLIhBISQQCgZREIJCSCASi0fDQSxrv5tRX5C7BnFAWycstk7yPxyX0
4/YzEd+A4SSi4poLiBNCYkmdmYuvl7Q7FHJJMu0aBdRLxqakS+tmNKFTDse7HHS60TIbIbmMdDtG
NNlIfQOGk4iKay6QJiArsaSu68TTS3LFcuolrWsF1k4b6iVX2mszulOcZVGT0AiueEzhYGc+fqKk
caGA2D6kqowLRNqp8P6ZJ63KscToxvCVFD+UkPaipBfR/BuAun3ckU5jIg1ljUfZOUZCBZIw/0Q0
ibeckNCLJmgoNosy9tX26rB2SoYxbKxdrtw+xj0Pw8SVWxiG9vVqUUu+zm37lOMs5WIoX2nEgu4K
2kxC2QOhOUntKwnXumKPmqtg7s4PYfDrS7SwNSdR5/a3mhkNRUljpGDeikqJ8iKiGq7erQ17rGqp
7JBD2i/T8ku+BpjZXj0DmRgCXQIrx1BmeTVHHH+FSYR0gcPdbm7uzenGtxKNfM0oLz/BWdLNSSJa
jXh6meygtaRL6CcdMFxdRK+5EDH5UkTVS0rrRW0MDNZbIoRAvSSi0Ytr1Es21HBFIBphwzYj6l41
XBGIQJs2xmm0ynCWRCCQkggEAimJQCAlEQhEo2HTS4rW3+571h3iRdIbHjJIeb1kuDv9lrNICPle
eUn/khH0km7JqCW+dCojvfSefO44lRbe4AlBSSLVlzrEi2RgAV1FDaGXDHenP4J8htqvL1kKab2k
WyvpUi9RZ1jqmYYp81Sj41OQEJS0D75alVK1HTvai2RItvqQKk6aja5B0pDMWZmkXj9I6z0brdzy
SM3tQLKB9dACSroGXyLpJHhPbJaS1kuG6nxRHKNH7N2NcwhEwnR4LbuN7h8e6a0kvSP2uJtM6CKS
BLRsR2qzwuzKjF56SzsV2WFPQJZodL2kVBW0VcsPJr3Xid69Q0M3fof6WY4oAg0XJcpKkhh0kZst
SQi9ZHAVBJNUkAYituHq92PnVnH07dROt3fNrSPKq8flsytj75LwIQK9T1KkZQh0CatWKOXzY+Re
v41mq5NwUsUIskn9AlQuS3Q3y+6TXUToWZLqd6mN11VQXspsGUkd4kUycPkU7BixMYrA2LJJL6ZT
3WKNoJeUloxaZXfx00tNiQgA6iURjZwTabLuBSlAvSQi4ZxsafQ9gO4c1gEiBHL+HSYXM35zUX74
e/e6nT8OzyMlEYiWoLZ26e7AwGabUxINV8ReweRvPQeweLNQbu9scpQs92Uz44WSueodUz8O5K0i
FcBxspiDUl8mc6kGtTEFMJh5HuBTk3r4JzPjfSUlbG8ROwSPAqu+WiGTZbVdKmQyfaz+6pnxeskn
Sh+LUuob5+qafc+OCUIO5bOZ/AEAks3mDqiTA2sidqXBNGubwmSwdcf6Qb2mRsyziENGhtVm1z5Z
brN9es+uKZkYM7JkTkiXWLFKfN61EPZQu4r+x/5e/XzjwWtJWUs+vL5y9yePf2zbmM9BndBPHzLn
9Z9bh9rJ8vXb1S+dLKdhpbr1tqu35ufh4tTVnYX3vaCGWRh54/azx/+0xsIWfvsfnkMimt1132lW
ff2nPn/xnz++/e9O/8cHRpZrXeMrn7r9yapXlIXPnWJRXjj/7NfrZl0D/O0pEBhdqZ195d+a2678
Zjm3ua205r5TK289/vHti9Osbf7yhcDsPby+lD27omRlYPvnf/auuW0Y6tIvNAza3ck/zC2nT1za
0oZl5dz8/PzdB6/XrERIqvy1m3+UsvL+lYNPfZZlen4YWmMnlv/qDYD9FeVw4zMHq8kwXP8AtiE3
sanOgOpYNtibK2XYMUA9m+mHrHKojO05Y6Q9Wr0CW1CeY38Oao+mXkzX4Vez2tmDo7lieeKeSvzZ
R5GJJp5Q/27B+fNwH3Ygt8SOs7A0AlueUX7nvnbvZGQWqkZdQ03M4I3q0oOQgv1T5cWq2gW3YSnH
rsO3jR9egpuzWlbWqw9ts5Tg17cdQT4Nc3Nw3paJ8t2pPBdiC2ZH9Hs9Wt534COtrPMDD97ZD7DM
/gH7d6t3KBGGaxeM5Gxmzf3vnBljTTMBA+NXCicGqurht7bWz3xBD1CFX4OngRkwddbslUxhmbXQ
0+XqTe1sL/zUSGkWashEE6XXlb9ZODAJafhzmDzAOnBKqcaLnlGeuq38vQjFokoxVtesQnu+4xH6
mf98+jbs/HeFZwo1rZkmJ9l1+Lbxw2HlKrrAqffCMXbl63ccQepKkMPq4Wd0Ig6PZhedIS5yef8Y
fCCbb9kqbpC+Bax3mv8Wyt9NAiXXpuHM5QK3nrnVC6fUgxMwMgfajap7Xf398KIeYIeNOL2QO6Y0
YGq979QvQ65w/NHscFbdjT8K3AoSKWlhXRmr4bXpd1yeeg3OTF9+R2obeuBYzqxXNz5c1EY2tbOr
df37MJT7TY/Qn5w5exhGZ7NnTqkNQbOXL187Y2sbPxhXUXBnZvYRNu86bwWMKn/+Wp19XtJoVj4x
dcsV4kUu7/9m6t/mTx9uVZXXlxw/LP3XSaBk+s7MNJx6l/VD8SR8T7tPo43O6hrhT+7f1Opbb7e/
KPVXp1KwcTWtWDsrWx/YXKr2q/S9BuagWIQUMtEBcvbVj44ehsfPXnm1TuD16xvFqaAo6m0Jva4/
Bxt9XuGKN0ExNWef0uzPR6qvXjn3uK1tJK5ipCQaTK2cbj6rfebq2aIrBK8lXq+m52C7VZW9+itD
us2q/XvgbatJoCQUV+78iM18U8acVi7rp7uUQ32hAq9ZyxHF2kqv1zbqXcZ3gGM96bOLO8q3DLzd
XFsjA13IwNJ51kdrylqyCsWNaqUe9J7rbqUdUkZdn37HmLrQ92NWl7auY2vJmq1tvKDcEB2Hcs1n
CFWCpJSMjCvfTl7WMjHE7ZZWQrAuU3I/Yau3rLaX3krv1+1W9pmbWkzEWrJ3rFj8BqvZFCyo987h
yI+ZtarMdRmYOcos1ClQOPr2GTNGD6vjXHaoeC4H+WcOHFNuAEGFwvSCmmou88fl4pi61NjHFk0I
O9IwWWEk64bKAXacf6ZGzmUCoxw9xhpDr+uJiQkAwf7M3uzCMWU9oQRWb9b1KGtJZdNKJWe0jReU
NKdg5gF2FRbx97IHlJTcQbJwbAa+qQQxMrGj2rvaEw7lN5bVJ+A5sB555LIHctDCfSnFqnH3afmB
oxsnIRGUvHt9I/OR0stApz6kEaj7vd//ATx/7RDcuvGJjR+uQn7qEOSnV9/P3XjLQ6FrdeODZSh8
ce03rrLVxGR3GrJH1Kpf/LuXDm6w9NQbEujowGVLlcYHr78Mr5QG1kqr8O3XC5WZoP2f3y1trI8s
Q16vaw/s6z6yfmMVVm9sbJTUFFcfGx+//orSNovQeySQFrdKFzauLqu3k7rX1kdEFt7S1fULJVtu
d7QbB+YTv+URdvUzXIBXutcGRlr6uGF9WJtpDt1rb6MtlhKk/HBmTe6GV2UBNwt0AMbAXzUxdHcz
bhLNxNDqm7B/0EnIdlOCxBNnFTfvSYXr/ey/wv7cCevfVH3L73whH7RGy0C9hTffy4d37rqWUJ1F
SQQi+VM/6iURCARSEoFASiIQCKQkAoGURCAQSEkEokNh8y/pcBMY+vV+ztfb6/s7XO+vB09PhEJv
ldTmZ0/o88XlAdLD943IwyEXRn8duJdLTfBwrul8Tb8oi0bCEZw9IvYsJWND8CJ6KnKx5HKM5vRm
6OeWgninYLl29PH3JfrOOZQjvkHEzjV1x4nEr5B63iI4e0Sg4co6DaX6+7LVI/6Qfai9zTxBgf8G
VnhneqD/o4Fd0eYuSKOocWlxCgRkZnZh1gJyImkcuMKLCkkjeORB4CxpzQWEnwf4mYFyE4cx4pvU
IQL36rbJivI+f4gnExxeaHi3Tz4p0KCX5euTmZQPeFmXAAbTqOX6QpRFc6AhEdcFiL1HSSpnkvL+
lwSeJt0WGRF14IBOLvZh6ZkC9fPa4c458ZwLrVVgHMp4F5IafjoiOHtE7DlKErDMyyCW0jAGHo3U
ocNFocRrug+IST3GmOa4HiLuWR+BCLy9I+HonoQgkchjJQ1HPtHSTGwhh1gjksAixqQMfxn3PSN0
j4GQpiT4PgsRO5o0vxEfB5RUisR2b41eUx0JT0UaNm7MSQznQERjKEnMJ4Gc8Wb5QdS9T4ptPEpE
rLJ5rPS4nMuho+X/G4KNT/tdV1FCHpe34no+lfDKoOuyEu5Pwzt7ROwtRNJLxvYx2JDLND6heBek
+PA/kWg3vWTorQJUauWYTMR6eI9sRLSGkqQBIXZ7JUZ244oEF4+IRgC3nSMQSEkEAoGURCCQkggE
Iiy42ztCdaNrs7QUXFvFqOshHL8NHbwVlA6ZoRYzkqiReu26QyDalJJ+j9XibizzIYO/QNEuMzTO
RRA1WuoWBCJphivlNJC6ONIhnbTOglhUaU+L6iJLS3GpSSs9CU8aOByAcPJHINp/lnRMN/y04pBO
gn2riltU6UiL2FSV6v+8uNDPgnUx0mkQh6QbTpOI5FEyYGpxbAm3vYJDlhxClknoH3kmhn80j2xE
JJSS+tQjLxekwkP3dyrPFP87McgtxJ6ipKWylZxXHGoIT/IQCWKTUFNbGMMVJ0lEgg1XWcE7oa4X
yVBfKjhfTMnrLCOwJwTLkJGIpFLSIQakdr0kuL/ZRZU2TaItEqe4VNPVX0wleMpoF0xCI0SNFB9M
IhKB5PmXjC9qRCA4oH/JuIj1yhpkJKLdkcA9rqRFcREIpCQCgZREIBBISQQCgZREIJCSCAQCKYlA
ICURCARSEoFASiIQCKQkAoGURCAQSEkEAimJQCCQkggEAimJQCAlEQgEUhKBQEoiEIjosL+hrnDK
eDVQ/rR6NKZ+UQ8PVGqp7sJimMTHYAJrGIGIPEvW8qfMo9PawcTExKtwXTkaunv/F+uwWsMqQyB2
i5JPCI6gfHcqr3y+NVooppfPkVo6D+XebO/YEAyN9Y6NFXPZgcHsk0WAS9lsP5sZx/py7A/J5krK
1JrrZWf6M9qZivKtfCmTrZex5hGIQEqWXjeP3jB/HB7Nqsbqv4afAVSAMfI0GT7bm4Ua+y8LsL02
evz+evUeDMzkr5wYYCEXb7M/O1fOKEbv4trZCgyeKOROME7Cg31n78HwTF9+/AjWPAIRSMn1/eZR
0ZwkT0zdUg9eBPZbEeowP31vc3r+F7DF/ssAfDet/tuBKsz1sz+Mt0rkW/2gWMFUOVOBuZvwTvbt
u4twHzZhdo5FRSAQItjfdm7djzGOKhdurKkH2dEvM6PzX05VYeA4/HAVsvWNvtSmEkz/lx1lH5M1
NaL6k3ZsnLm2pX/LnGOpTeKaFNEmSNrbzoeMe7Kb8E8AxyANter0VKUE6XNkNGMPWy7Du43jWhm6
bWfMC6XgyxMTyEgEQpaSY2P80Q7Mal9+MfWecq1yjML+s/kr58bgm3ASrvDxeuHoDEwb3/b/mNmr
1plHlWWn+W1hLI81j0BEmiV3QF9WPrSv+2Bf6u/StRPfL7/7+ycP9F6D6fN8yPkbGxdurJrpvucf
Td8d8yMbx60zLNyR6y9jzSMQEmtJeZT37Tv76pKneY57BBC4ltxdSmbrXXnvh4uZVBWbGoGUjIKe
iPGqyg0fT+AzDgSiSWtJBAKBlEQgkJIIBAIpiUAgkJIIBFISgUDIgn8IQon2lxLzO+UeW1IA4vXR
UbDK5CgkJV4BjbozfqBE+jrqJicSribtMT1DOUtBJDPmUwVaKr4h/GoHCO28/tJEShq1Z9QZcTWw
TlLXR2cxklijk62Q1DOgfsr8gYa4jh4+TE3aY/rQytFw1mgbtQqAH3O8QnjUjhaV0BY16wrAYCIp
qVWk8ZfqtUn8huPOHfWcYxL17sI0fE0Q13QWbfjYxSrwCeU7W9NdyavnoKQi5Ry/SDIo6ag2bVT1
rcu9Y4gQ6VM03FTQHEaKMtEcVgR1AeK2ZFvQYitJmTx6hE1GxCaO4DfHerPzlpXEPd42jl4Rq45E
6dzKKo5GGEEDq8DoAoFJt3aRM5iUPtfjGFhJyH5DOoyBjgKpvU3rzG1kTcqsO93nidQIGlwFzhCE
D+gzHeJtnQiUJCDgpPUL7ULraIMAAC7QSURBVPhKJXHHHfPWotwtV9LElaQgEzIGdXAVkKhpIKTQ
JbCJzEXkLg/+7ThphrJa9SoihACJy6jYo4tkJhpVBY0IgXCvJd1kpNxzJ6rNo9oNNttHZ02V1Fj2
BBTSCmhWVriHi3zoMDUZIqxVCuOYNKQKvEJQ4lk7ndhXmoEUVhKiYcayzMzfdsZW0t5Qh0A01P5E
8zW04YpA+Nq0sU6j6YqzJAKBlEQgEEhJBAIpiUAgGg+RXtL+3Reuh5hCRWXC1vReUkBXSVyKQE7E
RaSvE0F5KhOFP0mj6yUtuVlsvaReOXiDR56SQlFgmK4sllImrQm8pYDEKyBw+z8BJBWT0ZWnMlH4
k4Y2KoJe0oocXy+pVQ7qJcNQ0j7AUbWmzS0YWpOqvxNBEC/uJXkbHpEtiWvzqEypCQBEH7FIzPNN
rCiP2qG7y0bnxVLun0j7U5JosmWdgcQ99lGNkOYJIjG8d842Khq4Kdvodc3XgoSpU4sLEfIlQSRJ
veQu9wLiniWTqJcUlsYhAiDya0sjTnJnSptYsPEl4dZYoXaASqlUqWtXaiS9pGRm2n4HazL1ku5J
P35Fk2Qx0EcsGPZmV9QVbKMqlTju10XSS4oUQUK9pGP5ifdwGktJ7jZPuJkh6fqtuHrJCK+12oVa
o9zLB0NXgVt2iXrJ5sL+XNK6I+fSydGIjEzyNmPqUReeXTGcRrGpjKRRcxWrSIhmrSX11zoo928M
MZxjgDUsOTMIdIyi0ksK6KMZjEga4641V2thcugbRZC5KHpJrwVMBL0kQg6ol0SEXvPGWrqgXjKU
4YpAyFvErYi+Vw1XBMLTpo11unWLmNrgzt10ImoYZ0nEXsBA7xtb2X6cJRGItsDQ3VsAy7B8cN9S
ombJcl82M14omaveMfXjQN4MMFkAx8liDkp9mcylGtTGFMBg5nmAT03q4Z/MjPeVlLC9RewWAltq
nNWiUX/sw6p7b+TViq9lx5Q2UKvcC/xpNfxgmrVNYTLwEko/qNfUaHmWqSGo1TPj9ZKeppZePZPt
K6tH2lVqhWymUOPLdimT6VPjHChkslrJ8mNWCruKS8sL2sEv/lnLdVujO2cePry+cvcnj39sW/86
DPPKx+lD80aAn1uH2sny9dvVL50sp2GluvW2q7fm5+Hi1NWdhfe9oIZZGHnj9rPH/7TGwhZ++x+e
Qwo6UXyI1aJef/tOrbz1+Me3g0i877Ra8cVT7GN+fv7ug6Utr7Ds9E/e9o8aTdTwF6dZ2/zlC4HZ
enh9KXt2papYe9s//7N3zW13ja986vYnq2qza3cn/zC3nD5xSbm03u59pz//teNLHCdJqvy1m3+U
Ykf12mCG9QI26JxRMq13q13Ewqe/ka9oh/sra5955fOO88Pz7dUtuFnyD2AbchOb6gyojmWDvblS
hh2zas1m+iGrHNbYmJczRtqj1SuwBeU59uegtm5/MV2HX81qZw+O5orliXsq8WcfRQY6UVI6uVF/
27CUg52gKE/ozKzq89ndqZzfdEcmX+bC823jh5fg5iyoTF+vPrQNKdbwSyNgo/6nYW4OzquNrLX7
fTi/BPyAsgWzI6BmrlJb/JlSsidSLanlcuGXfgHL+xU+gvK5+FhfLTGGaxeM5Gxmzf3vnBljLTEB
A+NXCicGqurht7bWz3xBD1CFX4OngZkCddYclUxhmbX+0+XqTe1sL/zUSGkWakhBl2WpLgn0+qvC
5CT8eSCL31A/PqMvJoZHexd9Qj96Nn+SD8+1jR8OQ7HIcqS14YVjtxkpWRYv8kHqSpDDypHe7mmo
TELVGcKIM6Moo0qrrajkyvveYL0S+H+v9343KZRcm4Yzl/n1zK1eOKUenICROdhUD+919ffDi3qA
HTby9ELumNKAqfW+U78MucLxR7PDWXXX/ShwK0ikpOuWw05ZG7jU+qPZy5evnQmKs67W6IGXtAVR
+cSUn81Vrkxrp/XwfNv4YVajlIo7M7OPQA8cy5ltDlrTMvy1eqi1+2vTFy5PbTtD6HEqF4CNCest
eQTx0HX3b/V/mRRKpu/MTMOpd3FrnZPwPe0+jTLk6WuEP7l/U6tvvd3+otRfnUrBxtW0Yu2sbH1g
c6nar9L3GphL6SKkkIPO8VurHb3+Hqm+euXc43IxN5/VPnP1rN9ts2OjlSIfnm8bP1xTmaY33E02
mL5+fb04ZQtifdPb/fDZj746SpwhNF4vDI7+qGU3VVYqhzSb1fr3cHUlKZSE4sqdH7GZb8qY08pl
/XSXcqg3AbxmLUcUiya9XtuodxnfWUfoSZ9dVBdFGXi7OWAjA104eUFZsxv1t6WsJSVNiZOX1Zgw
BN1+wT6kGzZmeK5tPI3psTEYh3LNNoQWN7Yq9R4+SErpEONcP9hW1pJbXAjWZUpa76kNw0dbuGUn
vfHjIc1m3a/arUP9lTbfMcBRsnesWPwGs1JSsHBA/eHIj1mjKnNdBmaOMgtrChSOvn3GjNHDxsFc
dqh4Lgf5Zw4cU24AQYXC9IKaai7zx+WitmDaB2nkoAMTExPK4lyvvx5lLdkdKiYbPed8J1P1oTOj
hxEeKjmjbfySnoKZB1iTs4i/l2WN2svatkbOZfggWTg2A99Ugujt3qWsJdP6szElRBqOPgHPKT/s
r6+fb2lFn3/r/1Y/l9WF8psr7d4xuAa6e30j85HSy0CnPqQRqPu93/8BPH/tENy68YmNH65CfuoQ
5KdX38/deMtDoWt144NlKHxx7Teu3mI2bncaskfUW22Lf/fSwY3Sy9pNANyS4AG9/lYfGx+//kq4
qNvg+7j3Bec4ONm9CL1HckHJ3ipd2Liq9t+L3WvrI6vw7dcLlRnbRLd0df1CSf1Fb/dXrg+OX1/R
jV61/49sbJTUtXF19ImWPIzkZvkP/8qD2tEDP17f3/Y9IpYSpPxwZk0q4GBlATcLdADGwF81MXR3
M24STcLA3WXYv0NFvbDdlCDxxFnFzXtS4Xo/+6+wP3cAMqn6lu+Un18MSgHqrbn5XutL9Yl303UW
JRGI5E/9qJdEIBBISQQCKYlAIJCSCARSEoFAICURiA5FTP+Sdjhfb2+9Md3xo9MrnL+vQvOVsfpF
wqfg4dqQL6rYKaQ4XZvjIu/cUHyPKSIeJWODuL+7e6Tbh2WAr0LHK/1J+BQ8RhhqO0VAHEWQrs1N
o2duwjh0RCD8DVdKqf42bvWIP2Qfahc0T1Dgv4EV3pke6P+otMsMi0nEuHS4FMzLC/IUd/6iVupI
O0STZ0m380ibt2DKzR+U2P0UG55giHiyAcuVjXBe9Zx0ebdP8ilY9rTh74SLRDzIKZMzannK8M0N
shURi5JUziTl3YMQUXd1dkSB77Mor9gl0VMws0x8Zz3iF4SC0A0H8a6IJjl0ROwdShKwzMsgllKQ
I7PM6bYACeI0oRG8QEo5Z0Uggm7vkOCOGsbnIHXfApE3Oz0twJApSEcSByFREpZx6IhASFASfJ+F
UPESjHALLa95kkp3cdu6TTjTkNBMlItEJIeE6LlBIEJSUuQ8EuyuJu2LKu6byI+pFUc4awT4KpTw
vOifgtd17awPmy4Ncu0YxqEjAmEgkl4yto/BhlymgSmEvRLFPQCdg3bTS4beKkClVo4JQ8gn+shG
RBtRkjQgRMMu1bAUSPhkkZaIpgC3nSMQSEkEAoGURCCQkggEIiy42ztCdaP5nDHck3ni2srtfEDH
b0MHkVKROA64H8JoG63f8ckFImGU9OuxcYVMPjs9iTB56jygfFZCaBstzYp6MeQkIoGGK+U0kLo4
0iGdtM6CWFRpT4vqIktLcalJKyUIL0MhKjkqIBDJmiUd0w0voHdIJx1WoFtU6UiL2FSV6v+84lBg
wZr7tR3WqmBylHxCaG4LRGoikkZJdz/2/M2ujSTSz8+JaAILwRXKcRfbENHxlNSnKyrNEuptRNJg
C1OkuwpQ5ws3vCMQnUpJSycvOQfZX5lBPedDIkFs4wav++0b4szgbVTEnjBcZcXwxPWIwj0V2t8j
SZw/UeImrItn/mIobEZER1PSLg00qeCpkAS7qNImTbRF4hSXarr6+6moJ62EwuWw2kZ7vnFGRbQ5
kudfMh6pkJIIB9C/ZFzEep0NMhLR7kjgHlfSorgIBFISgUBKIhAIpCQCgUBKIhBISQQCgZREIJCS
CAQCKYlAICURCARSEoFASiIQCKQkAoGURCAQSEkEAoGURCCQkggEAimJQCAlEQhEoyhZGDOO8tpR
rZDNFGrK0ZgK37QmC7avVuiAeAgEQkjJWv6UeXRaO+g/9d3+UwPK0cSE9s8Hl09hfSIQDaTkE+6j
+3B+CbZ52hYy2dwkm/eKyuxZvpTJ1svs2+dzvSTLpkPjfCnXO6gEv5TN9mMlIxDRKFl63Tx6Qz9I
Q2USqlyYgW9trZ/5Ajv4s8KpHhie6fuH8SPs2//Ud7bCgk0Y58fO/P19JfRM/sqJAaxlBCISJdf3
m0dF/eC16QuXp/hZ8l5Xfz+8yA6Oz0EWNmH2Mdhi3+YX4T5//hSM3GLfNmGu38ZoBALhj+4c/20Y
5u1Hnz7z0b96Z3nL+on8pzfmvvrI/DA8+9zw6zvdj/zt38Kt+8PwuzCs/Dhvnf/d59jX7kd+9/8c
Vs7PY00j2hTDbdY5Ax6CbCtryS3uhw14LaselMvsTwq+PDFRA/f5ae3808rHu7HVEYgYlLQ9u+hS
1pJpW/i3z6gH5BgzXHvh6MJY3jg3BWXjfAVmhtnH38DRGUZPBALRoFnyleuD49dXuB/y06vvVw9e
WL++DPM3No5cXzXPTR0yzv/g+59QUmbnL9xYxVpGIKQR0XPWGExg3SE6Au3mOasnWrSpOjYlAtFG
lMQHGwhES9aSCAQCKYlAICURCARSEoFAICURCKQkAoGQhv0hCFU3DlAAoh9aP5rflJPmBx+jY2CV
xl5YVym9AjrrLOg6VD6Srb4Dqp06M0ckM+ZbMvMT7D3Ep3b4AtJO6inNpyQlNKjV9ABGOMr/2CmM
NEtjL6yrlF4BjWqRvQ41u7AMVQSX8wvLh9baN0YVKCCuJqfCPsD9wBeQ0JY27grAYKJmSa3izJZz
jZWugbDFFdxkEIlfGpm6BFVoM3LS2Ex65bqFncW6cIr/QhJCSWskdY2VTe2hibBoSVjmNLbHkhA5
EaXXFFMmMOOk5Z2F8LNku3faHnuD2Swb4r9E2RssJDbbLLDstBkUF+XKXFQG90fNxGEf7P/wl5SM
QZJxP2Gw/bPY49efKOwxiLuV1pklepweUHrMIhzLQw10xJavgIHTMHGI1KjiqgJXDEcIKlxc4j2c
xlCS2FlIiYiVnTxJEnFhScj4NFQtUbOmw1YtkUg2rEFNQodwXwj5GAddju7naLS9xUiPwtIQ5FJ7
JCEyvdIeWjKStBETIb1ohniDLoQQzpIeBhu/UKCaVWJfOZCOslT00ig2nq2wrlJaAb1CNGn1FeJy
lGsr7ZiEqoLgskv/gJBDCmsMEd5wiHq6Hc2sdnurAG6oQzTalG1m9D1uuCIQbps21mm89YOzJAKB
lEQgEEhJBAIpiUAgGg/bHld9/e13m9opo7RrRuwqyqQ+kworg3QJAyUfOEYSWZoNRQKiCErRHL1k
sJoU9ZJRKRmlsmwbHO0qyqTe7w4rg3QJAyXlo5FElmal04AaFpWiKXrJYDVpu+glVxKx61z0EEQT
TKqbV7RxlTpGQe6IiDaBtl4f1yCQkKOVXmISOvVo40bzUg9bBcT3bOv6g/2CKecPSdFLAnHOecQ+
CtqPvJuxo179QUBeGBiVZDQsI0N38hgrCR+DM8gWbV1/IM5ZMgl9ske8RgkaHd2M7My9jFRS0hSy
k4YLFpNEDdFL+lSBJd5s8y4wmIw+F2EtSSi3muk0BgrFgqFvVklS2PulY42Y84jDqomllyTeIUhw
Goh4hquMOaC1Ete6nTFJBvbWJhYzTOrWbZNQGWqOXtLdBZCPcdAl1Vd8v3ey2WrrirLCQNrU1CWj
0GZUQZPWqYjAtaR+G1W3P7Q7rpZijj8y78EKVJSJnSpDyiC9lIKS12lSpblK0Sy9pHHkfP0v6iUj
IpU8fRuipZYD6iVbb7giEI2ziFEvGcpwjbjeR+whoF4SZ0kEAimJQCCQkggEAimJQLQbHD5BwOVO
0rGZjNsBJvK92ElbqWzSF2M7mkeIUH4ffWswTNZ2yb+krewuvaT5MBscuXFKhwxtFt7gkaekD4iw
vV2+FzvJ0SRfFpvsTxQijN9H3xoMk7Xd8C/pLrtTL0nAplcQpKEf6cPCrj8FWUnMhnM/SlpKSV07
adODa54K9s6wZVoKPj5x+E4ZTi8ZryJJy8sOgZrt3d8JbcusUyZJkkhJu1LSGuuSocFplglLWkcM
74z5TJKN8S8ZWPYQbzfZtZ5DHLNkonqs0Jkd8RjHHYwU1nAn7s4IaVNKdz6dUaGXV6Y8LoyOM6Je
UrrsvgFbOYwPJqy3ufWS1J9XNLjZO+jGTnPnQGKsAUL2WF4BKU+CSHpJEhhCEBD1ks0xXP27EXSy
p/QYr8Non1fz7Z5/SRKYxl5d8URCV5jJkAbZIp25p5g2h5HNfY/frvmXlAiIXIw9S/L2p1mdhNpU
kkLfi53kaFIgOPQMYXZLTTMoZ7lFr7rd9y8ZXHafHyhasmGA/iURUUzz6BMi6iUjGq4IRFwzvhnR
96rhikB42rSxTqMBi7MkAoGURCAQSEkEAimJQCAaDw+9JKdw0560CTwhiuV+yXYtqeXd5RjRVmBR
QFddyNzGsFeZ3LO7MLrMGHpJv2qQ9TEpcLWmPqTEGzzylLQLlTWFGyXg4QlRLPdLtmtJvvB8Majj
d2dAZwWRMNcJ45QyjC4zhl7SrxoA5HxMClytqUNVm3SN9lVR2red81NciObjBXEd4loS3MUgYTqz
fK2FqSsuLGlVNfgUpf3nP6sgloryK22W8R4Zovk3EW+KdJZrSQLhWSNvg0bgFhHVeQgiRVtORK2G
8NTetRblVZTttnvHTskwho1dtEf2xDZGSctSds1GXS+rkc+HuaiUbaio/iVlR6Fo0s+WoX1VlD0Q
mpPUvpIgIZZCCbqxE2Vu0bfrhzD4bbu05ScREhzFrjSX9y8pVw0eXih9pZ+oB4ltuHpWIe3Y6iX+
BQ4sNWn8tSNHiaiXlKiGqAWlSEsZdAmsHO2PZ+01SImXIKLqBQ7sT+FuN1OIZrXKRWl8K/mkKFXw
PddvGjVLmpwkotUIfyenU5WSXo4RXbI/Ly+M4fxLCr/Jrg6bpJf0q4bg8tvck+6Z+wwNA+olEeGn
5ziaSdRLhjRcEYiYJnPTou7RtSQCIbGq9D8dI25zUf5Uvtz2tdudwx6G2COorV26+zlyz/Hr8DzO
kghEKzD5W88BvNn2z2E4Spb7spnxQslc9Y6pHwfyVpEK4DhZzEGpL5O5VIPamAIYzDwP8KlJPfyT
mfG+khK2t4gdgkeBVd+BQibLaluvvzGt/gItrwwLU6tnxuslqOWzmULNM30rRaNt0qxtCpPB12D9
oK6mW8tnMoUhI0G12bVPloNsn24C1rLKb4NPZnJ80rVLmUyf0Zf6lBCkN/PkJMgUsknof+zvlY+l
m1Yfb3fD9eH1lbs/efxj28Z8DuqEfvqQOa//3DrUTpav365+6WQ5DSvVrbddvTU/Dxenru4svO8F
NczCyBu3nz3+pzUWtvDb//AcEtHsrvtOs+qr1wYzrHb0+pufn189eL0WFPWzSsyu8ZVP3f5kte/M
5792fKnmlT5L8Sdv+0fltNE206xt/vKFwOw9vL6UPbtSZUcD2z//s3fNbcNQ1ymtMwyDdnfyD3PL
6ROXtrRhWTlHRn5Ie/49lxeSKn/t5h+l1H7wOSVE8TeWVt74Um1e71a7v4z8qzcA9leUw7X/sPhc
MgzXP4BtyE1sqjOgOpYN9uZKGXYMUM9m+iGrHNbY2G4Oh0erV2ALynPsz0FtUf9iug6/mtXOHhzN
FcsTquXePfsoMtHEE+rfSm3xZ7Bj1B/rM6eurQTFHBpV/mZhaYRFuQ/nl2DbM32WIpl8WW0Id9v4
4SW4OavmCNarD20rkolfd17l0zA3B+c1/lfVv9fK6S1+kbYFsyOgDfe/c1/5W52k6a2NltX5gQfv
7AdYZv9gP/xi6EAyDNcuGLHZHnD/O2fGWNNMwMD4lcKJgap6+K2t9TNf0ANU4dfgaWAGTJ11jUqm
sMza5uly9aZ2thd+aqQ0CzVkoonS6/rBDOvvev0BPFrNpYNivvWPyt+UEuUipKEyCVWf9B89mz+p
fKptU7O1jR8OQ7Go5khpwwvHbgNcv+MIUleCHFYPP6MubLZSuUyh7AxxUT186rZKzK58tnW3Owfp
W8B6p/Fv6Z8HE0HJtWk4c5m3s2/1win14ASMzMGmenivq78fXtQD7LARpxdyx5QGTK33nfplyBWO
P5odzqoFHgVuBYmUtLC+X/usXIC8WX/lzalAA6qWV5/q9cCxHGuD16YvXJ7a9k6/XJnWU1Ta5vdt
beOHWY1SKu7MzD4CsOG8FaBO1n+tzj4vqTQ7N/qZvlOHnSG0fvJhNfbs6HLh9COtqvL6kuMHmghK
pu/MTMOpd1k/FE/C97T7NMqQp68R/uT+Ta2+9Xb7i1J/dSoFG1fTirWzsvWBzaVqv0rfa2AOikVI
IROdWBgc/VHZqD84dnYz8B7YoHZ/7fXr68UpgC+c/eiroz63D4+NVrQU1bb5nK1t/HBNm4m1hrsp
HEynzKPNZ/WDp2ZtRvQUx2sdlRbaSqu/MqTZrNq/oR+mEkFJKK7c+RGb+aaMOa1c1k93KYcaNuA1
azmiWFDp9dpGvcv4zjpCT/rs4o7yLQNvN9fWSED3lDcMH2VjtVF/y9qs44tT71CW+VDc2KrUe9ja
n60lt7xDfwh49tnbxgvKDdFxKNd8hlAlSErpEOPKt5OX1SzZGKiEYF2mZOtcAo7uJpbeSu/X7db9
cHDw3clYS/aOFYvfYFZRCha01e+RH7NGVea6DMwcZRbWFCgcffuMGaOH1XEuO1Q8l4P8MweOKTeA
oEJhekFNNZf543JxTF1q7IM0ctCB/fV15QaJXn+Qg/8yMMrExISyns8/UyPnMqwp2FrSp143VU0B
o4fVNjmjbfyuMAUzD7AmZxF/L8si9gqCZOHYDHxTCaJnKQsz/8RCak84lN/ScPQJeA6sRx5ZePSf
hCvfXUKxajzNWz50ZwmSQcm71zcyHym9DHTqQ1pDd7/3+z+A568dgls3PrHxw1XITx2C/PTq+7kb
b3kodK1ufLAMhS+u/cbVW8zG7U5D9oh6q23x7146uFF6WbvBgI4OnKiOPqFMJ3r9scFtv2zMb79e
qMxQWLs+OH7d5ybtCwZf82bbLELvkcDtWrdKFzauKvMJXOxeWx9ZFc05V9cvlPjl2NqNC+NKnGvG
D8sjGxulM7YQx8dHtlu6hB/WZprhjf1t3TFiKUHKD2fW5G54VRZws0AHYAz8VRNDdzfjJtFMDK2+
CQeKi84ctZkSJNYe1+f6tyQX7J87i/25A3D79W7fpWiq715ACpnXfn6/Zdm/t/h/Fd687Py13bYK
oF4SsdenftRLIhAIpCQCgZREIBBISQQCKYlAIJCSCESHwsO/JNiPJOF8vb3pnxIcPzrfwu3yROhM
hnuzsfbKbncKNp+H1HldzWucl3tI4z3grgK7fSw6PC345SaiX0cEUrJhIO7v7q5IXMoYtydCKj6t
xycCbY3bM6YrjPt1/DaekYAg3Chj85zimZuIfh0RaLiKpjtK9bd7q0f8IftQu6B5ggL/DazwzvRA
/0epxCu6LRbozi71S4tToP5eZYR5CvcCbrdzaWqlLpEbBCLOLKmN74R3rsy7W6b8fEbs7ocNTzDE
c56j/ERI/GZb4vjJsIsFKbhfcW8zLtXzlgNp8OWQMIg9S4Ra7i1kcoMkRUSjJJUzSXn/S+6+Rtxm
GgngW0i7WMxYnvOCTImyYltcmmtCEilXXrlpsl9HRGdT0vQiSoNZGsrvU7Nfq2DzdhPGTSMl0ezY
MEtqeb+OCITX7R2JjkpCrMuo4BYIDccDQYemXreU/ExFicvSSAz1i9UGHsERCack+D4LoeIlGLEs
V895koaflIiXg2cilVnHdUnwAi/abCaRMAIRlZLEfBLIuQa0ubz3do7ovjXJxyHU+3IuT4SUOBP3
pq1fCh7XtYJ6PqPwdDXp+6TR6f4xnF9HxB5HJL1kLP+CDbtMA1MIeyWKD/87B+2mlwy9VYBKrRwT
hpCP8pGNiDaiJGlAiIZdqmEpkPDJIi0RTQFuO0cgkJIIBAIpiUAgJREIRFhwt3eE6kZLlRHmdoZr
/xh1PZlzbEklgiSM0wRCahvtcahdLIVAJIWSfj02Zlf22+JJhMnzO4R4qYmMttElXbF29KFwEZFE
w5VyGkhdHOmQTlpnQSyqtKdFdZGlpbjUpJWNIrzkqIBAJGuWBNHERAwZJK+QdFiBblGlIy1iU1Wq
//OKQ4EF671Rm3q+JMQfnNIRgUgWJd392PM3uzaSSD8/Fwp8ifxcyL1qBxmG6HxK6tMVlWYY9TYi
abCFKdJduSRX1EM4HSKXCERSKWnp5CXnILv0gnrOh0SC2OarMqhcVLyNiugsdHnSQ+qmCeGeVXhN
hYKJkopmRKLCOAQSPL9KMR2BSPos6ZD7USIyEflvdlGl7caMLRKnuFTT1d9PRT1pZekfQ2kb7XGE
GkwEol2RPP+S8UiFlEQ4gP4l4yLWe2yQkYiEriXbmpMtiotAICURCKQkAoFASiIQCKQkAoGURCAQ
SEkEAimJQCCQkggEUhKBQCAlEQikJAKBQEoiEEhJBAKBlEQgEEhJBAIpiUC0HmQQKYlAtA/K6/M1
pCQC0TYYfgsK5cRQckyF8e1AnjuhfhR7odaXydbLUNJCDmSZEVCv6OFzmcylmhK2F9+m4T9Qm/Xc
x/6WCplMXw1ql9hHySvKUCGTzQ9BqW9cqeNaPTNeL3HpWCiw7+W+bKauhsr2qb1PT3sw/TwLMBmc
Py0+w7W8lre+TKZQ0ruIGsRK+wDLfq7mzotVHhYiy2LreXfleJfr/i7Am4fbu39058zD+flhmJg3
vp0+ZB4Og3JYvvOfquSdn//y2X+d+srBpz47Pw+p/nvbtUJK6zRr6dv/677lGgubr771HBLPGy88
dP1nrPZg4XOnWMX+u9P/8YGR5RpJlb92849SXgNnbSB7fPSHL5x/9uv1lWrX+Mqnbn+yaqTDMbdL
SfHh9aXs2ZUqObecPnFpS1k+aWlfnL66s/CXLwTmT4/Pjr50/+efZ3nbd2rlrcc/vq32BO1tbn+Y
M9JmOftZ6c0dV16s8tRrg5njf1pjef8arFTntc7UKvwfb7I/a79UsU2c8+3VPwSG66Vsth8ybEiE
Wi6byRX1nx+d7YZNOD8H/wJ24CPKL/cXd2B/r3a2cq63mJvYUA6vnD2KvPPBfaVyGX7nvvJ3B3JL
sMX+mx2BnFeU9a3F1+CL7PzILFQhC0sjLIKRjoVfV2gDL8HNWTXFuTk4r/ygp/1iug6/mg3Onx5f
adTqQz9lR9uwlGP55PBpM22Ws1nodufFKk+ltvgzpZQwMqel2kJMKgPNflhr6+Wkm5IDM/krJwZY
5U1Af7m6ceaeYYrALKSAWStX4WPwgWy+DF0LXeWtm8bZnxkJ/BpUkXc+2IaNrLKeeeq28u3PYfIA
66p1KBbhonekJy98/zV2vqgMkGorXDTTsXD9jvL3sBKqrqV4VfnBSLv2dLl6Mzh/enwNRxnfqjA5
yfLJQU1Rt/96L0+vKnnJ5MvOEEZ5ZliWL/KptgrvWWJ/lmGxP1mUrMJcv06qyuH+34P7JiWLkIZj
X2eH/2bq3+ZPH4beI7lHM/8ho95VHgVjNmXVv4O888PUtfwp1p8/rNbYmenL70hts/pjeNE7zhc/
eOaX2ZiodvYeOJZTwurpWNhQU9RDjZo/62nnCscfzQ5nAx8C6PG1aWUD8kCzly9fO8MHUVP8a+34
zn9z9veVvBROH3aG0MtTucAS4VNFhKMkG99O6qQafMfHvwrnTKYBvPbUxv8wxayVanqODYwr1ZuV
W//jxm+r3QzMMbKINe+LjepJpfZ0PH72yqt1wurPv8cWn2JT6TWtHV6/vl6ccqZjQQ81ZQ0BWtor
Wx/YXKr2bwbl75rR2mxxOn5upgyPVF+9cu5x26DC5+wD8Dl3XrjyLAyO/qjMp9o67PsvFLsVDtxO
FiUBymV4t3pwDz74U46qZSh+uHqvnja+M4skWxxNq2NhGt5mRm95zScJNWUtWWXtUC4FPJHqYjZk
Wanc4sZWpe7tGHQcyjUWKqUEHtcisiMl7WM96bOLviaMckNUj6+05FrXlRVlXcjWkjU+iJU2CJim
hLDKUxuGj1LQ8t5qLP6/zG7dD+vFZFGyF47OwDQb1crwNLzNulOjrN/zmdr3zmUhlz2QU9fu78vC
Ma2tcsc2y5WxgjoUBfiR3evIZReOgXmbpRsqB9iAloajT4DnjepcZujHLAoLdIy1Q/6ZGjmXcaTD
T1AzD7BQrGlm4JvKU6kMHD0K/7tiQeZgesGX9xMTE0Z8FvFvYJ/Syj3KWrKbD2KlnXtm6CgoPWIh
x3qO9oRDCaGXh/2wv75+Xh2zWd43W1339ADj5GAuYYbr/I2NCzdW4flrh+DM1H9mjWxsHQnf7s5/
ghkhr3SvDYzMMwOgaxGOF9QCLn515+DAjRXt9sWnkXc+6Os+sn7jlvHtldLAWmkVlkc2NkpnPKOk
V9/D2uS7pY31kWX49uuFygx1pGPhVunCxtVlWLq6fqGk+k9ZUtI+zhaG3YvK+j8of3p8hv959NeV
GW/1sfHx66/wQay0+764OnJjDda6jwzcmNeNXgVWeaqjTyiJqHnfbnXdp9mk8eB2e/cPec9Z5Yd6
V6UC9m/dKSLxOhJj4O9laujuZtwkmozyA/U3HnLkaCKplITJ91akwuV7y9h5OxOZVN330WIhvxiU
AtRb+1CwuOOcWBJMSQSiI6d+9C+JQCCQkggEUhKBQCAlEQikJALRENCWRIWvtFmOkZIIRFuB3/tG
ifXXfiTLfGKPo48ExDU8ENeIQWxH1BbE+JHoF/FOgYtHiZEB4igidWfIFZe68+2TT+N3NXXCXUyc
UyBcTBKhnhF7hZKxQdzf3d2NuCZtqyfrR/au7ejoxDsFLiQ1M0Td40ZQXGIbAwLzafyu8ZiPRQQG
iiMBSpCRiGBKqmM4VXuMTizzUBnYqTnMKxOBNU8o36gZ3jW9GP0QiBy1uVmbUH5OEaZA+CFBn+fs
vNKiO5lGvIcUCGUvWNe0wrtyivzzWVC1aDFJ2yEq8aekxh3CTwD8lEC5GcMY6i3qUHfvts1zlJtS
/MlJHMeGXSxKwdH3Rca3PqpYFq3LgCXiaRRAikd6IOUCPmV1pbaXSdqwmohTia25rHfUHjnO2/s7
9ZtYiNsUE7GFhM8x8U7BXMX6V5KZc0FfsC+ErVVgnNYmwrFF4azGTMXGoBJmA2KvGq7E6Iw0mKU0
zAROm10M0ugkiI3GpNEZNewGIrgphkBK+nVPErYHexrCQpYS2UlS0GmphO3j1depe83qx6KYlPEr
KyUUeyEikJLg+yyECk+Y34S3EKlzuiSyZiuhxN+ODWHbU1FcCb7FnMQIrhybbOqQxF2WhKMkMZ8E
clabbfnjMOe4b1SwArPiCKcEQh1LLKrf8iWylqMwnpMHHpfXI1lX8Xwq4cqn/QPsNqlvGoR7lElw
LWmNmJFrIvJY15KL+l01kl6SkiZltDnphE0o3nUpPvxvQc1FHtZaclHfq4beUEcZdoeRrTOgaDuM
I2i4tnutx7goibKWjF5vpA2aKF5CsVcmSMvksLntLorbzhFtZrvu9aLiK1cR7dA/o885tNOMEqQk
on0MzyiTZEL56F1UNFwRaLa2VVF7bBaAYNQxxU4k3AWdUhDn0zd+GzqINJX2bdrx1YweokZEG1mv
LTBCSUsMX7+i9tgsAErCkzoSRR2Gh2ifOgWOQPHVjN6iRkR7Wa+7HJm020VFhiul1Pyg+jZ0avxM
Da5oZ8FxRo9rT4ud4U8a6VI/whtbdySKQcMNDghEO6NH3GvNaYWYCmJOIekw/9yiSkdaxKaqVP/n
VYUiC1awsTaemtHOa5wmEQmiZMD8at+8Smyv4JBlBwmYEN2nm6FmRCASQkkadt1LvY1IGmxhSrFq
d9SMCER0lItNo6SlhZecgxwyCE8qEQliuya/pqsZEe0PzZVs1MgTjiORY55YV9DwsMdVG2O4yird
CXWt/ajvLOh+HQclvoSlu7ipFtG2mGhI3IkmXUHD2ca44OoS0UzVeugfJsWITQLCf+OOiUMmYotk
Jaylq91+VbUl1GvepNptWisdT5mGHoQ6C+AoTghjGdFumMxnegehtwalHNT6MoWaNruxf2ODWShm
0k9OquGMc8VsvqyeLuUzuZJ6VM5llbavmGEdV8ilewn0lqDWC7VCmr8C6YViNpPTnKzWcpnPW9cZ
eDIzycKw/wZ6jWs1iJJ6ryfE+iCmtEH/bgS1TvBnCNHv8hA+GOFTACNdIy7Rf3dnRD9tRfWbFq1c
2Arg+MA5NcF477e3GCUyr8ATGehJb32ds/G+sQAb36x99X/TbD/93PJC79+oP7yzd6v3nerR3+QW
dtjHIAv7HtEVyrX8PciswStZ2P/1WmY/d+4ObOS3ynov+n8G/nvrOvDFq19g0yybJbvvcNdq2CzZ
5mjEu2pwkkzcYnJMmawq54GOwpvfgNrfQ+8c9PdaAR4rQs94pfIt9YtyLss+t4uzX9Z+mIU5LfCX
Z4vLCmlfqlQ2RVfIQZld4b+Cb6RhcwTmuDBz7Ao1I9bWyOKmdZ354vlZLdBskbtWNKAXZkQSGKkt
00rv2dk5M1F+qJqtqj9lttQP9k/5KB/ahoFFI7gtiHKUrikf7LvyUT60Ux9YdF+hPLySOztR/l9e
6N3kU9GTKL3rPqynreCuEPqRfq29Mksi9i5+M8VMSiimB9jUdK0MZe1X/QOK937Rt6YeKefqyooP
yloHnyobR11atOK9hefXBFf4pdT+77Gzzw9UtEj2K5ysLOT7jAS569hgXQspieh01NOzytLta8fZ
32oOZqoAxyrlI/rZXLF4WzuqHlPPwX52Wv0hnYOjmsVZOQpHtLD/7eOCK9z//2bfrayOjk8CbP4Y
jircn7SuUCmmtKP0zFCvdR0NmZp26p+MayElEZ2OwomDL7CP/mts5bZ9IP3UNsAHBz5g9OHvnMoM
FNSj7WpGOQddmeoP1B8m9mer2j2IH2xlv6qHFd0WLXzoISW571x7jKXyZGaLrTtXxx7qNs6+P72x
opHzL9aodR0Nk9oESp8wroVrSQRCtAJNGFL2jaMQTS8Z7g6msQM98htMJRxOut4nq4WRcTjJhwnW
ZhqbHxwvkJXzgmk6m8Q9SM2AcisnedgdvaQLJI4rDAmHk+63q1uvjgtyOMmFCdZm2mSdAb4lBWoZ
Yg5RyMjGI5GMjKmXtHz6mEpI6ght7sExEwc9FUqFWktqpeXIC9f99aeT1BRsEv85UuxPwVagaCOQ
j4qF+joQa8ZAh+gENEIvCZybScpbps7zAGYQsGso3YdOiSU4BJb+DifdXuT493xwmRI6nKRC0abQ
2Y5DoWIXkAX60aSxXgSF2CuU9BvXwcOrFrePVRjN4SHE90rEo7t7R5JxWSk2yz0cTjqZKPO+ZI85
0fkKIps9bXoYQS+TCD9KyuglG6ZT9NFayuZFcvG66zFFaZkMdA4p6GUS4U1JKb1ko+4REqk52X01
SYeTsss3D7GmfPJSniw9y4leJhEBhmvgmO3QRzpeAenqk5T4TIZeoinrHo3DNZ68w8kgxtAQcyGJ
QnWBb0kfz50IhIiSDheIlIhMVbu3Sf0JI+fBUXge3E4e3Q4srRMuD47yDiddfHH7gPT2dym8WyOq
In5cMh9MyvqW5DOFXiYRJhq+e0fYI9ttOpDNT9h842ubEbHx/wOswL6I0L1TFgAAAABJRU5ErkJg
gg==
</FILE>
</FIGURE>
<FIGURE FILENAME="ma842_funnel_plot_pain.png" FILE_TYPE="PNG" ID="FIG-04" MODIFIED="2014-08-17 07:57:38 -0400" MODIFIED_BY="Anne Lawson" NO="4" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Funnel plot for effects on knee or hip pain.<BR/>Numbers on x axis refer to standardised mean differences (SMDs), on y axis to standard errors of SMDs.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAdYAAAFVCAIAAADdXFl7AAANB0lEQVR42u3d627rthZFYb//o/bn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</FILE>
</FIGURE>
<FIGURE FILENAME="ma84_metaregression_plot_pain_dosage.png" FILE_TYPE="PNG" ID="FIG-05" MODIFIED="2014-08-17 07:58:00 -0400" MODIFIED_BY="Anne Lawson" NO="5" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Standardised mean differences of knee or hip pain (y axis) are plotted against total daily dose of morphine equivalents (x axis). The size of the circles is proportional to the random-effects weights that were used in the meta-regression. The dotted line indicates predicted treatment effects (regression line) from univariable meta-regression by using daily morphine equivalence doses the explanatory variable, and dashed lines represent the 95% confidence intervals.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAdYAAAFVCAIAAADdXFl7AAAR3ElEQVR42u3dW46kMBJA0dr/Uudz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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-06" MODIFIED="2014-08-21 15:44:24 -0400" MODIFIED_BY="[Empty name]" NO="6" REF_ID="CMP-001.02" SETTINGS="SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;SHOW_ROB_TABLE:NO;SHOW_MORE_DECIMALS:NO;SHOW_RAW_DATA_COLUMNS:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of 12 trials comparing the effects of any type of opioids and control (placebo or no intervention) on function. Values on x axis denote standardised mean differences. The plot is stratified according to type of opioids. Matsumoto 2005 contributed with two comparisons and the standard error was inflated and the number of participants in the placebo group was halved to avoid duplicate counting of participants when including both comparisons in the overall meta-analysis. Data relating to the 3, 3, and 2 active intervention arms in Caldwell 2002, Kivitz 2006, and Matsumoto 2005, respectively, were pooled.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAA5IAAAOACAMAAAB/sbywAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="ma842_funnel_plot_function.png" FILE_TYPE="PNG" ID="FIG-07" MODIFIED="2014-08-17 07:58:31 -0400" MODIFIED_BY="Anne Lawson" NO="7" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Funnel plot for effects on functioning of the knee or hip.<BR/>Numbers on x axis refer to standardised mean differences (SMDs), on y axis to standard errors of SMDs</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAdYAAAFVCAIAAADdXFl7AAAMHElEQVR42u3dbW7rNhRFUc9/qP3Z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</FILE>
</FIGURE>
<FIGURE FILENAME="ma84_metaregression_plot_function_dosage.png" FILE_TYPE="PNG" ID="FIG-08" MODIFIED="2014-08-17 07:58:58 -0400" MODIFIED_BY="Anne Lawson" NO="8" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Standardised mean differences of function (y axis) are plotted against total daily dose of morphine equivalents (x axis). The size of the circles is proportional to the random-effects weights that were used in the meta-regression. The dotted line indicates predicted treatment effects (regression line) from univariable meta-regression by using daily morphine equivalence doses the explanatory variable, and dashed lines represent the 95% confidence intervals.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAdYAAAFVCAIAAADdXFl7AAANgElEQVR42u3da27zuBmA0ex/qf3Z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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-09" MODIFIED="2014-08-21 15:44:24 -0400" MODIFIED_BY="[Empty name]" NO="9" REF_ID="CMP-001.03" SETTINGS="SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;SHOW_ROB_TABLE:NO;SHOW_MORE_DECIMALS:NO;SHOW_RAW_DATA_COLUMNS:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of 10 trials comparing participants experiencing any adverse event between any opioid and control (placebo or no intervention). Values on x axis denote risks ratios. The plot is stratified according to type of opioid. Matsumoto 2005, Hartrick 2009, Afilalo 2010, Etropolski 2011, and NCT00486811 contributed with two comparisons and the number of participants in the placebo group was halved to avoid duplicate counting of participants when including both comparisons in the overall meta-analysis.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAu8AAAQACAMAAABmn0cOAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="ma84_metaregression_plot_any_adverse_events_dosage.png" FILE_TYPE="PNG" ID="FIG-10" MODIFIED="2014-08-17 16:54:26 -0400" MODIFIED_BY="Anne Lawson" NO="10" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Risk ratios of participants experiencing any adverse event between opioids and control groups (y axis) are plotted against total daily dose of morphine equivalents (x axis). The size of the circles is proportional to the random-effects weights that were used in the meta-regression. The dotted line indicates predicted treatment effects (regression line) from univariable meta-regression by using daily morphine equivalence doses the explanatory variable, and dashed lines represent the 95% confidence intervals.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAdYAAAFVCAIAAADdXFl7AAAM2UlEQVR42u3d6Y6jOBSA0Xr/R52f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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-11" MODIFIED="2014-08-21 15:44:24 -0400" MODIFIED_BY="[Empty name]" NO="11" REF_ID="CMP-001.04" SETTINGS="SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;SHOW_ROB_TABLE:NO;SHOW_MORE_DECIMALS:NO;SHOW_RAW_DATA_COLUMNS:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of 21 trials comparing participants withdrawn or dropped out because of adverse events between any opioid and control (placebo or no intervention). Values on x axis denote risks ratios. The plot is stratified according to type of opioid. Matsumoto 2005, Hartrick 2009, Afilalo 2010, Etropolski 2011, and NCT00486811 contributed with two comparisons and the number of participants in the placebo group was halved to avoid duplicate counting of participants when including both comparisons in the overall meta-analysis. The risk ratio in one trial could not be estimated because no withdrawals or drop-outs because of adverse events occurred in either group.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAyMAAAUQCAMAAABgM3/OAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="ma84_metaregression_plot_dropouts_adverse_events_dosage.png" FILE_TYPE="PNG" ID="FIG-12" MODIFIED="2014-08-17 16:54:30 -0400" MODIFIED_BY="Anne Lawson" NO="12" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Risk ratios of participants withdrawn or dropped out because of adverse events between opioids and control groups (y axis) are plotted against total daily dose of morphine equivalents (x axis). The size of the circles is proportional to the random-effects weights that were used in the meta-regression. The dotted line indicates predicted treatment effects (regression line) from univariable meta-regression by using daily morphine equivalence doses the explanatory variable, and dashed lines represent the 95% confidence intervals.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAdYAAAFVCAIAAADdXFl7AAARyElEQVR42u3d7Y6kOBJA0X7/R92f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==
</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-13" MODIFIED="2014-08-21 15:44:24 -0400" MODIFIED_BY="[Empty name]" NO="13" REF_ID="CMP-001.05" SETTINGS="SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;SHOW_ROB_TABLE:NO;SHOW_MORE_DECIMALS:NO;SHOW_RAW_DATA_COLUMNS:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of three trials comparing participants experiencing any serious adverse event between any opioid and control (placebo or no intervention). Values on x axis denote risks ratios. The plot is stratified according to type of opioid. The risk ratio in one trial could not be estimated because no serious adverse event occurred in either group.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAyIAAAHACAMAAABpgCzMAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-14" MODIFIED="2014-08-21 15:44:24 -0400" MODIFIED_BY="[Empty name]" NO="14" REF_ID="CMP-001.06" SETTINGS="SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;SHOW_ROB_TABLE:NO;SHOW_MORE_DECIMALS:NO;SHOW_RAW_DATA_COLUMNS:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of 4 comparisons in three trials comparing participants experiencing withdrawal symptoms between any opioid and control (placebo or no intervention). Values on x axis denote odds ratios. The plot is stratified according to type of opioid. Afilalo 2010 contributed with two comparisons and the number of participants in the placebo group was halved to avoid duplicate counting of participants when including both comparisons in the overall meta-analysis.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAs0AAAHgCAMAAABpS6DGAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK MODIFIED="2009-03-03 03:57:10 -0500" MODIFIED_BY="[Empty name]"/>
<APPENDICES MODIFIED="2014-08-17 08:02:48 -0400" MODIFIED_BY="Anne Lawson">
<APPENDIX ID="APP-01" MODIFIED="2014-08-17 08:02:48 -0400" MODIFIED_BY="Anne Lawson" NO="1">
<TITLE MODIFIED="2014-08-17 08:02:40 -0400" MODIFIED_BY="Anne Lawson">MEDLINE, EMBASE, and CINAHL search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2014-08-17 08:02:48 -0400" MODIFIED_BY="Anne Lawson">
<TABLE COLS="3" ROWS="5">
<TR>
<TD VALIGN="TOP">
<P>
<B>Ovid MEDLINE</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>Ovid EMBASE</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>CINAHL through EBSCOhost</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Search terms for design</B>
</P>
<P>1. randomized controlled trial.pt.<BR/>2. controlled clinical trial.pt.<BR/>3. randomized controlled trial.sh.<BR/>4. random allocation.sh.<BR/>5. double blind method.sh.<BR/>6. single blind method.sh.<BR/>7. clinical trial.pt.<BR/>8. exp clinical trial/<BR/>9. (clin$ adj25 trial$).ti,ab.<BR/>10. ((singl$ or doubl$ or trebl$ or tripl$) adj25 (blind$ or mask$)).ti,ab.<BR/>11. placebos.sh.<BR/>12. placebo$.ti,ab.<BR/>13. random$.ti,ab.<BR/>14. research design.sh.<BR/>15. comparative study.sh.<BR/>16. exp evaluation studies/<BR/>17. follow up studies.sh.<BR/>18. prospective studies.sh.<BR/>19. (control$ or prospectiv$ or volunteer$).ti,ab.</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>Search terms for design</B>
</P>
<P>1. randomized controlled trial.sh.<BR/>2. randomization.sh.<BR/>3. double blind procedure.sh.<BR/>4. single blind procedure.sh.<BR/>5. exp clinical trials/<BR/>6. (clin$ adj25 trial$).ti,ab.<BR/>7. ((singl$ or doubl$ or trebl$ or tripl$) adj25 (blind$ or mask$)).ti,ab.<BR/>8. placebo.sh.<BR/>9. placebo$.ti,ab.<BR/>10. random$.ti,ab.<BR/>11. methodology.sh.<BR/>12. comparative study.sh.<BR/>13. exp evaluation studies/<BR/>14. follow up.sh.<BR/>15. prospective study.sh.<BR/>16. (control$ or prospectiv$ or volunteer$).ti,ab.</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>Search terms for design</B>
</P>
<P>1. (MH "Clinical Trials+")<BR/>2. (MH "Random Assignment")<BR/>3. (MH "Double-Blind Studies") or (MH "Single-Blind Studies")<BR/>4. TX (clin$ n25 trial$)<BR/>5. TX (sing$ n25 blind$)<BR/>6. TX (sing$ n25 mask$)<BR/>7. TX (doubl$ n25 blind$)<BR/>8. TX (doubl$ n25 mask$)<BR/>9. TX (trebl$ n25 blind$)<BR/>10. TX (trebl$ n25 mask$)<BR/>11. TX (tripl$ n25 blind$)<BR/>12. TX (tripl$ n25 mask$)<BR/>13. (MH "Placebos")<BR/>14. TX placebo$<BR/>15. TX random$<BR/>16. (MH "Study Design+")<BR/>17. (MH "Comparative Studies")<BR/>18. (MH "Evaluation Research")<BR/>19. (MH "Prospective Studies+")<BR/>20. TX (control$ or prospectiv$ or volunteer$)<BR/>21. S1 or S2 or (&#8230;&#8230;.) or S20</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Search terms for Osteoarthritis</B>
</P>
<P>20. exp osteoarthritis/<BR/>21. osteoarthriti$.ti,ab,sh.<BR/>22. osteoarthro$.ti,ab,sh.<BR/>23. gonarthriti$.ti,ab,sh.<BR/>24. gonarthro$.ti,ab,sh.<BR/>25. coxarthriti$.ti,ab,sh.<BR/>26. coxarthro$.ti,ab,sh.<BR/>27. arthros$.ti,ab.<BR/>28. arthrot$.ti,ab.<BR/>29. ((knee$ or hip$ or joint$) adj3 (pain$ or ach$ or discomfort$)).ti,ab.<BR/>30. ((knee$ or hip$ or joint$) adj3 stiff$).ti,ab.</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>Search terms for Osteoarthritis</B>
</P>
<P>17. exp osteoarthritis/<BR/>18. osteoarthriti$.ti,ab,sh.<BR/>19. osteoarthro$.ti,ab,sh.<BR/>20. gonarthriti$.ti,ab,sh.<BR/>21. gonarthro$.ti,ab,sh.<BR/>22. coxarthriti$.ti,ab,sh.<BR/>23. coxarthro$.ti,ab,sh.<BR/>24. arthros$.ti,ab.<BR/>25. arthrot$.ti,ab.<BR/>26. ((knee$ or hip$ or joint$) adj3 (pain$ or ach$ or discomfort$)).ti,ab.<BR/>27. ((knee$ or hip$ or joint$) adj3 stiff$).ti,ab.</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>Search terms for Osteoarthritis</B>
</P>
<P>22. osteoarthriti$<BR/>23. (MH "Osteoarthritis")<BR/>24. TX osteoarthro$<BR/>25. TX gonarthriti$<BR/>26. TX gonarthro$<BR/>27. TX coxarthriti$<BR/>28. TX coxarthro$<BR/>29. TX arthros$<BR/>30. TX arthrot$<BR/>31. TX knee$ n3 pain$<BR/>32. TX hip$ n3 pain$<BR/>33. TX joint$ n3 pain$<BR/>34. TX knee$ n3 ach$<BR/>35. TX hip$ n3 ach$<BR/>36. TX joint$ n3 ach$<BR/>37. TX knee$ n3 discomfort$<BR/>38. TX hip$ n3 discomfort$<BR/>39. TX joint$ n3 discomfort$<BR/>40. TX knee$ n3 stiff$<BR/>41. TX hip$ n3 stiff$<BR/>42. TX joint$ n3 stiff$<BR/>43. S22 or S23 or S24&#8230;.or S42</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Search terms for Opioids</B>
</P>
<P>31. exp Analgesics, Opioid/<BR/>32. exp Narcotics/<BR/>33. acetyldihydrocodeine.tw.<BR/>34. alfentanil.tw.<BR/>35. allylprodine.tw.<BR/>36. alphamethylfentanyl.tw.<BR/>37. alphaprodine.tw.<BR/>38. benzylmorphine.tw.<BR/>39. betaprodine.tw.<BR/>40. bezitriamide.tw.<BR/>41. buprenorphine.tw.<BR/>42. butorphanol.tw.<BR/>43. bremazocine.tw.<BR/>44. carfentan$.tw.<BR/>45. codeine.tw.<BR/>46. contin.tw.<BR/>47. dextromoramide.tw.<BR/>48. dextropropoxyphene.tw.<BR/>49. dezocine.tw.<BR/>50. diacetylmorphine.tw.<BR/>51. diamorphine.tw.<BR/>52. dihydrocodeine.tw.<BR/>53. dihydromorphine.tw.<BR/>54. dihydromorphone.tw.<BR/>55. diphenoxylate.tw.<BR/>56. dipipanone.tw.<BR/>57. enadoline.tw.<BR/>58. ethylketazocine.tw.<BR/>59. ethylmorphine.tw.<BR/>60. etonitazene.tw.<BR/>61. etorphine.tw.<BR/>62. fentanyl.tw.<BR/>63. heroin.tw.<BR/>64. hydrocodone.tw.<BR/>65. hydromorphin$.tw.<BR/>66. hydromorphone.tw.<BR/>67. ketazocine.tw.<BR/>68. ketobemidone.tw.<BR/>69. lefetamine.tw.<BR/>70. levomethadon.tw.<BR/>71. levomethadyl.tw.<BR/>72. levomethorphan$.tw.<BR/>73. levorphanol.tw.<BR/>74. loperamide.tw.<BR/>75. meperidine.tw.<BR/>76. meptazinol.tw.<BR/>77. methadone.tw.<BR/>78. methadyl.tw.<BR/>79. methylmorphine.tw.<BR/>80. morphin$.tw.<BR/>81. nalbuphine.tw.<BR/>82. narcotic$.tw.<BR/>83. nicocodeine.tw.<BR/>84. nicomorphine.tw.<BR/>85. normorphine.tw.<BR/>86. noscapin$.tw.<BR/>87. ohmefentanyl.tw.<BR/>88. opiate$.tw.<BR/>89. opioid$.tw.<BR/>90. opium.tw.<BR/>91. oripavine.tw.<BR/>92. oxycodone.tw.<BR/>93. oxycontin.tw.<BR/>94. oxymorphone.tw.<BR/>95. papaveretum.tw.<BR/>96. papaverin.tw.<BR/>97. pentazocine.tw.<BR/>98. percocet.tw.<BR/>99. peronine.tw.<BR/>100. pethidine.tw.<BR/>101. phenazocine.tw.<BR/>102. phencyclidine.tw.<BR/>103. pholcodine.tw.<BR/>104. piritramid$.tw.<BR/>105. prodine.tw.<BR/>106. promedol.tw.<BR/>107. propoxyphene.tw.<BR/>108. remifentanil.tw.<BR/>109. sufentanil.tw.<BR/>110. tapentadol.tw.<BR/>111. thebaine.tw.<BR/>112. tilidine.tw.</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>Search terms for Opioids</B>
</P>
<P>28. exp Analgesics, Opioid/<BR/>29. exp Narcotic Analgesic Agent/<BR/>30. acetyldihydrocodeine.tw.<BR/>31. alfentanil.tw.<BR/>32. allylprodine.tw.<BR/>33. alphamethylfentanyl.tw.<BR/>34. alphaprodine.tw.<BR/>35. benzylmorphine.tw.<BR/>36. betaprodine.tw.<BR/>37. bezitriamide.tw.<BR/>38. buprenorphine.tw.<BR/>39. butorphanol.tw.<BR/>40. bremazocine.tw.<BR/>41. carfentan$.tw.<BR/>42. codeine.tw.<BR/>43. contin.tw.<BR/>44. dextromoramide.tw.<BR/>45. dextropropoxyphene.tw.<BR/>46. dezocine.tw.<BR/>47. diacetylmorphine.tw.<BR/>48. diamorphine.tw.<BR/>49. dihydrocodeine.tw.<BR/>50. dihydromorphine.tw.<BR/>51. dihydromorphone.tw.<BR/>52. diphenoxylate.tw.<BR/>53. dipipanone.tw.<BR/>54. enadoline.tw.<BR/>55. ethylketazocine.tw.<BR/>56. ethylmorphine.tw.<BR/>57. etonitazene.tw.<BR/>58. etorphine.tw.<BR/>59. fentanyl.tw.<BR/>60. heroin.tw.<BR/>61. hydrocodone.tw.<BR/>62. hydromorphin$.tw.<BR/>63. hydromorphone.tw.<BR/>64. ketazocine.tw.<BR/>65. ketobemidone.tw.<BR/>66. lefetamine.tw.<BR/>67. levomethadon.tw.<BR/>68. levomethadyl.tw.<BR/>69. levomethorphan$.tw.<BR/>70. levorphanol.tw.<BR/>71. loperamide.tw.<BR/>72. meperidine.tw.<BR/>73. meptazinol.tw.<BR/>74. methadone.tw.<BR/>75. methadyl.tw.<BR/>76. methylmorphine.tw.<BR/>77. morphin$.tw.<BR/>78. nalbuphine.tw.<BR/>79. narcotic$.tw.<BR/>80. nicocodeine.tw.<BR/>81. nicomorphine.tw.<BR/>82. normorphine.tw.<BR/>83. noscapin$.tw.<BR/>84. ohmefentanyl.tw.<BR/>85. opiate$.tw.<BR/>86. opioid$.tw.<BR/>87. opium.tw.<BR/>88. oripavine.tw.<BR/>89. oxycodone.tw.<BR/>90. oxycontin.tw.<BR/>91. oxymorphone.tw.<BR/>92. papaveretum.tw.<BR/>93. papaverin.tw.<BR/>94. pentazocine.tw.<BR/>95. percocet.tw.<BR/>96. peronine.tw.<BR/>97. pethidine.tw.<BR/>98. phenazocine.tw.<BR/>99. phencyclidine.tw.<BR/>100. pholcodine.tw.<BR/>101. piritramid$.tw.<BR/>102. prodine.tw.<BR/>103. promedol.tw.<BR/>104. propoxyphene.tw.<BR/>105. remifentanil.tw.<BR/>106. sufentanil.tw.<BR/>107. tapentadol.tw.<BR/>108. thebaine.tw.<BR/>109. tilidine.tw.</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>Search terms for Opioids</B>
</P>
<P>44. MH " Analgesics, Opioid"<BR/>45. MH "Narcotics"<BR/>46. TX acetyldihydrocodeine<BR/>47. TX alfentanil<BR/>48. TX allylprodine<BR/>49. TX alphamethylfentanyl<BR/>50. TX alphaprodine<BR/>51. TX benzylmorphine<BR/>52. TX betaprodine<BR/>53. TX bezitriamide<BR/>54. TX buprenorphine<BR/>55. TX butorphanol<BR/>56. TX bremazocine<BR/>57. TX carfentan$<BR/>58. TX codeine<BR/>58. TX contin<BR/>60. TX dextromoramide<BR/>61. TX dextropropoxyphene<BR/>62. TX dezocine<BR/>63. TX diacetylmorphine<BR/>64. TX diamorphine<BR/>65. TX dihydrocodeine<BR/>66. TX dihydromorphine<BR/>67. TX dihydromorphone<BR/>68. TX diphenoxylate<BR/>69. TX dipipanone<BR/>70. TX enadoline<BR/>71. TX ethylketazocine<BR/>72. TX ethylmorphine<BR/>73. TX etonitazene<BR/>74. TX etorphine<BR/>75. TX fentanyl<BR/>76. TX heroin<BR/>77. TX hydrocodone<BR/>78. TX hydromorphin$<BR/>79. TX hydromorphone<BR/>80. TX ketazocine<BR/>81. TX ketobemidone<BR/>82. TX lefetamine<BR/>83. TX levomethadon<BR/>84. TX levomethadyl<BR/>85. TX levomethorphan$<BR/>86. TX levorphanol<BR/>87. TX loperamide<BR/>88. TX meperidine<BR/>89. TX meptazinol<BR/>90. TX methadone<BR/>91. TX methadyl<BR/>92. TX methylmorphine<BR/>93. TX morphin$<BR/>94. TX nalbuphine<BR/>95. TX narcotic$<BR/>96. TX nicocodeine<BR/>97. TX nicomorphine<BR/>98. TX normorphine<BR/>99. TX noscapin$<BR/>100. TX ohmefentanyl<BR/>101. TX opiate$<BR/>102. TX opioid$<BR/>103. TX opium<BR/>104. TX oripavine<BR/>105. TX oxycodone<BR/>106. TX oxycontin<BR/>107. TX oxymorphone<BR/>108. TX papaveretum<BR/>109. TX papaverin<BR/>110. TX pentazocine<BR/>111. TX percocet<BR/>112. TX peronine<BR/>113. TX pethidine<BR/>114. TX phenazocine<BR/>115. TX phencyclidine<BR/>116. TX pholcodine<BR/>117. TX piritramid$<BR/>118. TX prodine<BR/>119. TX promedol<BR/>120. TX propoxyphene<BR/>121. TX remifentanil<BR/>122. TX sufentanil<BR/>123. TX tapentadol<BR/>124. TX thebaine<BR/>125. TX tilidine<BR/>126. S44 or S45 or S125</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Combining terms</B>
</P>
<P>113. or/31-112<BR/>114. or/1-19<BR/>115. or/20-30<BR/>116. and/113-115<BR/>117. animal/<BR/>118. animal/ and human/<BR/>119. 117 not 118<BR/>120. 116 not 119<BR/>121. remove duplicates from 120</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>Combining terms</B>
</P>
<P>110. or/28-109<BR/>111. or/1-16<BR/>112. or/17-27<BR/>113. and/110-112<BR/>114. animal/<BR/>115. animal/ and human/<BR/>116. 114 not 115<BR/>117. 113 not 116<BR/>118. remove duplicates from 117</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>Combining terms</B>
</P>
<P>127. S21 and S43 and S126</P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2008-12-12 07:48:54 -0500" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2008-12-12 07:34:39 -0500" MODIFIED_BY="[Empty name]">CENTRAL search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2008-12-12 07:48:54 -0500" MODIFIED_BY="[Empty name]">
<TABLE COLS="1" ROWS="2">
<TR>
<TD VALIGN="TOP">
<P>
<B>CENTRAL</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<I>Search terms for Osteoarthritis</I>
</P>
<P>#1. MeSH descriptor Osteoarthritis explode all trees</P>
<P>#2. (osteoarthritis* OR osteoarthro* OR gonarthriti* OR gonarthro*<BR/>OR coxarthriti* OR coxarthro* OR arthros* OR arthrot* OR<BR/>((knee* OR hip* OR joint*) near/3 (pain* OR ach* OR discomfort*))<BR/>OR ((knee* OR hip* OR joint*) near/3 stiff*)) in Clinical Trials</P>
<P>
<I>Search terms for Opioids</I>
<BR/>
</P>
<P>#3. MeSH descriptor Analgesics, Opioid explode all trees</P>
<P>#4. MeSH descriptor Narcotics explode all trees</P>
<P>#5. (acetyldihydrocodeine OR alfentanil OR allylprodine OR<BR/>alphamethylfentanyl OR alphaprodine OR benzylmorphine OR<BR/>betaprodine OR bezitriamide OR buprenorphine OR butorphanol<BR/>OR bremazocine OR carfentan* OR codeine OR contin OR<BR/>dextromoramide OR dextropropoxyphene OR dezocine OR<BR/>diacetylmorphine OR diamorphine OR dihydrocodeine OR<BR/>dihydromorphine OR dihydromorphone OR diphenoxylate OR<BR/>dipipanone OR enadoline OR ethylketazocine OR ethylmorphine OR<BR/>etonitazene OR etorphine OR fentanyl OR heroin OR hydrocodone<BR/>OR hydromorphin* OR hydromorphone OR ketazocine OR <BR/>ketobemidone OR lefetamine OR levomethadon OR levomethadyl <BR/>OR levomethorphan* OR levorphanol OR loperamide OR <BR/>meperidine OR meptazinol OR methadone OR methadyl OR <BR/>methylmorphine OR morphin* OR nalbuphine OR narcotic* OR <BR/>nicocodeine OR nicomorphine OR normorphine OR noscapin* OR <BR/>ohmefentanyl OR opiate* OR opioid* OR opium OR oripavine OR <BR/>oxycodone OR oxycontin OR oxymorphone OR papaveretum OR <BR/>papaverin OR pentazocine OR percocet OR peronine OR pethidine <BR/>OR phenazocine OR phencyclidine OR pholcodine OR piritramid* <BR/>OR prodine OR promedol OR propoxyphene OR remifentanil OR <BR/>sufentanil OR tapentadol OR thebaine OR tilidine) in Clinical Trials</P>
<P>
<I>Combining terms</I>
</P>
<P>#6. (#1 OR #2)<BR/>#7. (#3 OR #4 OR #5)<BR/>#8. (#6 AND #7) in Clinical Trials</P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS MODIFIED="2009-03-03 03:57:10 -0500" MODIFIED_BY="[Empty name]"/>
</COCHRANE_REVIEW>